[go: up one dir, main page]

WO2023116911A1 - 抗FRα抗体及其抗体药物偶联物和用途 - Google Patents

抗FRα抗体及其抗体药物偶联物和用途 Download PDF

Info

Publication number
WO2023116911A1
WO2023116911A1 PCT/CN2022/141572 CN2022141572W WO2023116911A1 WO 2023116911 A1 WO2023116911 A1 WO 2023116911A1 CN 2022141572 W CN2022141572 W CN 2022141572W WO 2023116911 A1 WO2023116911 A1 WO 2023116911A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
antibody
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/141572
Other languages
English (en)
French (fr)
Inventor
汤伟佳
麦思琪
周鑫
严辉
李硕旭
范建军
沈静宜
梁世德
俞金泉
李胜峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Thera Solutions Ltd
Original Assignee
Bio Thera Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Thera Solutions Ltd filed Critical Bio Thera Solutions Ltd
Priority to EP22910217.3A priority Critical patent/EP4455164A1/en
Priority to US18/722,899 priority patent/US20250059274A1/en
Priority to JP2024537958A priority patent/JP2024547111A/ja
Publication of WO2023116911A1 publication Critical patent/WO2023116911A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the present invention relates to an anti-FR ⁇ antibody, an antibody-drug conjugate comprising the anti-FR ⁇ antibody and uses thereof.
  • Folate an essential vitamin required for DNA synthesis and repair, cell division processes, is transported by endocytosis by binding to folate receptors on the cell surface, where folate receptors are internalized and then recycled back to the cell membrane.
  • the folate receptor is a transmembrane single-chain glycoprotein linked to glycosylated phosphatidylinositol and has a high affinity for folate.
  • Folate receptors include three subtypes, namely folate receptor ⁇ (Folate Receptor ⁇ , FOLR1, FR ⁇ ), folate receptor ⁇ (Folate Receptor ⁇ , FOLR2) and folate receptor ⁇ (Folate Receptor ⁇ , FOLR3).
  • the expression of folate receptors is highly restricted in normal cells, but significantly high in tumor cells. Overexpression of folate receptor ⁇ has been found in a variety of malignant tumors, so it has become one of the popular targets of anticancer drugs.
  • the present invention provides an antibody that specifically recognizes and binds to folate receptor ⁇ (also known as "anti-folate receptor ⁇ antibody” or “anti-FR ⁇ antibody”).
  • the antibodies of the invention are capable of recognizing and binding to human folate receptor alpha.
  • the present invention provides an antibody or an antigen-binding unit thereof, which specifically binds folate receptor ⁇ , and comprises one or more of (a)-(f) indivual:
  • VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 5, or composed of its composition;
  • VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 6, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 6, or composed of its composition;
  • VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 7, or composed of its composition;
  • VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 8, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 8, or consists of its composition;
  • VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 9, or by its composition;
  • VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 10, or consists of its composition.
  • the antibody or its antigen-binding unit specifically binds folate receptor alpha, and comprises:
  • VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 5, or composed of its composition;
  • VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 6, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 6, or composed of its composition;
  • VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 7, or composed of its composition.
  • the antibody or its antigen binding unit comprises VH CDR1 as shown in SEQ ID NO:5, VH CDR2 as shown in SEQ ID NO:6 and VH CDR2 as shown in SEQ ID NO:7 VH CDR3.
  • the antibody or its antigen-binding unit specifically binds folate receptor alpha, and comprises:
  • VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 8, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 8, or consists of its composition;
  • VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 9, or by its composition;
  • VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 10, or consists of its composition.
  • the antibody or its antigen binding unit comprises VL CDR1 as shown in SEQ ID NO:8, VL CDR2 as shown in SEQ ID NO:9 and VL CDR2 as shown in SEQ ID NO:10 VL CDR3.
  • the antibody or its antigen-binding unit specifically binds folate receptor alpha, and comprises:
  • VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 5, or composed of its composition;
  • VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 6, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 6, or composed of its composition;
  • VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence with one or more site substitutions, deletions or insertions compared with the amino acid sequence shown in SEQ ID NO: 7, or composed of its composition;
  • VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 8, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 8, or consists of its composition;
  • VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 9, or by its composition;
  • VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, or has the amino acid sequence that one or more positions are substituted, deleted or inserted compared with the amino acid sequence shown in SEQ ID NO: 10, or consists of its composition.
  • the site substitutions, deletions or insertions are independently one, two or three.
  • the antibody or its antigen-binding unit comprises VH CDR1 as shown in SEQ ID NO:5, VH CDR2 as shown in SEQ ID NO:6, and VH CDR2 as shown in SEQ ID NO:7 VH CDR3, VL CDR1 as shown in SEQ ID NO:8, VL CDR2 as shown in SEQ ID NO:9, and VL CDR3 as shown in SEQ ID NO:10.
  • the antibody or antigen-binding unit thereof further comprises one or more of (g)-(n):
  • VHFR1 comprises the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:29, or has at least 90% sequence identity compared to the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:29 amino acid sequence, or an amino acid sequence having one or more substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:29;
  • VHFR2 comprises the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:30, or has at least 90% sequence identity compared to the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:30 amino acid sequence, or an amino acid sequence having one or more substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 30;
  • VH FR3 comprises the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:31, or has at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:31 A non-specific amino acid sequence, or an amino acid sequence with one or more substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:31;
  • VH FR4 comprises the amino acid sequence shown in SEQ ID NO: 11, or an amino acid sequence having at least 90% sequence identity compared to the amino acid sequence shown in SEQ ID NO: 11, or an amino acid sequence with SEQ ID NO: 11
  • the amino acid sequence shown has one or more site substitutions, deletions or insertions compared to the amino acid sequence;
  • VLFR1 comprises the amino acid sequence shown in SEQ ID NO: 12, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 12, or an amino acid sequence with SEQ ID NO: 12 Amino acid sequences having one or more site substitutions, deletions or insertions compared to the amino acid sequence shown;
  • VL FR2 comprises the amino acid sequence shown in SEQ ID NO: 13, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 13, or an amino acid sequence with SEQ ID NO: 13
  • the amino acid sequence shown has one or more site substitutions, deletions or insertions compared to the amino acid sequence;
  • VL FR3 comprises the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:32, or has at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:32 A non-specific amino acid sequence, or an amino acid sequence with one or more site substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 32;
  • VL FR4 comprises the amino acid sequence shown in SEQ ID NO: 14, or an amino acid sequence having at least 90% sequence identity compared to the amino acid sequence shown in SEQ ID NO: 14, or an amino acid sequence with SEQ ID NO: 14
  • the amino acid sequences shown are compared to amino acid sequences having one or more site substitutions, deletions or insertions.
  • the antibody or its antigen-binding unit specifically binds folate receptor alpha, and comprises:
  • VH FR1 comprises the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 29, or has at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 29 A non-specific amino acid sequence, or an amino acid sequence having one or more substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 29; and
  • VH FR2 comprises the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:30, or has at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:30 A non-specific amino acid sequence, or an amino acid sequence having one or more substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 30; and
  • VH FR3 comprises the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:31, or has at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:31 A non-specific amino acid sequence, or an amino acid sequence having one or more substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 31; and
  • VH FR4 comprises the amino acid sequence shown in SEQ ID NO: 11, or an amino acid sequence having at least 90% sequence identity compared to the amino acid sequence shown in SEQ ID NO: 11, or an amino acid sequence with SEQ ID NO: 11
  • the amino acid sequence shown has one or more site substitutions, deletions or insertions compared to the amino acid sequence; and/or
  • VL FR1 comprises the amino acid sequence shown in SEQ ID NO: 12, or an amino acid sequence having at least 90% sequence identity compared to the amino acid sequence shown in SEQ ID NO: 12, or an amino acid sequence with SEQ ID NO: 12 Amino acid sequences having one or more site substitutions, deletions or insertions compared to the amino acid sequence shown; and
  • VL FR2 comprises the amino acid sequence shown in SEQ ID NO: 13, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 13, or an amino acid sequence with SEQ ID NO: 13 Amino acid sequences having one or more site substitutions, deletions or insertions compared to the amino acid sequence shown; and
  • VL FR3 comprises the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:32, or has at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:32 A non-specific amino acid sequence, or an amino acid sequence having one or more substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 32; and
  • VL FR4 comprises the amino acid sequence shown in SEQ ID NO: 14, or an amino acid sequence having at least 90% sequence identity compared to the amino acid sequence shown in SEQ ID NO: 14, or an amino acid sequence with SEQ ID NO: 14
  • the amino acid sequences shown are compared to amino acid sequences having one or more site substitutions, deletions or insertions.
  • the antibody or its antigen-binding unit comprises VH FR1 as shown in SEQ ID NO:1, VH FR2 as shown in SEQ ID NO:2, VH FR2 as shown in SEQ ID NO:3 VH FR3 and VH FR4 as shown in SEQ ID NO:11.
  • the antibody or its antigen-binding unit comprises VL FR1 as shown in SEQ ID NO: 12, VL FR2 as shown in SEQ ID NO: 13, VL FR2 as shown in SEQ ID NO: 4 VL FR3 and VL FR4 as shown in SEQ ID NO:14.
  • the antibody or its antigen-binding unit comprises VHFR1 as shown in SEQ ID NO:1, VHFR2 as shown in SEQ ID NO:2, VHFR2 as shown in SEQ ID NO:3 VH FR3, VH FR4 as shown in SEQ ID NO:11, VL FR1 as shown in SEQ ID NO:12, VL FR2 as shown in SEQ ID NO:13, VL FR3 as shown in SEQ ID NO:4 and VL FR4 as shown in SEQ ID NO:14.
  • the antibody or its antigen binding unit comprises VHFR1 as shown in SEQ ID NO:29, VHFR2 as shown in SEQ ID NO:30, VHFR2 as shown in SEQ ID NO:31 VH FR3 and VH FR4 as shown in SEQ ID NO: 11.
  • the antibody or its antigen binding unit comprises VL FR1 as shown in SEQ ID NO: 12, VL FR2 as shown in SEQ ID NO: 13, VL FR2 as shown in SEQ ID NO: 32 VL FR3 and VL FR4 as shown in SEQ ID NO:14.
  • the antibody or its antigen binding unit comprises VHFR1 as shown in SEQ ID NO:29, VHFR2 as shown in SEQ ID NO:30, VHFR2 as shown in SEQ ID NO:31 VH FR3, VH FR4 as shown in SEQ ID NO:11, VL FR1 as shown in SEQ ID NO:12, VL FR2 as shown in SEQ ID NO:13, VL FR3 as shown in SEQ ID NO:32 and VL FR4 as shown in SEQ ID NO:14.
  • the present invention provides an antibody or an antigen-binding unit thereof, which specifically binds folate receptor ⁇ , and comprises a heavy chain variable region (VH) and/or or light chain variable region (VL), wherein:
  • the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 15, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 15, or an amino acid sequence with SEQ ID NO: Compared with the amino acid sequence shown in 15, there is an amino acid sequence with one or more site substitutions, deletions or insertions; and/or
  • the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 16, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 16, or an amino acid sequence with SEQ ID NO: Compared with the amino acid sequence shown in 16, there is one or more amino acid sequences with substitution, deletion or insertion.
  • the antibody or antigen binding unit thereof comprises a heavy chain variable region as set forth in SEQ ID NO: 15 and a light chain variable region as set forth in SEQ ID NO: 16.
  • the antibody or antigen-binding unit thereof further comprises a heavy chain constant region, a light chain constant region, an Fc region, or a combination thereof.
  • the light chain constant region is a kappa or lambda chain constant region.
  • the antibody or antigen binding unit thereof is of an isotype of IgG, IgM, IgA, IgE or IgD.
  • the isotype is IgGl, IgG2, IgG3 or IgG4.
  • the antibody or antigen-binding unit thereof is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody.
  • the antibody or antigen binding unit thereof is scFv, Fab, Fab' or F(ab) 2 . In one or more embodiments, the antibody or antigen-binding unit thereof is a monoclonal antibody.
  • the antibody or antigen binding unit thereof comprises a heavy chain constant region (CH) and/or a light chain constant region (CL), wherein:
  • the heavy chain constant region comprises an amino acid sequence as shown in SEQ ID NO: 17, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 17, or an amino acid sequence with SEQ ID NO: Compared with the amino acid sequence shown in 17, the amino acid sequence having one or more site substitutions, deletions or insertions; and/or
  • the light chain constant region comprises an amino acid sequence as shown in SEQ ID NO: 18, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 18, or an amino acid sequence with SEQ ID NO:
  • the amino acid sequence shown in 18 has one or more substitutions, deletions or insertions compared to the amino acid sequence.
  • the antibody or antigen binding unit thereof comprises a heavy chain constant region as set forth in SEQ ID NO: 17 and a light chain constant region as set forth in SEQ ID NO: 18.
  • the invention provides an antibody specifically binding folate receptor ⁇ , the heavy chain of the antibody comprising the heavy chain variable region shown in SEQ ID NO: 15 and the heavy chain variable region shown in SEQ ID NO: The heavy chain constant region shown in 17; the light chain of the antibody comprises the light chain variable region shown in SEQ ID NO: 16 and the light chain constant region shown in SEQ ID NO: 18.
  • the invention provides an antibody that specifically binds folate receptor alpha, and the antibody comprises a heavy chain (H) and a light chain (L), wherein:
  • the heavy chain comprises an amino acid sequence as shown in SEQ ID NO: 19, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 19, or an amino acid sequence with the amino acid sequence shown in SEQ ID NO: 19 Amino acid sequences having one or more site substitutions, deletions or insertions compared to the amino acid sequence shown; and/or
  • the light chain comprises an amino acid sequence as shown in SEQ ID NO: 20, or an amino acid sequence having at least 90% sequence identity compared with the amino acid sequence shown in SEQ ID NO: 20, or an amino acid sequence with the amino acid sequence shown in SEQ ID NO: 20 Amino acid sequences having one or more site substitutions, deletions or insertions compared to the amino acid sequences shown.
  • the antibody comprises a heavy chain set forth in SEQ ID NO: 19 and a light chain set forth in SEQ ID NO: 20.
  • the substitutions are conservative amino acid substitutions.
  • the antibody or antigen binding unit thereof is chimeric, humanized or fully human.
  • the antibody or antigen-binding unit thereof is a monoclonal antibody (including a full-length monoclonal antibody), a multispecific antibody or an antigen-binding unit thereof (e.g., a bispecific antibody or an antigen-binding unit thereof) ).
  • the antibodies have two heavy chains of identical sequence and two light chains of identical sequence.
  • the Fc regions pair to form disulfide bonds.
  • an antibody or antigen-binding unit thereof of the invention is an isolated antibody or antigen-binding unit thereof.
  • an antibody of the invention or an antigen-binding unit thereof, is a monoclonal antibody or fragment thereof.
  • the present invention also provides a biological material for
  • An expression vector comprising a polynucleotide encoding the antibody of the present invention or an antigen-binding unit thereof; or,
  • a cell comprising one or more polynucleotides encoding the antibody of the present invention or an antigen-binding unit thereof.
  • the present invention also provides a pharmaceutical composition comprising the antibody or antigen-binding unit thereof provided in the present invention.
  • a pharmaceutical composition comprising the antibody or antigen-binding unit thereof provided in the present invention.
  • These compositions may be included in kits, such as diagnostic kits.
  • the present invention also provides methods for alleviating or treating symptoms of cancer or other disorders by administering to a patient one or more folate receptor alpha-binding antibodies or antigen-binding units thereof in need thereof.
  • the antibody is administered in a dose sufficient to alleviate or treat the symptoms of cancer or other disorders in the patient.
  • the patient is a human.
  • the anti-FR ⁇ antibodies of the invention are used in combination with one or more other therapies.
  • Suitable additional therapies include drugs, radiotherapy and/or surgical therapies already available for a particular application (eg, cancer).
  • the anti-FR ⁇ antibody is used in combination with one or more other chemotherapeutic or antineoplastic agents.
  • the other chemotherapy is radiation therapy.
  • the chemotherapeutic agent is a cell death inducer.
  • the anti-FR ⁇ antibody and other agent are formulated as a single therapeutic composition and the anti-FR ⁇ antibody and other agent are administered simultaneously.
  • the anti-FR ⁇ antibody and other agent are independent of each other, for example prepared as separate therapeutic compositions, and the anti-FR ⁇ antibody and other agent are administered at the same time, or the anti-FR ⁇ antibody and other agent are administered at different times during the treatment regimen.
  • other reagents for example, the anti-FR ⁇ antibody is administered before the other agent, the anti-FR ⁇ antibody is administered after the other agent, or the anti-FR ⁇ antibody and the other agent are administered on an alternating schedule.
  • the anti-FR ⁇ antibodies and other agents are administered in a single dose or in multiple doses.
  • the present invention also provides an antibody-drug conjugate (ADC), which comprises the antibody or its antigen-binding unit of the present invention coupled to a drug through a linker, or a pharmaceutically acceptable Accepted salts or solvates.
  • ADC antibody-drug conjugate
  • the linker is a cleavable linker.
  • the drug is an anticancer drug, a cytotoxic drug, a cell differentiation factor, a stem cell trophic factor, a steroid drug, a drug for treating an autoimmune disease, an anti-inflammatory drug or a drug for treating an infectious disease .
  • the drug is an anticancer drug.
  • the drug is a tubulin inhibitor, a DNA damaging agent, or a DNA topoisomerase inhibitor.
  • the tubulin inhibitor is selected from dolastatin, auristatin, and maytansine.
  • the drug is auristatin (auristatin), selected from monomethyl auristatin E (monomethyl auristatin E; MMAE), monomethyl auristatin F (monomethyl auristatin F; MMAF) or auristatin (auristatin F; AF).
  • auristatin selected from monomethyl auristatin E (monomethyl auristatin E; MMAE), monomethyl auristatin F (monomethyl auristatin F; MMAF) or auristatin (auristatin F; AF).
  • the drug is a DNA damaging agent, such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine and diazepines).
  • a DNA damaging agent such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine and diazepines).
  • the drug is a DNA topoisomerase inhibitor or a salt thereof, such as irinotecan, irinotecan hydrochloride, exinotecan derivatives, camptothecin, 9-amino Camptothecin, 9-nitrocamptothecin, 10-hydroxycamptothecin, 9-chloro-10-hydroxycamptothecin, camptothecin derivatives SN-38, 22-hydroxycamptothecin, topose Kang, Letotecan, Belotecan, Exitecan, Homosilatecan, 6,8-Dibromo-2-methyl-3-[2-(D-xylopyranosyl Amino)phenyl]-4(3H)-quinazolinone, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-(2E)-2-propene Amide, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(3E)-2-propen
  • the DNA topoisomerase inhibitor is camptothecin, 10-hydroxycamptothecin, topotecan, belotecan, irinotecan, 22-hydroxycamptothecin Or Exitecan.
  • the drug has an amino group or an amino group substituted by an alkyl group, which is connected to the linker through an amide bond.
  • the drug is or its stereoisomers, wherein
  • X 1 and X 2 are each independently:
  • amino amino substituted by an amino protecting group
  • C1-C6 aminoalkyl optionally substituted by an amino protecting group or C1-C6 alkyl at the amino portion
  • C1-C6 alkyl connected to a heterocycle optionally substituted by one or more C1-C6 alkyl, C1-C6 alkoxy, amino, halogen, nitro or cyano,
  • An amino-substituted heterocyclic group which is optionally substituted by a protecting group or one or more C1-C6 alkyl groups at the nitrogen atom of the heterocyclic part or the amino part,
  • Heterocyclic amino which is optionally substituted by a protecting group or a C1-C6 alkyl group at the nitrogen atom of the heterocyclic part or the amino part,
  • a carbamoyl group optionally substituted by a carbamoyl protecting group or a C1-C6 alkyl group,
  • X 3 is C1-C6 alkyl
  • X 4 is H, -(CH 2 ) q -CH 3 , -(CHR n ) q -CH 3 , C3-C8 carbocyclyl, -O-(CH 2 ) q -CH 3 , arylene group -CH 3 , -(CH 2 ) q -arylene-CH 3 , -arylene-(CH 2 ) q -CH 3 , -(CH 2 ) q -(C3-C8 carbocyclyl)-CH 3 , -( C3-C8 carbocyclyl)-(CH 2 ) q -CH 3 , C3-C8 heterocyclyl, -(CH 2 ) q -(C3-C8 heterocyclyl)-CH 3 , -(C3-C8 heterocyclyl base)-(CH 2 ) q -CH 3 , -(CH 2 ) q C(O)NR n (CH 2 )
  • y 0, 1 or 2;
  • Y is O, S or CR 1 R 2 , wherein R 1 and R 2 are each independently H or C1-C6 alkyl;
  • s and t are each independently 0, 1 or 2, but not 0 at the same time.
  • X 4 is H or C1-C6 alkyl.
  • the heterocycle is azetidine, niverazine, morpholine, pyrrolidine, piperidine, imidazole, thiazole, oxazole, or pyridine.
  • the amino protecting group is formyl, acetyl, trityl, tert-butoxycarbonyl, benzyl or p-methoxybenzyloxycarbonyl.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to the linker.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to the linker.
  • X 1 and X 2 are each —CH 3 .
  • X and X are each independently F, Cl, Br or I.
  • X and X are each F.
  • X 1 and X 2 are each independently —CH 3 , F, or —OH.
  • X 1 and X 2 are each independently F or —CH 3 .
  • X 1 is —CH 3 and X 2 is F.
  • the antibody drug conjugate provided by the present invention has the structure shown in formula I, or a stereoisomer, or a pharmaceutically acceptable salt or solvate thereof:
  • Abu is an antibody or its antigen-binding unit; the antibody or its antigen-binding unit specifically binds folate receptor ⁇ ; D is a drug;
  • R is selected from: -(CH 2 ) r -, -(CHR m ) r -, C3-C8 carbocyclyl, -O-(CH 2 ) r -, arylene , -(CH 2 ) r -arylene-, -arylene-(CH 2 )r-, -(CH 2 ) r -(C3-C8 carbocyclyl)-, -(C3-C8 carbocyclyl )-(CH 2 ) r -, C3-C8 heterocyclyl, -(CH 2 ) r -(C3-C8 heterocyclyl)-, -(C3-C8 heterocyclyl)-(CH 2 ) r -, -(CH 2 ) r C(O)NR m (CH 2 ) r -, -(CH 2 CH 2 O) r -, -
  • L is -(AA) i -(FF) f -, wherein, AA is an amino acid or a polypeptide, and i is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; each FF is independently Wherein each R F is independently C1-C6 alkyl, C1-C6 alkoxy, -NO 2 or halogen; z is 0, 1, 2, 3 or 4; f is 1, 2, 3, 4, 5, 6 , 7, 8, 9 or 10; where * connects to AA, ** connects to D;
  • n is an integer of 1-24, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;
  • p is an integer of 1-10, eg 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the drugs are anticancer drugs, cytotoxic drugs, cell differentiation factors, stem cell trophic factors, steroid drugs, drugs for treating autoimmune diseases, anti-inflammatory drugs or drugs for treating infectious diseases.
  • the drug is an anticancer drug.
  • the drug is a tubulin inhibitor, a DNA damaging agent, or a DNA topoisomerase inhibitor.
  • the tubulin inhibitor is selected from dolastatins, auristatins, and maytansines.
  • the drug is an auristatin such as MMAE, MMAF or AF.
  • the drug is a DNA damaging agent, such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • a DNA damaging agent such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • the drug is a DNA topoisomerase inhibitor or a salt thereof, such as irinotecan, irinotecan hydrochloride, camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin Camptothecin, 10-hydroxycamptothecin, 9-chloro-10-hydroxycamptothecin, camptothecin derivatives SN-38, 22-hydroxycamptothecin, topotecan, letotecan, belo Tecan, Exitecan, Exitecan Derivatives, Homosilatecan, 6,8-Dibromo-2-methyl-3-[2-(D-xylopyranosylamino) Phenyl]-4(3H)-quinazolinone, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-(2E)-2-acrylamide, 2-cyano-3-(3,4-dihydroxyphenyl)-
  • the DNA topoisomerase inhibitor is camptothecin, 10-hydroxycamptothecin, topotecan, belotecan, irinotecan, 22-hydroxycamptothecin Or Exitecan.
  • the drug is Tubulysins, taxane drug derivatives, leptomycine derivatives, CC-1065 and its analogs, Amatoxins, splice body inhibitors, benzo (and) diazepines (PBD ) dimers, doxorubicin, methotrexate, vincristine, vinblastine, daunorubicin, mitomycin C, melphalan or chlorambucil derivatives.
  • PBD diazepines
  • the drug has an amino group or an amino group substituted with an alkyl group, which is linked to FF through an amide bond.
  • the drug is in one or more embodiments.
  • X 1 and X 2 are each independently:
  • amino amino substituted by an amino protecting group
  • C1-C6 aminoalkyl optionally substituted by an amino protecting group or C1-C6 alkyl at the amino portion
  • C1-C6 alkyl connected to a heterocycle optionally substituted by one or more C1-C6 alkyl, C1-C6 alkoxy, amino, halogen, nitro or cyano,
  • An amino-substituted heterocyclic group which is optionally substituted by a protecting group or one or more C1-C6 alkyl groups at the nitrogen atom of the heterocyclic part or the amino part,
  • Heterocyclic amino which is optionally substituted by a protecting group or a C1-C6 alkyl group at the nitrogen atom of the heterocyclic part or the amino part,
  • a carbamoyl group optionally substituted by a carbamoyl protecting group or a C1-C6 alkyl group,
  • X 3 is C1-C6 alkyl
  • X 4 is H, -(CH 2 ) q -CH 3 , -(CHR n ) q -CH 3 , C3-C8 carbocyclyl, -O-(CH 2 ) q -CH 3 , arylene group -CH 3 , -(CH 2 ) q -arylene-CH 3 , -arylene-(CH 2 ) q -CH 3 , -(CH 2 ) q -(C3-C8 carbocyclyl)-CH 3 , -( C3-C8 carbocyclyl)-(CH 2 ) q -CH 3 , C3-C8 heterocyclyl, -(CH 2 ) q -(C3-C8 heterocyclyl)-CH 3 , -(C3-C8 heterocyclyl base)-(CH 2 ) q -CH 3 , -(CH 2 ) q C(O)NR n (CH 2 )
  • y 0, 1 or 2;
  • Y is O, S or CR 1 R 2 , wherein R 1 and R 2 are each independently H or C1-C6 alkyl;
  • s and t are each independently 0, 1 or 2, but not 0 at the same time.
  • X 4 is H or C1-C6 alkyl.
  • the heterocycle is azetidine, niverazine, morpholine, pyrrolidine, piperidine, imidazole, thiazole, oxazole, or pyridine.
  • the amino protecting group is formyl, acetyl, trityl, tert-butoxycarbonyl, benzyl or p-methoxybenzyloxycarbonyl.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to L.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to L.
  • X 1 and X 2 are each —CH 3 .
  • X and X are each independently F, Cl, Br or I.
  • X and X are each F.
  • X 1 and X 2 are each independently —CH 3 , F, or —OH.
  • X 1 and X 2 are each independently F or —CH 3 .
  • X 1 is —CH 3 and X 2 is F.
  • R is -(CH 2 ) r -.
  • R is -(CH 2 ) r -, and r is 1 or 5.
  • each AA is independently selected from the following amino acid or peptide sequences: Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile -Cit, Trp, Cit, Phe-Ala, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala - Leu-Ala-Leu, ⁇ -Ala-Leu-Ala-Leu and Gly-Phe-Leu-Gly.
  • AA is Val-Cit and i is 1.
  • each FF is independently Wherein each R F is independently C1-C6 alkyl, C1-C6 alkoxy, -NO 2 or halogen; wherein * is connected to AA, ** is connected to D.
  • halo is F and z is 0, 1, 2, 3 or 4.
  • R F is -CH 3 , F, -NO 2 or -OCH 3 .
  • z is 0.
  • z is 1 or 2.
  • each FF is independently Among them, * is connected to AA, and ** is connected to D.
  • f is 1.
  • FF is f is 1; where * connects to AA, ** connects to D.
  • L is Where * connects to B, ** connects to D.
  • L is Where * connects to B, ** connects to D.
  • G is n is 4-12.
  • n is 4-8.
  • n 4.
  • n 8.
  • p is 2-8.
  • p is 4-8.
  • p is 6-8.
  • p is 7-8.
  • p is 7.
  • p 7.4.
  • p is 8.
  • the Abu is an antibody or an antigen-binding unit thereof provided by the present invention.
  • the antibody drug conjugate has the structure shown in formula I-1 or its stereoisomer or pharmaceutically acceptable salt or solvate:
  • Abu is an antibody or an antigen-binding unit thereof provided by the present invention.
  • R is selected from: -(CH 2 ) r -, -(CHR m )r-, C3-C8 carbocyclyl, -O-(CH 2 ) r -, arylene, -(CH 2 ) r -arylene Base-, -arylene-(CH 2 )r-, -(CH 2 ) r -(C3-C8 carbocyclyl)-, -(C3-C8 carbocyclyl)-(CH 2 ) r -, C3 -C8 heterocyclyl, -(CH 2 ) r -(C3-C8 heterocyclyl)-, -(C3-C8 heterocyclyl)-(CH 2 ) r -, -(CH 2 ) r C(O) NR m (CH 2 ) r -, -(CH 2 CH 2 O) r -, -(CH 2 CH 2 O) r -CH 2 -
  • D is a drug
  • n is an integer of 1-24, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23 or 24;
  • p is 1-10, eg 1, 2, 3, 4, 5, 6, 7, 7.4, 8, 9 or 10.
  • the drugs are anticancer drugs, cytotoxic drugs, cell differentiation factors, stem cell trophic factors, steroid drugs, drugs for treating autoimmune diseases, anti-inflammatory drugs or drugs for treating infectious diseases.
  • the drug is a tubulin inhibitor, a DNA damaging agent, or a DNA topoisomerase inhibitor.
  • the tubulin inhibitor is selected from dolastatin, auristatins and maytansines.
  • the drug is an auristatin such as MMAE, MMAF or AF.
  • the drug is a DNA damaging agent, such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • a DNA damaging agent such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • the drug is a DNA topoisomerase inhibitor or a salt thereof, such as irinotecan, irinotecan hydrochloride, camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin Camptothecin, 10-hydroxycamptothecin, 9-chloro-10-hydroxycamptothecin, camptothecin derivatives SN-38, 22-hydroxycamptothecin, topotecan, letotecan, belo Tecan, Exitecan, Homosilatecan, 6,8-Dibromo-2-methyl-3-[2-(D-xylopyranosylamino)phenyl]-4(3H )-quinazolone, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-(2E)-2-acrylamide, 2-cyano-3- (3,4-dihydroxyphenyl)-N-(3-hydroxyphenylprop
  • the DNA topoisomerase inhibitor is camptothecin, 10-hydroxycamptothecin, topotecan, belotecan, irinotecan, 22-hydroxycamptothecin Or Exitecan.
  • the drug is Tubulysins, taxane drug derivatives, leptomycine derivatives, CC-1065 and its analogs, Amatoxins, splice body inhibitors, benzo (and) diazepines (PBD ) dimers, doxorubicin, methotrexate, vincristine, vinblastine, daunorubicin, mitomycin C, melphalan, or chlorambucil derivatives.
  • PBD diazepines
  • the drug is in one or more embodiments.
  • X 1 and X 2 are each independently:
  • amino amino substituted by an amino protecting group
  • C1-C6 aminoalkyl optionally substituted by an amino protecting group or C1-C6 alkyl at the amino portion
  • C1-C6 alkyl connected to a heterocycle optionally substituted by one or more C1-C6 alkyl, C1-C6 alkoxy, amino, halogen, nitro or cyano,
  • An amino-substituted heterocyclic group which is optionally substituted by a protecting group or one or more C1-C6 alkyl groups at the nitrogen atom of the heterocyclic part or the amino part,
  • Heterocyclic amino which is optionally substituted by a protecting group or a C1-C6 alkyl group at the nitrogen atom of the heterocyclic part or the amino part,
  • a carbamoyl group optionally substituted by a carbamoyl protecting group or a C1-C6 alkyl group,
  • X 3 is C1-C6 alkyl
  • X 4 is H, -(CH 2 ) q -CH 3 , -(CHR n ) q -CH 3 , C3-C8 carbocyclyl, -O-(CH 2 ) q -CH 3 , arylene group -CH 3 , -(CH 2 ) q -arylene-CH 3 , -arylene-(CH 2 ) q -CH 3 , -(CH 2 ) q -(C3-C8 carbocyclyl)-CH 3 , -( C3-C8 carbocyclyl)-(CH 2 ) q -CH 3 , C3-C8 heterocyclyl, -(CH 2 ) q -(C3-C8 heterocyclyl)-CH 3 , -(C3-C8 heterocyclyl base)-(CH 2 ) q -CH 3 , -(CH 2 ) q C(O)NR n (CH 2 )
  • y 0, 1 or 2;
  • Y is O, S or CR 1 R 2 , wherein R 1 and R 2 are each independently H or C1-C6 alkyl;
  • s and t are each independently 0, 1 or 2, but not 0 at the same time.
  • X 4 is H or C1-C6 alkyl.
  • the heterocycle is azetidine, acetalzine, morpholine, pyrrolidine, piperidine, imidazole, thiazole, oxazole or pyridine.
  • the amino protecting group is formyl, acetyl, trityl, tert-butoxycarbonyl, benzyl or p-methoxybenzyloxycarbonyl.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • X 1 and X 2 are each —CH 3 .
  • X and X are each independently F, Cl, Br or I.
  • X and X are each F.
  • X 1 and X 2 are each independently —CH 3 , F, or —OH.
  • X 1 and X 2 are each independently F or —CH 3 .
  • X 1 is —CH 3 and X 2 is F.
  • R is -(CH 2 ) r -.
  • R is -(CH 2 ) r -, and r is 1 or 5.
  • n is 4-12.
  • n is 4-8.
  • n 4.
  • n 8.
  • p is 2-8.
  • p is 4-8.
  • p is 6-8.
  • p is 7-8.
  • p is 7.
  • p 7.4.
  • p is 8.
  • the antibody drug conjugate has the structure shown in formula I-2 or I-2-1 or its stereoisomer or pharmaceutically acceptable salt or solvate:
  • Abu is an antibody or an antigen-binding unit thereof provided by the present invention.
  • R is selected from: -(CH 2 ) r -, -(CHR m )r-, C3-C8 carbocyclyl, -O-(CH 2 ) r -, arylene, -(CH 2 ) r -arylene Base-, -arylene-(CH 2 )r-, -(CH 2 ) r -(C3-C8 carbocyclyl)-, -(C3-C8 carbocyclyl)-(CH 2 ) r -, C3 -C8 heterocyclyl, -(CH 2 ) r -(C3-C8 heterocyclyl)-, -(C3-C8 heterocyclyl)-(CH 2 ) r -, -(CH 2 ) r C(O) NR m (CH 2 ) r -, -(CH 2 CH 2 O) r -, -(CH 2 CH 2 O) r -CH 2 -
  • D is a drug
  • n is an integer of 1-24, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23 or 24;
  • p is 1-10, eg 1, 2, 3, 4, 5, 6, 7, 7.4, 8, 9 or 10.
  • the drugs are anticancer drugs, cytotoxic drugs, cell differentiation factors, stem cell trophic factors, steroid drugs, drugs for treating autoimmune diseases, anti-inflammatory drugs or drugs for treating infectious diseases.
  • the drug is a tubulin inhibitor, a DNA damaging agent, or a DNA topoisomerase inhibitor.
  • the tubulin inhibitor is selected from dolastatins, auristatins, and maytansines.
  • the drug is an auristatin such as MMAE, MMAF or AF.
  • the drug is a DNA damaging agent, such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • a DNA damaging agent such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • the drug is a DNA topoisomerase inhibitor or a salt thereof, such as irinotecan, irinotecan hydrochloride, camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin Camptothecin, 10-hydroxycamptothecin, 9-chloro-10-hydroxycamptothecin, camptothecin derivatives SN-38, 22-hydroxycamptothecin, topotecan, letotecan, belo Tecan, Exitecan, Homosilatecan, 6,8-Dibromo-2-methyl-3-[2-(D-xylopyranosylamino)phenyl]-4(3H )-quinazolone, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-(2E)-2-acrylamide, 2-cyano-3- (3,4-dihydroxyphenyl)-N-(3-hydroxyphenylprop
  • the DNA topoisomerase inhibitor is camptothecin, 10-hydroxycamptothecin, topotecan, belotecan, irinotecan, 22-hydroxycamptothecin Or Exitecan.
  • the drug is Tubulysins, taxane drug derivatives, leptomycine derivatives, CC-1065 and its analogs, Amatoxins, splice body inhibitors, benzo (and) diazepines (PBD ) dimers, doxorubicin, methotrexate, vincristine, vinblastine, daunorubicin, mitomycin C, melphalan, or chlorambucil derivatives.
  • PBD diazepines
  • the drug is in one or more embodiments.
  • X 1 and X 2 are each independently:
  • amino amino substituted by an amino protecting group
  • C1-C6 aminoalkyl optionally substituted by an amino protecting group or C1-C6 alkyl at the amino portion
  • C1-C6 alkyl connected to a heterocycle optionally substituted by one or more C1-C6 alkyl, C1-C6 alkoxy, amino, halogen, nitro or cyano,
  • An amino-substituted heterocyclic group which is optionally substituted by a protecting group or one or more C1-C6 alkyl groups at the nitrogen atom of the heterocyclic part or the amino part,
  • Heterocyclic amino which is optionally substituted by a protecting group or a C1-C6 alkyl group at the nitrogen atom of the heterocyclic part or the amino part,
  • a carbamoyl group optionally substituted by a carbamoyl protecting group or a C1-C6 alkyl group,
  • X 3 is C1-C6 alkyl
  • X 4 is H, -(CH 2 ) q -CH 3 , -(CHR n ) q -CH 3 , C3-C8 carbocyclyl, -O-(CH 2 ) q -CH 3 , arylene group -CH 3 , -(CH 2 ) q -arylene-CH 3 , -arylene-(CH 2 ) q -CH 3 , -(CH 2 ) q -(C3-C8 carbocyclyl)-CH 3 , -( C3-C8 carbocyclyl)-(CH 2 ) q -CH 3 , C3-C8 heterocyclyl, -(CH 2 ) q -(C3-C8 heterocyclyl)-CH 3 , -(C3-C8 heterocyclyl base)-(CH 2 ) q -CH 3 , -(CH 2 ) q C(O)NR n (CH 2 )
  • y 0, 1 or 2;
  • Y is O, S or CR 1 R 2 , wherein R 1 and R 2 are each independently H or C1-C6 alkyl;
  • s and t are each independently 0, 1 or 2, but not 0 at the same time.
  • X 4 is H or C1-C6 alkyl.
  • the heterocycle is azetidine, acetalzine, morpholine, pyrrolidine, piperidine, imidazole, thiazole, oxazole or pyridine.
  • the amino protecting group is formyl, acetyl, trityl, tert-butoxycarbonyl, benzyl or p-methoxybenzyloxycarbonyl.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • X 1 and X 2 are each —CH 3 .
  • X and X are each independently F, Cl, Br or I.
  • X and X are each F.
  • X 1 and X 2 are each independently —CH 3 , F, or —OH.
  • X 1 and X 2 are each independently F or —CH 3 .
  • X 1 is —CH 3 and X 2 is F.
  • R is -(CH 2 ) r -.
  • R is -(CH 2 ) r -, and r is 1 or 5.
  • n is 4-12.
  • n is 4-8.
  • n 4.
  • n 8.
  • p is 2-8.
  • p is 4-8.
  • p is 6-8.
  • p is 7-8.
  • p is 7.
  • p 7.4.
  • p is 8.
  • the antibody drug conjugate has the structure shown in formula I-3 or its stereoisomer or pharmaceutically acceptable salt or solvate:
  • Abu is an antibody or an antigen-binding unit thereof provided by the present invention.
  • D is a drug
  • n is an integer of 1-24, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23 or 24;
  • p is 1-10, eg 1, 2, 3, 4, 5, 6, 7, 7.4, 8, 9 or 10.
  • the drugs are anticancer drugs, cytotoxic drugs, cell differentiation factors, stem cell trophic factors, steroid drugs, drugs for treating autoimmune diseases, anti-inflammatory drugs or drugs for treating infectious diseases.
  • the drug is a tubulin inhibitor, a DNA damaging agent, or a DNA topoisomerase inhibitor.
  • the tubulin inhibitor is selected from dolastatin, auristatins and maytansines.
  • the drug is an auristatin such as MMAE, MMAF or AF.
  • the drug is a DNA damaging agent, such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • a DNA damaging agent such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • the drug is a DNA topoisomerase inhibitor or a salt thereof, such as irinotecan, irinotecan hydrochloride, camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin Camptothecin, 10-hydroxycamptothecin, 9-chloro-10-hydroxycamptothecin, camptothecin derivatives SN-38, 22-hydroxycamptothecin, topotecan, letotecan, belo Tecan, Exitecan, Homosilatecan, 6,8-Dibromo-2-methyl-3-[2-(D-xylopyranosylamino)phenyl]-4(3H )-quinazolone, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-(2E)-2-acrylamide, 2-cyano-3- (3,4-dihydroxyphenyl)-N-(3-hydroxyphenylprop
  • the DNA topoisomerase inhibitor is camptothecin, 10-hydroxycamptothecin, topotecan, belotecan, irinotecan, 22-hydroxycamptothecin Or Exitecan.
  • the drug is Tubulysins, taxane drug derivatives, leptomycine derivatives, CC-1065 and its analogs, Amatoxins, splice body inhibitors, benzo (and) diazepines (PBD ) dimers, doxorubicin, methotrexate, vincristine, vinblastine, daunorubicin, mitomycin C, melphalan, or chlorambucil derivatives.
  • PBD diazepines
  • the drug is in one or more embodiments.
  • X 1 and X 2 are each independently:
  • amino amino substituted by an amino protecting group
  • C1-C6 aminoalkyl optionally substituted by an amino protecting group or C1-C6 alkyl at the amino portion
  • C1-C6 alkyl connected to a heterocycle optionally substituted by one or more C1-C6 alkyl, C1-C6 alkoxy, amino, halogen, nitro or cyano,
  • An amino-substituted heterocyclic group which is optionally substituted by a protecting group or one or more C1-C6 alkyl groups at the nitrogen atom of the heterocyclic part or the amino part,
  • Heterocyclic amino which is optionally substituted by a protecting group or a C1-C6 alkyl group at the nitrogen atom of the heterocyclic part or the amino part,
  • a carbamoyl group optionally substituted by a carbamoyl protecting group or a C1-C6 alkyl group,
  • X 3 is C1-C6 alkyl
  • X 4 is H, -(CH 2 ) q -CH 3 , -(CHR n ) q -CH 3 , C3-C8 carbocyclyl, -O-(CH 2 ) q -CH 3 , arylene group -CH 3 , -(CH 2 ) q -arylene-CH 3 , -arylene-(CH 2 ) q -CH 3 , -(CH 2 ) q -(C3-C8 carbocyclyl)-CH 3 , -( C3-C8 carbocyclyl)-(CH 2 ) q -CH 3 , C3-C8 heterocyclyl, -(CH 2 ) q -(C3-C8 heterocyclyl)-CH 3 , -(C3-C8 heterocyclyl base)-(CH 2 ) q -CH 3 , -(CH 2 ) q C(O)NR n (CH 2 )
  • y 0, 1 or 2;
  • Y is O, S or CR 1 R 2 , wherein R 1 and R 2 are each independently H or C1-C6 alkyl;
  • s and t are each independently 0, 1 or 2, but not 0 at the same time.
  • X 4 is H or C1-C6 alkyl.
  • the heterocycle is azetidine, acetalzine, morpholine, pyrrolidine, piperidine, imidazole, thiazole, oxazole or pyridine.
  • the amino protecting group is formyl, acetyl, trityl, tert-butoxycarbonyl, benzyl or p-methoxybenzyloxycarbonyl.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • X 1 and X 2 are each —CH 3 .
  • X and X are each independently F, Cl, Br or I.
  • X and X are each F.
  • X 1 and X 2 are each independently —CH 3 , F, or —OH.
  • X 1 and X 2 are each independently F or —CH 3 .
  • X 1 is —CH 3 and X 2 is F.
  • n is 4-12.
  • n is 4-8.
  • n 4.
  • n 8.
  • p is 2-8.
  • p is 4-8.
  • p is 6-8.
  • p is 7-8.
  • p is 7.
  • p 7.4.
  • p is 8.
  • the antibody drug conjugate has the structure shown in formula I-4 or I-4-1 or its stereoisomer or pharmaceutically acceptable salt or solvate:
  • Abu is an antibody or an antigen-binding unit thereof provided by the present invention.
  • D is a drug
  • n is an integer of 1-24, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23 or 24;
  • p is 1-10, eg 1, 2, 3, 4, 5, 6, 7, 7.4, 8, 9 or 10.
  • the drugs are anticancer drugs, cytotoxic drugs, cell differentiation factors, stem cell trophic factors, steroid drugs, drugs for treating autoimmune diseases, anti-inflammatory drugs or drugs for treating infectious diseases.
  • the drug is a tubulin inhibitor, a DNA damaging agent, or a DNA topoisomerase inhibitor.
  • the tubulin inhibitor is selected from dolastatins, auristatins, and maytansines.
  • the drug is an auristatin such as MMAE, MMAF or AF.
  • the drug is a DNA damaging agent, such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, Aza), DNA topoisomerase inhibitors.
  • a DNA damaging agent such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, Aza), DNA topoisomerase inhibitors.
  • the drug is a DNA topoisomerase inhibitor or a salt thereof, such as irinotecan, irinotecan hydrochloride, camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin Camptothecin, 10-hydroxycamptothecin, 9-chloro-10-hydroxycamptothecin, camptothecin derivatives SN-38, 22-hydroxycamptothecin, topotecan, letotecan, belo Tecan, Exitecan, Homosilatecan, 6,8-Dibromo-2-methyl-3-[2-(D-xylopyranosylamino)phenyl]-4(3H )-quinazolone, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-(2E)-2-acrylamide, 2-cyano-3- (3,4-dihydroxyphenyl)-N-(3-hydroxyphenylprop
  • the DNA topoisomerase inhibitor is camptothecin, 10-hydroxycamptothecin, topotecan, belotecan, irinotecan, 22-hydroxycamptothecin Or Exitecan.
  • the drug is Tubulysins, taxane drug derivatives, leptomycine derivatives, CC-1065 and its analogs, Amatoxins, splice body inhibitors, benzo (and) diazepines (PBD ) dimers, doxorubicin, methotrexate, vincristine, vinblastine, daunorubicin, mitomycin C, melphalan, or chlorambucil derivatives.
  • PBD diazepines
  • the drug is in one or more embodiments.
  • X 1 and X 2 are each independently:
  • amino amino substituted by an amino protecting group
  • C1-C6 aminoalkyl optionally substituted by an amino protecting group or C1-C6 alkyl at the amino portion
  • C1-C6 alkyl connected to a heterocycle optionally substituted by one or more C1-C6 alkyl, C1-C6 alkoxy, amino, halogen, nitro or cyano,
  • An amino-substituted heterocyclic group which is optionally substituted by a protecting group or one or more C1-C6 alkyl groups at the nitrogen atom of the heterocyclic part or the amino part,
  • Heterocyclic amino which is optionally substituted by a protecting group or a C1-C6 alkyl group at the nitrogen atom of the heterocyclic part or the amino part,
  • a carbamoyl group optionally substituted by a carbamoyl protecting group or a C1-C6 alkyl group,
  • X 3 is C1-C6 alkyl
  • X 4 is H, -(CH 2 ) q -CH 3 , -(CHR n ) q -CH 3 , C3-C8 carbocyclyl, -O-(CH 2 ) q -CH 3 , arylene group -CH 3 , -(CH 2 ) q -arylene-CH 3 , -arylene-(CH 2 ) q -CH 3 , -(CH 2 ) q -(C3-C8 carbocyclyl)-CH 3 , -( C3-C8 carbocyclyl)-(CH 2 ) q -CH 3 , C3-C8 heterocyclyl, -(CH 2 ) q -(C3-C8 heterocyclyl)-CH 3 , -(C3-C8 heterocyclyl base)-(CH 2 ) q -CH 3 , -(CH 2 ) q C(O)NR n (CH 2 )
  • y 0, 1 or 2;
  • Y is O, S or CR 1 R 2 , wherein R 1 and R 2 are each independently H or C1-C6 alkyl;
  • s and t are each independently 0, 1 or 2, but not 0 at the same time.
  • X 4 is H or C1-C6 alkyl.
  • the heterocycle is azetidine, acetalzine, morpholine, pyrrolidine, piperidine, imidazole, thiazole, oxazole or pyridine.
  • the amino protecting group is formyl, acetyl, trityl, tert-butoxycarbonyl, benzyl or p-methoxybenzyloxycarbonyl.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • X 1 and X 2 are each independently —CH 3 , F, Cl, Br, or I.
  • X and X are each F.
  • X 1 and X 2 are each independently —CH 3 , F, or —OH.
  • X 1 and X 2 are each —CH 3 .
  • X 1 and X 2 are each independently F or —CH 3 .
  • X 1 is —CH 3 and X 2 is F.
  • n is 4-12.
  • n is 4-8.
  • n 4.
  • n 8.
  • p is 2-8.
  • p is 4-8.
  • p is 6-8.
  • p is 7-8.
  • p is 7.
  • p 7.4.
  • p is 8.
  • the antibody drug conjugate has the formula I-5, I-5-1, I-6, I-6-1, I-7, I-7-1, I- 8.
  • Abu is an antibody or an antigen-binding unit thereof provided by the present invention.
  • D is a drug
  • p is 1-10, eg 1, 2, 3, 4, 5, 6, 7, 7.4, 8, 9 or 10.
  • the drugs are anticancer drugs, cytotoxic drugs, cell differentiation factors, stem cell trophic factors, steroid drugs, drugs for treating autoimmune diseases, anti-inflammatory drugs or drugs for treating infectious diseases.
  • the drug is a tubulin inhibitor, a DNA damaging agent, or a DNA topoisomerase inhibitor.
  • the tubulin inhibitor is selected from dolastatins, auristatins, and maytansines.
  • the drug is an auristatin such as MMAE, MMAF or AF.
  • the drug is a DNA damaging agent, such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • a DNA damaging agent such as calicheamicins, duocarmycins, antramycin derivatives PBD (pyrrolobenzodiazepine, pyrrolobenzodiazepine, aza).
  • the drug is a DNA topoisomerase inhibitor or a salt thereof, such as irinotecan, irinotecan hydrochloride, camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin Camptothecin, 10-hydroxycamptothecin, 9-chloro-10-hydroxycamptothecin, camptothecin derivatives SN-38, 22-hydroxycamptothecin, topotecan, letotecan, belo Tecan, Exitecan, Homosilatecan, 6,8-Dibromo-2-methyl-3-[2-(D-xylopyranosylamino)phenyl]-4(3H )-quinazolone, 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-(2E)-2-acrylamide, 2-cyano-3- (3,4-dihydroxyphenyl)-N-(3-hydroxyphenylprop
  • the DNA topoisomerase inhibitor is camptothecin, 10-hydroxycamptothecin, topotecan, belotecan, irinotecan, 22-hydroxycamptothecin Or Exitecan.
  • the drug is Tubulysins, taxane drug derivatives, leptomycine derivatives, CC-1065 and its analogs, Amatoxins, splice body inhibitors, benzo (and) diazepines (PBD ) dimers, doxorubicin, methotrexate, vincristine, vinblastine, daunorubicin, mitomycin C, melphalan, or chlorambucil derivatives.
  • PBD diazepines
  • the drug is in one or more embodiments.
  • X 1 and X 2 are each independently:
  • amino amino substituted by an amino protecting group
  • C1-C6 aminoalkyl optionally substituted by an amino protecting group or C1-C6 alkyl at the amino portion
  • C1-C6 alkyl connected to a heterocycle optionally substituted by one or more C1-C6 alkyl, C1-C6 alkoxy, amino, halogen, nitro or cyano,
  • An amino-substituted heterocyclic group which is optionally substituted by a protecting group or one or more C1-C6 alkyl groups at the nitrogen atom of the heterocyclic part or the amino part,
  • Heterocyclic amino which is optionally substituted by a protecting group or a C1-C6 alkyl group at the nitrogen atom of the heterocyclic part or the amino part,
  • a carbamoyl group optionally substituted by a carbamoyl protecting group or a C1-C6 alkyl group,
  • X 3 is C1-C6 alkyl
  • X 4 is H, -(CH 2 ) q -CH 3 , -(CHR n ) q -CH 3 , C3-C8 carbocyclyl, -O-(CH 2 ) q -CH 3 , arylene group -CH 3 , -(CH 2 ) q -arylene-CH 3 , -arylene-(CH 2 ) q -CH 3 , -(CH 2 ) q -(C3-C8 carbocyclyl)-CH 3 , -( C3-C8 carbocyclyl)-(CH 2 ) q -CH 3 , C3-C8 heterocyclyl, -(CH 2 ) q -(C3-C8 heterocyclyl)-CH 3 , -(C3-C8 heterocyclyl base)-(CH 2 ) q -CH 3 , -(CH 2 ) q C(O)NR n (CH 2 )
  • y 0, 1 or 2;
  • Y is O, S or CR 1 R 2 , wherein R 1 and R 2 are each independently H or C1-C6 alkyl;
  • s and t are each independently 0, 1 or 2, but not 0 at the same time.
  • X 4 is H or C1-C6 alkyl.
  • the heterocycle is azetidine, acetalzine, morpholine, pyrrolidine, piperidine, imidazole, thiazole, oxazole or pyridine.
  • the amino protecting group is formyl, acetyl, trityl, tert-butoxycarbonyl, benzyl or p-methoxybenzyloxycarbonyl.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • the drug is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 1 and X 2 are each independently C1-C6 alkyl, halogen or -OH; ** is connected to other parts of the antibody drug conjugate.
  • the C1-C6 alkyl is -CH 3 .
  • the halogen is F.
  • X 1 and X 2 are each independently —CH 3 , F, or —OH.
  • X 1 and X 2 are each —CH 3 .
  • X and X are each independently F, Cl, Br or I.
  • X and X are each F.
  • X 1 and X 2 are each independently F or —CH 3 .
  • X 1 is —CH 3 and X 2 is F.
  • p is 2-8.
  • p is 4-8.
  • p is 6-8.
  • p is 7-8.
  • p is 7.
  • p 7.4.
  • p is 8.
  • the antibody drug conjugate has the formula I-12, I-12-1, I-13, I-13-1, I-14, I-14-1, I- 15. I-15-1, I-16, I-16-1, I-17, I-17-1, I-18, I-18-1, I-19, I-19-1, I- 20. I-20-1, I-21, I-21-1, I-22, I-22-1, I-23, I-23-1, I-24, I-24-1, I- 25. Or the structure shown in I-25-1 or its stereoisomer or pharmaceutically acceptable salt or solvate:
  • Abu is an antibody or an antigen-binding unit thereof provided by the present invention.
  • p is 1-10, eg 1, 2, 3, 4, 5, 6, 7, 7.4, 8, 9 or 10.
  • p is 2-8.
  • p is 4-8.
  • p is 6-8.
  • p is 7-8.
  • p is 7.
  • p 7.4.
  • p is 8.
  • the antibody drug conjugate in the medicament has a DAR(p) of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In one or more embodiments, the antibody drug conjugate in medicament has an average DAR(p) of 2-9. In one or more embodiments, the antibody drug conjugate in medicament has an average DAR(p) of 4-9. In one or more embodiments, the antibody drug conjugate in medicament has an average DAR(p) of 6-8.5. In one or more embodiments, the average DAR(p) of the antibody drug conjugate in medicament is 6-8. In one or more embodiments, the average DAR(p) of the antibody drug conjugate in medicament is 7-8.
  • the antibody drug conjugates of the invention are used in combination with one or more other therapies.
  • Suitable additional therapies include existing pharmaceutical and/or surgical therapies for a particular application, such as cancer.
  • the antibody drug conjugate is used in combination with one or more other chemotherapeutic or antineoplastic agents.
  • the other chemotherapeutic agent is radiation therapy.
  • the chemotherapeutic agent is a cell death inducer.
  • the antibody drug conjugate and other agent are prepared as a single therapeutic composition and the antibody drug conjugate and other agent are administered simultaneously.
  • the antibody drug conjugate and other reagents are independent of each other, for example, prepared as separate therapeutic compositions, and the antibody drug conjugate and other reagents are administered at the same time, or administered at different times during the treatment regimen.
  • Antibody drug conjugates and other reagents are administered before the other agent, the antibody drug conjugate is administered after the other agent, or the antibody drug conjugate and other agent are administered on an alternating schedule.
  • the antibody drug conjugates and other agents are administered in a single dose or in multiple doses.
  • the present invention also provides a pharmaceutical composition, which comprises the antibody of the present invention or its antigen-binding unit, or antibody-drug conjugate, as well as pharmaceutically acceptable carriers, excipients and / or excipients.
  • the pharmaceutical composition further comprises optional other anticancer drugs.
  • the pharmaceutical composition provided by the present invention can be administered by any convenient route, such as by infusion or bolus injection, absorbed through the epithelium or mucous membrane of the skin (such as oral mucosa, rectal and intestinal mucosa, etc.), and can be co-administered with other biologically active agents .
  • the pharmaceutical composition can be administered intravenously, orally, rectally, parenterally, intracerebrally, intravaginally, intraperitoneally, externally (e.g. by powder, ointment, drops, etc.) or transdermal patch), orally, or by oral or nasal spray.
  • the present invention provides the antibody or its antigen binding unit, biological material (selected from polynucleotides, expression vectors and cells), antibody drug conjugates, pharmaceutical compositions Use of at least one in the preparation of medicaments for treating and/or preventing diseases.
  • the disease is a disease associated with folate receptor alpha expression.
  • the disease is a disease associated with overexpression of folate receptor alpha.
  • the disease is a folate receptor alpha expressing tumor.
  • the disease is a tumor that overexpresses folate receptor alpha.
  • the disease is a folate receptor alpha expressing cancer.
  • the disease is a cancer that overexpresses folate receptor alpha.
  • the drug for treating tumors also includes other anticancer drugs.
  • the present invention provides antibodies or antigen-binding units thereof, biological materials (selected from polynucleotides, expression vectors, and cells), antibody-drug conjugates as described herein, and/or The application of the pharmaceutical composition in the treatment and/or prevention of diseases.
  • the disease is a disease associated with folate receptor alpha expression.
  • the disease is a disease associated with overexpression of folate receptor alpha.
  • the disease is a folate receptor alpha expressing tumor.
  • the disease is a tumor that overexpresses folate receptor alpha.
  • the disease is a folate receptor alpha expressing cancer.
  • the disease is a cancer that overexpresses folate receptor alpha.
  • the disease is cancer, autoimmune disease, inflammatory disease or infectious disease.
  • One or more embodiments provide a method for treating and/or preventing a disease, the method comprising administering to a patient in need an effective amount of an antibody or an antigen-binding unit thereof, a biological material (selected from polynucleotide , expression vectors and cells), antibody drug conjugates and/or pharmaceutical compositions comprising them.
  • the disease is a disease associated with folate receptor alpha expression.
  • the disease is a disease associated with overexpression of folate receptor alpha.
  • the disease is a folate receptor alpha expressing tumor.
  • the disease is a tumor that overexpresses folate receptor alpha.
  • the disease is a folate receptor alpha expressing cancer. In one or more embodiments, the disease is a cancer that overexpresses folate receptor alpha. In one or more embodiments, the effective amount refers to the amount of active compound or agent that results in the biological or pharmaceutical effect of a tissue, system, animal, individual, and human being sought by the researcher, veterinarian, physician, or other clinician. With response, this includes treating a disease.
  • cancer examples include, but are not limited to, solid tumors, hematological cancers, and metastatic lesions. Specific examples of such cancers include, but are not limited to, colorectal cancer, lung cancer, ovarian cancer, uterine cancer, endometrial cancer, peritoneal cancer, fallopian tube cancer, pancreatic cancer, squamous cell carcinoma of the head and neck, nasopharyngeal cancer, laryngeal cancer, lung adenocarcinoma Cancer, liver cancer, breast cancer, brain cancer, kidney cancer, renal cell carcinoma, colon cancer, testicular cancer, cervical cancer, bladder cancer, retinoblastoma, glioblastoma, mesothelioma, oral epithelioid carcinoma, Choriocarcinoma and head and neck cancer.
  • the antibody or its antigen-binding unit or antibody-drug conjugate can be formulated into a pharmaceutical composition and administered to the patient in a form suitable for the selected route of administration, such as gastrointestinal Topically, intravenously (iv), intramuscularly, topically or subcutaneously.
  • the dosage (such as a single dosage) of the antibody or its antigen-binding unit or antibody-drug conjugate is 1 mg/kg-10 mg/kg; or, 1.2 mg/kg -8.0mg/kg; alternatively, 1.2mg/kg-6.5mg/kg; alternatively, 1.2mg/kg-5.0mg/kg; alternatively, 1.2mg/kg-3.5mg/kg; alternatively, 1.2mg/kg-2.4 mg/kg; or, 2.4mg/kg-8.0mg/kg; or, 2.4mg/kg-6.5mg/kg; or, 2.4mg/kg-5.0mg/kg; or, 2.4mg/kg-3.5mg/kg kg; or, 3.5mg/kg-8.0mg/kg; or, 3.5mg/kg-6.5mg/kg; or, 3.5mg/kg-5.0mg/kg; or, 5.0mg/kg-8.0mg/kg; or, 5.0mg/kg-8.0mg/kg; or,
  • the dosage (such as a single dosage) of the antibody or its antigen-binding unit or antibody-drug conjugate is about 1 mg/kg, 1.2 mg/kg, 1.5 mg/kg , about 2.0mg/kg, 2.4mg/kg, about 3.0mg/kg, about 3.5mg/kg, about 4.0mg/kg, about 4.5mg/kg, about 5.0mg/kg, about 5.5mg/kg, about 6.0 mg/kg, about 6.5 mg/kg, about 7.0 mg/kg, about 7.5 mg/kg, about 8.0 mg/kg, about 8.5 mg/kg, about 9 mg/kg, about 10 mg/kg, or any two of these values range between values (inclusive) or any value therein.
  • the single administration dose of the antibody or its antigen-binding unit or antibody-drug conjugate is 1 mg/kg-10 mg/kg; or, 1.2 mg/kg-8.0 mg/kg; or, 1.2mg/kg-6.5mg/kg; or, 1.2mg/kg-5.0mg/kg; or, 1.2mg/kg-3.5mg/kg; or, 1.2mg/kg-2.4mg/kg; or, 2.4mg/kg-8.0mg/kg; or, 2.4mg/kg-6.5mg/kg; or, 2.4mg/kg-5.0mg/kg; or, 2.4mg/kg-3.5mg/kg; or, 3.5mg /kg-8.0mg/kg; or, 3.5mg/kg-6.5mg/kg; or, 3.5mg/kg-5.0mg/kg; or, 5.0mg/kg-8.0mg/kg; or, 5.0mg/kg-8.0mg/kg; or, 5.0mg/kg-8.0mg/
  • the single administration dose of the antibody or its antigen binding unit or antibody drug conjugate is about 1 mg/kg, 1.2 mg/kg, 1.5 mg/kg, about 2.0 mg/kg , 2.4mg/kg, about 3.0mg/kg, about 3.5mg/kg, about 4.0mg/kg, about 4.5mg/kg, about 5.0mg/kg, about 5.5mg/kg, about 6.0mg/kg, about 6.5 mg/kg, about 7.0 mg/kg, about 7.5 mg/kg, about 8.0 mg/kg, about 8.5 mg/kg, about 9 mg/kg, about 10 mg/kg, or a range between any two of these values (including endpoints) or any value in them.
  • the dosage of the antibody or its antigen-binding unit or antibody drug conjugate (for example, a single dosage) is 50 mg-1000 mg; or, 50 mg-600 mg; or, 60 mg- 600mg; or, 100mg-600mg; or, 72mg-480mg; or, 72mg-390mg; or, 72mg-300mg; or, 72mg-210mg; or, 72mg-144mg; or, 144mg-480mg; or, 144mg-300mg; or, 144mg-210mg; or, 210mg-480mg; or, 210mg-390mg; or, 210mg-300mg; or, 300mg-480mg; or, 300mg-390mg; or, 84mg-455mg; or, 84mg-350mg; or, 84mg-245mg; or, 84mg-168mg; or, 168mg-5
  • the antibody or its antigen-binding unit or antibody-drug conjugate is administered at a dosage (such as a single dosage) of about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg , about 72mg, about 80mg, about 84mg, about 90mg, about 95mg, about 100mg, about 105mg, about 110mg, about 120mg, about 130mg, about 140mg, about 144mg, about 145mg, about 150mg, about 155mg, about 160mg, about 165mg, about 168mg, about 170mg, about 175mg, about 180mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 245mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, About 300mg, about 310mg,
  • the single administration dose of the antibody or its antigen-binding unit or antibody drug conjugate is 50 mg-1000 mg; or, 50 mg-600 mg; or, 60 mg-600 mg; or, 100 mg- 600mg; or, 72mg-480mg; or, 72mg-390mg; or, 72mg-300mg; or, 72mg-210mg; or, 72mg-144mg; or, 144mg-480mg; or, 144mg-390mg; or, 144mg-210mg; or, 210mg-480mg; or, 210mg-390mg; or, 210mg-300mg; or, 300mg-480mg; or, 300mg-390mg; or, 390mg-480mg; 84mg-455mg; or, 84mg-350mg; or, 84mg-245mg; or, 84mg-168mg; or, 168mg-5
  • the single administration dose of the antibody or its antigen binding unit or antibody drug conjugate is about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 72 mg, about 84 mg , about 90mg, about 100mg, about 105mg, about 110mg, about 120mg, about 130mg, about 140mg, about 144mg, about 145mg, about 150mg, about 155mg, about 160mg, about 165mg, about 168mg, about 170mg, about 175mg, about 180mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 245mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 315mg, about 320mg, About 330mg, about 340mg, about
  • the method comprises at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 treatment cycles.
  • a treatment cycle is at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, or at least 7 weeks.
  • a treatment cycle is 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or the range between any two of these values (including endpoints ) or any value in it.
  • the antibody, or antigen-binding unit thereof, or antibody-drug conjugate is administered in a single dose.
  • the dose is administered every 2 days to once every 6 weeks.
  • the administration is administered twice in about 1 week, or administered once in about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, or about 7 weeks.
  • the administration is once every 2 days, once every 3 days, once every 4 days, once every 5 days, twice a week, once a week Dosing once, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks or once every 6 weeks.
  • the patient is treated for one treatment cycle. In one or more embodiments, the patient receives multiple (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) treatment cycles treat. In one or more embodiments, the patient is treated until the condition is in remission and no longer requires treatment.
  • the antibody or antigen-binding unit thereof or antibody-drug conjugate or pharmaceutical composition comprising the same is administered by injection.
  • the antibody or antigen binding unit thereof or antibody drug conjugate or pharmaceutical composition comprising the same is administered by subcutaneous (s.c.) injection, intraperitoneal (i.p.) injection, parenteral injection, arterial Administration by intravenous injection or intravenous (i.v.) injection.
  • the antibody or its antigen-binding unit or antibody-drug conjugate or pharmaceutical composition comprising the same is administered by infusion.
  • the antibody or its antigen-binding unit or antibody-drug conjugate or pharmaceutical composition comprising the same is administered by bolus injection.
  • the antibody or its antigen-binding unit or antibody-drug conjugate or pharmaceutical composition comprising the same is administered by intravenous injection. In one or more embodiments, the antibody or antigen binding unit thereof or antibody drug conjugate or pharmaceutical composition comprising the same is administered by intravenous infusion.
  • the amount of antibody or antigen-binding unit thereof or antibody drug conjugate administered will depend on the nature of the drug, the extent to which the cell surface triggers internalization, transport and release of the drug, and the disease being treated and the condition of the patient (e.g., age, sex, weight, etc.).
  • the antibody or antigen binding unit thereof or antibody drug conjugate or pharmaceutical composition comprising the same is administered by intravenous (i.v.) infusion (ie, intravenous infusion).
  • intravenous infusion ie, intravenous infusion
  • the duration of the intravenous infusion is about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 55 minutes, about 60 minutes , about 65 minutes, about 70 minutes, about 75 minutes, about 81 minutes, about 87 minutes, about 90 minutes, about 95 minutes, or a range between any two of these values (inclusive) or any value therein.
  • the intravenous infusion time is ⁇ 30 minutes.
  • the intravenous infusion time is > 60 minutes.
  • the intravenous infusion time is > 90 minutes.
  • the present invention provides a pharmaceutical composition suitable for injection, such as a bolus injection pharmaceutical composition or an infusion solution (drip) comprising the antibody or its antigen-binding unit or antibody drug conjugate type pharmaceutical composition.
  • Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include solvents or dispersion media of physiological saline, bacteriostatic water, or phosphate buffered saline (PBS), ethanol, polyalcohols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and suitable mixture.
  • the pharmaceutical composition further includes a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier may comprise antibacterial and/or antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • the pharmaceutically acceptable carrier may contain isotonic agents, such as sugars, polyalcohols (such as mannitol, sorbitol), sodium chloride.
  • the pharmaceutical composition comprises at least 0.1% of the antibody or its antigen-binding unit or antibody drug conjugate. The percentage of antibody can vary and is between about 2% and 90% by weight of a given dosage form. The amount of the antibody or its antigen-binding unit or antibody-drug conjugate in this pharmaceutical composition can be an effective amount for administration.
  • the present invention provides a method for preparing a pharmaceutical composition: separately combining the antibody or its antigen-binding unit or antibody-drug conjugate described herein with a pharmaceutically acceptable carrier (such as water for injection, saline, etc.) mixed.
  • a pharmaceutically acceptable carrier such as water for injection, saline, etc.
  • the method of mixing the above-mentioned antibody or its antigen-binding unit or antibody-drug conjugate with a pharmaceutically acceptable carrier is generally known in the art.
  • the present invention provides a kit comprising the antibody or its antigen-binding unit, antibody-drug conjugate or pharmaceutical composition comprising it described herein and instructions for guiding patient administration .
  • One or more embodiments also provide a product comprising the anti-FR ⁇ antibody of the present invention or its antigen-binding unit, antibody-drug conjugate, or a pharmaceutical composition comprising the same;
  • a package insert, instructions or label indicating that the anti-FR ⁇ antibody, antibody drug conjugate or pharmaceutical composition comprising the same of the present invention is used for treating and/preventing diseases related to the expression of folate receptor ⁇ .
  • antibodies of the invention have a variety of uses.
  • antibodies of the invention can be used as therapeutic agents, as reagents in diagnostic kits or as diagnostic tools, or as reagents in competition assays to generate therapeutic agents.
  • Figure 1 shows a schematic diagram of the ADC conjugation.
  • FIG. 1 shows the endocytosis of ADC1.
  • FIG. 3 shows the bystander effect of ADC1.
  • Figure 4 shows the tumor suppressive effect of ADC1 in vivo.
  • Figure 5 shows the tumor suppressive effect of ADC1 in vivo.
  • Figure 6 shows the growth curves (mean ⁇ standard error) of the tumor volume of mice in each group in the LU11554 xenograft model.
  • Figure 7 shows the growth curves (mean ⁇ standard error) of the tumor volume of mice in each group in the LU5197 xenograft model.
  • an entity refers to one or more such entities, for example "an antibody” should be understood as one or more antibodies, therefore, the term “a” (or “an” ), “one or more” and “at least one” may be used interchangeably herein.
  • the term “comprising” or “comprising” means that the antibody, composition or method, etc. includes the listed elements, such as components or steps, but does not exclude others.
  • “Consisting essentially of” means that the antibody, composition or method excludes other elements that have a fundamental influence on the characteristics of the combination, but does not exclude elements that have no essential influence on the antibody, composition or method.
  • Consisting of means excluding elements not specifically recited.
  • antibody refers to immunoglobulin (Ig) molecules and immunologically active portions of immunoglobulin molecules, ie, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen.
  • “Specific binding” or “immunoreactive” or “against” means that the antibody reacts with one or more epitopes of the target antigen and does not react with other polypeptides, or with very low affinity (KD>10 -6 g/ ml) combined with other polypeptides.
  • Antibodies include, but are not limited to, monoclonal antibodies, chimeric antibodies, dAbs (domain antibodies), single chain antibodies, Fab, Fab- and F(ab') 2 fragments, Fv and Fab expression libraries.
  • antibody includes a wide variety of polypeptides that can be distinguished biochemically.
  • classes of heavy chains include gamma, mu, alpha, delta or epsilon ( ⁇ , ⁇ , ⁇ , ⁇ , ⁇ ), with some subclasses (eg ⁇ 1- ⁇ 4).
  • the nature of this chain determines the "class” of the antibody as IgG, IgM, IgA, IgG or IgE, respectively.
  • the immunoglobulin subclasses (isotypes), eg, IgGl, IgG2, IgG3, IgG4, IgG5, etc., are well characterized and the functional specificities conferred are also known.
  • the immunoglobulin molecule is of the IgG class.
  • the two heavy chains and the two light chains are linked by disulfide bonds in a "Y" configuration, where the light chains begin at the mouth of the "Y” and continue through the variable region surrounding the heavy chains.
  • Antibodies, antigen binding units or derivatives disclosed in the present invention include but are not limited to polyclonal, monoclonal, multispecific, fully human, humanized, primatized, chimeric antibodies, single chain antibodies, epitope binding Fragments (eg Fab-like, Fab'-like and F(ab') 2- like), single-chain Fvs-like (scFv)-like.
  • Light chains can be classified as kappa ( ⁇ ) or lambda ( ⁇ ). Each heavy chain can be associated with a kappa or lambda light chain.
  • ⁇ kappa
  • lambda ⁇
  • Each heavy chain can be associated with a kappa or lambda light chain.
  • immunoglobulins are produced by hybridomas, B cells, or genetically engineered host cells, their light and heavy chains are joined by a covalent bond, and the "tail" portions of the two heavy chains are linked by a covalent disulfide bond or non-covalent bonding.
  • the amino acid sequence extends from the N-terminus at the forked end of the Y configuration to the C-terminus at the bottom of each chain.
  • the variable region of an immunoglobulin kappa light chain is V ⁇ ; the variable region of an immunoglobulin lambda light chain is V ⁇ .
  • variable region of the light chain (VL) and the variable region of the heavy chain (VH) determine antigen recognition and specificity.
  • the light chain constant region (CL) and the heavy chain constant region (CH) confer important biological properties such as secretion, transplacental movement, Fc receptor binding, complement fixation, etc.
  • the numbering of constant regions increases as they become farther away from the antigen-binding site or amino terminus of the antibody.
  • the N-terminal portion is the variable region and the C-terminal portion is the constant region; the CH3 and CL domains actually comprise the carboxy-terminal ends of the heavy and light chains, respectively.
  • each antigen-binding domain In naturally occurring antibodies, the six “complementarity determining regions" or “CDRs” present in each antigen-binding domain are short, A non-contiguous sequence of amino acids that specifically binds to an antigen. The remaining other amino acids in the antigen-binding domain, referred to as the "framework" regions, show less intermolecular variability.
  • the framework regions mostly adopt a ⁇ -sheet conformation, and the CDRs form loop structures attached to them, or in some cases form part of the ⁇ -sheet structure. Thus, the framework regions position the CDRs in the correct orientation by forming a scaffold through non-covalent interchain interactions.
  • the antigen-binding domain with the CDRs in specific positions forms a surface complementary to the epitope on the antigen that facilitates the non-covalent binding of the antibody to its antigenic epitope.
  • a surface complementary to the epitope on the antigen that facilitates the non-covalent binding of the antibody to its antigenic epitope.
  • those of ordinary skill in the art can identify the amino acids comprising CDR and framework regions by known methods (see Kabat, E., et al., U.S. Department of Health and Human Services, Sequences of Proteins of Immunological Interest, (1983) and Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987)).
  • mAb monoclonal antibody
  • CDRs complementarity determining regions
  • single-chain antibody refers to an antibody formed by linking the heavy chain variable region (VH) and the light chain variable region (VL) through a 15-20 amino acid linker.
  • Linkers can be rich in glycine for flexibility, and serine or threonine for solubility, and can link the N-terminus of VH to the C-terminus of VL, or vice versa.
  • the protein has had its constant regions removed and a linker introduced, it retains the specificity of the original immunoglobulin.
  • ScFv molecules are generally known in the art, for example as described in US Pat. No. 5,892,019.
  • antigen binding site or "binding portion” refers to that portion of an immunoglobulin molecule that is involved in antigen binding.
  • the antigen binding site is formed by the amino acid residues of the N-terminal variable (V) regions of the heavy (H) and light (L) chains.
  • VH heavy-chain variable region
  • VL light-chain variable region
  • FR framework region
  • FR amino acid sequences in immunoglobulins that occur naturally between or adjacent to hypervariable regions.
  • the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are arranged relative to each other in three-dimensional space to form an antigen-binding surface.
  • the antigen-binding surface is complementary to the three-dimensional surface of the bound antigen, and the three hypervariable regions of each heavy and light chain are referred to as "complementarity determining regions" or "CDRs.”
  • CDRs complementarity determining regions
  • the heavy chain variable region comprises VH FR1, VH CDR1, VH FR2, VH CDR2, VH FR3, VH CDR3, and VH FR4.
  • the light chain variable region comprises VL FR1 , VL CDR1 , VL FR2, VL CDR2, VL FR3, VL CDR3 and VL FR4.
  • the alignment of the amino acids of each domain can be compared with Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health (1987 and 1991)) or the article of Chothia and Lesk (J.Mol.Biol.196:901-917 (1987); Chothia et al., Nature 342:878-883 (1989)) agree with the definition.
  • the framework region and CDR region of the humanized antibody do not have to correspond exactly to the parental sequence, for example, the CDR or consensus framework of the donor antibody can be mutated by substitution, insertion and/or deletion of at least one amino acid residue, making the CDR at this site Or the framework residues do not correspond to the donor antibody or the consensus framework.
  • the term "consensus framework” refers to the framework regions in the consensus immunoglobulin sequences.
  • the term "consensus immunoglobulin sequence” refers to a sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related immunoglobulin sequences (see, e.g., Winnaker, From Genes to Clones [From Genes to Clones] to cloning] (Verlagsgesellschaft, Weinheim, Germany 1987)). In a family of immunoglobulins, each position in the consensus sequence is occupied by the amino acid in that family that occurs most frequently at that position. If two amino acids occur equally frequently, either can be included in the consensus sequence.
  • CDR complementarity determining regions
  • Kabat et al. also defined a numbering system applicable to the variable region sequences of any antibody.
  • One of ordinary skill in the art can apply this "Kabat numbering" system to any variable region sequence independently of other experimental data other than the sequence itself.
  • “Kabat numbering” refers to the numbering system proposed by Kabat et al., U.S. Dept. of Health and Human Services in "Sequence of Proteins of Immunological Interest” (1983).
  • Antibodies can also use the EU or Chothia numbering system.
  • Antibodies disclosed in the present invention may be derived from any animal, including but not limited to fish, birds and mammals.
  • the antibody is of human, murine, donkey, rabbit, goat, camel, llama, horse or chicken origin.
  • the variable regions may be of condricthoid origin (eg, from sharks).
  • a "heavy chain constant region” includes at least one of a CH1 domain, a hinge (eg, upper, middle, and/or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment.
  • the heavy chain constant regions of antibodies can be derived from different immunoglobulin molecules.
  • the heavy chain constant region of a polypeptide can include a CH1 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule.
  • the heavy chain constant region may comprise a hinge region derived partly from an IgG1 molecule and partly from an IgG3 molecule.
  • part of the heavy chain may comprise a chimeric hinge region derived partly from an IgGl molecule and partly from an IgG4 molecule.
  • a “light chain constant region” includes a portion of the amino acid sequence from an antibody light chain.
  • the light chain constant region comprises at least one of a constant kappa domain or a constant lambda domain.
  • a “light chain-heavy chain pair” refers to a collection of light and heavy chains that can form dimers through disulfide bonds between the CL domain of the light chain and the CH1 domain of the heavy chain.
  • a "VH domain” includes the amino-terminal variable domain of an immunoglobulin heavy chain.
  • a "CH1 domain” comprises the first constant region of an immunoglobulin heavy chain.
  • the CH2 domain is not closely paired with other domains, but rather two N-linked branched carbohydrate chains are inserted between the two CH2 domains of the intact native IgG molecule.
  • the CH3 domain extends from the CH2 domain to the C-terminus of the IgG molecule and contains approximately 108 residues.
  • a "hinge region” includes part of the heavy chain region connecting the CH1 domain and the CH2 domain.
  • the hinge region comprises approximately 25 residues and is flexible, allowing the two N-terminal antigen-binding regions to move independently.
  • the hinge region can be subdivided into three distinct domains: upper, middle and lower hinge domains (Roux et al., J. Immunol 161:4083 (1998)).
  • Disulfide bond refers to a covalent bond formed between two sulfur atoms.
  • a thiol group of cysteine can form a disulfide bond or bridge with a second thiol group.
  • the CH1 and CL regions are linked by a disulfide bond.
  • a “chimeric antibody” refers to any antibody whose variable regions are obtained or derived from a first species and whose constant regions (which may be complete, partial or modified) are derived from a second species.
  • the variable regions are of non-human origin (eg, mouse or primate) and the constant regions are of human origin.
  • epitope as used herein includes any determinant region of a protein capable of specifically binding to an immunoglobulin or fragment thereof or a T cell receptor.
  • Epitope-determining regions usually consist of chemically active surface groups of molecules (such as amino acids or sugar side chains) and usually have specific three-dimensional structural properties as well as specific charge properties.
  • the term "specific binding” refers to the type of non-covalent interaction that occurs between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific.
  • the strength or affinity of an immunological binding interaction can be expressed in terms of the equilibrium dissociation constant (KD) of the interaction, where a smaller KD represents a greater affinity.
  • KD equilibrium dissociation constant
  • the immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen binding site/antigen complex formation and dissociation, where those rates depend on the concentration of the complex partners, the affinity of the interaction, and geometric parameters that affect the rates equally in both directions.
  • association rate constants (k on ) and “dissociation rate constants” (k off ) can be determined by calculating concentrations and actual association and dissociation rates (see Nature 361:186-87 (1993)).
  • the koff / kon ratio eliminates all affinity-independent parameters and is equal to the equilibrium dissociation constant, KD (see generally Davies et al. (1990) Annual Rev Biochem 59:439-473).
  • Specific binding can be measured by radioligand binding assays, surface plasmon resonance (SPR), flow cytometry binding assays, or similar assays known to those of skill in the art.
  • isolated used in the present invention with respect to cells, nucleic acids, polypeptides, etc.
  • isolated DNA, RNA, polypeptide refers to one or the other components in the natural environment of the cell, such as DNA or RNA.
  • isolated molecules refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or cell culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
  • isolated nucleic acid is intended to include fragments of nucleic acid that do not occur in nature, and do not exist in nature.
  • isolated is also used herein to refer to cells or polypeptides that are separated from other cellular proteins or tissues.
  • Isolated polypeptide is intended to include purified and recombinant polypeptides. Isolated polypeptides and the like will usually be prepared by at least one purification step.
  • the isolated nucleic acid, polypeptide, etc. has a purity of at least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or values thereof The range between any two values in (inclusive) or any value in it.
  • an “isolated” antibody is one that has been separated and/or recovered from a component of its natural environment. Some components of its natural environment are substances that would preclude the diagnostic or therapeutic use of the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
  • the antibody is purified to the following extent: (1) the antibody is greater than 95% by weight, such as greater than 99%, as determined by the Lowry method; (2) by using rotor cup sequencing or (3) by SDS-PAGE under reducing or non-reducing conditions, using Coomassie blue or silver staining to detect homogeneity.
  • Isolated antibody includes antibody in situ within recombinant cells. Ordinarily, isolated antibody will be prepared by at least one or more purification steps. In some embodiments, the isolated antibody is at least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99% pure, or any two of these values The range in between (inclusive) or any value therein.
  • encoding when applied to a polynucleotide refers to a polynucleotide which is said to "encode” a polypeptide which, in its native state or when manipulated by methods well known to those skilled in the art, is transcribed and/or Or translation may result in the polypeptide and/or fragments thereof.
  • polypeptides or polynucleotides refers to polypeptides or polynucleotides, meaning forms of polypeptides or polynucleotides that do not occur in nature, non-limiting examples may be produced by combination of polynucleotides or polynucleotides that do not normally exist or peptide.
  • sequence identity means that two polynucleotide or amino acid sequences are identical (ie, are identical on a nucleotide-by-nucleotide or residue-by-residue basis) over the window of comparison.
  • percent sequence identity is calculated by comparing two optimally aligned sequences over a comparison window, determining the number of positions where the same amino acid residue occurs in both sequences to give the number of matching positions, dividing The number of matching positions was divided by the total number of positions in the comparison window (ie, the window size), and the result was multiplied by 100 to obtain the percent sequence identity.
  • At least 90% sequence identity is about 90% sequence identity, about 91% sequence identity, about 92% sequence identity, about 93% sequence identity, about 95% sequence identity, about 96% sequence identity , about 97% sequence identity, about 98% sequence identity, about 99% sequence identity, or a range between any two of these values, inclusive, or any value therein.
  • amino acid refers to an organic compound containing both amino and carboxyl groups, such as an ⁇ -amino acid, which can be encoded by a nucleic acid directly or in the form of a precursor.
  • a single amino acid is encoded by a nucleic acid consisting of three nucleotides (so-called codons or base triplets). Each amino acid is encoded by at least one codon. The fact that the same amino acid is encoded by different codons is called “degeneracy of the genetic code”.
  • Amino acids include natural amino acids and unnatural amino acids.
  • the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology-A Synthesis (2nd ed., edited by E.S. Golub and D.R. Gren, Sinauer Associates, Sunderland 7 Mass. (1991)). Stereoisomers of the twenty conventional amino acids (e.g., D-amino acids), unnatural amino acids (such as ⁇ -, ⁇ -disubstituted amino acids), N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable for use in Components of the polypeptides of the disclosure.
  • Examples of unconventional amino acids include: 4-hydroxyproline, ⁇ -carboxyglutamate, ⁇ -N,N,N-trimethyllysine, ⁇ -N-acetyllysine, O-phosphoserine , N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysyl, ⁇ -N-methylarginine and other similar amino acids and imino acids (such as 4 - hydroxyproline).
  • the left-hand direction is the amino-terminal direction and the right-hand direction is the carboxy-terminal direction, consistent with standard usage and convention.
  • Conventional (or natural) amino acids include alanine (three-letter code: Ala, one-letter code: A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D ), cysteine (Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y) and valine (Val, V).
  • polypeptide is intended to encompass the singular as well as the plural “polypeptides” and refers to a molecule formed of amino acid monomers linked linearly by amide bonds (also known as peptide bonds).
  • polypeptide refers to any chain or chains of two or more amino acids, and does not refer to a specific length of the product.
  • the definition of “polypeptide” includes peptide, dipeptide, tripeptide, oligopeptide, "protein”, “amino acid chain” or any other term used to refer to a chain of two or more amino acids, and the term “polypeptide” may Used in place of, or interchangeably with, any of the above terms.
  • polypeptide is also intended to refer to the products of post-expression modifications of the polypeptide, including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, or non-natural Amino acid modifications that occur.
  • a polypeptide may be derived from a natural biological source or produced by recombinant techniques, but it need not be translated from a specified nucleic acid sequence, it may be produced by any means including chemical synthesis.
  • substantially identical means that two peptide sequences share at least 80% sequence identity, preferably at least 90% sequence identity when optimally aligned such as by the GAP or BESTFIT programs using default gap weights identity, more preferably at least 95% sequence identity, and most preferably at least 99% sequence identity.
  • amino acid or polypeptide when an amino acid or polypeptide is a constituent part of a molecule (such as an antibody or ADC), the amino acid or polypeptide refers to the amino acid residue or polypeptide residue (whether written or not), that is, its interaction with other parts of the molecule
  • some of its groups such as a hydrogen atom of its amino group and/or a hydroxyl group of a carboxyl group
  • covalent bonds such as amide bonds
  • a polynucleotide is composed of a specific sequence of four bases: adenine (A), cytosine (C), guanine (G), thymine (T), or when the polynucleotide is RNA Thymine was replaced with uracil (U).
  • a "polynucleotide sequence” may be denoted by the letters of the polynucleotide molecule. This letter designation can be entered into a database in a computer with a central processing unit and used in bioinformatics applications such as for functional genomics and homology searches.
  • polynucleotide polynucleotide
  • oligonucleotide oligonucleotide
  • a polynucleotide can have any three-dimensional structure and can perform any function, known or unknown.
  • polynucleotides genes or gene fragments (e.g., probes, primers, EST or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribose Somatic RNA, ribozyme, cDNA, dsRNA, siRNA, miRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers.
  • a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs.
  • nucleotides can be made before or after assembly of the polynucleotide.
  • the sequence of nucleotides may be interrupted by non-nucleotide components.
  • Polynucleotides may be further modified after polymerization, for example by conjugation with labeling components.
  • the term also refers to double-stranded and single-stranded molecules. Unless otherwise stated or required, any embodiment of a polynucleotide of the present disclosure includes the double-stranded form and each of the two complementary single-stranded forms known or predicted to constitute the double-stranded form.
  • Identity or sequence identity of a nucleic acid or polynucleotide sequence (or polypeptide or antibody sequence) with another sequence having a certain percentage (e.g. 90%, 95%, 98% or 99%) means when the sequence When aligned, this percentage of bases (or amino acids) is identical in the two sequences being compared.
  • This alignment and percent identity or sequence identity can be determined visually or using software programs known in the art, such as those described by Ausubel et al.eds. (2007) in Current Protocols in Molecular Biology. It is preferred to use the default parameters for the alignment.
  • Biologically equivalent polynucleotides are polynucleotides that share the above indicated percentages of identity and encode polypeptides having the same or similar biological activity.
  • the left-hand end of a single-stranded polynucleotide sequence is the 5' end, and the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5' direction.
  • the direction of addition of 5' to 3' of the nascent RNA transcript is called the direction of transcription; the sequence region on the DNA strand that is identical to the RNA sequence and 5' at the 5' end of the RNA transcript is called the "upstream sequence"; the DNA The region of sequence on the strand identical to the RNA sequence and 3' to the 3' end of the RNA transcript is referred to as "downstream sequence".
  • residue positions that are not identical differ by conservative amino acid substitutions.
  • amino acid sequence of an antibody or immunoglobulin molecule are encompassed by the present disclosure, provided that the amino acid sequence identity remains at least 90%, such as at least 92%, 95%, 98% or 99%.
  • the changes are conservative amino acid substitutions.
  • Conservative amino acid substitutions are substitutions that occur within a family of amino acids that are related in their side chains.
  • Amino acids encoded by genes can be roughly divided into the following categories: (1) acidic amino acids are aspartate and glutamate; (2) basic amino acids are lysine, arginine, and histidine; (3) non-polar amino acids alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan); Glycine, Asparagine, Glutamine, Cysteine, Serine, Threonine, Tyrosine.
  • amino acids include (i) the aliphatic-hydroxyl family of serine and threonine; (ii) the amide-containing family of asparagine and glutamine; (iii) the aliphatic family of alanine, valine, leucine and isoleucine; and (iv) phenylalanine, tryptophan and tyrosine of the aromatic family.
  • conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, Glutamic acid-aspartic acid, and asparagine-glutamine.
  • amino acid substitutions have the effect of (1) reducing susceptibility to proteolysis, (2) reducing susceptibility to oxidation, (3) altering binding affinity for protein complex formation, ( 4) altering binding affinity, and (5) conferring or improving other physicochemical or functional properties of such analogs.
  • Analogs may include various muteins that differ in sequence from the naturally occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in naturally occurring sequences (preferably in portions of the polypeptide other than domains that form intermolecular contacts).
  • Conservative amino acid substitutions should not significantly alter the structural properties of the parent sequence (eg, the substituted amino acid should not tend to disrupt the helical structure present in the parent sequence, or disrupt other types of secondary structure that characterize the parent sequence).
  • Examples of secondary and tertiary structures of artificially recognized polypeptides are described in Proteins, Structures and Molecular Principles (Creighton ed., W.H. Freeman and Company, New York (1984)); Introduction to Protein Structure (C. Branden and J. Tooze eds. , Garland Publishing, New York, N.Y. (1991)); and Thornton et al. Nature 354:105 (1991).
  • the number of amino acids for conservative amino acid substitutions of VL and VH can be about 1, about 2, about 3, about 4, about 5, about 6, about 8, about 9, about 10, about 11 1, about 13, about 14, about 15 conservative amino acid substitutions, or a range between any two of these values (inclusive) or any value therein.
  • the heavy chain constant region, the light chain constant region, the conservative amino acid substitutions of the heavy chain or the light chain can have about 1, about 2, about 3, about 4, about 5, about 6, about 8 amino acids about 9, about 10, about 11, about 13, about 14, about 15, about 18, about 19, about 22, about 24, about 25, about 29, About 31, about 35, about 38, about 41, about 45 conservative amino acid substitutions, or a range between any two of these values (inclusive) or any value therein.
  • agent means a chemical compound, a mixture of chemical compounds, a biological macromolecule or an extract made from a biological material.
  • label refers to the incorporation of a detectable label, for example, by incorporation of a radioactively labeled amino acid, or attachment to avidin that can be labeled (for example, containing a fluorescent label or optically detectable). Enzymatic activity detected by the method or calorimetric method (streptavidin) detected by the biotin-based moiety of the polypeptide. In certain instances, markers or markers may also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and can be used.
  • labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (eg, 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I ), fluorescent labels (eg, FITC, rhodamine, lanthanide phosphors), enzyme labels (eg, horseradish peroxidase, ⁇ -galactosidase, luciferase, alkaline phosphatase), chemiluminescence Tag, biotinyl, predetermined polypeptide epitope recognized by the secondary reporter gene (eg, leucine zipper pair sequence, secondary antibody binding site, metal binding domain, epitope tag).
  • radioisotopes or radionuclides eg, 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I
  • fluorescent labels eg, FITC, rhodamine
  • labels are attached via spacer arms of various lengths to reduce possible steric hindrance.
  • the term “medicament” or “drug” refers to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.
  • EC 50 means the half-maximal effect concentration (concentration for 50% of maximal effect, EC 50 ) refers to the concentration that can cause 50% of the maximal effect.
  • IC50 means 50% inhibitory concentration, ie the concentration of drug or inhibitor required to inhibit a given biological process by half.
  • Treatment means therapeutic treatment and prophylactic or preventive measures, the purpose of which is to prevent, slow down, ameliorate or stop an undesirable physiological change or disorder, such as the progression of a disease, including but not limited to the following whether detectable or undetectable Relief of symptoms, reduction of disease extent, stabilization of disease state (i.e. not worsening), delay or slowing of disease progression, amelioration, remission, alleviation or disappearance of disease state (whether partial or total), prolongation and Expected survival without treatment, etc.
  • Patients in need of treatment include those who already have a condition or disorder, are susceptible to having a condition or disorder, or are in need of prevention of the condition or disorder, and can or are expected to benefit from the administration of an antibody or pharmaceutical composition disclosed herein for detection , patients who benefit from the diagnostic process and/or treatment.
  • cancer means or is intended to describe the physiological condition in mammals that is typically characterized by uncontrolled cell growth.
  • examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, or leukemia. More specific examples of such cancers include, but are not limited to, colorectal cancer, lung cancer, ovarian cancer, uterine cancer, endometrial cancer, salivary gland cancer, peritoneal cancer, fallopian tube cancer, pancreatic cancer, thyroid cancer, squamous cell carcinoma of the head and neck, nasopharyngeal Carcinoma, laryngeal cancer, lung adenocarcinoma, lung squamous cell carcinoma, liver cancer, hepatocellular carcinoma, gastrointestinal cancer, glioblastoma, breast cancer, brain cancer, kidney cancer, renal cell carcinoma, colon cancer, rectal cancer, prostate cancer carcinoma, vulvar cancer, testicular cancer, squamous cell carcinoma, small cell lung cancer, cervical cancer, bladder cancer,
  • overexpressed or “overexpressed” interchangeably refer to a gene that is usually transcribed or translated at a detectably higher level in certain cells, such as cancer cells, compared to normal cells.
  • Overexpression can be of protein or RNA (due to increased transcription, posttranscriptional processing, translation, posttranslational processing, altered stability, and altered protein degradation), as well as localized overexpression due to altered protein trafficking patterns (nuclear localization increased) and enhanced functional activity, such as, for example, increased enzymatic hydrolysis of substrates.
  • Overexpression can be 5%, 10%, 20%, 30%, 50%, 60%, 70%, 80%, 90% or more compared to normal or control cells.
  • the anti-FR ⁇ antibodies and antibody drug conjugates of the present invention are used to treat solid tumors that may overexpress folate receptor ⁇ .
  • tumor overexpressing folate receptor alpha refers to a tumor (including benign tumors and cancers) overexpressing folate receptor alpha.
  • folate receptor alpha expression in a tumor sample above background levels in immune tissue indicates that the tumor is a folate receptor alpha overexpressing tumor.
  • Methods for detecting folate receptor alpha expression in tumors are known in the art, such as immunohistochemical assays.
  • "FR ⁇ negative cells” are cells in a sample of cells that lack folate receptor alpha above background (eg, as determined by immunohistochemical techniques).
  • administering means delivering a substance (eg, an anti-folate receptor alpha antibody or ADC) for a therapeutic purpose (eg, treating a folate receptor alpha-related disorder).
  • a substance eg, an anti-folate receptor alpha antibody or ADC
  • Modes of administration can be parenteral, enteral and topical.
  • Parenteral administration is usually by injection, including but not limited to intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, vesicular Subarachnoid, intraspinal, and intrasternal injections and infusions.
  • an effective amount refers to an amount of a drug, such as an antibody or ADC, sufficient to reduce or ameliorate the severity and/or amelioration of a disorder (e.g., cancer) or one or more symptoms thereof or duration; prevent progression of a condition; cause regression of a condition; prevent recurrence, development, onset, or progression of one or more symptoms associated with a condition; detect a condition; The amount of prophylactic or therapeutic effect.
  • an effective amount of an antibody can inhibit tumor growth (e.g., inhibit an increase in tumor volume); reduce tumor growth (e.g., reduce tumor volume); reduce the number of cancer cells; one or more symptoms.
  • an effective amount can improve disease free survival (DFS), improve overall survival (OS), or reduce the likelihood of relapse.
  • DFS disease free survival
  • OS overall survival
  • patient and “subject” are used interchangeably and refer to any mammal in need of diagnosis, prognosis or treatment, including but not limited to humans, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle etc.
  • the patient is a human.
  • the term "in need” means that a patient has been identified as being in need of a particular method or treatment. In some embodiments, identification may be by any diagnostic means. A patient may in need thereof during any of the methods and treatments described herein.
  • administering refers to administering a substance for a therapeutic purpose (eg, treating a tumor).
  • tumor-treating drug refers to an agent having the functional property of inhibiting the development or progression of tumors in humans, especially malignant (cancerous) lesions such as carcinoma, sarcoma, lymphoma or leukemia. Inhibition of metastasis is in many cases a property of antineoplastic agents.
  • pharmaceutically acceptable carrier generally refers to any type of non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary, etc.
  • carrier refers to a diluent, adjuvant, excipient or carrier with which the active ingredient can be administered to a patient.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerol, Propylene, ethylene glycol, water, ethanol, etc.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents such as acetates, citrates or phosphates.
  • Antibacterial agents such as benzyl alcohol or methylparaben, antioxidants such as ascorbic acid or sodium bisulfite, chelating agents such as ethylenediaminetetraacetic acid, and tonicity adjusting agents such as sodium chloride or dextrose are also contemplated.
  • These compositions may take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations and the like.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
  • compositions will contain a clinically effective dose of the antibody or antigen-binding fragment, preferably in purified form, together with an appropriate amount of carrier to provide a form suitable for administration to the patient.
  • the formulation should be suitable for the mode of administration.
  • the parent formulation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • antibody drug conjugate refers to a binding protein (such as an antibody or antigen-binding unit thereof) linked to one or more chemical drugs, which may optionally be therapeutic or cytotoxic agents.
  • the ADC comprises an antibody, a drug (eg, a cytotoxic drug) and a linker enabling attachment or conjugation of the drug to the antibody.
  • Non-limiting examples of drugs that may be included in the ADC are mitotic inhibitors, antitumor antibiotics, immunomodulators, vectors for gene therapy, alkylating agents, antiangiogenic agents, antimetabolites, boron-containing agents, chemical Protective agents, hormones, antihormonal agents, corticosteroids, photoactive therapeutic agents, oligonucleotides, radionuclide agents, topoisomerase inhibitors, kinase inhibitors (eg, TEC-family kinase inhibitors and serine/threonine amino acid kinase inhibitors) and radiosensitizers.
  • mitotic inhibitors eg, TEC-family kinase inhibitors and serine/threonine amino acid kinase inhibitors
  • antibody drug conjugate and “ADC” are used interchangeably.
  • anti-folate receptor alpha antibody drug conjugate and “anti-FR ⁇ antibody drug conjugate” and “anti-folate receptor alpha ADC” are used interchangeably and refer to compounds that specifically bind folate receptor An ADC of an antibody in which the antibody is conjugated to one or more drugs.
  • the anti-FR ⁇ ADC comprises an antibody conjugated to exixetecan.
  • the anti-FR ⁇ antibody or ADC binds to folate receptor alpha (eg, human folate receptor alpha).
  • DAR drug antibody conjugation ratio
  • the term “drug antibody conjugation ratio” or “DAR” refers to the amount of drug (eg, exinotecan) of an ADC to which an antibody is attached.
  • the DAR of an ADC can range from 1 to 10, but depending on the number of attachment sites on the antibody, higher loadings (eg 20) are also possible.
  • the term DAR may be used when referring to the amount of drug loaded onto a single antibody, or alternatively, the average or mean DAR of a group of ADCs. In some embodiments, its value is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the average binding number of the small molecule drug that is, the average drug binding number of the antibody, or called the average drug-antibody coupling ratio
  • its value is selected from about 0 to about 10, or about 2 to about 8.
  • the drug antibody conjugation ratio is about 3 to about 6.
  • the drug-to-antibody conjugation ratio is about 6 to about 8, or about 7 to about 8.
  • the DAR value can be denoted by p in this paper. Those skilled in the art understand that different batches of the same ADC may have slightly different average DAR values (p).
  • the DAR value of ADC can be determined by ultraviolet-visible absorption spectroscopy (UV-Vis), high-performance liquid chromatography-hydrophobic chromatography (HPLC-HIC), high-performance liquid chromatography-reversed-phase chromatography (RP-HPLC), liquid chromatography-mass spectrometry (LC-MS) and other determinations. These techniques are described in Ouyang, J. Methods Mol Biol, 2013, 1045: p.275-83.
  • substituents are defined below.
  • substituents e.g., alkyl, alkenyl, alkynyl, alkoxy, aminoalkoxy, aminoalkyl, aminoalkylamino, alkylamino, heterocyclyl, heterocyclylamino, and aryl
  • Cx-Cy or “Cx-y”
  • x is the minimum value of carbon atoms
  • y is the maximum value of carbon atoms.
  • C1-C6 alkyl refers to an alkyl group containing from 1 to 6 carbon atoms.
  • a substituent is described as "substituted by,” a hydrogen atom on carbon or nitrogen is replaced by a non-hydrogen group.
  • a substituted alkyl substituent is an alkyl substituent in which at least one hydrogen atom on the alkyl is replaced by a non-hydrogen group.
  • a monofluoroalkyl is an alkyl group substituted with one fluoro group
  • a difluoroalkyl group is an alkyl group substituted with two fluoro groups. It should be recognized that if more than one substitution is present on a substituent, each substitution may be the same or different (unless otherwise stated).
  • substituents include, but are not limited to, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 aminoalkoxy, halogen, nitro, cyano , mercapto, alkylthio, amino, C1-C6 aminoalkyl, C1-C6 aminoalkylamino, C1-C6 alkyl attached to a heterocycle, C1-C6 alkylamino attached to a heterocycle, heterocyclyl , amino-substituted heterocyclyl, heterocyclic amino, carbamoyl, morpholin-1-yl, piperidin-1-yl, -(CH 2 ) q -CH 3 , -(CHR n ) q -CH 3 , C3-C8
  • Alkyl means a saturated aliphatic hydrocarbyl group, and the term includes straight and branched chain hydrocarbyl groups.
  • C1-C20 alkyl such as C1-C6 alkyl.
  • C1-C20 alkyl refers to an alkyl group having 1 to 20 carbon atoms, for example having 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, 10 carbon atoms, 11 carbon atoms, 12 carbon atoms, 13 carbon atoms, 14 carbon atoms, 15 carbon atoms, 16 carbon atoms, 17 carbon atoms carbon atoms, 18 carbon atoms, 19 carbon atoms or 20 carbon atoms.
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, and the like.
  • the alkyl group may be unsubstituted or substituted with one or more substituents including, but not limited to, alkyl, alkoxy, cyano, hydroxyl, carbonyl, carboxy, aryl, heteroaryl, Amino, halogen, sulfonyl, sulfinyl, phosphono, etc.
  • alkenyl by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl group having at least one carbon-carbon double bond by removal of the double bond from a single carbon atom of the parent alkene obtained from a hydrogen atom.
  • Typical alkenyl groups include, but are not limited to, vinyl; propenyl (e.g., prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl, prop-2-enyl -2-yl, cycloprop-1-en-1-yl); cycloprop-2-en-1-yl; butenyl (such as but-1-en-1-yl, but-1-en-2 -yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, but-1,3-dien-1-yl , But-1,3-dien-2-yl, Cyclobut-1-en-1-yl, Cyclobut-1-en-3-yl, Cyclobut-1,3-dien-1-yl, etc. )wait.
  • propenyl e.g., prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl, prop-2
  • alkynyl by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl group having at least one carbon-carbon triple bond through a single carbon atom from the parent alkyne Obtained by removing a hydrogen atom.
  • Typical alkynyl groups include, but are not limited to, ethynyl; propynyl (such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.); butynyl (such as but-1-yn-1 -yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.) and the like.
  • Carbocyclyl means a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting only of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from 3 to 15 carbon atoms, e.g. Has 3 to 10 (eg 3, 4, 5, 6, 7, 8, 9 or 10) carbon atoms and is saturated or unsaturated and attached to the remainder of the molecule by a single bond.
  • Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, and the like.
  • carbocyclic groups may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, cyano, nitro, oxo, aryl, aralkyl radical, carbocyclyl, carbocyclylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl.
  • Aryl refers to an all-carbon monocyclic or all-carbon fused ring with a fully conjugated pi-electron system, typically having 5-14 carbon atoms, eg, 6, 10, 12, 14 carbon atoms.
  • Aryl groups may be unsubstituted or substituted with one or more substituents including, but not limited to, alkyl, alkoxy, cyano, hydroxyl, carboxy, aryl, aralkyl, amine, Halogen, sulfonyl, sulfinyl, phosphono.
  • unsubstituted aryl groups include, but are not limited to, phenyl, naphthyl, and anthracenyl.
  • Heterocyclyl means a stable 3- to 18-membered aromatic or non-aromatic ring substituent consisting of 2 to 8 (eg 2, 3, 4, 5, 6, 7 or 8) carbon atoms and It consists of 1 to 6 (1, 2, 3, 4, 5 or 6) heteroatoms selected from nitrogen, oxygen and sulfur.
  • the heterocyclyl group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl group can optionally be replaced by oxidized; the nitrogen atom is optionally quaternized; and the heterocyclyl can be partially or fully saturated.
  • heterocyclic groups include, but are not limited to, dioxolanyl, dioxinyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, iso Thiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl , oxazolidinyl, piperidinyl, piperazinyl, 4-piperidinonyl, piperrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, 1,2,4-thiadiazole -5(4H)-yl, tetrahydrofuranyl, trioxanyl, trithianyl, triazin
  • the heterocyclic group may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halogen, haloalkyl, cyano, oxo, thioxo , nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted hetero Arylalkyl.
  • Alkoxy means the formula -O-(alkyl), wherein alkyl is as defined herein.
  • alkoxy groups are methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy , tert-butoxyl. Alkoxy groups can be substituted or unsubstituted.
  • Halogen means fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
  • Amino refers to -NH2 .
  • Niro refers to -NO2 .
  • Carboxy means -COOH.
  • Stereoisomer refers to isomeric compounds that have the same sequence of bonding of the atoms but differ in the arrangement of the atoms in space. Stereoisomers can have one or more stereocenters and each center can exist as R or S, and stereoisomers can also be cis-trans isomers. Stereoisomers of compounds provided herein include any one or appropriate mixtures of all diastereomeric, enantiomeric and cis-trans isomeric forms thereof.
  • Pharmaceutically acceptable salts include pharmaceutically acceptable salts of compounds with a wide variety of organic and inorganic counterions well known in the art, only exemplary salts include, when the molecule contains an acidic functional group, organic or inorganic salts Such as lithium salt, sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-di Ethylaminoethanol, Dicyclohexylamine, Lysine, Arginine, Histidine, Caffeine, Procaine, Choline, Betaine, Ethylenediamine, Glucosamine, Methylglucosamine, Cocoa Alkali, purine piperazine, piperidine, N-ethyl, piperidine, polyamine resin and tetraalkylammonium salt, etc.; and when the molecule contains basic functional groups, organic or inorganic acid
  • acids include sulfuric acid, nitric acid, phosphoric acid, propionic acid, glycolic acid, pyruvic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic cinnamic acid, mandelic acid, methanesulfonic acid, Ethylsulfonic acid, p-toluenesulfonic acid salicylic acid, etc.
  • Solvates include hydrates.
  • the antibody provided by the invention is an anti-folate receptor ⁇ antibody or an antigen-binding unit thereof.
  • an antibody of the invention is capable of specifically binding human folate receptor alpha.
  • the invention provides a humanized anti-FR ⁇ antibody or an antigen-binding unit thereof.
  • these antibodies are collectively referred to as anti-FR ⁇ antibodies.
  • the anti-FR ⁇ antibody or its antigen-binding unit of the present invention has characteristics including but not limited to binding to FR ⁇ (such as human FR ⁇ ) in vitro, binding to cells expressing FR ⁇ , high affinity, and strong internalization ability.
  • the anti-FR ⁇ antibody of the present invention can specifically bind to folate receptor ⁇ (FOLR1), but not to folate receptor ⁇ (FOLR2) or folate receptor ⁇ (FOLR3).
  • FOLR1 folate receptor ⁇
  • FOLR2 folate receptor ⁇
  • FOLR3 folate receptor ⁇
  • the antigen-binding fragment or antigen-binding unit of an anti-FR ⁇ antibody is a Fab, Fab', F(ab') 2 , Fv, disulfide-linked Fv, scFv, single domain antibody or diabody Antibody.
  • the anti-FR ⁇ antibody is a multispecific antibody (eg, a bispecific antibody).
  • the anti-FR ⁇ antibody can be a monoclonal antibody.
  • the binding specificity of the antibody disclosed in the present invention or its antigen-binding unit can be determined by in vitro experiments, such as co-immunoprecipitation, radioimmunoassay (RIA), surface plasmon resonance, flow cytometry (Facs) or enzyme-linked immunosorbent assay (ELISA). ) to detect.
  • in vitro experiments such as co-immunoprecipitation, radioimmunoassay (RIA), surface plasmon resonance, flow cytometry (Facs) or enzyme-linked immunosorbent assay (ELISA).
  • the invention also includes antibodies that bind to the same epitope as the anti-FR ⁇ antibodies described herein.
  • an antibody of the invention specifically binds an epitope comprising one or more amino acid residues on human FR ⁇ .
  • the antibody comprises a heavy chain constant region, such as an IgGl, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant region.
  • an anti-FR ⁇ antibody or an antigen-binding unit thereof comprises a human IgG constant domain, a human IgA constant domain, a human IgE constant domain, a human IgM constant domain, and a human IgD constant domain.
  • Immunoglobulin heavy chain constant domain such as an IgGl, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant region.
  • the anti-FR ⁇ antibody or antigen binding unit thereof comprises an IgG1 heavy chain constant region, an IgG2 heavy chain constant region, an IgG3 heavy chain constant region, or an IgG4 heavy chain constant region.
  • the heavy chain constant region is an IgGl heavy chain constant region or an IgG4 heavy chain constant region.
  • the antibody or antigen binding unit thereof comprises a light chain constant region, eg, a kappa light chain constant region or a lambda light chain constant region. In one or more embodiments, the antibody or antigen binding unit thereof comprises a kappa light chain constant region.
  • the Fc portion of an antibody mediates several important effector functions (e.g., cytokine induction, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, complement-dependent cytotoxicity (CDC), and antibody and antigen-antibody complexing drug half-life/clearance). In some cases, these effector functions are desirable for therapeutic antibodies, but in other cases may be unnecessary or even deleterious, depending on the therapeutic goal.
  • Certain human IgG isotypes, particularly IgGl and IgG3, mediate ADCC and CDC via binding to Fc ⁇ Rs and complement CIq, respectively.
  • the nascent Fc receptor (FcRn) is a key component determining the circulating half-life of antibodies.
  • At least one amino acid residue in the constant region of the antibody is substituted such that the effector function of the antibody is altered.
  • substitution of amino acid residues in the Fc region of an antibody to alter antibody effector function is described in US Pat. Nos. 5,648,260 and 5,624,821, which are incorporated herein by reference.
  • the invention includes labeled anti-FR ⁇ antibodies, or antigen-binding units thereof, wherein the antibody is derivatized or linked to one or more functional molecules (eg, another peptide or protein).
  • a labeled antibody can be derived by functionally linking (by chemical coupling, gene fusion, non-covalent association or otherwise) an antibody of the invention, or an antigen-binding unit thereof, to one or more other molecular entities, which One or more other molecular entities such as another antibody (e.g., a bispecific or diabody), a detectable reagent, a pharmaceutical agent, can mediate the interaction of an antibody or its antigen-binding unit with another molecule (such as an avidin streptavidin core region or polyhistidine tag) and/or a cytotoxic or therapeutic agent selected from the group consisting of: mitotic inhibitors, antitumor antibiotics, immunomodulators, gene therapy Carriers, alkylating agents, antiangiogenic agents, antimetabolites,
  • an antibody of the invention is linked to a detectable reagent, for example, by incorporation of a radiolabeled amino acid, or by attachment to an avidin that can be labeled (for example, containing a fluorescent label or Polypeptides with biotinyl moieties detectable by optical methods or calorimetrically detected enzymatic activity (streptavidin).
  • a detectable reagent for example, by incorporation of a radiolabeled amino acid, or by attachment to an avidin that can be labeled (for example, containing a fluorescent label or Polypeptides with biotinyl moieties detectable by optical methods or calorimetrically detected enzymatic activity (streptavidin).
  • markers or markers may also be therapeutic.
  • Various methods of labeling polypeptides and glycoproteins are known in the art and can be used.
  • labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (eg, 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I ), fluorescent labels (eg, FITC, rhodamine, lanthanide phosphors), enzyme labels (eg, horseradish peroxidase, ⁇ -galactosidase, luciferase, alkaline phosphatase), chemiluminescence Tag, biotinyl, predetermined polypeptide epitope recognized by the secondary reporter gene (eg, leucine zipper pair sequence, secondary antibody binding site, metal binding domain, epitope tag).
  • labels are attached via spacer arms of various lengths to reduce possible steric hindrance.
  • an antibody of the invention or an antigen-binding unit thereof can be used to detect the presence of FRa (eg, human FRa) in a sample.
  • the antibody comprises a detectable reagent.
  • the antibodies are polyclonal antibodies, or more preferably monoclonal antibodies. Whole antibodies or antigen-binding units thereof (eg, Fab, scFv or F(ab') 2 ) can be used.
  • the detection methods of the described embodiments can be used to detect analyte mRNA, protein or genomic DNA in a biological sample both in vitro and in vivo.
  • in vitro detection techniques for analyte mRNA include Northern hybridization and in situ hybridization
  • in vitro detection techniques for analyte protein include enzyme-linked immunosorbent assay (ELISA), Western blot, immunoprecipitation, and immunofluorescence
  • in vitro detection techniques for analyte genomic DNA include Southern hybridization.
  • techniques for in vivo detection of analyte proteins include introducing into a patient a labeled anti-analyte protein antibody.
  • antibodies can be labeled with a radioactive label, the presence and location of which can then be detected in the patient by standard imaging techniques.
  • folate receptor alpha can be detected in a biological sample as part of a clinical testing procedure, eg, to determine the efficacy of a given treatment regimen. Detection can be facilitated by conjugating (eg, physically linking) the antibody to a detectable substance.
  • detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic complexes include streptavidin/biotin and avidin/ Biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylfluorescein, dansyl chloride, or phycoerythrin;
  • an example of a luminescent material includes luciferin Minol;
  • bioluminescent materials include luciferase, luciferin, and aequorin;
  • suitable radioactive materials include125I,131I , 35S , or3H .
  • the anti-FR ⁇ antibody of the present invention includes a humanized antibody or an antigen-binding unit thereof. These antibodies, or antigen-binding units thereof, are suitable for administration to a human without causing an adverse immune response in the human to the administered immunoglobulin.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen binding unit comprises VH CDR1 as shown in SEQ ID NO:5; VH CDR2 as shown in SEQ ID NO:6; and as shown in VH CDR3 shown in SEQ ID NO:7.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises VL CDR1 as shown in SEQ ID NO: 8; VL CDR2 as shown in SEQ ID NO: 9; and as shown in VL CDR3 shown in SEQ ID NO:10.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises VH CDR1 shown in SEQ ID NO: 5; VH CDR2 shown in SEQ ID NO: 6; VH CDR3 shown in ID NO:7; VL CDR1 shown in SEQ ID NO:8; VL CDR2 shown in SEQ ID NO:9; VL CDR3 shown in SEQ ID NO:10.
  • the humanized anti-FR ⁇ antibody or antigen-binding unit thereof of the invention further comprises a framework region.
  • the framework regions of the exemplary antibody VH and VL herein are shown in Table 1.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises VH FR1 as shown in SEQ ID NO: 1; VH CDR1 as shown in SEQ ID NO: 5; VH FR2 as shown in SEQ ID NO:2; VH CDR2 as shown in SEQ ID NO:6; VH FR3 as shown in SEQ ID NO:3; VH CDR3 as shown in SEQ ID NO:7; VH FR4 shown in SEQ ID NO: 11.
  • the humanized anti-FR ⁇ antibody or antigen-binding unit thereof of the present invention comprises VH FR1 as shown in SEQ ID NO:29; VH CDR1 as shown in SEQ ID NO:5; VH FR2 as shown in SEQ ID NO:30; VH CDR2 as shown in SEQ ID NO:6; VH FR3 as shown in SEQ ID NO:31; VH CDR3 as shown in SEQ ID NO:7; VH FR4 shown in SEQ ID NO: 11.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises VL FR1 as shown in SEQ ID NO: 12; VL CDR1 as shown in SEQ ID NO: 8; VL FR2 as shown in SEQ ID NO:13; VL CDR2 as shown in SEQ ID NO:9; VLFR3 as shown in SEQ ID NO:4; VL CDR3 as shown in SEQ ID NO:10; VLFR4 shown in ID NO:14.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises VL FR1 as shown in SEQ ID NO: 12; VL CDR1 as shown in SEQ ID NO: 8; VL FR2 as shown in SEQ ID NO:13; (4) VL CDR2 as shown in SEQ ID NO:9; VLFR3 as shown in SEQ ID NO:32; VL CDR3 as shown in SEQ ID NO:10; and VL FR4 as shown in SEQ ID NO:14.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises: a heavy chain variable region comprising VH FR1 as shown in SEQ ID NO: 1; as shown in SEQ ID NO VH CDR1 shown in :5; VH FR2 shown in SEQ ID NO:2; VH CDR2 shown in SEQ ID NO:6; VH FR3 shown in SEQ ID NO:3; VH CDR3 as shown; and VH FR4 as shown in SEQ ID NO:11; and light chain variable region, comprising VL FR1 as shown in SEQ ID NO:12; VL CDR1 as shown in SEQ ID NO:8 VL FR2 as shown in SEQ ID NO:13; VL CDR2 as shown in SEQ ID NO:9; VL FR3 as shown in SEQ ID NO:4; VL CDR3 as shown in SEQ ID NO:10; and VLFR4 as shown in SEQ ID NO:14.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises: a heavy chain variable region comprising VH FR1 as shown in SEQ ID NO: 29; as shown in SEQ ID NO VH CDR1 shown in :5; VH FR2 shown in SEQ ID NO:30; VH CDR2 shown in SEQ ID NO:6; VH FR3 shown in SEQ ID NO:31; VH CDR3 as shown; and VH FR4 as shown in SEQ ID NO:11; and light chain variable region, comprising VL FR1 as shown in SEQ ID NO:12; VL CDR1 as shown in SEQ ID NO:8 VL FR2 as shown in SEQ ID NO:13; VL CDR2 as shown in SEQ ID NO:9; VL FR3 as shown in SEQ ID NO:32; VL CDR3 as shown in SEQ ID NO:10; and VL FR4 as shown in SEQ ID NO:14.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen binding unit, its heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 15, or with SEQ ID NO: 15
  • the indicated amino acid sequence has suitable sequence identity to an amino acid sequence, such as at least 80% sequence identity, or at least 90% sequence identity, or at least 95% sequence identity, or at least 99% sequence identity
  • And/or its light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 16, or an amino acid sequence with suitable sequence identity compared with the amino acid sequence shown in SEQ ID NO: 16, such as having at least 80 % sequence identity, or at least 90% sequence identity, or at least 95% sequence identity, or at least 99% sequence identity.
  • at least the CDRs of these amino acid sequences having sequence identity are unchanged.
  • the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises a heavy chain variable region as shown in SEQ ID NO: 15 and a light chain as shown in SEQ ID NO: 16 variable region.
  • the humanized anti-FR ⁇ antibody or antigen binding unit thereof of the present invention further comprises a heavy chain constant region comprising the amino acid sequence shown in SEQ ID NO: 17, or An amino acid sequence having suitable sequence identity compared to the amino acid sequence shown in SEQ ID NO: 17, such as having at least 80% sequence identity, or at least 90% sequence identity, or at least 95% sequence identity, or at least 99% sequence identity.
  • the humanized anti-FR ⁇ antibody or antigen binding unit thereof of the present invention further comprises a light chain constant region comprising the amino acid sequence shown in SEQ ID NO: 18, or An amino acid sequence having suitable sequence identity compared to the amino acid sequence shown in SEQ ID NO: 18, such as having at least 80% sequence identity, or at least 90% sequence identity, or at least 95% sequence identity, or at least 99% sequence identity.
  • the heavy chain of the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises the amino acid sequence shown in SEQ ID NO: 19, or the amino acid sequence shown in SEQ ID NO: 19 Amino acid sequences having suitable sequence identity compared to the sequences, such as having at least 80% sequence identity, alternatively at least 90% sequence identity, alternatively at least 95% sequence identity, alternatively at least 99% sequence identity.
  • the light chain of the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit comprises the amino acid sequence shown in SEQ ID NO: 20, or the amino acid sequence shown in SEQ ID NO: 20 Amino acid sequences having suitable sequence identity compared to the sequences, such as having at least 80% sequence identity, alternatively at least 90% sequence identity, alternatively at least 95% sequence identity, alternatively at least 99% sequence identity.
  • the heavy chain of the humanized anti-FR ⁇ antibody or its antigen binding unit of the present invention further comprises a signal peptide, such as MDWTWRILFLVAAATGAHS (SEQ ID NO: 21), its nucleotide sequence is atggattggacctggagaatcctgttcctggtggccgccgccaccggcgctcattct (SEQ ID NO:25).
  • a signal peptide such as MDWTWRILFLVAAATGAHS (SEQ ID NO: 21)
  • its nucleotide sequence is atggattggacctggagaatcctgttcctggtggccgccgccaccggcgctcattct (SEQ ID NO:25).
  • the light chain of the humanized anti-FR ⁇ antibody or its antigen binding unit of the present invention further comprises a signal peptide, such as MEAPAQLLFLLLLWLPDTTG (SEQ ID NO: 22), its nucleotide sequence is atggaggcccctgcccagctgctgttcctgctgctgctgtggctgcctgataccaccggc (SEQ ID NO:26).
  • a signal peptide such as MEAPAQLLFLLLLWLPDTTG (SEQ ID NO: 22
  • its nucleotide sequence is atggaggcccctgcccagctgctgttccctgctgctgtggctgcctgataccaccggc (SEQ ID NO:26).
  • the binding dissociation equilibrium constant (KD) of the humanized anti-FR ⁇ antibody or antigen-binding unit thereof of the invention to FR ⁇ is about 1 ⁇ M or less. In one or more embodiments, the humanized anti-FR ⁇ antibody of the invention or an antigen-binding unit thereof binds to FR ⁇ with a KD between about 100 nM and about 1 pM or lower. In one or more embodiments, the humanized anti-FR ⁇ antibody of the invention or an antigen-binding unit thereof binds to FR ⁇ with a KD between about 10 nM and about 1 pM or lower. In one or more embodiments, the humanized anti-FR ⁇ antibody of the invention or an antigen-binding unit thereof binds to FR ⁇ with a KD between about 1 nM and about 0.1 nM or lower.
  • the KD of the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit binding to human FR ⁇ is about 1 ⁇ M to about 1 pM between or lower. In one or more embodiments, the KD of the humanized anti-FR ⁇ antibody of the present invention or its antigen-binding unit binding to human FR ⁇ is between about 100 nM to about 1 pM or lower; or, between about 10 nM to about 1 pM or lower; or, between about 1 nM to about 1 pM or lower.
  • the anti-FR ⁇ antibody or its antigen-binding unit of the present invention can be coupled with a drug to form an anti-FR ⁇ antibody-drug conjugate (anti-FR ⁇ ADC).
  • antibody drug conjugates (ADCs) can selectively deliver one or more drugs to target tissues (e.g., tumors expressing FR ⁇ ), antibody drug conjugates (ADCs) can increase the efficacy of antibodies in treating diseases (e.g., cancer ) in the therapeutic effect.
  • the antibody drug conjugate (ADC) of the present invention comprises the anti-FR ⁇ antibody or its antigen-binding unit described herein and at least one drug (such as exinotecan).
  • the ADC of the present invention has properties including but not limited to binding to FRa (such as human FRa) in vitro, binding to cells expressing FRa, high affinity, strong internalization ability, and reducing or inhibiting the growth of cancer cells or tumors.
  • Antigen-binding fragments or antigen-binding units of anti-FR ⁇ antibodies of the invention can be conjugated to the drugs described herein. Therefore, in one or more embodiments, the antigen-binding fragment or antigen-binding unit of the anti-FR ⁇ antibody described herein is coupled to a drug through a linker to form an anti-FR ⁇ ADC.
  • Anti-FR ⁇ ADCs of the invention comprise an antibody or antigen-binding unit thereof that specifically binds FR ⁇ (eg, human FR ⁇ ) linked to one or more drugs.
  • the specificity of the ADC can be determined by the specificity of the antibody (eg, anti-FR ⁇ antibody).
  • the anti-FR ⁇ antibody is linked to one or more drugs (eg, DNA topoisomerase inhibitors) that are delivered to the FR ⁇ -expressing cells, especially cancer cells expressing FR ⁇ .
  • the anti-FR ⁇ antibody drug conjugate comprises an anti-FR ⁇ antibody coupled to a drug (eg, exinotecan) via a linker.
  • the anti-FR ⁇ antibodies described herein provide ADCs with the ability to bind FR ⁇ such that drugs attached to the antibodies can be delivered to cells expressing FR ⁇ , particularly cancer cells expressing FR ⁇ .
  • the ADC is a structure as shown in Formula I or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof.
  • Abu is Antibody 1.
  • the ADC is ADC1 or ADC2, or a pharmaceutically acceptable salt or solvate thereof.
  • the antibody-drug conjugates of the present invention have obvious bystander effect.
  • the ADC of the invention binds to FRa with a binding-dissociation equilibrium constant (KD) of about 1 ⁇ or less. In one or more embodiments, the ADC of the invention binds FRa with a KD between about 100 nM and about 1 pM or lower. In one or more embodiments, the ADC of the invention binds FRa with a KD between about 10 nM to about 1 pM or lower. In one or more embodiments, the ADC of the invention binds FRa with a KD between about 1 nM to about 1 pM or lower.
  • KD binding-dissociation equilibrium constant
  • the ADC of the present invention binds to human FR ⁇ (such as the antigen FR ⁇ -His shown in SEQ ID NO: 28) with a KD of about 1 ⁇ M or lower. In one or more embodiments, the ADC of the present invention binds to human FR ⁇ with a KD between about 100 nM to about 1 pM or lower; or, between about 10 nM to about 1 pM or lower; or, between about 1 nM to about 1 pM or lower; Between about 1 pM or less; alternatively, between about 1 nM to about 0.1 nM or less; alternatively, between about 0.5 nM to about 0.1 nM or less.
  • the invention also provides the preparation method of the intermediate and the antibody drug conjugate.
  • the intermediates and antibody drug conjugates of the present invention can be prepared by known preparations and methods.
  • the methods for preparing intermediate compounds 1-7 and compound 7 are as follows.
  • the first step the compound of general formula 1-1 and the compound of general formula 1-1' react under alkaline conditions to obtain the compound of general formula 1-2;
  • the second step reacting the compound of general formula 1-2 and general formula (AA) i -(FF 1 ) f under alkaline conditions in the presence of a condensing agent to obtain the compound of general formula 1-3;
  • the third step remove the amino protecting group W of the compound of general formula 1-3 to obtain the compound of general formula 1-4;
  • the fourth step the compound of general formula 1-4 and the compound of general formula 1-5 are reacted under alkaline conditions to obtain the compound of general formula 1-6;
  • the fifth step reacting the compound of general formula 1-6 and bis(p-nitrophenyl)carbonate under basic conditions to obtain the compound of general formula 1-7.
  • the first step the compound of general formula 1 and the compound of general formula 1' react under alkaline conditions to obtain the compound of general formula 2;
  • the second step the compound of general formula 2 reacts with the compound of general formula (AA) i -(FF 1 ) f under alkaline conditions in the presence of a condensing agent to obtain the compound of general formula 3;
  • the third step remove the amino protecting group W of the compound of general formula 3 to obtain the compound of general formula 4;
  • the fourth step the compound of general formula 4 and the compound of general formula 5 are reacted under alkaline conditions to obtain the compound of general formula 6;
  • the fifth step the compound of general formula 6 is reacted with bis(p-nitrophenyl)carbonate under basic conditions to obtain the compound of general formula 7.
  • W 1 is an amino protecting group, such as 9-fluorenylmethoxycarbonyl
  • W 2 is a carboxylic acid active ester, such as succinimide ester.
  • R F is F.
  • z is 0.
  • z is 1 or 2.
  • the intermediate is:
  • R, n are as described herein.
  • the intermediate is:
  • R, n are as described herein.
  • the intermediate is:
  • n is as described herein.
  • the intermediate is:
  • n is as described herein.
  • the intermediate is:
  • the above-mentioned basic conditions can be provided by reagents, which include organic bases and inorganic bases, and said organic bases include but not limited to triethylamine, diethylamine, N-methylmorpholine, pyridine, hexahydropyridine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide or potassium tert-butoxide, the inorganic bases include but not limited to sodium hydride, potassium phosphate , sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide and lithium hydroxide.
  • organic bases include but not limited to triethylamine, diethylamine, N-methylmorpholine, pyridine, hexahydropyridine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium
  • the above-mentioned condensing agent can be selected from N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)urea hexafluorophosphate, 4-(4,6-dimethyl Oxy-1,3,5-triazin-2-yl)-4-methylmorpholine chloride, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethane Carbodiimide Hydrochloride, N,N'-Dicyclohexylcarbodiimide, N,N'-Diisopropylcarbodiimide, O-Benzotriazole-N,N,N ',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole, O-benzotriazole-N,N,N ',N'-tetramethyluronium hexafluorophosphate
  • the methods for preparing intermediate compounds 1-8 and compound 8 are as follows.
  • the compound of general formula 7 is reacted with D in the presence of a condensing agent under basic conditions to obtain the compound of general formula 8.
  • n, AA, R, i, f, FF 2 , FF, D are as described herein.
  • the intermediate shown is:
  • R, n, D are as described herein.
  • the intermediate is:
  • R, n, D are as described herein.
  • the intermediate is:
  • n and D are as described herein.
  • the intermediate is:
  • n and D are as described herein.
  • the intermediate is:
  • the above-mentioned basic conditions can be provided by reagents, which include organic bases and inorganic bases, and said organic bases include but not limited to triethylamine, diethylamine, N-methylmorpholine, pyridine, hexahydropyridine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide or potassium tert-butoxide, the inorganic bases include but not limited to sodium hydride, potassium phosphate , sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide and lithium hydroxide.
  • organic bases include but not limited to triethylamine, diethylamine, N-methylmorpholine, pyridine, hexahydropyridine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium
  • the above-mentioned condensing agent can be selected from N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)urea hexafluorophosphate, 4-(4,6-dimethyl Oxy-1,3,5-triazin-2-yl)-4-methylmorpholine chloride, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethane Carbodiimide Hydrochloride, N,N'-Dicyclohexylcarbodiimide, N,N'-Diisopropylcarbodiimide, O-Benzotriazole-N,N,N ',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole, O-benzotriazole-N,N,N ',N'-tetramethyluronium hexafluorophosphate
  • the methods for preparing intermediate compounds 1-9 and compound 9 are as follows.
  • n, AA, R, i, f, FF, D, Abu are as described herein.
  • the coupling schematic diagram is shown in Figure 1.
  • the interchain disulfide bond on the anti-FR ⁇ antibody provided by the present invention is reduced and opened by a thiol reducing agent to generate a free sulfhydryl group, and then undergoes a coupling reaction with the compound of formula 8 , to obtain the antibody-drug conjugate shown in formula 9.
  • the above-mentioned weakly acidic conditions can be provided by reagents, which include organic acids and inorganic acids, and said organic acids include but are not limited to acetic acid, benzoic acid, tartaric acid, oxalic acid, malic acid, citric acid, ascorbic acid, citric acid, citrate Rhenic acid, salicylic acid, caffeic acid, sorbic acid, quinic acid, oleanolic acid, succinic acid, chlorogenic acid, formic acid, propionic acid, the inorganic acids include but not limited to carbonic acid, nitrous acid, acetic acid , hypochlorous acid, hydrofluoric acid, sulfurous acid, hydrogen sulfuric acid, silicic acid, metasilicate, phosphoric acid, metaphosphoric acid, sodium bicarbonate, sodium bisulfite.
  • organic acids include but are not limited to acetic acid, benzoic acid, tartaric acid, oxalic acid, malic acid, citric acid, ascorbic acid,
  • the drug conjugate can be purified by conventional methods, such as preparative high-performance liquid chromatography (prep-HPLC) and other methods.
  • pre-HPLC preparative high-performance liquid chromatography
  • the anti-FR ⁇ antibody or its antigen-binding unit, and the antibody-drug conjugate coupled with the anti-FR ⁇ antibody of the present invention can be incorporated into a pharmaceutical composition suitable for administration.
  • a pharmaceutical composition suitable for administration suitable for administration.
  • the principles and considerations involved in the preparation of such compositions and guidance for selecting components are well known in the art, see, e.g., Remington's Pharmaceutical Sciences: The Science And Practice Of Pharmacy, 19th Ed., Mack Pub. Co., Easton , Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; Peptide And Protein Drug Delivery, Advances In Parenteral Sciences, Volume 4, 1991, M. Dekker , New York.
  • compositions generally comprise an antibody or an antigen-binding unit thereof or an antibody-drug conjugate and a pharmaceutically acceptable carrier.
  • antibody fragments or antigen binding units are used as minimal inhibitory fragments that specifically bind to a target protein binding domain.
  • the pharmaceutical composition further comprises an anti-cancer agent (eg, an immune checkpoint inhibitor).
  • the term "pharmaceutically acceptable carrier” is intended to include any and all solvents, stabilizers, buffers, dispersion media, coatings, bacteriostats, isotonic and absorption delaying agents compatible with pharmaceutical administration. agent etc. Suitable carriers are described in Remington's Pharmaceutical Sciences. Such carriers or diluents may optionally include, but are not limited to, water, physiological saline, Ringer's solution, dextrose solution, and 5% human serum albumin.
  • formulations to be used for in vivo administration must be sterile, which is readily accomplished by filtration through sterile membrane filters.
  • compositions can be formulated in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form as used herein refers to physically separable units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of a drug calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. or a plurality of said antibodies.
  • the pharmaceutical composition can be presented in a container or dispenser and packaged with instructions for administration.
  • compositions of the present invention may also contain other active ingredients, preferably those with complementary activities that do not adversely affect each other, depending on the particular condition to be treated.
  • the composition may include agents that enhance its function, such as cytotoxic agents, cytokines, chemotherapeutics, or growth inhibitory agents.
  • active ingredients are suitably present in combination in amounts effective for the intended purpose.
  • the pharmaceutical composition provided by the present invention can be administered by any convenient route, such as by infusion or bolus injection, absorbed through the epithelium or mucous membrane of the skin (such as oral mucosa, rectal and intestinal mucosa, etc.), and can be co-administered with other biologically active agents .
  • the pharmaceutical composition can be administered intravenously, orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, externally (e.g. by powder, ointment, drops, etc.) or transdermal patch), orally, or by oral or nasal spray.
  • the pharmaceutical composition is formulated into a pharmaceutical composition suitable for intravenous injection into a human body according to conventional procedures.
  • Pharmaceutical compositions for intravenous administration are generally solutions in sterile isotonic aqueous buffer.
  • the pharmaceutical composition may also contain a solubilizer and a local anesthetic such as lidocaine to relieve pain at the injection site.
  • the active ingredients are presented alone or in combination in unit dosage form, eg, as a dry lyophilized powder or water-free concentrate, in a hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent.
  • the composition may be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water or saline for injection can be used so that the active ingredient can be mixed before administration.
  • compositions of the present invention may be formulated as neutral or salt forms.
  • the antibodies or antigen-binding units thereof or ADCs described herein are useful in a variety of applications including, but not limited to, methods of therapy, such as the treatment of tumors.
  • the antibody or antigen-binding unit thereof or ADC can be used to inhibit tumor growth, reduce tumor volume, and/or reduce tumorigenicity of a tumor.
  • the method of use can be an in vitro, ex vivo or in vivo method.
  • an antibody, or antigen-binding unit thereof, or ADC described herein is an antagonist of the FR ⁇ to which it binds.
  • the method of inhibiting tumor growth comprises contacting a tumor with an anti-FR ⁇ antibody or antigen binding unit thereof or ADC or a pharmaceutical composition comprising the same in vitro.
  • an immortalized cell line or cancer cell expressing FR ⁇ is cultured in a medium supplemented with an anti-FR ⁇ antibody or antigen-binding unit thereof or ADC or a pharmaceutical composition comprising the same.
  • tumor cells are isolated from a patient sample and added to a culture medium containing an anti-FR ⁇ antibody or antigen-binding unit thereof or ADC or a pharmaceutical composition comprising the same.
  • the method of inhibiting tumor growth comprises contacting a tumor or tumor cells in vivo with an anti-FR ⁇ antibody or antigen binding unit thereof or ADC or a pharmaceutical composition comprising the same.
  • the antibody or its antigen-binding unit or ADC provided by the present invention or the pharmaceutical composition comprising it can be used for diagnosis, prognosis, monitoring, treatment, alleviation and/or prevention of diseases and disorders related to abnormal expression of FR ⁇ in patients.
  • diseases and conditions associated with abnormal expression of FR ⁇ are identified in patients by using conventional methods, the antibody or its antigen-binding unit or ADC of the present invention or a pharmaceutical composition comprising the same can be administered.
  • the degree of FR ⁇ expression is detected by immunohistochemistry (IHC), flow cytometry or nucleic acid hybridization and the like.
  • IHC immunohistochemistry
  • WO 2014/036495 and WO 2015/031815 provide exemplary antibodies, detection methods and kits for detecting FR ⁇ , all of which are incorporated herein by reference.
  • the present invention relates to a method for treating a disease related to FR ⁇ as a therapeutic target, thereby improving, slowing down, inhibiting, treating or preventing any disease associated with abnormal expression of FR ⁇ (for example, overexpression of FR ⁇ ) or Disease; relates to providing methods for treating tumors (including benign tumors and cancers) in patients, methods for relieving symptoms of tumors (including benign tumors and cancers) in patients, and methods for avoiding recurrence of tumors (including benign tumors and cancers) in patients, the methods comprising adding The patient is administered an effective amount of any antibody or antigen-binding unit thereof or ADC described herein.
  • the present invention provides a method for preventing, treating or improving diseases, the method comprising administering an effective amount of an anti-FR ⁇ antibody or its antigen-binding unit or ADC or a pharmaceutical combination comprising the same to a patient in need things.
  • the present invention provides the use of the antibody or its antigen-binding unit or ADC in the preparation of medicaments for preventing, treating or improving diseases.
  • the present invention provides the use of the antibody or its antigen-binding unit or ADC in preventing, treating or improving diseases.
  • the disease is a disease associated with abnormal expression of FR ⁇ . In one or more embodiments, the disease is a disease associated with overexpression of FR ⁇ .
  • the disease is a tumor expressing FRa. In one or more embodiments, the disease is a tumor overexpressing FRa. In one or more embodiments, the disease is a cancer that overexpresses FRa. In one or more embodiments, the disease is a cancer overexpressing human FRa.
  • the present invention provides a method for treating tumors (including benign tumors and cancers), the method comprising administering to a patient in need thereof an effective amount of an anti-FR ⁇ antibody or an antigen-binding unit thereof or ADC or comprising pharmaceutical composition.
  • the present invention provides the use of the antibody or its antigen-binding unit or ADC in the preparation of a medicament for treating tumors (including benign tumors and cancers).
  • the present invention provides the use of the antibody or its antigen-binding unit or ADC in the treatment of tumors (including benign tumors and cancers).
  • cancer examples include, but are not limited to, solid tumors, hematological cancers, and metastatic lesions. Specific examples of such cancers include, but are not limited to, colorectal cancer, lung cancer, ovarian cancer, uterine cancer, endometrial cancer, peritoneal cancer, fallopian tube cancer, pancreatic cancer, squamous cell carcinoma of the head and neck, nasopharyngeal cancer, laryngeal cancer, lung adenocarcinoma Cancer, liver cancer, breast cancer, brain cancer, kidney cancer, renal cell carcinoma, colon cancer, testicular cancer, cervical cancer, bladder cancer, retinoblastoma, glioblastoma, mesothelioma, oral epithelioid carcinoma, Choriocarcinoma and head and neck cancer.
  • cancers include ovarian cancer, epithelial ovarian cancer, primary peritoneal cancer of the ovary, or fallopian tube cancer.
  • the cancer is metastatic or advanced cancer.
  • the patient is a patient with increased expression levels of FR ⁇ .
  • the patient is a human.
  • the patient can be a mammal into which FRa has been introduced (eg, by administering FRa or by expressing a FRa transgene).
  • Antibodies or antigen-binding units thereof or ADCs of the invention can be administered to human patients for therapeutic purposes.
  • an antibody of the invention, or an antigen-binding unit thereof, or an ADC can be administered to a non-human mammal expressing FRa (for veterinary purposes or as an animal model of human disease).
  • Animal models of such human diseases can be used to assess the therapeutic efficacy of the antibodies of the invention, or antigen-binding units thereof, or ADCs (eg, dose testing and dosing time courses).
  • the specific dosage and treatment regimen for any particular patient will depend on various factors, including the particular antibody or derivative (e.g., ADC or pharmaceutical composition) used, the patient's age and weight, general health, sex, and diet, and Timing of administration, frequency of metabolism, drug combination, and severity of the particular disease being treated. These factors are in the judgment of the medical caregiver, who is within the purview of those of ordinary skill in the art.
  • the dosage will also depend on the individual patient to be treated, the route of administration, the type of formulation, the nature of the compound employed, the severity of the disease and the effect desired.
  • the dosage used can be determined by principles of pharmacology and pharmacokinetics well known in the art.
  • the effective amount refers to the amount of active compound or agent that results in the biological or pharmaceutical response of the tissue, system, animal, individual and human being sought by the researcher, veterinarian, physician or other clinician, including the treatment of a disease .
  • the effective dose ranges from about 0.1 mg/kg to about 100 mg/kg, and the dosing frequency can be, for example, once a month, once every two weeks, or once every three weeks Once, twice every three weeks, three times every four weeks, once a week, twice a week, etc.
  • the administration method can be intravenous infusion, intravenous injection, subcutaneous injection, intramuscular injection, etc. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated.
  • the specific dosage regimen can be adjusted at any time according to the needs of the patient and the professional judgment of the person administering the composition or supervising the administration of the composition, and the dosage ranges set forth herein are exemplary only, It is not intended to limit the scope or practice of the claimed compositions.
  • Methods of administration of an antibody or antigen-binding unit thereof or ADC include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, nasal, epidural, and oral.
  • the pharmaceutical compositions may be administered by any convenient route, such as by infusion or bolus injection, absorbed through the epithelium or mucous membranes (eg, oral mucosa, rectal and intestinal mucosa, etc.), and may be co-administered with other biologically active agents.
  • compositions containing an antibody of the invention may be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (such as by powder, ointment, drops or transdermal patch), oral administration or nasal spray administration.
  • parenteral refers to modes of administration including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
  • the mode of administration can be systemic administration or local administration.
  • Pulmonary administration is also possible, for example by use of an inhaler or nebulizer, and by use of nebulized formulations.
  • Antibodies of the invention, or antigen-binding units thereof, or ADCs may be administered topically to the area in need of treatment; by, but not limited to, local infusion during surgery, for example local application in conjunction with post-operative wound dressings, by injection, by catheter, This is achieved by means of a suppository or by means of an implant, which is a porous, non-porous or gelatinous material comprising membranes (eg silicone rubber membranes) or fibers.
  • an antibody of the invention, or an antigen-binding unit thereof, or an ADC care must be taken to use materials that do not absorb proteins.
  • the methods for treating diseases are usually tested in vitro, including administering the antibody or ADC of the present invention, then testing the desired therapeutic or preventive activity in an acceptable animal model in vivo, and finally administering to humans.
  • Suitable animal models including transgenic animals, are known to those of ordinary skill in the art.
  • in vitro assays for demonstrating therapeutic use of the antibodies or antigen binding units thereof or ADCs of the invention include the effect of the antibodies or antigen binding units thereof or ADCs on cell lines or patient tissue samples.
  • the effect of antibodies or antigen binding units thereof or ADCs on cell lines and/or tissue samples can be detected using techniques known to those skilled in the art, such as those disclosed elsewhere herein.
  • In vitro assays useful in determining whether to administer an antibody, or antigen-binding unit thereof, or ADC, in accordance with the present invention include in vitro cell culture assays in which patient tissue samples are grown in culture and exposed to or otherwise administered the antibody or its Antigen binding unit or ADC, and observe the effect of such antibody or antigen binding unit or ADC on the tissue sample.
  • Various known delivery systems can be used to administer the antibodies of the invention, or antigen-binding units thereof, or polynucleotides or ADCs encoding the same, such as encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compounds, subject Body-mediated endocytosis (see, eg, Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of nucleic acids as part of retroviruses or other vectors, etc.
  • the antibodies of the invention, or antigen-binding units thereof, or ADCs may be combined with other therapeutic or prophylactic regimens, comprising one or more antibodies of the invention, or antigen-binding units thereof, or ADCs, and one or more other The therapeutic agents or methods are used together or in combination.
  • the antibody or antigen-binding unit thereof, or ADC, and the other therapeutic agent may be administered simultaneously or separately.
  • an antibody of the invention, or an antigen-binding unit thereof, or ADC may be administered before or after another other therapeutic agent is administered.
  • the antibody of the present invention or its antigen-binding unit or ADC when administered to the patient, the antibody disclosed herein or its antigen-binding unit or ADC or pharmaceutical composition or immunoconjugate may also be administered to the patient in combination.
  • antibodies of the invention, or antigen-binding units thereof, or ADCs may be used with immune checkpoint inhibitors. In one or more embodiments, antibodies of the invention, or antigen-binding units thereof, or ADCs, are administered in combination with other therapeutic or prophylactic regimens, such as radiation therapy.
  • Such combination therapy encompasses simultaneous administration (where two or more formulations are contained in the same formulation or in separate formulations), and separate administration, in which case it may be followed by administration of other therapies, such as treatment modalities and/or Administration of an antibody or antigen-binding unit thereof or ADC of the invention occurs before, simultaneously with, and/or after the therapeutic agent.
  • Antibodies or antigen binding units thereof or ADCs and/or other therapies, eg therapeutics or treatment modalities may be administered during active disease or during remission or less active disease.
  • Antibodies or antigen-binding units thereof or ADCs can be administered before, concurrently with, after, or during remission of other treatments.
  • the antibodies, antigen-binding units, or derivatives disclosed herein are modified to reduce their immunogenicity using art-recognized techniques.
  • antibodies can be humanized, primatized, deimmunized or chimeric antibodies can be prepared. These types of antibodies are derived from non-human antibodies, usually murine or primate antibodies, which retain or substantially retain the antigen-binding properties of the parent antibody but are less immunogenic in humans.
  • framework residues in the human framework regions will be replaced by corresponding residues from the CDR donor antibody, such as residues that improve antigen binding.
  • These framework substitutions can be identified by methods known in the art, such as by simulating the interaction of CDRs and framework residues to identify framework residues important for antigen binding and by sequence alignment to identify abnormal framework residues at specific positions ( See US Patent 5,585,089; the entire contents of which are incorporated herein by reference).
  • Antibodies can be humanized using various techniques known in the art, such as CDR grafting (EP 239,400; WO 91/09967; US Patents 5,225,539, 5,530,101 and 5,585,089), repair or surface rearrangement (EP 592,106; EP 519,596) , and chain rearrangements (US Patent 5,565,332), the entire contents of which are incorporated herein by reference.
  • Antibodies can be engineered by recombinant DNA techniques to replace CH1, CH2, CH3, hinge and/or framework domains with corresponding human sequences (see WO 92102190 and U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,761; 5,693,792; 5,714,350; and 5,777,085).
  • Ig cDNA to construct chimeric immunoglobulin genes is also known in the art (Liu et al. P.N.A.S. 84:3439 (1987) and J. Immunol. 139:3521 (1987)).
  • mRNA is isolated from antibody-producing hybridomas or other cells and used to produce cDNA.
  • cDNA can be amplified by polymerase chain reaction using specific primers (US Patents 4,683,195 and 4,683,202).
  • libraries are constructed and screened to isolate sequences of interest.
  • the DNA sequences encoding the antibody variable regions are then fused to human constant region sequences.
  • the sequence of the human constant region gene can be found in Sequences of Proteins of immunological Interest published by Kabat et al.
  • Human C region genes can be easily obtained from known clones. The choice of isotype will be guided by the desired effector function, such as activity in complement fixation or antibody-dependent cellular cytotoxicity. Preferred isotypes are IgG1 and IgG2. Either human light chain constant region, kappa or lambda, can be used, and chimeric humanized antibodies can be expressed by conventional methods.
  • Deimmunization can also be used to reduce the immunogenicity of antibodies.
  • the term "deimmunization” includes altering antibodies to modify T cell epitopes (see eg WO/9852976 A1 and WO/0034317 A2).
  • the heavy and light chain variable region sequences from a starting antibody are analyzed and a human T cell epitope "map" from each variable region is generated, showing the epitopes relative to the complementarity determining regions (CDRs) and the positions of other key residues within the sequence.
  • CDRs complementarity determining regions
  • Individual T-cell epitopes from T-cell epitope maps are analyzed to identify alternative amino acid substitutions with lower risk of altering antibody activity.
  • a series of alternative heavy chain variable region sequences and light chain variable region sequences comprising combinations of amino acid substitutions are designed and these sequences are subsequently incorporated into a series of binding polypeptides.
  • Genes for the complete heavy and light chains containing the modified variable and human constant regions are then cloned into expression vectors, and the plasmids are subsequently transformed into cell lines to produce complete antibodies.
  • Antibodies are then compared using appropriate biochemical and biological assays to identify the best antibody.
  • Fully human antibodies that recognize selective epitopes can be produced using a technique known as "guided selection.” In this approach, selected non-human monoclonal antibodies are used to guide the selection of fully human antibodies that recognize the same epitope (see US Patent 5,565,332, the entire contents of which are incorporated herein by reference).
  • Single-chain Fv can be found in techniques for producing single-chain units (US Patent 4,694,778).
  • Single-chain fusion peptides are generated by amino acid bridging of the heavy and light chain fragments of the Fv region to form single-chain units.
  • the technique of assembling functional Fv fragments in E. coli can also be used (Skerra et al., Science 242:1038-1041 (1988)).
  • antigen-binding fragments such as Fab, F(ab') 2 and Fv can be prepared by cleavage of intact proteins, eg, by protease or chemical cleavage. Including but not limited to: (i) digesting antibody molecules with pepsin to obtain F(ab') 2 fragments; (ii) obtaining Fab fragments by reducing the disulfide bond of F(ab') 2 fragments; (iii) using papain and Treatment of antibody molecules with reducing agents produces Fab fragments, and (iv) Fv fragments.
  • one or more CDRs of an antibody of the invention can be inserted into a framework region, eg, into a human framework region, to construct a humanized antibody.
  • the framework regions may be naturally occurring or consensus framework regions, preferably human framework regions (see Chothia et al., J. Mol. Biol. 278:457-479 (1998) for a list of human framework regions).
  • Some polynucleotides may encode an antibody that specifically binds at least one epitope of an antigen of interest produced by a combination of framework regions and CDRs.
  • One or more amino acid substitutions may be made within the framework regions, and the amino acid substitutions may be selected to improve binding of the antibody to its antigen.
  • substitution or deletion of cysteine residues in one or more variable regions involved in interchain disulfide bond formation can be performed in this way, thereby producing antibody molecules lacking one or more interchain disulfide bonds.
  • Other modifications to polynucleotides within the skill of the art are also encompassed in the present invention.
  • Antibodies can be prepared using conventional recombinant DNA techniques. Antibody-producing vectors, cell lines, and the like can be selected, constructed, and cultured using techniques known to those skilled in the art. These techniques are described in various laboratory manuals and major publications, such as Recombinant DNA Technology for Production of Protein Therapeutics in Cultured Mammalian Cells, D.L. hacker, F.M. Wurm, in Reference Module in Life Sciences, 2017, which in its entirety includes The supplementary content is incorporated by reference in its entirety.
  • the anti-FR ⁇ antibody or antigen-binding unit thereof of the present invention is modified in glycosylation.
  • an aglycosylated antibody can be prepared (ie, the antibody lacks glycosylation).
  • Glycosylation can be altered, for example, to increase the affinity of the antibody for antigen.
  • modifications can be accomplished, for example, by altering one or more glycosylation sites within the antibody sequence.
  • one or more amino acid substitutions can be made to eliminate one or more variable region glycosylation sites, thereby eliminating glycosylation at that site.
  • deglycosylation increases the affinity of the antibody for antigen.
  • Antibody (eg, anti-FR ⁇ antibody) genes can be inserted into expression vectors by standard methods (eg, ligation of antibody gene fragments and complementary restriction sites on the vector, or blunt ligation if no restriction sites are present).
  • Expression vectors can be plasmids, retroviruses, YACs, EBV-derived episomes, and the like.
  • DNA encoding the full-length light and heavy chains can be inserted into expression vectors such that the genes are operably linked to transcriptional and translational control sequences.
  • “Operably linked” means that the antibody gene is linked into the vector such that the transcriptional and translational control sequences within the vector perform their intended function of regulating the transcription and translation of the antibody gene.
  • the consensus sequences of the heavy and light chain J regions can be used to design oligonucleotides used as primers to introduce useful restriction sites within the J region for subsequent ligation of the V region segment to the human C region segment.
  • the C region cDNA can be modified by site-directed mutagenesis to place a restriction site at an analogous position in the human sequence.
  • the expression vector already carries antibody constant region sequences prior to insertion of antibody-related light or heavy chain gene sequences.
  • one approach to converting the VH and VL sequences associated with an anti-FR ⁇ antibody into a full-length antibody gene is to insert them into expression vectors already encoding the heavy and light chain constant regions, respectively, such that the VH segment is operably linked to a CH segment within the vector, and the VL segment is operably linked to a CL segment within the vector.
  • Recombinant expression vectors can encode signal peptides that promote secretion of antibody heavy and light chains from host cells.
  • the antibody heavy and light chain genes can be cloned into a vector encoding a signal peptide that promotes secretion of the antibody heavy and light chains from the host cell such that the signal peptide is linked in frame to the amino termini of the antibody heavy and light chain genes.
  • the signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin protein), for example, MDWTWRILFLVAAATGAHS (SEQ ID NO: 21), MEAPAQLLFLLLLWLPDTTG (SEQ ID NO: 22).
  • a heterologous signal peptide i.e., a signal peptide from a non-immunoglobulin protein
  • the recombinant expression vector may also carry regulatory sequences that control the expression of the antibody chain genes in the host cell. Regulatory sequences include promoters, enhancers and other expression control elements (eg, polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA, 1990. Those skilled in the art understand that the design of expression vectors, including the selection of regulatory sequences, may depend on factors such as the selection of host cells to be transformed, the expression level of the desired protein, and the like.
  • Suitable regulatory sequences for expression in mammalian host cells include viral elements that direct high-level protein expression in mammalian cells, such as those derived from cytomegalovirus (CMV) (e.g., CMV promoter/enhancer), Simian virus 40 (SV40 ) (eg SV40 promoter/enhancer), adenovirus (eg adenovirus major late promoter (AdMLP)) and polyoma promoters and/or enhancers.
  • CMV cytomegalovirus
  • SV40 Simian virus 40
  • AdMLP adenovirus major late promoter
  • recombinant expression vectors can carry additional sequences, such as sequences that regulate replication of the vector in a host cell (eg, an origin of replication) and selectable marker genes.
  • a selectable marker gene facilitates selection of host cells into which the vector has been introduced (see, eg, US Patents 4,399,216, 4,634,665, and 5,179,017).
  • marker genes that confer resistance to drugs such as G418, hygromycin, or methotrexate to host cells into which the vector has been introduced can often be selected.
  • Suitable selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in DHFR-host cells with methotrexate selection/amplification), the neo gene (for G418 selection) and the GS gene .
  • DHFR dihydrofolate reductase
  • neo for G418 selection
  • GS gene for G418 selection
  • expression vectors encoding the heavy and light chains are transfected into host cells by standard techniques.
  • Antibodies of the present invention can be produced by recombinantly expressing the heavy and light chain genes of the antibody in host cells.
  • host cells are transfected with one or more recombinant expression vectors carrying heavy and light chain DNA fragments encoding antibodies, so that the heavy and light chains are expressed in the host cells, and the expressed antibodies can be secreted into the cultured host cells. within the culture medium from which the antibody can be recovered.
  • Transfection refers to a wide variety of techniques commonly used to introduce exogenous DNA into eukaryotic host cells, such as electroporation, lipofection, calcium phosphate precipitation, DEAE-dextran transfection, and the like.
  • Standard recombinant DNA methods for obtaining antibody heavy and light chain genes, incorporating these genes into expression vectors, and introducing the vectors into host cells are well known in the art, e.g., Molecular Cloning; A Laboratory Manual, Second Edition (Sambrook, Fritsch and Maniatis (eds., Cold Spring Harbor, N.Y., 1989), Current Protocols in Molecular Biology (Ausubel, F.M. et al., eds., Greene Publishing Associates, 1989), and those described in U.S. Patent No. 4,816,397.
  • the DNA expressing the antibody heavy chain and light chain can be placed in the same vector or placed in different vectors; if placed in different vectors, the vector expressing the antibody heavy chain and the vector expressing the antibody light chain can be transfected into host cells in an appropriate ratio (such as Tihomir S.
  • an antibody expression vector includes at least one promoter element, an antibody coding sequence, a transcription termination signal, and a polyA tail.
  • GCCACC Kozak sequences
  • Other elements may include enhancers, Kozak sequences (GCCACC, as shown in SEQ ID NO: 33), and donor and acceptor sites for RNA splicing flanking the insert.
  • High-efficiency transcription can be obtained through the early and late promoters of SV40, long terminal repeats from retroviruses such as RSV, HTLV1, HIVI, and early promoters of cytomegalovirus, and other cellular promoters such as muscle Kinetin promoter.
  • Suitable expression vectors may include pIRES1neo, pRetro-Off, pRetro-On, pLXSN, pLNCX, pcDNA3.1(+/-), pcDNA/Zeo(+/-), pcDNA3.1/Hygro(+/-), pSVL , pMSG, pRSVcat, pSV2dhfr, pBC12MI, pCS2 or pCHO1.0, etc.
  • Antibodies (eg, anti-FR ⁇ antibodies) of the invention can be expressed in eukaryotic host cells.
  • expression of antibodies is performed in eukaryotic cells, such as mammalian host cells.
  • Exemplary host cells for expressing antibodies of the invention include Chinese hamster ovary cells (CHO cells) such as CHO-K1 cells, or CHO-S, CHO-dhfr-, CHO/DG44 or ExpiCHO, NSO bone marrow modified from CHO cells Tumor cells, COS cells, Cos1 cells, Cos7 cells, SP2 cells, CV1 cells, mouse L cells, human embryonic kidney cells HEK293 or HEK293T, HEK293F or HEK293E cells modified from HEK293 cells.
  • CHO cells Chinese hamster ovary cells
  • CHO-K1 cells such as CHO-K1 cells, or CHO-S, CHO-dhfr-, CHO/DG44 or ExpiCHO
  • the host cell After the recombinant expression vector encoding the antibody chain gene is introduced into the host cell, the host cell is cultured in a medium for a period of time allowing the expression of the antibody in the host cell or the secretion of the antibody into the medium to produce the antibody.
  • Antibodies can be recovered from the culture medium using standard protein purification methods.
  • Antibody-producing cell lines can be selected, constructed and cultured by using techniques well known to those skilled in the art. These techniques are described in various laboratory manuals and major publications, such as Recombinant DNA Technology for Production of Protein Therapeutics in Cultured Mammalian Cells, D.L. hacker, F.M. Wurm, in Reference Module in Life Sciences, 2017, which in its entirety includes The supplementary content is incorporated by reference in its entirety.
  • host cells can be co-transfected with two recombinant expression vectors, the first recombinant expression vector encoding the antibody heavy chain, and the second recombinant expression vector encoding the antibody light chain.
  • the two recombinant expression vectors may contain the same selectable marker, or they may each contain separate selectable markers.
  • host cells can be transfected with recombinant expression vectors encoding the antibody heavy and light chains.
  • Antibodies of the present invention can also be produced by chemical synthesis (e.g., by the method described in Solid Phase Peptide Synthesis, 2nd Edition, 1984 The Pierce Chemical Co., Rockford, Ill.). Variant antibodies can also be generated using cell-free platforms (see, e.g., Chu et al., Biochemia No. 2, 2001 (Roche Molecular Biologicals) and Murray et al., 2013, Current Opinion in Chemical Biology, 17:420-426).
  • Antibodies of the invention (e.g., anti-FR ⁇ antibodies) produced by recombinant expression can be purified by any method known in the art for purifying immunoglobulin molecules, such as by chromatography (e.g., ion exchange, affinity layers analytical and fractional column chromatography), centrifugation, differential solubility, or any other standard technique for purifying proteins. For example affinity chromatography using protein A or protein G, which mainly provides the IgG fraction in the immune serum. Alternatively, the specific antigen targeted by the immunoglobulin or its epitope can be immobilized on a column to purify the immunospecific antibody by immunoaffinity chromatography.
  • chromatography e.g., ion exchange, affinity layers analytical and fractional column chromatography
  • centrifugation e.g., centrifugation
  • differential solubility e.g., differential solubility
  • affinity chromatography e.g., affinity chromatography using protein A or protein G, which mainly provides the IgG fraction
  • Antibodies of the invention can be fused to heterologous polypeptide sequences known in the art to facilitate purification.
  • the purification of immunoglobulin can refer to the article of D. Wilkinson (The Engineer, published by The Engineer, Inc., Philadelphia Pa., Vol. 14, No. 8 (April 17, 2000), pages 25-28) .
  • mutations can be introduced in the nucleotide sequences encoding the antibodies of the invention using standard techniques known to those skilled in the art, including but not limited to site-directed mutagenesis and PCR-mediated mutations resulting in amino acid substitutions.
  • Variants encode substitutions of less than 50 amino acids relative to the original heavy chain variable region VH CDR1, VH CDR2, VH CDR3 and light chain variable region VL CDR1, VL CDR2, VL CDR3, less than 40 amino acid substitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions
  • a substitution of amino acids a substitution of less than 4 amino acids, a substitution of less than 3 amino acids, or a substitution of less than 2 amino acids.
  • mutations can be introduced randomly along all or part of the coding sequence, for example by saturation mutagenesis, and the resulting mutants can be screened for biological activity to identify mutants that retain activity.
  • substitutions described herein are conservative amino acid substitutions.
  • amino acid sequence of the heavy chain of the exemplary antibody 1 of the present invention is shown in SEQ ID NO: 19, and its coding gene sequence is shown in SEQ ID NO: 23.
  • SEQ ID NO: 19 is as follows:
  • SEQ ID NO: 23 is as follows:
  • amino acid sequence of the light chain of the exemplary antibody 1 of the present invention is shown in SEQ ID NO: 20, and its coding gene sequence is shown in SEQ ID NO: 24.
  • SEQ ID NO: 20 is as follows:
  • SEQ ID NO:24 is as follows:
  • Antigen FR ⁇ -His preparation the amino acid sequence of coding antigen FR ⁇ -His (antigen FR ⁇ -His as shown in SEQ ID NO: 28, by human FR ⁇ ectodomain (as shown in SEQ ID NO: 27, the underlined part is signal Peptide) C-terminus added 8 ⁇ HIS tag (constructed by HHHHHHHH)) cloned into the expression vector to construct the recombinant expression vector, and then stably transformed into CHO-K1 cells, cultured and purified to obtain the antigen FR ⁇ -His.
  • the heavy chain of the anti-FR ⁇ antibody is composed of VH and CH, and the light chain is composed of VL and CL; the amino acid sequence of CH is shown in SEQ ID NO:17, and the amino acid sequence of CL is shown in SEQ ID NO:18.
  • VH CDR and VL CDR are shown in Table 2
  • the framework regions of the heavy chain and the light chain are shown in Table 3
  • the amino acid sequences of the variable regions are shown in Table 4
  • the amino acid sequences of the constant regions are shown in Table 5.
  • the amino acid sequences of the heavy chain and light chain of the control antibody huMOV19 are shown in Table 6.
  • the gene sequences encoding the heavy chain and light chain of the antibody were respectively cloned into expression vectors to construct recombinant expression vectors, then transiently transfected into HEK293F cells, cultivated and purified to obtain antibodies. After sequencing, it was consistent with the expected sequence.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种抗FRα抗体及其抗体药物偶联物，以及上述抗FRα抗体、抗体药物偶联物在治疗FRα表达相关的疾病中的应用。

Description

抗FRα抗体及其抗体药物偶联物和用途 技术领域
本发明涉及抗FRα抗体、包含该抗FRα抗体的抗体药物偶联物及其用途。
背景技术
叶酸作为DNA合成和修复、细胞分裂过程所需的一种必要维生素，通过结合细胞表面的叶酸受体，通过内吞作用实现叶酸的转运，其中叶酸受体被内化，然后再循环回细胞膜。叶酸受体是一种与糖基化磷脂酰肌醇连接的跨膜单链糖蛋白，与叶酸具有高度亲和性。叶酸受体包括三种亚型，分别是叶酸受体α(Folate Receptorα，FOLR1，FRα)、叶酸受体β(Folate Receptorβ，FOLR2)和叶酸受体γ(Folate Receptorγ，FOLR3)。叶酸受体的表达在正常细胞中高度受限，在肿瘤细胞上则明显高表达，其中叶酸受体α在多种恶性肿瘤中均发现过量表达，因此成为抗癌药物的热门靶点之一。
发明内容
本发明提供了特异性识别并结合叶酸受体α的抗体(又称“抗叶酸受体α抗体”或“抗FRα抗体”)。在一个或多个实施方式中，本发明的抗体能够识别并结合人叶酸受体α。
在一个或多个实施方式中，本发明提供一种抗体或其抗原结合单元，所述抗体或其抗原结合单元特异性结合叶酸受体α，并且包含(a)-(f)中一个或多个：
(a)VH CDR1包含如SEQ ID NO:5所示的氨基酸序列，或与SEQ ID NO:5所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；
(b)VH CDR2包含如SEQ ID NO:6所示的氨基酸序列，或与SEQ ID NO:6所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；
(c)VH CDR3包含如SEQ ID NO:7所示的氨基酸序列，或与SEQ ID NO:7所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；
(d)VL CDR1包含如SEQ ID NO:8所示的氨基酸序列，或与SEQ ID NO:8所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；
(e)VL CDR2包含如SEQ ID NO:9所示的氨基酸序列，或与SEQ ID NO:9所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；
(f)VL CDR3包含如SEQ ID NO:10所示的氨基酸序列，或与SEQ ID NO:10所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成。
在一个或多个实施方式中，所述抗体或其抗原结合单元特异性结合叶酸受体α，且包含：
(a)VH CDR1包含如SEQ ID NO:5所示的氨基酸序列，或与SEQ ID NO:5所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(b)VH CDR2包含如SEQ ID NO:6所示的氨基酸序列，或与SEQ ID NO:6所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(c)VH CDR3包含如SEQ ID NO:7所示的氨基酸序列，或与SEQ ID NO:7所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:5所示的VH CDR1、如SEQ ID NO:6所示的VH CDR2和如SEQ ID NO:7所示的VH CDR3。
在一个或多个实施方式中，所述抗体或其抗原结合单元特异性结合叶酸受体α，且包含：
(d)VL CDR1包含如SEQ ID NO:8所示的氨基酸序列，或与SEQ ID NO:8所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(e)VL CDR2包含如SEQ ID NO:9所示的氨基酸序列，或与SEQ ID NO:9所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(f)VL CDR3包含如SEQ ID NO:10所示的氨基酸序列，或与SEQ ID NO:10所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:8所示的VL CDR1、如SEQ ID NO:9所示的VL CDR2和如SEQ ID NO:10所示的VL CDR3。
在一个或多个实施方式中，所述抗体或其抗原结合单元特异性结合叶酸受体α，且包含：
(a)VH CDR1包含如SEQ ID NO:5所示的氨基酸序列，或与SEQ ID NO:5所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(b)VH CDR2包含如SEQ ID NO:6所示的氨基酸序列，或与SEQ ID NO:6所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(c)VH CDR3包含如SEQ ID NO:7所示的氨基酸序列，或与SEQ ID NO:7所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(d)VL CDR1包含如SEQ ID NO:8所示的氨基酸序列，或与SEQ ID NO:8所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(e)VL CDR2包含如SEQ ID NO:9所示的氨基酸序列，或与SEQ ID NO:9所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成；和
(f)VL CDR3包含如SEQ ID NO:10所示的氨基酸序列，或与SEQ ID NO:10所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列，或由其组成。
在一个或多个实施方式中，所述位点取代、缺失或插入独立的为一个、两个或三个。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:5所示的VH CDR1、如SEQ ID NO:6所示的VH CDR2、如SEQ ID NO:7所示的VH CDR3、如SEQ ID NO:8所示的VL CDR1、如SEQ ID NO:9所示的VL CDR2和如SEQ ID NO:10所示的VL CDR3。
在一个或多个实施方式中，所述抗体或其抗原结合单元还包含(g)-(n)中一个或多个：
(g)VHFR1包含如SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列，或与SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
(h)VHFR2包含如SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列，或与SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
(i)VH FR3包含如SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列，或与SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
(j)VH FR4包含如SEQ ID NO:11所示的氨基酸序列，或与SEQ ID NO:11所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:11所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
(k)VLFR1包含如SEQ ID NO:12所示的氨基酸序列，或与SEQ ID NO:12所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:12所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
(l)VL FR2包含如SEQ ID NO:13所示的氨基酸序列，或与SEQ ID NO:13所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:13所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
(m)VL FR3包含如SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列，或与SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列相比具有至少90％序列同一性的氨 基酸序列，或与SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
(n)VL FR4包含如SEQ ID NO:14所示的氨基酸序列，或与SEQ ID NO:14所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:14所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
在一个或多个实施方式中，所述抗体或其抗原结合单元特异性结合叶酸受体α，且包含：
(g)VH FR1包含如SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列，或与SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和
(h)VH FR2包含如SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列，或与SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和
(i)VH FR3包含如SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列，或与SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和
(j)VH FR4包含如SEQ ID NO:11所示的氨基酸序列，或与SEQ ID NO:11所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:11所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和/或
(k)VL FR1包含如SEQ ID NO:12所示的氨基酸序列，或与SEQ ID NO:12所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:12所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和
(l)VL FR2包含如SEQ ID NO:13所示的氨基酸序列，或与SEQ ID NO:13所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:13所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和
(m)VL FR3包含如SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列，或与SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和
(n)VL FR4包含如SEQ ID NO:14所示的氨基酸序列，或与SEQ ID NO:14所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:14所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:1所示的VH FR1、如SEQ ID NO:2所示的VH FR2、如SEQ ID NO:3所示的VH FR3和如SEQ ID NO:11所示的VH FR4。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:12所示的VL FR1、如SEQ ID NO:13所示的VL FR2、如SEQ ID NO:4所示的VL FR3和如SEQ ID NO:14所示的VL FR4。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:1所示的VH FR1、如SEQ ID NO:2所示的VHFR2、如SEQ ID NO:3所示的VH FR3、如SEQ ID NO:11所示的VH FR4、如SEQ ID NO:12所示的VL FR1、如SEQ ID NO:13所示的VL FR2、如SEQ ID NO:4所示的VL FR3和如SEQ ID NO:14所示的VL FR4。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:29所示的VH FR1、如SEQ ID NO:30所示的VHFR2、如SEQ ID NO:31所示的VH FR3和如SEQ ID NO:11所示的VH FR4。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:12所示的VL FR1、如SEQ ID NO:13所示的VL FR2、如SEQ ID NO:32所示的VL FR3和如SEQ ID NO:14所示的VL FR4。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:29所示的VH FR1、如SEQ ID NO:30所示的VHFR2、如SEQ ID NO:31所示的VH FR3、如SEQ ID NO:11所示的VH FR4、如SEQ ID NO:12所示的VL FR1、如SEQ ID NO:13所示的VL FR2、如SEQ ID NO:32所示的VL FR3和如SEQ ID NO:14所示的VL FR4。
在一个或多个实施方式中，本发明提供了一种抗体或其抗原结合单元，所述抗体或其抗原结合单元特异性结合叶酸受体α，并且包含重链可变区(VH)和/或轻链可变区(VL)，其中：
所述重链可变区包含如SEQ ID NO:15所示的氨基酸序列，或与SEQ ID NO:15所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:15所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和/或
所述轻链可变区包含如SEQ ID NO:16所示的氨基酸序列，或与SEQ ID NO:16所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:16所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:15所示的重链可变区和如SEQ ID NO:16所示的轻链可变区。
在一个或多个实施方式中，所述抗体或其抗原结合单元还包含重链恒定区、轻链恒定区、Fc区或其组合。在一个或多个实施方式中，轻链恒定区是κ或λ链恒定区。在一个或多个实施方式中，抗体或其抗原结合单元是IgG、IgM、IgA、IgE或IgD其中一种同种型。在一个或多个实施方式中，同种型是IgG1、IgG2、IgG3或IgG4。在一个或多个实施方式中，抗体或其抗原结合单元是鼠源抗体、嵌合抗体、人源化抗体或全人源抗体。
在一个或多个实施方式中，所述抗体或其抗原结合单元为scFV、Fab、Fab'或F(ab) 2。在一个或多个实施方式中，所述抗体或其抗原结合单元为单克隆抗体。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含重链恒定区(CH)和/或轻链恒定区(CL)，其中：
所述重链恒定区包含如SEQ ID NO:17所示的氨基酸序列，或与SEQ ID NO:17所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:17所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和/或
所述轻链恒定区包含如SEQ ID NO:18所示的氨基酸序列，或与SEQ ID NO:18所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:18所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
在一个或多个实施方式中，所述抗体或其抗原结合单元包含如SEQ ID NO:17所示的重链恒定区和如SEQ ID NO:18所示的轻链恒定区。
在一个或多个实施方式中，本发明提供了特异性结合叶酸受体α的抗体，所述抗体的重链包含如SEQ ID NO:15所示的重链可变区和如SEQ ID NO:17所示的重链恒定区；所述抗体的轻链包含如SEQ ID NO:16所示的轻链可变区和如SEQ ID NO:18所示的轻链恒定区。
在一个或多个实施方式中，本发明提供了一种抗体，所述抗体特异性结合叶酸受体α，并且所述抗体包含重链(H)和轻链(L)，其中：
所述重链包含如SEQ ID NO:19所示的氨基酸序列，或与SEQ ID NO:19所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:19所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和/或
所述轻链包含如SEQ ID NO:20所示的氨基酸序列，或与SEQ ID NO:20所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:20所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
在一个或多个实施方式中，所述抗体包含如SEQ ID NO:19所示的重链和如SEQ ID NO:20所示的轻链。
在一个或多个实施方式中，所述取代为保守氨基酸取代。
在一个或多个实施方式中，所述抗体或其抗原结合单元是嵌合、人源化或全人源的。
在一个或多个实施方式中，所述抗体或其抗原结合单元为单克隆抗体(包括全长单克隆抗体)、多特异性抗体或其抗原结合单元(例如双特异性抗体或其抗原结合单元)。
在一个或多个实施方式中，所述抗体具有两条序列相同的重链和两条序列相同的轻链。在一个或多个实施方式中，Fc区配对形成二硫键。在一个或多个实施方式中，本发明的抗体或其抗原结合单元为分离的抗体或其抗原结合单元。
在一个或多个实施方式中，本发明的抗体或其抗原结合单元为单克隆抗体或其片段。
在一个或多个实施方式中，本发明还提供一种生物材料，为
(1)一种多聚核苷酸，其编码本发明所述抗体或其抗原结合单元；或其一部分，
(2)一种表达载体，其包含编码本发明所述抗体或其抗原结合单元的多聚核苷酸；或，
(3)一种细胞，其包含编码本发明所述抗体或其抗原结合单元的一种或多种多聚核苷酸。
在一个或多个实施方式中，本发明还提供一种药物组合物，其包含本发明提供的抗体或其抗原结合单元。这些组合物可包括于试剂盒中，如诊断试剂盒。
在一个或多个实施方式中，本发明还提供了通过给予患者其所需的一种或多种结合叶酸受体α的抗体或其抗原结合单元从而缓解或治疗癌症或其他病症症状的方法。所述抗体的给药剂量应足够缓解或治疗患者的癌症或其他病症症状。在一个或多个实施方式中，所述患者是人。
在一个或多个实施方式中，本发明所述抗FRα抗体与一种或多种其它疗法组合联用。合适的其它疗法包括现有的用于特定应用(如癌症)的药物、放疗和/或手术疗法。例如，所述抗FRα抗体与一种或多种其它化疗或抗肿瘤试剂联用。或者，其它化疗法是放射疗法。在一个或多个实施方式中，所述化疗剂是细胞死亡诱导剂。
在一个或多个实施方式中，所述抗FRα抗体和其它试剂被制备为单个治疗组合物，并同时给予所述抗FRα抗体和其它试剂。或者，所述抗FRα抗体和其它试剂彼此独立，例如分别制备为独立的治疗组合物，并同时给予所述抗FRα抗体和其它试剂，或在治疗方案期间在不同时间给予所述抗FRα抗体和其它试剂。例如，在给予其它试剂前给予所述抗FRα抗体，在给予其它试剂后给予所述抗FRα抗体，或在以交替的方案给予所述抗FRα抗体和其它试剂。本文中，以单个剂量或多个剂量给予所述抗FRα抗体和其它试剂。
在一个或多个实施方式中，本发明还提供一种抗体药物偶联物(ADC)，其包含通过接头与药物偶联的本发明所述的抗体或其抗原结合单元，或其药学上可接受的盐或溶剂合物。
在一个或多个实施方式中，所述接头为可裂解的接头。
在一个或多个实施方式中，所述药物为抗癌药物、细胞毒性药物、细胞分化因子、干细胞营养因子、类固醇类药物、治疗自身免疫疾病的药物、抗炎症药物或治疗传染性疾病的药物。
在一个或多个实施方式中，所述药物为抗癌药物。
在一个或多个实施方式中，所述药物为微管蛋白抑制剂、DNA损伤剂或DNA拓扑异构酶抑制剂。
在一个或多个实施方式中，所述微管蛋白抑制剂选自海兔毒素(dolastatin)、奥瑞他汀类(auristatin)、及美登素类(maytansine)。
在一个或多个实施方式中，所述药物为奥瑞他汀类(auristatin)，选自一甲基澳瑞他汀E(monomethyl auristatin E；MMAE)、一甲基澳瑞他汀F(monomethyl auristatin F；MMAF)或澳瑞他汀(auristatin F；AF)。
在一个或多个实施方式中，所述药物为DNA损伤剂，例如卡奇霉素(calicheamicin)类、倍癌霉素(duocarmycin)类、安曲霉素类衍生物PBD(pyrrolobenzodiazepine，吡咯并苯并二氮杂)。
在一个或多个实施方式中，所述药物为DNA拓扑异构酶抑制剂或其盐，例如伊立替康、伊立替康盐酸盐、依喜替康衍生物，喜树碱、9-氨基喜树碱、9-硝基喜树碱、10-羟基喜树碱、9-氯-10-羟基喜树碱、喜树碱类衍生物SN-38、22-羟基旱莲木碱、拓扑替康、勒托替康、贝洛替康、依喜替康、硅基高喜树碱(homosilatecan)、6,8-二溴-2-甲基-3-[2-(D-吡喃木糖基氨基)苯基]-4(3H)-喹唑啉酮、2-氰基-3-(3,4-二羟基苯基)-N-(苯基甲基)-(2E)-2-丙烯酰胺、2-氰基-3-(3,4-二羟基苯基)-N-(3-羟基苯基丙基)-(E)-2-丙烯酰胺、12-β-D-吡喃萄萄糖基-12,13-二氢-2,10-二羟基-6-[[2-羟基-1-(羟基甲基)乙基] 氨基]-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺二盐酸盐、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺。
在一个或多个实施方式中，所述DNA拓扑异构酶抑制剂为喜树碱、10-羟基喜树碱、拓扑替康、贝洛替康、伊立替康、22-羟基旱莲木碱或依喜替康。
在一个或多个实施方式中，所述药物具有氨基或被一个烷基取代氨基，其与接头通过酰胺键连接。
在一个或多个实施方式中，所述药物为
Figure PCTCN2022141572-appb-000001
或其立体异构体，其中
X 1和X 2各自独立地为：
H，
羟基，
C1-C6烷基，
被一个或多个羟基、卤素、硝基或氰基取代的C1-C6烷基，
C2-C6烯基，
C2-C6炔基，
C1-C6烷氧基，
C1-C6氨基烷氧基，
卤素，
硝基，
氰基，
巯基，
烷硫基，
氨基，被氨基保护基取代的氨基，在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基，
在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基氨基，
连接至杂环的C1-C6烷基，所述杂环任选被一个或多个C1-C6烷基、C1-C6烷氧基、氨基、卤素、硝基或氰基取代，
连接至杂环的C1-C6烷基氨基，所述杂环任选被C1-C6烷基、C1-C6烷氧基取代，所述氨基任选被氨基保护基、卤素、硝基、氰基或保护基取代，
氨基取代的杂环基，其在杂环部分的氮原子或氨基部分任选被保护基或一个或多个C1-C6烷基取代，
杂环氨基，其在杂环部分的氮原子或氨基部分任选被保护基或C1-C6烷基取代，
任选被氨基甲酰基保护基或C1-C6烷基取代的氨基甲酰基，
吗啉-1-基，或
哌啶-1-基；
X 3为C1-C6烷基；
X 4为H、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10；
**与所述接头连接；
y为0、1或2；
Y为O、S或CR 1R 2，其中R 1和R 2各自独立地为H或C1-C6烷基；
s和t各自独立为0、1或2，但不同时为0。
在一个或多个实施方式中，X 4为H或C1-C6烷基。
在一个或多个实施方式中，所述杂环为氮杂环丁烷、乙醛嗪(niverazine)、吗啉、吡咯烷、哌啶、咪唑、噻唑、噁唑或吡啶。
在一个或多个实施方式中，所述氨基保护基为甲酰基、乙酰基、三苯甲基、叔丁氧基羰基、苄基或对甲氧基苄氧基羰基。
在一个或多个实施方式中，所述药物为
Figure PCTCN2022141572-appb-000002
Figure PCTCN2022141572-appb-000003
或其立体异构体，其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述接头连接。
在一个或多个实施方式中，所述药物为
Figure PCTCN2022141572-appb-000004
Figure PCTCN2022141572-appb-000005
或其立体异构体，其中X 1和 X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述接头连接。
在一个或多个实施方式中，X 1和X 2各自为-CH 3。
在一个或多个实施方式中，X 1和X 2各自独立地为F、Cl、Br或I。
在一个或多个实施方式中，X 1和X 2各自为F。
在一个或多个实施方式中，X 1和X 2各自独立地为-CH 3、F或-OH。
在一个或多个实施方式中，X 1和X 2各自独立地为F或-CH 3。
在一个或多个实施方式中，X 1为-CH 3及X 2为F。
在一个或多个实施方式中，本发明提供的抗体药物偶联物，其具有式I所示的结构、或立体异构体、或其药学上可接受的盐或溶剂合物：
Figure PCTCN2022141572-appb-000006
其中
Abu为抗体或其抗原结合单元；所述抗体或其抗原结合单元特异性结合叶酸受体α；D为药物；
M为
Figure PCTCN2022141572-appb-000007
其中*连接Abu，**连接B，R选自：-(CH 2) r-、-(CHR m) r-、C3-C8碳环基、-O-(CH 2) r-、亚芳基、-(CH 2) r-亚芳基-、-亚芳基-(CH 2)r-、-(CH 2) r-(C3-C8碳环基)-、-(C3-C8碳环基)-(CH 2) r-、C3-C8杂环基、-(CH 2) r-(C3-C8杂环基)-、-(C3-C8杂环基)-(CH 2) r-、-(CH 2) rC(O)NR m(CH 2) r-、-(CH 2CH 2O) r-、-(CH 2CH 2O) r-CH 2-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-CH 2-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-CH 2-和-(CH 2CH 2O) rC(O)NR m(CH 2) r-；其中各R m独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各r独立为1、2、3、4、5、6、7、8、9或10；
B为
Figure PCTCN2022141572-appb-000008
例如为
Figure PCTCN2022141572-appb-000009
其中*连接M，**连接L，***连接G；
L为-(AA) i-(FF) f-，其中，AA为氨基酸或多肽，i是1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20；各FF独立为
Figure PCTCN2022141572-appb-000010
其中各R F独立为C1-C6烷基、C1-C6烷氧基、-NO 2或卤素；z为0、1、2、3或4；f为1、2、3、4、5、6、7、8、9或10；其中*连接AA，**连接D；
G为
Figure PCTCN2022141572-appb-000011
其中n为1-24的整数，例如1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23或24；
p为1-10的整数，例如1、2、3、4、5、6、7、8、9或10。
在一个或多个实施方式中，药物为抗癌药物、细胞毒性药物、细胞分化因子、干细胞营养因子、类固醇类药物、治疗自身免疫疾病的药物、抗炎症药物或治疗传染性疾病的药物。
在一个或多个实施方式中，药物为抗癌药物。
在一个或多个实施方式中，药物为微管蛋白抑制剂、DNA损伤剂或DNA拓扑异构酶抑制剂。
在一个或多个实施方式中，所述微管蛋白抑制剂选自海兔毒素(dolastatin)、奥瑞他汀(auristatin)类、美登素(maytansine)类。
在一个或多个实施方式中，药物为奥瑞他汀(auristatin)类，例如MMAE、MMAF或AF。
在一个或多个实施方式中，药物为DNA损伤剂，例如卡奇霉素(calicheamicin)类、倍癌霉素(duocarmycin)类、安曲霉素类衍生物PBD(pyrrolobenzodiazepine，吡咯并苯并二氮杂)。
在一个或多个实施方式中，药物为DNA拓扑异构酶抑制剂或其盐，例如伊立替康、伊立替康盐酸盐、喜树碱、9-氨基喜树碱、9-硝基喜树碱、10-羟基喜树碱、9-氯-10-羟基喜树碱、喜树碱类衍生物SN-38、22-羟基旱莲木碱、拓扑替康、勒托替康、贝洛替康、依喜替康、依喜替康衍生物，硅基高喜树碱(homosilatecan)、6,8-二溴-2-甲基-3-[2-(D-吡喃木糖基氨基)苯基]-4(3H)-喹唑啉酮、2-氰基-3-(3,4-二羟基苯基)-N-(苯基甲基)-(2E)-2-丙烯酰胺、2-氰基-3-(3,4-二羟基苯基)-N-(3-羟基苯基丙基)-(E)-2-丙烯酰胺、12-β-D-吡喃萄萄糖基-12,13-二氢-2,10-二羟基-6-[[2-羟基-1-(羟基甲基)乙基]氨基]-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺二盐酸盐、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺。
在一个或多个实施方式中，所述DNA拓扑异构酶抑制剂为喜树碱、10-羟基喜树碱、拓扑替康、贝洛替康、伊立替康、22-羟基旱莲木碱或依喜替康。
在一个或多个实施方式中，药物为Tubulysin类、紫杉类药物衍生物、leptomycine衍生物、CC-1065及其类似物、Amatoxin类、剪接体抑制剂、苯(并)二卓氮(PBD)二聚 体类、阿霉素、甲氨蝶呤，长春新碱，长春碱，柔红霉素，丝裂霉素C，马法兰或苯丁酸氮芥衍生物。
在一个或多个实施方式中，药物具有氨基或被一个烷基取代氨基，其与FF通过酰胺键连接。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000012
其中
X 1和X 2各自独立地为：
H，
羟基，
C1-C6烷基，
被一个或多个羟基、卤素、硝基或氰基取代的C1-C6烷基，
C2-C6烯基，
C2-C6炔基，
C1-C6烷氧基，
C1-C6氨基烷氧基，
卤素，
硝基，
氰基，
巯基，
烷硫基，
氨基，被氨基保护基取代的氨基，在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基，
在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基氨基，
连接至杂环的C1-C6烷基，所述杂环任选被一个或多个C1-C6烷基、C1-C6烷氧基、氨基、卤素、硝基或氰基取代，
连接至杂环的C1-C6烷基氨基，所述杂环任选被C1-C6烷基、C1-C6烷氧基取代，所述氨基任选被氨基保护基、卤素、硝基、氰基或保护基取代，
氨基取代的杂环基，其在杂环部分的氮原子或氨基部分任选被保护基或一个或多个C1-C6烷基取代，
杂环氨基，其在杂环部分的氮原子或氨基部分任选被保护基或C1-C6烷基取代，
任选被氨基甲酰基保护基或C1-C6烷基取代的氨基甲酰基，
吗啉-1-基，或
哌啶-1-基；
X 3为C1-C6烷基；
X 4为H、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10；
**与L连接；
y为0、1或2；
Y为O、S或CR 1R 2，其中R 1和R 2各自独立地为H或C1-C6烷基；
s和t各自独立为0、1或2，但不同时为0。
在一个或多个实施方式中，X 4为H或C1-C6烷基。
在一个或多个实施方式中，所述杂环为氮杂环丁烷、乙醛嗪(niverazine)、吗啉、吡咯烷、哌啶、咪唑、噻唑、噁唑或吡啶。
在一个或多个实施方式中，所述氨基保护基为甲酰基、乙酰基、三苯甲基、叔丁氧基羰基、苄基或对甲氧基苄氧基羰基。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000013
Figure PCTCN2022141572-appb-000014
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与L连接。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000015
Figure PCTCN2022141572-appb-000016
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与L连接。
在一个或多个实施方式中，X 1和X 2各自为-CH 3。
在一个或多个实施方式中，X 1和X 2各自独立地为F、Cl、Br或I。
在一个或多个实施方式中，X 1和X 2各自为F。
在一个或多个实施方式中，X 1和X 2各自独立地为-CH 3、F或-OH。
在一个或多个实施方式中，X 1和X 2各自独立地为F或-CH 3。
在一个或多个实施方式中，X 1为-CH 3及X 2为F。
在一个或多个实施方式中，R为-(CH 2) r-。
在一个或多个实施方式中，R为-(CH 2) r-，r为1或5。
在一个或多个实施方式中，各AA独立选自以下的氨基酸或肽序列：Val-Cit、Val-Lys、Phe-Lys、Lys-Lys、Ala-Lys、Phe-Cit、Leu-Cit、Ile-Cit、Trp、Cit、Phe-Ala、Phe-Phe-Lys、D-Phe-Phe-Lys、Gly-Phe-Lys、Leu-Ala-Leu、Ile-Ala-Leu、Val-Ala-Val、Ala-Leu-Ala-Leu、β-Ala-Leu-Ala-Leu和Gly-Phe-Leu-Gly。
在一个或多个实施方式中，AA为Val-Cit，i为1。
在一个或多个实施方式中，各FF独立为
Figure PCTCN2022141572-appb-000017
Figure PCTCN2022141572-appb-000018
其中各R F独立为C1-C6烷基、C1-C6烷氧基、-NO 2或卤素；其中*连接AA，**连接D。
在一个或多个实施方式中，卤素为F，z为0、1、2、3或4。
在一个或多个实施方式中，R F为-CH 3、F、-NO 2或-OCH 3。
在一个或多个实施方式中，z为0。
在一个或多个实施方式中，z为1或2。
在一个或多个实施方式中，各FF独立为
Figure PCTCN2022141572-appb-000019
Figure PCTCN2022141572-appb-000020
Figure PCTCN2022141572-appb-000021
其中*连接AA，**连接D。
在一个或多个实施方式中，f为1。
在一个或多个实施方式中，FF为
Figure PCTCN2022141572-appb-000022
f为1；其中*连接AA，**连接D。
在一个或多个实施方式中，L为
Figure PCTCN2022141572-appb-000023
其中*连接B，**连接D。
在一个或多个实施方式中，L为
Figure PCTCN2022141572-appb-000024
Figure PCTCN2022141572-appb-000025
其中*连接B，**连接D。
在一个或多个实施方式中，G为
Figure PCTCN2022141572-appb-000026
n为4-12。
在一个或多个实施方式中，n为4-8。
在一个或多个实施方式中，n为4。
在一个或多个实施方式中，n为8。
在一个或多个实施方式中，p为2-8。
在一个或多个实施方式中，p为4-8。
在一个或多个实施方式中，p为6-8。
在一个或多个实施方式中，p为7-8。
在一个或多个实施方式中，p为7。
在一个或多个实施方式中，p为7.4。
在一个或多个实施方式中，p为8。
在一个或多个实施方式中，所述Abu为本发明提供的抗体或其抗原结合单元。
在一个或多个实施方式中，所述抗体药物偶联物具有式I-1所示的结构或其立体异构体或药学上可接受的盐或溶剂合物：
Figure PCTCN2022141572-appb-000027
其中
Abu为本发明提供的抗体或其抗原结合单元；
R选自：-(CH 2) r-、-(CHR m)r-、C3-C8碳环基、-O-(CH 2) r-、亚芳基、-(CH 2) r-亚芳基-、-亚芳基-(CH 2)r-、-(CH 2) r-(C3-C8碳环基)-、-(C3-C8碳环基)-(CH 2) r-、C3-C8杂环基、-(CH 2) r-(C3-C8杂环基)-、-(C3-C8杂环基)-(CH 2) r-、-(CH 2) rC(O)NR m(CH 2) r-、-(CH 2CH 2O) r-、-(CH 2CH 2O) r-CH 2-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-CH 2-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-CH 2-和-(CH 2CH 2O) rC(O)NR m(CH 2) r-；其中各R m独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各r独立为1、2、3、4、5、6、7、8、9或10；
D为药物；
n为1-24的整数，例如1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23或24；
p为1-10，例如1、2、3、4、5、6、7、7.4、8、9或10。
在一个或多个实施方式中，药物为抗癌药物、细胞毒性药物、细胞分化因子、干细胞营养因子、类固醇类药物、治疗自身免疫疾病的药物、抗炎症药物或治疗传染性疾病的药物。
在一个或多个实施方式中，药物为微管蛋白抑制剂、DNA损伤剂或DNA拓扑异构酶抑制剂。
在一个或多个实施方式中，所述微管蛋白抑制剂选自海兔毒素(dolastatin)、奥瑞他汀(auristatin)类及美登素(maytansine)类。
在一个或多个实施方式中，药物为奥瑞他汀(auristatin)类，例如MMAE、MMAF或AF。
在一个或多个实施方式中，药物为DNA损伤剂，例如卡奇霉素(calicheamicin)类、倍癌霉素(duocarmycin)类、安曲霉素类衍生物PBD(pyrrolobenzodiazepine，吡咯并苯并二氮杂)。
在一个或多个实施方式中，药物为DNA拓扑异构酶抑制剂或其盐，例如伊立替康、伊立替康盐酸盐、喜树碱、9-氨基喜树碱、9-硝基喜树碱、10-羟基喜树碱、9-氯-10-羟基喜树碱、喜树碱类衍生物SN-38、22-羟基旱莲木碱、拓扑替康、勒托替康、贝洛替康、依喜替康、硅基高喜树碱(homosilatecan)、6,8-二溴-2-甲基-3-[2-(D-吡喃木糖基氨基)苯基]-4(3H)-喹唑啉酮、2-氰基-3-(3,4-二羟基苯基)-N-(苯基甲基)-(2E)-2-丙烯酰胺、2-氰基-3-(3,4-二羟基苯基)-N-(3-羟基苯基丙基)-(E)-2-丙烯酰胺、12-β-D-吡喃萄萄糖基-12,13-二氢-2,10-二羟基-6-[[2-羟基-1-(羟基甲基)乙基]氨基]-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺二盐酸盐、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺。
在一个或多个实施方式中，所述DNA拓扑异构酶抑制剂为喜树碱、10-羟基喜树碱、拓扑替康、贝洛替康、伊立替康、22-羟基旱莲木碱或依喜替康。
在一个或多个实施方式中，药物为Tubulysin类、紫杉类药物衍生物、leptomycine衍生物、CC-1065及其类似物、Amatoxin类、剪接体抑制剂、苯(并)二卓氮(PBD)二聚体类、阿霉素、甲氨蝶呤，长春新碱，长春碱，柔红霉素，丝裂霉素C，马法兰，或苯丁酸氮芥衍生物。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000028
其中
X 1和X 2各自独立地为：
H，
羟基，
C1-C6烷基，
被一个或多个羟基、卤素、硝基或氰基取代的C1-C6烷基，
C2-C6烯基，
C2-C6炔基，
C1-C6烷氧基，
C1-C6氨基烷氧基，
卤素，
硝基，
氰基，
巯基，
烷硫基，
氨基，被氨基保护基取代的氨基，在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基，
在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基氨基，
连接至杂环的C1-C6烷基，所述杂环任选被一个或多个C1-C6烷基、C1-C6烷氧基、氨基、卤素、硝基或氰基取代，
连接至杂环的C1-C6烷基氨基，所述杂环任选被C1-C6烷基、C1-C6烷氧基取代，所述氨基任选被氨基保护基、卤素、硝基、氰基或保护基取代，
氨基取代的杂环基，其在杂环部分的氮原子或氨基部分任选被保护基或一个或多个C1-C6烷基取代，
杂环氨基，其在杂环部分的氮原子或氨基部分任选被保护基或C1-C6烷基取代，
任选被氨基甲酰基保护基或C1-C6烷基取代的氨基甲酰基，
吗啉-1-基，或
哌啶-1-基；
X 3为C1-C6烷基；
X 4为H、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10；
**与所述抗体药物偶联物其他部分连接；
y为0、1或2；
Y为O、S或CR 1R 2，其中R 1和R 2各自独立地为H或C1-C6烷基；
s和t各自独立为0、1或2，但不同时为0。
在一个或多个实施方式中，X 4为H或C1-C6烷基。
在一个或多个实施方式中，所述杂环为氮杂环丁烷、乙醛嗪、吗啉、吡咯烷、哌啶、咪唑、噻唑、噁唑或吡啶。
在一个或多个实施方式中，所述氨基保护基为甲酰基、乙酰基、三苯甲基、叔丁氧基羰基、苄基或对甲氧基苄氧基羰基。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000029
Figure PCTCN2022141572-appb-000030
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000031
Figure PCTCN2022141572-appb-000032
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，X 1和X 2各自为-CH 3。
在一个或多个实施方式中，X 1和X 2各自独立地为F、Cl、Br或I。
在一个或多个实施方式中，X 1和X 2各自为F。
在一个或多个实施方式中，X 1和X 2各自独立地为-CH 3、F或-OH。
在一个或多个实施方式中，X 1和X 2各自独立地为F或-CH 3。
在一个或多个实施方式中，X 1为-CH 3及X 2为F。
在一个或多个实施方式中，R为-(CH 2) r-。
在一个或多个实施方式中，R为-(CH 2) r-，r为1或5。
在一个或多个实施方式中，n为4-12。
在一个或多个实施方式中，n为4-8。
在一个或多个实施方式中，n为4。
在一个或多个实施方式中，n为8。
在一个或多个实施方式中，p为2-8。
在一个或多个实施方式中，p为4-8。
在一个或多个实施方式中，p为6-8。
在一个或多个实施方式中，p为7-8。
在一个或多个实施方式中，p为7。
在一个或多个实施方式中，p为7.4。
在一个或多个实施方式中，p为8。
在一个或多个实施方式中，所述抗体药物偶联物具有式I-2或I-2-1所示的结构或其立体异构体或药学上可接受的盐或溶剂合物：
Figure PCTCN2022141572-appb-000033
其中
Abu为本发明提供的抗体或其抗原结合单元；
R选自：-(CH 2) r-、-(CHR m)r-、C3-C8碳环基、-O-(CH 2) r-、亚芳基、-(CH 2) r-亚芳基-、-亚芳基-(CH 2)r-、-(CH 2) r-(C3-C8碳环基)-、-(C3-C8碳环基)-(CH 2) r-、C3-C8杂环基、-(CH 2) r-(C3-C8杂环基)-、-(C3-C8杂环基)-(CH 2) r-、-(CH 2) rC(O)NR m(CH 2) r-、-(CH 2CH 2O) r-、-(CH 2CH 2O) r-CH 2-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-CH 2-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-CH 2-和-(CH 2CH 2O) rC(O)NR m(CH 2) r-；其中各R m独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各r独立为1、2、3、4、5、6、7、8、9或10；
D为药物；
n为1-24的整数，例如1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23或24；
p为1-10，例如1、2、3、4、5、6、7、7.4、8、9或10。
在一个或多个实施方式中，药物为抗癌药物、细胞毒性药物、细胞分化因子、干细胞营养因子、类固醇类药物、治疗自身免疫疾病的药物、抗炎症药物或治疗传染性疾病的药物。
在一个或多个实施方式中，药物为微管蛋白抑制剂、DNA损伤剂或DNA拓扑异构酶抑制剂。
在一个或多个实施方式中，所述微管蛋白抑制剂选自海兔毒素(dolastatin)、奥瑞他汀(auristatin)类、及美登素(maytansine)类。
在一个或多个实施方式中，药物为奥瑞他汀(auristatin)类，例如MMAE、MMAF或AF。
在一个或多个实施方式中，药物为DNA损伤剂，例如卡奇霉素(calicheamicin)类、倍癌霉素(duocarmycin)类、安曲霉素类衍生物PBD(pyrrolobenzodiazepine，吡咯并苯并二氮杂)。
在一个或多个实施方式中，药物为DNA拓扑异构酶抑制剂或其盐，例如伊立替康、伊立替康盐酸盐、喜树碱、9-氨基喜树碱、9-硝基喜树碱、10-羟基喜树碱、9-氯-10-羟基喜树碱、喜树碱类衍生物SN-38、22-羟基旱莲木碱、拓扑替康、勒托替康、贝洛替康、依喜替康、硅基高喜树碱(homosilatecan)、6,8-二溴-2-甲基-3-[2-(D-吡喃木糖基氨基)苯基]-4(3H)-喹唑啉酮、2-氰基-3-(3,4-二羟基苯基)-N-(苯基甲基)-(2E)-2-丙烯酰胺、2-氰基-3-(3,4-二羟基苯基)-N-(3-羟基苯基丙基)-(E)-2-丙烯酰胺、12-β-D-吡喃萄萄糖基-12,13-二氢-2,10-二羟基-6-[[2-羟基-1-(羟基甲基)乙基]氨基]-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺二盐酸盐、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺。
在一个或多个实施方式中，所述DNA拓扑异构酶抑制剂为喜树碱、10-羟基喜树碱、拓扑替康、贝洛替康、伊立替康、22-羟基旱莲木碱或依喜替康。
在一个或多个实施方式中，药物为Tubulysin类、紫杉类药物衍生物、leptomycine衍生物、CC-1065及其类似物、Amatoxin类、剪接体抑制剂、苯(并)二卓氮(PBD)二聚体类、阿霉素、甲氨蝶呤，长春新碱，长春碱，柔红霉素，丝裂霉素C，马法兰，或苯丁酸氮芥衍生物。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000034
其中
X 1和X 2各自独立地为：
H，
羟基，
C1-C6烷基，
被一个或多个羟基、卤素、硝基或氰基取代的C1-C6烷基，
C2-C6烯基，
C2-C6炔基，
C1-C6烷氧基，
C1-C6氨基烷氧基，
卤素，
硝基，
氰基，
巯基，
烷硫基，
氨基，被氨基保护基取代的氨基，在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基，
在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基氨基，
连接至杂环的C1-C6烷基，所述杂环任选被一个或多个C1-C6烷基、C1-C6烷氧基、氨基、卤素、硝基或氰基取代，
连接至杂环的C1-C6烷基氨基，所述杂环任选被C1-C6烷基、C1-C6烷氧基取代，所述氨基任选被氨基保护基、卤素、硝基、氰基或保护基取代，
氨基取代的杂环基，其在杂环部分的氮原子或氨基部分任选被保护基或一个或多个C1-C6烷基取代，
杂环氨基，其在杂环部分的氮原子或氨基部分任选被保护基或C1-C6烷基取代，
任选被氨基甲酰基保护基或C1-C6烷基取代的氨基甲酰基，
吗啉-1-基，或
哌啶-1-基；
X 3为C1-C6烷基；
X 4为H、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10；
**与所述抗体药物偶联物其他部分连接；
y为0、1或2；
Y为O、S或CR 1R 2，其中R 1和R 2各自独立地为H或C1-C6烷基；
s和t各自独立为0、1或2，但不同时为0。
在一个或多个实施方式中，X 4为H或C1-C6烷基。
在一个或多个实施方式中，所述杂环为氮杂环丁烷、乙醛嗪、吗啉、吡咯烷、哌啶、咪唑、噻唑、噁唑或吡啶。
在一个或多个实施方式中，所述氨基保护基为甲酰基、乙酰基、三苯甲基、叔丁氧基羰基、苄基或对甲氧基苄氧基羰基。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000035
Figure PCTCN2022141572-appb-000036
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000037
Figure PCTCN2022141572-appb-000038
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，X 1和X 2各自为-CH 3。
在一个或多个实施方式中，X 1和X 2各自独立地为F、Cl、Br或I。
在一个或多个实施方式中，X 1和X 2各自为F。
在一个或多个实施方式中，X 1和X 2各自独立地为-CH 3、F或-OH。
在一个或多个实施方式中，X 1和X 2各自独立地为F或-CH 3。
在一个或多个实施方式中，X 1为-CH 3及X 2为F。
在一个或多个实施方式中，R为-(CH 2) r-。
在一个或多个实施方式中，R为-(CH 2) r-，r为1或5。
在一个或多个实施方式中，n为4-12。
在一个或多个实施方式中，n为4-8。
在一个或多个实施方式中，n为4。
在一个或多个实施方式中，n为8。
在一个或多个实施方式中，p为2-8。
在一个或多个实施方式中，p为4-8。
在一个或多个实施方式中，p为6-8。
在一个或多个实施方式中，p为7-8。
在一个或多个实施方式中，p为7。
在一个或多个实施方式中，p为7.4。
在一个或多个实施方式中，p为8。
在一个或多个实施方式中，所述抗体药物偶联物具有式I-3所示的结构或其立体异构体或药学上可接受的盐或溶剂合物：
Figure PCTCN2022141572-appb-000039
其中
Abu为本发明提供的抗体或其抗原结合单元；
D为药物；
n为1-24的整数，例如1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23或24；
p为1-10，例如1、2、3、4、5、6、7、7.4、8、9或10。
在一个或多个实施方式中，药物为抗癌药物、细胞毒性药物、细胞分化因子、干细胞营养因子、类固醇类药物、治疗自身免疫疾病的药物、抗炎症药物或治疗传染性疾病的药物。
在一个或多个实施方式中，药物为微管蛋白抑制剂、DNA损伤剂或DNA拓扑异构酶抑制剂。
在一个或多个实施方式中，所述微管蛋白抑制剂选自海兔毒素(dolastatin)、奥瑞他汀(auristatin)类及美登素(maytansine)类。
在一个或多个实施方式中，药物为奥瑞他汀(auristatin)类，例如MMAE、MMAF或AF。
在一个或多个实施方式中，药物为DNA损伤剂，例如卡奇霉素(calicheamicin)类、倍癌霉素(duocarmycin)类、安曲霉素类衍生物PBD(pyrrolobenzodiazepine，吡咯并苯并二氮杂)。
在一个或多个实施方式中，药物为DNA拓扑异构酶抑制剂或其盐，例如伊立替康、伊立替康盐酸盐、喜树碱、9-氨基喜树碱、9-硝基喜树碱、10-羟基喜树碱、9-氯-10-羟基喜树碱、喜树碱类衍生物SN-38、22-羟基旱莲木碱、拓扑替康、勒托替康、贝洛替康、依喜替康、硅基高喜树碱(homosilatecan)、6,8-二溴-2-甲基-3-[2-(D-吡喃木糖基氨基)苯基]-4(3H)-喹唑啉酮、2-氰基-3-(3,4-二羟基苯基)-N-(苯基甲基)-(2E)-2-丙烯酰胺、2-氰基-3-(3,4-二羟基苯基)-N-(3-羟基苯基丙基)-(E)-2-丙烯酰胺、12-β-D-吡喃萄萄糖基-12,13-二氢-2,10-二羟基-6-[[2-羟基-1-(羟基甲基)乙基]氨基]-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺二盐酸盐、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺。
在一个或多个实施方式中，所述DNA拓扑异构酶抑制剂为喜树碱、10-羟基喜树碱、拓扑替康、贝洛替康、伊立替康、22-羟基旱莲木碱或依喜替康。
在一个或多个实施方式中，药物为Tubulysin类、紫杉类药物衍生物、leptomycine衍生物、CC-1065及其类似物、Amatoxin类、剪接体抑制剂、苯(并)二卓氮(PBD)二聚体类、阿霉素、甲氨蝶呤，长春新碱，长春碱，柔红霉素，丝裂霉素C，马法兰，或苯丁酸氮芥衍生物。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000040
其中
X 1和X 2各自独立地为：
H，
羟基，
C1-C6烷基，
被一个或多个羟基、卤素、硝基或氰基取代的C1-C6烷基，
C2-C6烯基，
C2-C6炔基，
C1-C6烷氧基，
C1-C6氨基烷氧基，
卤素，
硝基，
氰基，
巯基，
烷硫基，
氨基，被氨基保护基取代的氨基，在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基，
在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基氨基，
连接至杂环的C1-C6烷基，所述杂环任选被一个或多个C1-C6烷基、C1-C6烷氧基、氨基、卤素、硝基或氰基取代，
连接至杂环的C1-C6烷基氨基，所述杂环任选被C1-C6烷基、C1-C6烷氧基取代，所述氨基任选被氨基保护基、卤素、硝基、氰基或保护基取代，
氨基取代的杂环基，其在杂环部分的氮原子或氨基部分任选被保护基或一个或多个C1-C6烷基取代，
杂环氨基，其在杂环部分的氮原子或氨基部分任选被保护基或C1-C6烷基取代，
任选被氨基甲酰基保护基或C1-C6烷基取代的氨基甲酰基，
吗啉-1-基，或
哌啶-1-基；
X 3为C1-C6烷基；
X 4为H、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10；
**与所述抗体药物偶联物其他部分连接；
y为0、1或2；
Y为O、S或CR 1R 2，其中R 1和R 2各自独立地为H或C1-C6烷基；
s和t各自独立为0、1或2，但不同时为0。
在一个或多个实施方式中，X 4为H或C1-C6烷基。
在一个或多个实施方式中，所述杂环为氮杂环丁烷、乙醛嗪、吗啉、吡咯烷、哌啶、咪唑、噻唑、噁唑或吡啶。
在一个或多个实施方式中，所述氨基保护基为甲酰基、乙酰基、三苯甲基、叔丁氧基羰基、苄基或对甲氧基苄氧基羰基。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000041
Figure PCTCN2022141572-appb-000042
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000043
Figure PCTCN2022141572-appb-000044
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，X 1和X 2各自为-CH 3。
在一个或多个实施方式中，X 1和X 2各自独立地为F、Cl、Br或I。
在一个或多个实施方式中，X 1和X 2各自为F。
在一个或多个实施方式中，X 1和X 2各自独立地为-CH 3、F或-OH。
在一个或多个实施方式中，X 1和X 2各自独立地为F或-CH 3。
在一个或多个实施方式中，X 1为-CH 3及X 2为F。
在一个或多个实施方式中，n为4-12。
在一个或多个实施方式中，n为4-8。
在一个或多个实施方式中，n为4。
在一个或多个实施方式中，n为8。
在一个或多个实施方式中，p为2-8。
在一个或多个实施方式中，p为4-8。
在一个或多个实施方式中，p为6-8。
在一个或多个实施方式中，p为7-8。
在一个或多个实施方式中，p为7。
在一个或多个实施方式中，p为7.4。
在一个或多个实施方式中，p为8。
在一个或多个实施方式中，所述抗体药物偶联物具有式I-4或I-4-1所示的结构或其立体异构体或药学上可接受的盐或溶剂合物：
Figure PCTCN2022141572-appb-000045
其中
Abu为本发明提供的抗体或其抗原结合单元；
D为药物；
n为1-24的整数，例如1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23或24；
p为1-10，例如1、2、3、4、5、6、7、7.4、8、9或10。
在一个或多个实施方式中，药物为抗癌药物、细胞毒性药物、细胞分化因子、干细胞营养因子、类固醇类药物、治疗自身免疫疾病的药物、抗炎症药物或治疗传染性疾病的药物。
在一个或多个实施方式中，药物为微管蛋白抑制剂、DNA损伤剂或DNA拓扑异构酶抑制剂。
在一个或多个实施方式中，所述微管蛋白抑制剂选自海兔毒素(dolastatin)、奥瑞他汀(auristatin)类、及美登素(maytansine)类。
在一个或多个实施方式中，药物为奥瑞他汀(auristatin)类，例如MMAE、MMAF或AF。
在一个或多个实施方式中，药物为DNA损伤剂，例如卡奇霉素(calicheamicin)类、倍癌霉素(duocarmycin)类、安曲霉素类衍生物PBD(pyrrolobenzodiazepine，吡咯并苯并二氮杂)、DNA拓扑异构酶抑制剂。
在一个或多个实施方式中，药物为DNA拓扑异构酶抑制剂或其盐，例如伊立替康、伊立替康盐酸盐、喜树碱、9-氨基喜树碱、9-硝基喜树碱、10-羟基喜树碱、9-氯-10-羟基喜树碱、喜树碱类衍生物SN-38、22-羟基旱莲木碱、拓扑替康、勒托替康、贝洛替康、依喜替康、硅基高喜树碱(homosilatecan)、6,8-二溴-2-甲基-3-[2-(D-吡喃木糖基氨基)苯基]-4(3H)-喹唑啉酮、2-氰基-3-(3,4-二羟基苯基)-N-(苯基甲基)-(2E)-2-丙烯酰胺、2-氰基-3-(3,4-二羟基苯基)-N-(3-羟基苯基丙基)-(E)-2-丙烯酰胺、12-β-D-吡喃萄萄糖基-12,13-二氢-2,10-二羟基-6-[[2-羟基-1-(羟基甲基)乙基]氨基]-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺二盐酸盐、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺。
在一个或多个实施方式中，所述DNA拓扑异构酶抑制剂为喜树碱、10-羟基喜树碱、拓扑替康、贝洛替康、伊立替康、22-羟基旱莲木碱或依喜替康。
在一个或多个实施方式中，药物为Tubulysin类、紫杉类药物衍生物、leptomycine衍生物、CC-1065及其类似物、Amatoxin类、剪接体抑制剂、苯(并)二卓氮(PBD)二聚体类、阿霉素、甲氨蝶呤，长春新碱，长春碱，柔红霉素，丝裂霉素C，马法兰，或苯丁酸氮芥衍生物。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000046
其中
X 1和X 2各自独立地为：
H，
羟基，
C1-C6烷基，
被一个或多个羟基、卤素、硝基或氰基取代的C1-C6烷基，
C2-C6烯基，
C2-C6炔基，
C1-C6烷氧基，
C1-C6氨基烷氧基，
卤素，
硝基，
氰基，
巯基，
烷硫基，
氨基，被氨基保护基取代的氨基，在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基，
在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基氨基，
连接至杂环的C1-C6烷基，所述杂环任选被一个或多个C1-C6烷基、C1-C6烷氧基、氨基、卤素、硝基或氰基取代，
连接至杂环的C1-C6烷基氨基，所述杂环任选被C1-C6烷基、C1-C6烷氧基取代，所述氨基任选被氨基保护基、卤素、硝基、氰基或保护基取代，
氨基取代的杂环基，其在杂环部分的氮原子或氨基部分任选被保护基或一个或多个C1-C6烷基取代，
杂环氨基，其在杂环部分的氮原子或氨基部分任选被保护基或C1-C6烷基取代，
任选被氨基甲酰基保护基或C1-C6烷基取代的氨基甲酰基，
吗啉-1-基，或
哌啶-1-基；
X 3为C1-C6烷基；
X 4为H、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10；
**与所述抗体药物偶联物其他部分连接；
y为0、1或2；
Y为O、S或CR 1R 2，其中R 1和R 2各自独立地为H或C1-C6烷基；
s和t各自独立为0、1或2，但不同时为0。
在一个或多个实施方式中，X 4为H或C1-C6烷基。
在一个或多个实施方式中，所述杂环为氮杂环丁烷、乙醛嗪、吗啉、吡咯烷、哌啶、咪唑、噻唑、噁唑或吡啶。
在一个或多个实施方式中，所述氨基保护基为甲酰基、乙酰基、三苯甲基、叔丁氧基羰基、苄基或对甲氧基苄氧基羰基。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000047
Figure PCTCN2022141572-appb-000048
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000049
Figure PCTCN2022141572-appb-000050
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，X 1和X 2各自独立地为-CH 3、F、Cl、Br或I。
在一个或多个实施方式中，X 1和X 2各自为F。
在一个或多个实施方式中，X 1和X 2各自独立地为-CH 3、F或-OH。
在一个或多个实施方式中，X 1和X 2各自为-CH 3。
在一个或多个实施方式中，X 1和X 2各自独立地为F或-CH 3。
在一个或多个实施方式中，X 1为-CH 3及X 2为F。
在一个或多个实施方式中，n为4-12。
在一个或多个实施方式中，n为4-8。
在一个或多个实施方式中，n为4。
在一个或多个实施方式中，n为8。
在一个或多个实施方式中，p为2-8。
在一个或多个实施方式中，p为4-8。
在一个或多个实施方式中，p为6-8。
在一个或多个实施方式中，p为7-8。
在一个或多个实施方式中，p为7。
在一个或多个实施方式中，p为7.4。
在一个或多个实施方式中，p为8。
在一个或多个实施方式中，所述抗体药物偶联物具有式I-5、I-5-1、I-6、I-6-1、I-7、I-7-1、I-8、I-8-1、I-9、I-9-1、I-10、I-10-1、I-11、或I-11-1所示的结构或其立体异构体或药学上可接受的盐或溶剂合物：
Figure PCTCN2022141572-appb-000051
Figure PCTCN2022141572-appb-000052
Figure PCTCN2022141572-appb-000053
Figure PCTCN2022141572-appb-000054
Figure PCTCN2022141572-appb-000055
其中
Abu为本发明提供的抗体或其抗原结合单元；
D为药物；
p为1-10，例如1、2、3、4、5、6、7、7.4、8、9或10。
在一个或多个实施方式中，药物为抗癌药物、细胞毒性药物、细胞分化因子、干细胞营养因子、类固醇类药物、治疗自身免疫疾病的药物、抗炎症药物或治疗传染性疾病的药物。
在一个或多个实施方式中，药物为微管蛋白抑制剂、DNA损伤剂或DNA拓扑异构酶抑制剂。
在一个或多个实施方式中，所述微管蛋白抑制剂选自海兔毒素(dolastatin)、奥瑞他汀(auristatin)类、及美登素(maytansine)类。
在一个或多个实施方式中，药物为奥瑞他汀(auristatin)类，例如MMAE、MMAF或AF。
在一个或多个实施方式中，药物为DNA损伤剂，例如卡奇霉素(calicheamicin)类、倍癌霉素(duocarmycin)类、安曲霉素类衍生物PBD(pyrrolobenzodiazepine，吡咯并苯并二氮杂)。
在一个或多个实施方式中，药物为DNA拓扑异构酶抑制剂或其盐，例如伊立替康、伊立替康盐酸盐、喜树碱、9-氨基喜树碱、9-硝基喜树碱、10-羟基喜树碱、9-氯-10-羟基喜树碱、喜树碱类衍生物SN-38、22-羟基旱莲木碱、拓扑替康、勒托替康、贝洛替康、依喜替康、硅基高喜树碱(homosilatecan)、6,8-二溴-2-甲基-3-[2-(D-吡喃木糖基氨基)苯基]-4(3H)-喹唑啉酮、2-氰基-3-(3,4-二羟基苯基)-N-(苯基甲基)-(2E)-2-丙烯酰胺、2-氰基-3-(3,4-二羟基苯基)-N-(3-羟基苯基丙基)-(E)-2-丙烯酰胺、12-β-D-吡喃萄萄糖基-12,13-二氢-2,10-二羟基-6-[[2-羟基-1-(羟基甲基)乙基]氨基]-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺二盐酸盐、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺。
在一个或多个实施方式中，所述DNA拓扑异构酶抑制剂为喜树碱、10-羟基喜树碱、拓扑替康、贝洛替康、伊立替康、22-羟基旱莲木碱或依喜替康。
在一个或多个实施方式中，药物为Tubulysin类、紫杉类药物衍生物、leptomycine衍生物、CC-1065及其类似物、Amatoxin类、剪接体抑制剂、苯(并)二卓氮(PBD)二聚体类、阿霉素、甲氨蝶呤，长春新碱，长春碱，柔红霉素，丝裂霉素C，马法兰，或苯丁酸氮芥衍生物。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000056
其中
X 1和X 2各自独立地为：
H，
羟基，
C1-C6烷基，
被一个或多个羟基、卤素、硝基或氰基取代的C1-C6烷基，
C2-C6烯基，
C2-C6炔基，
C1-C6烷氧基，
C1-C6氨基烷氧基，
卤素，
硝基，
氰基，
巯基，
烷硫基，
氨基，被氨基保护基取代的氨基，在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基，
在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基氨基，
连接至杂环的C1-C6烷基，所述杂环任选被一个或多个C1-C6烷基、C1-C6烷氧基、氨基、卤素、硝基或氰基取代，
连接至杂环的C1-C6烷基氨基，所述杂环任选被C1-C6烷基、C1-C6烷氧基取代，所述氨基任选被氨基保护基、卤素、硝基、氰基或保护基取代，
氨基取代的杂环基，其在杂环部分的氮原子或氨基部分任选被保护基或一个或多个C1-C6烷基取代，
杂环氨基，其在杂环部分的氮原子或氨基部分任选被保护基或C1-C6烷基取代，
任选被氨基甲酰基保护基或C1-C6烷基取代的氨基甲酰基，
吗啉-1-基，或
哌啶-1-基；
X 3为C1-C6烷基；
X 4为H、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10；
**与所述抗体药物偶联物其他部分连接；
y为0、1或2；
Y为O、S或CR 1R 2，其中R 1和R 2各自独立地为H或C1-C6烷基；
s和t各自独立为0、1或2，但不同时为0。
在一个或多个实施方式中，X 4为H或C1-C6烷基。
在一个或多个实施方式中，所述杂环为氮杂环丁烷、乙醛嗪、吗啉、吡咯烷、哌啶、咪唑、噻唑、噁唑或吡啶。
在一个或多个实施方式中，所述氨基保护基为甲酰基、乙酰基、三苯甲基、叔丁氧基羰基、苄基或对甲氧基苄氧基羰基。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000057
Figure PCTCN2022141572-appb-000058
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，药物为
Figure PCTCN2022141572-appb-000059
Figure PCTCN2022141572-appb-000060
其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；**与所述抗体药物偶联物其他部分连接。
在一个或多个实施方式中，所述C1-C6烷基为-CH 3。
在一个或多个实施方式中，所述卤素为F。
在一个或多个实施方式中，X 1和X 2各自独立地为-CH 3、F或-OH。
在一个或多个实施方式中，X 1和X 2各自为-CH 3。
在一个或多个实施方式中，X 1和X 2各自独立地为F、Cl、Br或I。
在一个或多个实施方式中，X 1和X 2各自为F。
在一个或多个实施方式中，X 1和X 2各自独立地为F或-CH 3。
在一个或多个实施方式中，X 1为-CH 3及X 2为F。
在一个或多个实施方式中，p为2-8。
在一个或多个实施方式中，p为4-8。
在一个或多个实施方式中，p为6-8。
在一个或多个实施方式中，p为7-8。
在一个或多个实施方式中，p为7。
在一个或多个实施方式中，p为7.4。
在一个或多个实施方式中，p为8。
在一个或多个实施方式中，所述抗体药物偶联物具有式I-12、I-12-1、I-13、I-13-1、I-14、I-14-1、I-15、I-15-1、I-16、I-16-1、I-17、I-17-1、I-18、I-18-1、I-19、I-19-1、I-20、I-20-1、I-21、I-21-1、I-22、I-22-1、I-23、I-23-1、I-24、I-24-1、I-25、或I-25-1所示的结构或其立体异构体或药学上可接受的盐或溶剂合物：
Figure PCTCN2022141572-appb-000061
Figure PCTCN2022141572-appb-000062
Figure PCTCN2022141572-appb-000063
Figure PCTCN2022141572-appb-000064
Figure PCTCN2022141572-appb-000065
Figure PCTCN2022141572-appb-000066
Figure PCTCN2022141572-appb-000067
Figure PCTCN2022141572-appb-000068
Figure PCTCN2022141572-appb-000069
Figure PCTCN2022141572-appb-000070
其中
Abu为本发明提供的抗体或其抗原结合单元；
p为1-10，例如1、2、3、4、5、6、7、7.4、8、9或10。
在一个或多个实施方式中，p为2-8。
在一个或多个实施方式中，p为4-8。
在一个或多个实施方式中，p为6-8。
在一个或多个实施方式中，p为7-8。
在一个或多个实施方式中，p为7。
在一个或多个实施方式中，p为7.4。
在一个或多个实施方式中，p为8。
一个或多个实施方式提供了抗体药物偶联物，其用作药物。在一个或多个实施方式中，在药物中的抗体药物偶联物的DAR(p)为1、2、3、4、5、6、7、8、9或10。在一个或多个实施方式中，在药物中的抗体药物偶联物的平均DAR(p)为2-9。在一个或多个实施方式中，在药物中的抗体药物偶联物的平均DAR(p)为4-9。在一个或多个实施方式中，在药物中的抗体药物偶联物的平均DAR(p)为6-8.5。在一个或多个实施 方式中，在药物中的抗体药物偶联物的平均DAR(p)为6-8。在一个或多个实施方式中，在药物中的抗体药物偶联物的平均DAR(p)为7-8。
在一个或多个实施方式中，本发明抗体药物偶联物与一种或多种其它疗法组合联用。合适的其它疗法包括现有的用于特定应用(如癌症)的药物和/或手术疗法。例如，所述抗体药物偶联物与一种或多种其它化疗或抗肿瘤试剂联用。或者，其它化疗剂是放射疗法。在一个或多个实施方式中，所述化疗剂是细胞死亡诱导剂。
在一个或多个实施方式中，所述抗体药物偶联物和其它试剂被制备为单个治疗组合物，并同时给予所述抗体药物偶联物和其它试剂。或者，所述抗体药物偶联物和其它试剂彼此独立，例如分别制备为独立的治疗组合物，并同时给予所述抗体药物偶联物和其它试剂，或在治疗方案期间在不同时间给予所述抗体药物偶联物和其它试剂。例如，在给予其它试剂前给予所述抗体药物偶联物，在给予其它试剂后给予所述抗体药物偶联物，或在以交替的方案给予所述抗体药物偶联物和其它试剂。本文中，以单个剂量或多个剂量给予所述抗体药物偶联物和其它试剂。
在一个或多个实施方式中，本发明还提供了一种药物组合物，其包含本发明所述抗体或其抗原结合单元、或抗体药物偶联物以及药物可接受的载体、赋形剂和/或辅料。在一个或多个实施方式中，所述药物组合物还包含任选的其他抗癌药物。本发明提供的药物组合物可以通过任何方便的途径施用，例如通过输注或推注，通过上皮或皮肤粘膜(例如口腔粘膜、直肠和肠粘膜等)吸收，并且可以与其他生物活性剂共同施用。因此，所述药物组合物可以静脉给药、口服给药、直肠给药、肠胃外给药、脑内给药、阴道内给药、腹腔内给药、外敷(如通过粉末，软膏，滴剂或透皮贴剂)、口腔给药或通过口服或鼻腔喷雾给药。
在一个或多个实施方式中，本发明提供了所述抗体或其抗原结合单元、生物材料(选自多聚核苷酸、表达载体和细胞)、抗体药物偶联物、药物组合物中的至少一种在制备治疗和/或预防疾病的药物中的应用。在一个或多个实施方式中，所述疾病为叶酸受体α表达相关的疾病。在一个或多个实施方式中，所述疾病为叶酸受体α过表达相关的疾病。在一个或多个实施方式中，所述疾病为表达叶酸受体α的肿瘤。在一个或多个实施方式中，所述疾病为过表达叶酸受体α的肿瘤。在一个或多个实施方式中，所述疾病为表达叶酸受体α的癌症。在一个或多个实施方式中，所述疾病为过表达叶酸受体α的癌症。在一个或多个实施方式中，所述治疗肿瘤的药物还包含其他抗癌药物。
在一个或多个实施方式中，本发明提供了本文所述抗体或其抗原结合单元、生物材料(选自多聚核苷酸、表达载体和细胞)、抗体药物偶联物和/或包含其的药物组合物在治疗和/或预防疾病中的应用。在一个或多个实施方式中，所述疾病为叶酸受体α表达相关的疾病。在一个或多个实施方式中，所述疾病为叶酸受体α过表达相关的疾病。在一个或多个实施方式中，所述疾病为表达叶酸受体α的肿瘤。在一个或多个实施方式中，所述疾病为过表达叶酸受体α的肿瘤。在一个或多个实施方式中，所述疾病为表达叶酸受体α的癌症。在一个或多个实施方式中，所述疾病为过表达叶酸受体α的癌症。在一个或多个实施方式中，所述疾病为癌症、自身免疫性疾病、炎症性疾病或感染性疾病。
一个或多个实施方式提供了治疗和/或预防疾病的方法，该方法包括向有需要的患者给药有效量的本文所述抗体或其抗原结合单元、生物材料(选自多聚核苷酸、表达 载体和细胞)、抗体药物偶联物和/或包含其的药物组合物。在一个或多个实施方式中，所述疾病为叶酸受体α表达相关的疾病。在一个或多个实施方式中，所述疾病为叶酸受体α过表达相关的疾病。在一个或多个实施方式中，所述疾病为表达叶酸受体α的肿瘤。在一个或多个实施方式中，所述疾病为过表达叶酸受体α的肿瘤。在一个或多个实施方式中，所述疾病为表达叶酸受体α的癌症。在一个或多个实施方式中，所述疾病为过表达叶酸受体α的癌症。在一个或多个实施方式中，所述有效量是指活性化合物或药剂的量，其导致研究人员、兽医、医生或其他临床医生正寻求的组织、系统、动物、个体以及人的生物或药用响应，这包含治疗一种疾病。
癌症的实例包括但不限于实体瘤、血液学癌及转移性病灶。此类癌症的具体实例包括但不限于大肠癌、肺癌、卵巢癌、子宫癌、子宫内膜癌、腹膜癌、输卵管癌、胰腺癌、头颈鳞形细胞癌、鼻咽癌、喉癌、肺腺癌、肝癌、乳腺癌、脑癌、肾癌、肾细胞癌、结肠癌、睾丸癌、子宫颈癌、膀胱癌、视网膜母细胞瘤、神经胶母细胞瘤、间皮瘤、口腔上皮样癌、绒毛膜癌和头颈癌。
在一个或多个实施方式中，可以将抗体或其抗原结合单元或抗体药物偶联物配制成药物组合物，并以适合于所选给药途径的形式向患者给药，给药途径例如肠胃外、静脉内(iv)、肌肉内、局部或皮下。
在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物的给药剂量(例如单次给药剂量)为1mg/kg-10mg/kg；或者，1.2mg/kg-8.0mg/kg；或者，1.2mg/kg-6.5mg/kg；或者，1.2mg/kg-5.0mg/kg；或者，1.2mg/kg-3.5mg/kg；或者，1.2mg/kg-2.4mg/kg；或者，2.4mg/kg-8.0mg/kg；或者，2.4mg/kg-6.5mg/kg；或者，2.4mg/kg-5.0mg/kg；或者，2.4mg/kg-3.5mg/kg；或者，3.5mg/kg-8.0mg/kg；或者，3.5mg/kg-6.5mg/kg；或者，3.5mg/kg-5.0mg/kg；或者，5.0mg/kg-8.0mg/kg；或者，5.0mg/kg-6.5mg/kg；或者，6.5mg/kg-8.0mg/kg；或者，1.5mg/kg-8.5mg/kg；或者，1.5mg/kg-6.5mg/kg；或者，1.5mg/kg-4.5mg/kg；或者，1.5mg/kg-3.0mg/kg；或者，3.0mg/kg-8.5mg/kg；或者，3.0mg/kg-6.5mg/kg；或者，3.0mg/kg-4.5mg/kg；或者，4.5mg/kg-8.5mg/kg；或者，4.5mg/kg-6.5mg/kg；或者，6.5mg/kg-8.5mg/kg。在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物的给药剂量(例如单次给药剂量)为约1mg/kg、1.2mg/kg、1.5mg/kg、约2.0mg/kg、2.4mg/kg、约3.0mg/kg、约3.5mg/kg、约4.0mg/kg、约4.5mg/kg、约5.0mg/kg、约5.5mg/kg、约6.0mg/kg、约6.5mg/kg、约7.0mg/kg、约7.5mg/kg、约8.0mg/kg、约8.5mg/kg、约9mg/kg、约10mg/kg，或这些数值中任何两个值之间的范围(包括端点)或其中任何值。
在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物的单次给药剂量为1mg/kg-10mg/kg；或者，1.2mg/kg-8.0mg/kg；或者，1.2mg/kg-6.5mg/kg；或者，1.2mg/kg-5.0mg/kg；或者，1.2mg/kg-3.5mg/kg；或者，1.2mg/kg-2.4mg/kg；或者，2.4mg/kg-8.0mg/kg；或者，2.4mg/kg-6.5mg/kg；或者，2.4mg/kg-5.0mg/kg；或者，2.4mg/kg-3.5mg/kg；或者，3.5mg/kg-8.0mg/kg；或者，3.5mg/kg-6.5mg/kg；或者，3.5mg/kg-5.0mg/kg；或者，5.0mg/kg-8.0mg/kg；或者，5.0mg/kg-6.5mg/kg；或者，6.5mg/kg-8.0mg/kg；或者，1.5mg/kg-8.5mg/kg；或者，1.5mg/kg-6.5mg/kg；或者，1.5mg/kg-4.5mg/kg；或者，1.5mg/kg-3.0mg/kg；或者，3.0mg/kg-8.5mg/kg；或者，3.0mg/kg-6.5mg/kg；或者，3.0mg/kg-4.5mg/kg；或者，4.5mg/kg-8.5mg/kg； 或者，4.5mg/kg-6.5mg/kg；或者，6.5mg/kg-8.5mg/kg。在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物的单次给药剂量为约1mg/kg、1.2mg/kg、1.5mg/kg、约2.0mg/kg、2.4mg/kg、约3.0mg/kg、约3.5mg/kg、约4.0mg/kg、约4.5mg/kg、约5.0mg/kg、约5.5mg/kg、约6.0mg/kg、约6.5mg/kg、约7.0mg/kg、约7.5mg/kg、约8.0mg/kg、约8.5mg/kg、约9mg/kg、约10mg/kg，或这些数值中任何两个值之间的范围(包括端点)或其中任何值。
在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物的给药剂量(例如单次给药剂量)为50mg-1000mg；或者，50mg-600mg；或者，60mg-600mg；或者，100mg-600mg；或者，72mg-480mg；或者，72mg-390mg；或者，72mg-300mg；或者，72mg-210mg；或者，72mg-144mg；或者，144mg-480mg；或者，144mg-390mg；或者，144mg-300mg；或者，144mg-210mg；或者，210mg-480mg；或者，210mg-390mg；或者，210mg-300mg；或者，300mg-480mg；或者，300mg-390mg；或者，390mg-480mg；或者，84mg-560mg；或者，84mg-455mg；或者，84mg-350mg；或者，84mg-245mg；或者，84mg-168mg；或者，168mg-560mg；或者，168mg-455mg；或者，168mg-350mg；或者，168mg-245mg；或者，245mg-560mg；或者，245mg-455mg；或者，245mg-350mg；或者，350mg-560mg；或者，350mg-455mg；或者，455mg-560mg；或者，90mg-595mg；或者，90mg-510mg；或者，90mg-390mg；或者，90mg-270mg；或者，90mg-180mg；或者，180mg-510mg；或者，180mg-390mg；或者，180mg-270mg；或者，270mg-510mg；或者，270mg-390mg；或者，390mg-510mg；或者，105mg-595mg；或者，105mg-455mg；或者，105mg-315mg；或者，105mg-210mg；或者，210mg-595mg；或者，210mg-455mg；或者，210mg-315mg；或者，315mg-595mg；或者，315mg-455mg；或者，455mg-595mg。在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物的给药剂量(例如单次给药剂量)为约50mg、约55mg、约60mg、约65mg、约70mg、约72mg、约80mg、约84mg、约90mg、约95mg、约100mg、约105mg、约110mg、约120mg、约130mg、约140mg、约144mg、约145mg、约150mg、约155mg、约160mg、约165mg、约168mg、约170mg、约175mg、约180mg、约190mg、约200mg、约210mg、约220mg、约230mg、约240mg、约245mg、约250mg、约260mg、约270mg、约280mg、约290mg、约300mg、约310mg、约315mg、约320mg、约330mg、约340mg、约350mg、约360mg、约370mg、约380mg、约390mg、约400mg、约410mg、约420mg、约430mg、约440mg、约450mg、约455mg、约460mg、约470mg、约480mg、约490mg、约500mg、约510mg、约550mg、约560mg、约595mg、约600mg、约650mg、约700mg、约750mg、约800mg、约850mg、约900mg、约950mg、约1000mg，或这些数值中任何两个值之间的范围(包括端点)或其中任何值。
在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物的单次给药剂量为50mg-1000mg；或者，50mg-600mg；或者，60mg-600mg；或者，100mg-600mg；或者，72mg-480mg；或者，72mg-390mg；或者，72mg-300mg；或者，72mg-210mg；或者，72mg-144mg；或者，144mg-480mg；或者，144mg-390mg；或者，144mg-300mg；或者，144mg-210mg；或者，210mg-480mg；或者，210mg- 390mg；或者，210mg-300mg；或者，300mg-480mg；或者，300mg-390mg；或者，390mg-480mg；或者，84mg-560mg；或者，84mg-455mg；或者，84mg-350mg；或者，84mg-245mg；或者，84mg-168mg；或者，168mg-560mg；或者，168mg-455mg；或者，168mg-350mg；或者，168mg-245mg；或者，245mg-560mg；或者，245mg-455mg；或者，245mg-350mg；或者，350mg-560mg；或者，350mg-455mg；或者，455mg-560mg；或者，90mg-595mg；或者，90mg-510mg；或者，90mg-390mg；或者，90mg-270mg；或者，90mg-180mg；或者，180mg-510mg；或者，180mg-390mg；或者，180mg-270mg；或者，270mg-510mg；或者，270mg-390mg；或者，390mg-510mg；或者，105mg-595mg；或者，105mg-455mg；或者，105mg-315mg；或者，105mg-210mg；或者，210mg-595mg；或者，210mg-455mg；或者，210mg-315mg；或者，315mg-595mg；或者，315mg-455mg；或者，455mg-595mg。在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物的单次给药剂量为约50mg、约55mg、约60mg、约65mg、约70mg、约72mg、约84mg、约90mg、约100mg、约105mg、约110mg、约120mg、约130mg、约140mg、约144mg、约145mg、约150mg、约155mg、约160mg、约165mg、约168mg、约170mg、约175mg、约180mg、约190mg、约200mg、约210mg、约220mg、约230mg、约240mg、约245mg、约250mg、约260mg、约270mg、约280mg、约290mg、约300mg、约310mg、约315mg、约320mg、约330mg、约340mg、约350mg、约360mg、约370mg、约380mg、约390mg、约400mg、约410mg、约420mg、约430mg、约440mg、约450mg、约455mg、约460mg、约470mg、约480mg、约490mg、约500mg、约510mg、约520mg、约530mg、约540mg、约550mg、约560mg、约570mg、约580mg、约590mg、约595mg、约600mg，或这些数值中任何两个值之间的范围(包括端点)或其中任何值。
在一个或多个实施方式中，所述方法包括至少1个、至少2个、至少3个、至少4个、至少5个或至少6个治疗周期。在一个或多个实施方式中，一个治疗周期为至少1周、至少2周、至少3周、至少4周、至少5周、至少6周或至少7周。在一个或多个实施方式中，一个治疗周期为1周、2周、3周、4周、5周、6周、7周，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值。
在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物为单次给药。在一个或多个实施方式中，每2天给药1次到每6周给药1次。在一个或多个实施方式中，约1周给药2次，或约1周、约2周、约3周、约4周、约5周、约6周、约7周给药1次。在一个或多个实施方式中，每2天给药1次、每3天给药1次、每4天给药1次、每5天给药1次、每周给药2次、每周给药1次、每2周给药1次、每3周给药1次、每4周给药1次、每5周给药1次或每6周给药1次。
在一个或多个实施方式中，患者接受一个治疗周期治疗。在一个或多个实施方式中，患者接受多个(例如2个、3个、4个、5个、6个、7个、8个、9个、10个、11个或12个)治疗周期治疗。在一个或多个实施方式中，患者接受治疗直至病症得到缓解而不再需要治疗。
在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物或包含其的药物组合物是通过注射给药。在一个或多个实施方式中，所述抗体或其抗原结合 单元或抗体药物偶联物或包含其的药物组合物是通过皮下(s.c.)注射、腹膜内(i.p.)注射、肠胃外注射、动脉内注射或静脉内(i.v.)注射等方式给药。在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物或包含其的药物组合物是输液方式进行给药。在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物或包含其的药物组合物是推注方式进行给药。在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物或包含其的药物组合物是通过静脉注射给药。在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物或包含其的药物组合物是通过静脉输注给药。抗体或其抗原结合单元或抗体药物偶联物的给药量将取决于药物的性质、细胞表面触发药物的内在化、运输和释放的程度，以及所治疗的疾病和患者的状况(如年龄、性别、体重等)。
在一个或多个实施方式中，所述抗体或其抗原结合单元或抗体药物偶联物或包含其的药物组合物是通过静脉内(i.v.)输液方式(即静脉输注)进行给药。在一个或多个实施方式中，静脉内输液持续时间为约10分钟、约15分钟、约20分钟、约25分钟、约30分钟、约40分钟、约50分钟、约55分钟、约60分钟、约65分钟、约70分钟、约75分钟、约81分钟、约87分钟、约90分钟、约95分钟，或这些数值中任何两个值之间的范围(包括端点)或其中任何值。在一个或多个实施方式中，静脉输注时间≤30分钟。在一个或多个实施方式中，静脉输注时间≥60分钟。在一个或多个实施方式中，静脉输注时间≥90分钟。
在一个或多个实施方式中，本发明提供了包含所述抗体或其抗原结合单元或抗体药物偶联物的适合注射用的药物组合物，如推注型药物组合物或输液(滴注)型药物组合物。适于注射用途的药物组合物包括无菌水性溶液或分散体以及用于即时制备无菌注射液或分散体的无菌粉末。对于静脉内施用，合适的载体包括生理盐水、抑菌水或磷酸盐缓冲盐水(PBS)、乙醇、多元醇(例如，甘油、丙二醇和液体聚乙二醇等)的溶剂或分散介质，及其适宜的混合物。在一个或多个实施方式中，药物组合物还包括药学可接受的载体。在一个或多个实施方式中，药学上可接受的载体可以包含抗细菌剂和/或抗真菌剂，如对羟基苯甲酸酯、氯代丁醇、苯酚、抗坏血酸、硫柳汞等来实现。在一个或多个实施方式中，药学上可接受的载体可以包含等渗剂，如糖、多元醇(诸如甘露糖醇、山梨醇)、氯化钠。在一个或多个实施方式中，药物组合物至少包含0.1％的抗体或其抗原结合单元或抗体药物偶联物。抗体的百分比可以变化，并且为给定剂型重量的约2％至90％之间。这种药物组合物中的抗体或其抗原结合单元或抗体药物偶联物的量可以为给药的有效量。
在一个或多个实施方式中，本发明提供了药物组合物的制备方法：分别将本文所述的抗体或其抗原结合单元或抗体药物偶联物与药学上可接受的载体(例如注射用水，生理盐水等)混合。上述抗体或其抗原结合单元或抗体药物偶联物与药学上可接受的载体的混合方法是本领域通常已知的。
在一个或多个实施方式中，本发明提供了一种试剂盒，包含本文所述抗体或其抗原结合单元、抗体药物偶联物或包含其的药物组合物以及用于指导患者给药的说明书。
一个或多个实施方式还提供了制品，其包含本发明所述抗FRα抗体或其抗原结合单元、抗体药物偶联物或者包含其的药物组合物；
容器；和
包装插页、说明书或标签，其指示本发明所述抗FRα抗体、抗体药物偶联物或者包含其的药物组合物用于治疗和/预防叶酸受体α表达相关的疾病。
本领域技术人员应理解本发明的抗体有多种用途。例如，本发明的抗体可用作治疗剂、用作诊断试剂盒中的试剂或用作诊断工具、或用作竞争实验中的试剂以生成治疗剂。
附图说明
图1显示了ADC的偶联示意图。
图2显示了ADC1的内吞作用。
图3显示了ADC1的旁观者效应。
图4显示了ADC1的体内肿瘤抑制作用。
图5显示了ADC1的体内肿瘤抑制作用。
图6显示了在LU11554异种移植模型中各组小鼠肿瘤体积的生长曲线(平均值±标准误)。
图7显示了在LU5197异种移植模型中各组小鼠肿瘤体积的生长曲线(平均值±标准误)。
具体实施方式
除非另有定义，本发明中使用的科学和技术术语的含义是本领域技术人员所通常理解的含义。通常，本文所述的细胞培养、分子生物学以及蛋白质纯化使用的命名和技术是本领域公知且普遍使用的。对于重组DNA、寡核苷酸合成和细胞培养与转化(如电穿孔、脂质转染)，使用了标准技术。酶促反应和纯化技术根据生产商的说明书或本领域普遍使用或本文所述的方法进行。前述技术和方法通常根据本领域公知且本说明书中引用和讨论的多部综合和较具体的文献中描述的那样使用。参见例如Sambrook等，Molecular Cloning:A Laboratory Manual(《分子克隆：实验室手册》)(第2版，冷泉港实验室出版社(Cold Spring Harbor Laboratory Press)，纽约冷泉港(1989))。
定义
应当注意的是，术语“一种”实体是指一种或多种该实体，例如“一种抗体”应当被理解为一种或多种抗体，因此，术语“一种”(或“一个”)、“一种或多种”和“至少一种”可以在本文中互换使用。
本文所用的术语“包含”或“包括”意味着抗体、组合物或方法等包括所列举的元素，例如组份或步骤，但不排除其它。“基本上由……组成”意味着抗体、组合物或方法等排除对组合的特征有根本影响的其它元素，但不排除对抗体、组合物或方法等无本质上影响的元素。“由……组成”意味着排除未特别列举的元素。
本文所用术语“抗体”指免疫球蛋白(Ig)分子和免疫球蛋白分子的免疫活性部分，即包含特异性结合抗原(与其免疫反应)的抗原结合位点的分子。“特异性结合”或“发生免疫反应”或“针对”是指抗体与目标抗原的一个或多个抗原决定簇反应且不与其它多肽反应，或者以很低亲和力(KD>10 -6g/ml)与其它多肽结合。抗体包括但不限于单克隆抗体、嵌合抗体、dAb(结构域抗体)、单链抗体、Fab、Fab-和F(ab’) 2片段、Fv和 Fab表达库。
术语“抗体”包括可以在生物化学上区分的各种广泛种类的多肽。本领域技术人员将会理解，重链的类别包括gamma、mu、alpha、delta或epsilon(γ、μ、α、δ、ε)，其中还有一些亚类(例如γ1-γ4)。该链的性质决定了抗体的“种类”分别为IgG、IgM、IgA、IgG或IgE。免疫球蛋白亚类(同种型)，例如IgG1、IgG2、IgG3、IgG4、IgG5等已被充分表征并且赋予的功能特异性也已知。所有的免疫球蛋白种类都在本发明公开的保护范围内。在一个或多个实施方式中，免疫球蛋白分子为IgG种类。两条重链和两条轻链通过二硫键以“Y”构型连接，其中轻链从“Y”口开始并延续通过可变区包围重链。
本发明公开的抗体、抗原结合单元或衍生物包括但不限于多克隆、单克隆、多特异性、全人源、人源化、灵长类化、嵌合抗体、单链抗体、表位结合片段(例如类Fab、类Fab'和类F(ab') 2)、类单链Fvs(scFv)。
轻链可以分为kappa(κ)或lambda(λ)。每个重链可以与κ或λ轻链结合。一般来说，当由杂交瘤、B细胞或基因工程宿主细胞生产免疫球蛋白时，其轻链和重链通过共价键结合，两条重链的“尾巴”部分通过共价二硫键或非共价键结合。在重链中，氨基酸序列从Y构型的叉状末端的N末端延伸至每条链底部的C末端。免疫球蛋白κ轻链可变区为V κ；免疫球蛋白λ轻链可变区为V λ。
术语“恒定的”和“可变的”根据功能被使用。轻链可变区(VL)和重链可变区(VH)决定了抗原识别和特异性。轻链恒定区(CL)和重链恒定区(CH)赋予重要的生物学性质，如分泌、经胎盘移动、Fc受体结合、补体结合等。按照惯例，恒定区的编号随着它们变得更远离抗体的抗原结合位点或氨基末端而增加。N端部分是可变区，C端部分是恒定区；CH3和CL结构域实际上分别包含重链和轻链的羧基端。
在天然存在的抗体中，假设抗体在含水环境中呈现其三维构型时，存在于每个抗原结合域中的六个“互补决定区”或“CDR”是形成抗原结合结构域的短的、非连续的与抗原特异性结合的氨基酸序列。抗原结合结构域中被称为“框架”区域的剩余其它氨基酸显示出较小的分子间可变性。框架区大部分采用β-折叠构象，CDR形成与之连接的环状结构，或在某些情况下形成β折叠结构的一部分。因此，框架区通过形成支架从而通过链间非共价相互作用使CDR定位在正确的方位上。具有特定位置的CDR的抗原结合域形成了与抗原上的表位互补的表面，该互补表面促进抗体和其抗原表位的非共价结合。对于给定的重链或轻链可变区，本领域普通技术人员都可以通过已知方法鉴定出包含CDR和框架区的氨基酸(参见Kabat,E.,et al.,U.S.Department of Health and Human Services,Sequences of Proteins of Immunological Interest,(1983)和Chothia and Lesk,J.Mol.Biol.,196:901-917(1987))。如本文所用，术语“单克隆抗体”(mAb)是指一群这样的抗体分子：其只含有由独特的轻链基因产物和独特的重链基因产物组成的抗体分子中的一种分子种类。具体地，单克隆抗体的互补决定区(CDR)在该群体的所有分子中是相同的。MAb含有能够与抗原的特定表位发生免疫反应的抗原结合位点。
术语“单链抗体”(scFv)是指由抗体重链可变区(VH)和轻链可变区(VL)通过15～20个氨基酸的接头(linker)连接而成的抗体。接头可以富含甘氨酸以增加柔韧性，以及富含丝氨酸或苏氨酸以增加溶解性，并且可以连接VH的N端和VL的C端，反 之亦然。尽管该蛋白质被除去了恒定区和引入了接头，但其保留了原始免疫球蛋白的特异性。ScFv分子通常是本领域中已知的，例如在美国专利5,892,019中有相关描述。
术语“抗原结合位点”或“结合部分”指免疫球蛋白分子中参与抗原结合的部分。该抗原结合位点由重(H)链和轻(L)链的N端可变(V)区的氨基酸残基形成。重链可变区(VH)和轻链可变区(VL)中三个高度分化的分支(被称作“高变区”)位于较保守的分支(被称作“框架区”或“FR”)之间。因此，术语“FR”表示免疫球蛋白中在天然情况下存在于高变区之间或邻近高变区的氨基酸序列。在抗体分子中，轻链的三个高变区和重链的三个高变区在三维空间中彼此相对排列，以形成抗原结合表面。抗原结合表面与所结合抗原的三维表面互补，且每条重链和轻链的三个高变区均被称作“互补决定区”或“CDR”。按照位置顺序，重链可变区包含VH FR1、VH CDR1、VH FR2、VH CDR2、VH FR3、VH CDR3以及VH FR4。按照位置顺序，轻链可变区包含VL FR1、VL CDR1、VL FR2、VL CDR2、VL FR3、VL CDR3以及VL FR4。每个结构域氨基酸的比对可与Kabat Sequences of Proteins of Immunological Interest(National Institutes of Health(1987和1991))或Chothia和Lesk的文章(J.Mol.Biol.196:901-917(1987)；Chothia等，Nature 342:878-883(1989))的定义一致。
人源化抗体的框架区及CDR区不必准确对应于亲本序列，例如供体抗体CDR或共有框架可通过至少一个氨基酸残基的取代、插入和/或缺失而突变诱发，使得该位点的CDR或框架残基不对应于供体抗体或共有框架。通常，至少80％、至少85％、更至少90％或至少95％的人源化抗体残基将对应于亲本FR及CDR序列的那些残基。如本文使用的，术语“共有框架”是指共有免疫球蛋白序列中的框架区。如本文使用的，术语“共有免疫球蛋白序列”是指由相关免疫球蛋白序列家族中最频繁出现的氨基酸(或核苷酸)形成的序列(参见例如，Winnaker,From Genes to Clones[从基因到克隆](Verlagsgesellschaft,Weinheim,德国1987))。在免疫球蛋白家族中，共有序列中的各位置由该家族中最频繁出现于该位置的氨基酸占据。若两个氨基酸同等频繁地出现，则共有序列中可包括任一个。
在本领域中使用和/或接受的术语有两个或多个定义的情况下，除非明确地对立指出，否则本文使用的术语的定义包括所有这些含义。一个具体的例子是使用“互补决定区”(“CDR”)一词来描述在重链和轻链多肽的可变区内发现的非连续的抗原结合位点。这一特定区域在Kabat et al.,U.S.Dept.of Health and Human Services,Sequences of Proteins of Immunological Interest(1983)和Chothia等在J.Mol.Biol.196:901-917(1987)有相关描述，其通过引用全部并入本文。
Kabat等人还定义了适用于任何抗体的可变区序列的编号系统。本领域普通技术人员可以不依赖于序列本身以外的其他实验数据将该“Kabat编号”系统应用到任何可变区序列。“Kabat编号”是指由Kabat et al.,U.S.Dept.of Health and Human Services在“Sequence of Proteins of Immunological Interest”(1983)提出的编号系统。抗体还可以用EU或Chothia编号系统。
本发明公开的抗体可以来源于任何动物，包括但不限于鱼类、鸟类和哺乳动物。较佳地，抗体是人源、鼠源、驴源、兔源、山羊源、骆驼源、美洲驼源、马源或鸡源抗体。在另一实施方案中，可变区可以是软骨鱼纲(condricthoid)来源(例如来自鲨鱼)。
“重链恒定区”包括CH1结构域、铰链(例如上、中和/或下铰链区)结构域、CH2结构域、CH3结构域，或变体或片段中的至少一种。抗体的重链恒定区可以来源于不同的免疫球蛋白分子。例如，多肽的重链恒定区可以包括源自IgG1分子的CH1结构域和源自IgG3分子的铰链区。在另一实施方案中，重链恒定区可以包括部分源自IgG1分子和部分源自IgG3分子的铰链区。在另一实施方案中，部分重链可以包括部分源自IgG1分子和部分源自IgG4分子的嵌合铰链区。
“轻链恒定区”包括来自抗体轻链的一部分氨基酸序列。较佳地，轻链恒定区包含恒定κ结构域或恒定λ结构域中的至少一个。“轻链-重链对”是指可通过轻链的CL结构域和重链的CH1结构域之间的二硫键形成二聚体的轻链和重链的集合。
“VH结构域”包括免疫球蛋白重链的氨基末端可变结构域。“CH1结构域”包括免疫球蛋白重链的第一个恒定区。CH2结构域不与其它结构域紧密配对，而是在完整的天然IgG分子的两个CH2结构域之间插入两个N-连接的分支碳水化合物链。CH3结构域从CH2结构域开始延伸到IgG分子的C-末端，大约包含108个残基。“铰链区”包括连接CH1结构域和CH2结构域的部分重链区域。所述铰链区包含约25个残基并且是有韧性的，从而使得两个N端抗原结合区能够独立移动。铰链区可以被细分为三个不同的结构域：上、中和下铰链结构域(Rouxetal.,J.Immunol 161:4083(1998))。
“二硫键”指两个硫原子之间形成的共价键。半胱氨酸的硫醇基团可以与第二个硫醇基团形成二硫键或桥接。在大多数天然存在的IgG分子中，CH1和CL区通过二硫键连接。
“嵌合抗体”指其可变区从第一个物种中获得或衍生，而其恒定区(可以是完整的、部分的或修饰过的)来源于第二个物种的任何抗体。某些实施方案中，可变区来自非人源(例如小鼠或灵长类动物)，而恒定区来自人源。
本文所用术语“表位”包括任意能够特异性结合免疫球蛋白或其片段或T细胞受体的蛋白决定区。表位决定区通常由分子的化学活性表面基团(如氨基酸或糖侧链)组成且通常有特定的三维结构性质以及特定的电荷性质。
如本文所用，术语“特异性结合”是指在免疫球蛋白分子与免疫球蛋白特异的抗原之间发生的非共价相互作用类型。免疫学结合相互作用的强度或亲和力可以以相互作用的平衡解离常数(KD)表示，其中较小的KD代表较大的亲和力。所选多肽的免疫结合特性可使用本领域熟知方法进行定量。一种此类方法需要测量抗原结合位点/抗原复合物形成和解离的速率，其中那些速率取决于复合物配偶体的浓度、相互作用的亲和力和在两个方向同等影响该速率的几何参数。因此，“结合速率常数”(k on)和“解离速率常数”(k off)两者可通过计算浓度和实际的缔合和解离速率测定(参见Nature361:186-87(1993))。k off/k on比率能够消除所有与亲和力无关的参数，并且等于平衡解离常数KD(通常参见Davies等人(1990)Annual Rev Biochem 59:439-473)。特异性结合可由放射性配体结合测定、表面等离子体共振(SPR)、流式细胞术结合测定、或本领域技术人员已知的类似测定所测。
本发明中关于细胞、核酸、多肽等所使用的术语“分离的”，例如“分离的”DNA、RNA、多肽是指分别于细胞天然环境中的其它组分如DNA或RNA中的一种或多种所分离的分子。本发明使用的术语“分离的”还指当通过重组DNA技术产生时基本上不含细胞材料、病毒材料或细胞培养基的核酸或肽，或化学合成时的化学前体或其他化学 品。此外，“分离的核酸”意在包括不以天然状态存在的核酸片段，并且不会以天然状态存在。术语“分离的”在本发明中也用于指从其他细胞蛋白质或组织分离的细胞或多肽。分离的多肽意在包括纯化的和重组的多肽。分离的多肽等通常通过至少一个纯化步骤制备。在一个或多个实施方式中，分离的核酸、多肽等的纯度至少为约50％、约60％、约70％、约80％、约90％、约95％、约99％，或这些数值中的任何两个值之间的范围(包括端值)或其中任何值。
“分离的”抗体是从其天然环境的组分中分离和/或回收的抗体。其天然环境的一些组分是将妨碍抗体的诊断或治疗用途的物质，并且可包括酶、激素、以及其它蛋白质或非蛋白质溶质。在一些实施方案中，将所述抗体纯化到以下程度：(1)所述抗体按重量百分比计大于95％，如大于99％，如由Lowry方法所测；(2)通过使用转杯式测序仪可以获得N-末端或内部氨基酸序列的至少15个残基；或者(3)通过还原或非还原条件下的SDS-PAGE，使用考马斯蓝或银染色测出具有同质性。分离的抗体包括重组细胞内的原位抗体。通常，分离的抗体将通过至少一个或多个纯化步骤制备。在一些实施方案中，分离的抗体的纯度至少为约50％、约60％、约70％、约80％、约90％、约95％、约99％，或这些数值中的任何两个值之间的范围(包括端值)或其中任何值。
术语“编码”应用于多聚核苷酸时，是指被称为“编码”多肽的多聚核苷酸，在其天然状态或当通过本领域技术人员公知的方法操作时，经转录和/或翻译可以产生该多肽和/或其片段。
术语“重组”涉及多肽或多聚核苷酸，意指天然不存在的多肽或多聚核苷酸的形式，不受限制的实施例可以通过组合产生通常并不存在的多聚核苷酸或多肽。
术语“序列同一性”指的是：在比较窗口中两个多核苷酸或氨基酸序列是相同的(即基于核苷酸对核苷酸或残基对残基是相同的)。术语“序列同一性百分比”通过如下方式计算：在比较窗口中比较两个最佳比对的序列，确定在两个序列中出现相同氨基酸残基的位置的数目以得到匹配的位置的数目，将匹配的位置的数目除以比较窗口中位置的总数目(即窗口尺寸)，然后将结果乘以100以得到序列同一性百分比。“至少90％序列同一性”为约90％序列同一性、约91％序列同一性、约92％序列同一性、约93％序列同一性、约95％序列同一性、约96％序列同一性、约97％序列同一性、约98％序列同一性、约99％序列同一性，或这些数值中的任何两个值之间的范围(包括端值)或其中任何值。
“氨基酸”是指既含氨基又含羧基的有机化合物，比如α-氨基酸，其可直接或以前体的形式由核酸编码。单个氨基酸由三个核苷酸(所谓的密码子或碱基三联体)组成的核酸编码。每一个氨基酸由至少一个密码子编码。相同氨基酸由不同密码子编码称为“遗传密码的简并性”。氨基酸包括天然氨基酸和非天然氨基酸。
如本文所用，二十种常规氨基酸及其缩写遵循常规用法。参见Immunology-A Synthesis(第2版，E.S.Golub和D.R.Gren编辑，Sinauer Associates,Sunderland 7Mass.(1991))。二十种常规氨基酸的立体异构体(例如，D-氨基酸)、非天然氨基酸(诸如α-、α-二取代氨基酸)、N-烷基氨基酸、乳酸及其它非常规氨基酸也可为适用于本公开多肽的组分。非常规氨基酸的示例包括：4-羟脯氨酸、γ-羧基谷氨酸盐、ε-N,N,N-三甲基赖氨酸、ε-N-乙酰赖氨酸、O-磷酸丝氨酸、N-乙酰丝氨酸、N-甲酰甲硫 氨酸、3-甲基组氨酸、5-羟赖氨酰、σ-N-甲基精氨酸及其它类似的氨基酸和亚氨基酸(例如4-羟脯氨酸)。在本文所用的多肽表示方法中，左手方向为氨基末端方向，并且右手方向为羧基末端方向，与标准用法和惯例一致。常规(或天然)氨基酸包括丙氨酸(三字母代码：Ala，一字母代码：A)、精氨酸(Arg，R)、天冬酰胺(Asn，N)、天冬氨酸(Asp，D)、半胱氨酸(Cys，C)、谷氨酰胺(Gln，Q)、谷氨酸(Glu，E)、甘氨酸(Gly，G)、组氨酸(His，H)、异亮氨酸(Ile，I)、亮氨酸(Leu，L)、赖氨酸(Lys，K)、甲硫氨酸(Met，M)、苯丙氨酸(Phe，F)、脯氨酸(Pro，P)、丝氨酸(Ser，S)、苏氨酸(Thr，T)、色氨酸(Trp，W)、酪氨酸(Tyr，Y)和缬氨酸(Val，V)。
术语“多肽”旨在涵盖单数的“多肽”以及复数的“多肽”，并且是指由通过酰胺键(也称为肽键)线性连接的氨基酸单体形成的分子。术语“多肽”是指两个或更多个氨基酸的任何单条链或多条链，并且不涉及产物的特定长度。因此，“多肽”的定义中包括肽、二肽、三肽、寡肽、“蛋白质”、“氨基酸链”或用于指两个或多个氨基酸链的任何其他术语，并且术语“多肽”可以用来代替上述任何一个术语，或者与上述任何一个术语交替使用。术语“多肽”也意在指多肽表达后修饰的产物，包括但不限于糖基化、乙酰化、磷酸化、酰胺化、通过已知的保护/封闭基团衍生化、蛋白水解切割或非天然发生的氨基酸修饰。多肽可以源自天然生物来源或通过重组技术产生，但其不必从指定的核酸序列翻译所得，它可能以包括化学合成的任何方式产生。
当应用于多肽时，术语“基本上相同”是指两个肽序列在诸如通过GAP或BESTFIT程序使用默认空位权重进行最佳比对时，共享至少80％序列同一性，优选至少90％序列同一性，更优选至少95％序列同一性，并最优选至少99％序列同一性。
本领域技术人员理解当氨基酸或多肽作为一个分子(如抗体或ADC)的组成部分时，氨基酸或多肽指氨基酸残基或多肽残基(不论是否写明)，即其在与该分子的其他部分结合时，其部分基团(例如其氨基一个氢原子和/或羧基的羟基)因其与分子的其他部分形成共价键(如酰胺键)而失去后的剩余部分。
多聚核苷酸是由四个碱基的特定序列组成：腺嘌呤(A)、胞嘧啶(C)、鸟嘌呤(G)、胸腺嘧啶(T)，或当多聚核苷酸是RNA时胸腺嘧啶换为尿嘧啶(U)。“多聚核苷酸序列”可以以多聚核苷酸分子的字母表示。该字母表示可以被输入到具有中央处理单元的计算机中的数据库中，并用于生物信息学应用，例如用于功能基因组学和同源性搜索。
术语“多核苷酸”、“多聚核苷酸”和“寡核苷酸”可互换使用，是指任何长度的核苷酸的聚合形式，无论是脱氧核糖核苷酸还是核糖核苷酸或其类似物。多聚核苷酸可以具有任何三维结构并且可以执行已知或未知的任何功能。以下是不受限制的多聚核苷酸的实施例：基因或基因片段(例如探针、引物、EST或SAGE标签)、外显子、内含子、信使RNA(mRNA)、转运RNA、核糖体RNA、核糖酶、cDNA、dsRNA、siRNA、miRNA、重组多聚核苷酸、分支的多聚核苷酸、质粒、载体、任何序列的分离的DNA、任何序列的分离的RNA、核酸探针和引物。多聚核苷酸可以包含修饰的核苷酸，例如甲基化的核苷酸和核苷酸类似物。如果存在该修饰，则对核苷酸的结构修饰可以在组装多聚核苷酸之前或之后进行。核苷酸的序列可以被非核苷酸组分中断。聚合后可以进一步修饰多聚核苷酸，例如通过与标记组分缀合。这个术语也指双链和 单链分子。除另有说明或要求外，本公开的任何多聚核苷酸的实施例包括双链形式和已知或预测构成双链形式的两种可互补单链形式中的每一种。
核酸或多聚核苷酸序列(或多肽或抗体序列)与另一序列有具有一定百分比(例如90％、95％、98％或者99％)的“同一性或序列同一性”是指当序列比对时，所比较的两个序列中该百分比的碱基(或氨基酸)相同。可以使用目测或本领域已知的软件程序来确定该比对和同一性百分比或序列同一性，比如Ausubel et al.eds.(2007)在Current Protocols in Molecular Biology中所述的软件程序。优选使用默认参数进行比对。其中一种比对程序是使用默认参数的BLAST，例如BLASTN和BLASTP，两者使用下列默认参数：Geneticcode＝standard；filter＝none；strand＝both；cutoff＝60；expect＝10；Matrix＝BLOSUM62；Descriptions＝50sequences；sortby＝HIGHSCORE；Databases＝non-redundant；GenBank+EMBL+DDBJ+PDB+GenBankCDStranslations+SwissProtein+SPupdate+PIR。生物学上等同的多聚核苷酸是具有上述指定百分比的同一性并编码具有相同或相似生物学活性的多肽的多聚核苷酸。
除非另外指明，否则单链多核苷酸序列的左手末端是5'端，双链多核苷酸序列的左手方向被称为5'方向。新生的RNA转录物的5’至3’的添加方向被称为转录方向；DNA链上与RNA序列相同，且在RNA转录物5’端5’的序列区被称为“上游序列”；DNA链上与RNA序列相同，且在RNA转录物3’端3’的序列区被称为“下游序列”。
在一些实施方案中，不相同的残基位置区别在于保守氨基酸取代。
抗体或免疫球蛋白分子的氨基酸序列的微小变化都涵盖在本公开之内，条件是氨基酸序列的同一性保持至少90％，如至少92％、95％、98％或99％。在一些实施方案中，变化为保守氨基酸取代。保守氨基酸取代是在其侧链中相关的氨基酸家族内发生的取代。基因编码的氨基酸大致分以下类：(1)酸性氨基酸为天冬氨酸盐、谷氨酸盐；(2)碱性氨基酸为赖氨酸、精氨酸、组氨酸；(3)非极性氨基酸为丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸、色氨酸)；以及(4)无电荷的极性氨基酸为甘氨酸、天冬酰胺、谷氨酰胺、半胱氨酸、丝氨酸、苏氨酸、酪氨酸。其它家族的氨基酸包括(i)脂肪族-羟基家族的丝氨酸和苏氨酸；(ii)含酰胺家族的天冬酰胺和谷氨酰胺；(iii)脂肪族家族的丙氨酸、缬氨酸、亮氨酸和异亮氨酸；以及(iv)芳族家族的苯丙氨酸、色氨酸和酪氨酸。在一些实施方案中，保守氨基酸取代组为：缬氨酸-亮氨酸-异亮氨酸、苯丙氨酸-酪氨酸、赖氨酸-精氨酸、丙氨酸-缬氨酸、谷氨酸-天冬氨酸、以及天冬酰胺-谷氨酰胺。例如，可以合理地预测用异亮氨酸或缬氨酸单独的置换亮氨酸，用谷氨酸盐置换天冬氨酸盐，用丝氨酸置换苏氨酸，或用一个结构相关的氨基酸类似的置换一个氨基酸，且对所得分子的结合或特性不会有重要影响，特别是该置换不涉及结合位点内的氨基酸。氨基酸改变是否产生功能性肽可以容易地通过测定多肽衍生物的比活性来确定。所述测定在本文进行了详细描述。抗体或免疫球蛋白分子的片段或类似物可由本领域普通技术人员容易地制备。
在一些实施方案中，氨基酸取代具有如下效果：(1)降低对蛋白水解作用的敏感性，(2)降低对氧化作用的敏感性，(3)改变用于形成蛋白复合物的结合亲和力，(4)改变结合亲和力，和(5)赋予或改进此类类似物的其它物理化学或功能特性。类似物可包括序列不同于天然存在的肽序列的各种突变蛋白。例如，可在天然存在的序列(优选在形成分子间接触的结构域之外的多肽部分中)中进行单个或多个氨基酸 取代(优选保守氨基酸取代)。保守氨基酸取代不应当显著改变亲本序列的结构特性(例如，置换的氨基酸不应当趋于破坏亲本序列中存在的螺旋结构，或破坏表征亲本序列的其它类型二级结构)。人工识别的多肽的二级和三级结构的示例描述于Proteins,Structures and Molecular Principles(Creighton编辑，W.H.Freeman and Company,New York(1984))；Introduction to Protein Structure(C.Branden和J.Tooze编辑，Garland Publishing,New York,N.Y.(1991))；和Thornton等人Nature 354:105(1991)。
VL、VH的保守氨基酸取代的氨基酸数目可以为约1个、约2个、约3个、约4个、约5个、约6个、约8个、约9个、约10个、约11个、约13个、约14个、约15个保守氨基酸取代，或这些数值中的任何两个值之间的范围(包括端值)或其中任何值。重链恒定区、轻链恒定区、重链或轻链的保守氨基酸取代的氨基酸数目可以为约1个、约2个、约3个、约4个、约5个、约6个、约8个、约9个、约10个、约11个、约13个、约14个、约15个、约18个、约19个、约22个、约24个、约25个、约29个、约31个、约35个、约38个、约41个、约45个保守氨基酸取代，或这些数值中的任何两个值之间的范围(包括端值)或其中任何值。
本文所用术语“试剂”表示化学化合物、化学化合物混合物、生物大分子或由生物材料制得的提取物。
如本文所用，术语“标记”或“经标记的”是指掺入可检测标记，例如，通过掺入放射性标记的氨基酸，或者附着于可由标记的亲和素(例如，含有荧光标记或可由光学方法或量热法检测的酶活性的链霉亲和素)检测的生物素基部分的多肽。在某些情况下，标记物或标记也可为治疗性的。标记多肽和糖蛋白的各种方法是本领域已知的并且可以使用。用于多肽的标记物的示例包括但不限于以下项：放射性同位素或放射性核素(例如， 3H、 14C、 15N、 35S、 90Y、 99Tc、 111In、 125I、 131I)，荧光标记物(例如，FITC、罗丹明、镧系磷光体)，酶标记物(例如，辣根过氧化酶、β-半乳糖苷酶、荧光素酶、碱性磷酸酶)，化学发光标记，生物素酰基，被二级报告基因识别的预定多肽表位(例如，亮氨酸拉链对序列、二级抗体结合位点、金属结合结构域、表位标签)。在一些实施方案中，标记通过各种长度的间隔臂连接以减小可能的空间位阻。术语“药剂”或“药物”是指适当施用于患者时能够诱导期望的治疗效果的化合物或组合物。
“约”指相关技术领域技术人员容易知道的相应数值的常规误差范围。在一些实施方式中，本文中提到“约”指所描述的数值以及其±10％、±5％或±1％的范围。
“EC 50”即半最大效应浓度(concentration for 50％of maximal effect,EC 50)是指能引起50％最大效应的浓度。
“IC 50”表示50％抑制浓度，即对指定的生物过程抑制一半时所需的药物或者抑制剂的浓度。
“治疗”是指治疗性治疗和预防性或防治性措施，其目的是预防、减缓、改善或停止不良的生理改变或紊乱，例如疾病的进程，包括但不限于以下无论是可检测还是不可检测的结果，症状的缓解、疾病程度的减小、疾病状态的稳定(即不恶化)、疾病进展的延迟或减缓、疾病状态的改善、缓和、减轻或消失(无论是部分还是全部)、延长与不接受治疗时预期的生存期限等。需要治疗的患者包括已经患有病症或紊乱的患者，容易患有病症或紊乱的患者，或者需要预防该病症或紊乱的患者，可以或预期从施用本发明公开的抗体或药物组合物用于检测、诊断过程和/或治疗中受益的患者。
术语“癌症”意指或意在描述哺乳动物的生理状态，其典型特征是细胞生长失控。癌症的实例包括但不限于癌、淋巴瘤、母细胞瘤、肉瘤或白血病。此类癌症的更具体实例包括但不限于大肠癌、肺癌、卵巢癌、子宫癌、子宫内膜癌、唾液腺癌、腹膜癌、输卵管癌、胰腺癌、甲状腺癌、头颈鳞形细胞癌、鼻咽癌、喉癌、肺腺癌、肺鳞癌、肝癌、肝细胞癌、胃肠道癌、成胶质细胞瘤、乳腺癌、脑癌、肾癌、肾细胞癌、结肠癌、直肠癌、前列腺癌、外阴癌、睾丸癌、鳞状细胞癌、小细胞肺癌、子宫颈癌、膀胱癌、视网膜母细胞瘤、神经胶母细胞瘤、间皮瘤、口腔上皮样癌、绒毛膜癌和头颈癌。
术语“过表达”或“过表达的”可互换地指一种基因，与正常细胞相比，其通常在某些细胞，如癌细胞中以可检测到的更高水平的转录或翻译。过表达可以是蛋白质或RNA的过表达(由于增加的转录，转录后加工，翻译，翻译后加工，改变的稳定性和改变的蛋白质降解)，以及蛋白质运输模式改变导致的局部过表达(核定位增加)和增强的功能活性，例如，如增加底物的酶水解。与正常细胞或对照细胞相比，过表达可以是5％、10％、20％、30％、50％、60％、70％、80％、90％或更多。在某些实施例中，本发明的抗FRα抗体及抗体药物偶联物用于治疗可能过表达叶酸受体α的实体瘤。
如本文使用，术语“过表达叶酸受体α的肿瘤”是指过表达叶酸受体α的肿瘤(包括良性肿瘤和癌症)。在一些实施例中，肿瘤样品中的叶酸受体α表达高于免疫组织的背景水平(例如用免疫组织化学染色测定)表明肿瘤是过表达叶酸受体α的肿瘤。检测肿瘤中叶酸受体α表达的方法是本领域已知的，例如免疫组织化学测定法。在一些实施例中，“FRα阴性细胞”为细胞样品中缺乏高于背景的叶酸受体α的细胞(例如通过免疫组织化学技术测定)。
如本文所用，术语“给予”意指递送物质(例如，抗叶酸受体α抗体或ADC)以实现治疗目的(例如，治疗叶酸受体α相关失调)。给予方式可以是肠胃外、肠内和局部。肠胃外给予通常是通过注射，包括但不限于静脉、肌肉内、动脉内、鞘内、囊内、眶内、心内、皮内、腹膜内、经气管、皮下、表皮下、关节内、囊下、蛛网膜下、脊柱内、以及胸骨内注射和输注。
如本文所用，术语“有效量”或“治疗有效量”是指药物，例如抗体或ADC的量，该量足以降低或改善病症(例如癌症)或其一种或多种症状的严重程度和/或持续时间；预防病症进展；引起病症消退；预防与病症相关的一种或多种症状复发、发展、发作或进展；检测病症；或增强或改善另一疗法(例如预防剂或治疗剂)的预防或治疗效果的量。例如，抗体的有效量可以抑制肿瘤生长(例如，抑制肿瘤体积的增加)；减少肿瘤生长(例如，减小肿瘤体积)；减少癌细胞的数量；和/或在一定程度上缓解与癌症相关的一种或多种症状。例如，有效量可以改善无病生存(DFS)、改善总体存活(OS)或降低复发的可能性。
术语“患者”和“受试者”可互换使用，是指需要诊断、预后或治疗的任何哺乳动物，包括但不限于人类、狗、猫、豚鼠、兔子、大鼠、小鼠、马、牛等。在一些实施方案中，患者是人。
如本文所用，术语“有需要”是指已将患者鉴定为需要特定方法或治疗。在一些实施例中，可以通过任何诊断方式进行识别。在本文描述的任何方法和治疗中，患者可能需要。
本文所用术语“给药”是指施用一种物质以实现治疗目的(例如，治疗肿瘤)。
本文所用术语“治疗肿瘤的药物”是指具有抑制肿瘤在人体中发展或累进的功能特性的试剂，尤其是恶性(癌性)病变，诸如癌、肉瘤、淋巴瘤或白血病。抑制转移在很多情况下是抗肿瘤药的特性。
术语“药物可接受的载体”通常指是任何类型的无毒固体、半固体或液体填充剂、稀释剂、包封材料或制剂助剂等。
术语“载体”是指可以与活性成分一起施用于患者的稀释剂、佐剂、赋形剂或载体。这此类药物载体可以是无菌液体，如水和油，包括石油、动植物或合成来源的油，如花生油、大豆油、矿物油、芝麻油等。当药物组合物静脉内给药时，水是优选的载体。盐水溶液和葡萄糖水溶液和甘油溶液也可用作液体载体，特别是用于注射溶液。合适的药物赋形剂包括淀粉、葡萄糖、乳糖、蔗糖、明胶、麦芽、大米、面粉、白垩、硅胶、硬脂酸钠、单硬脂酸甘油酯、滑石、氯化钠、脱脂奶粉、甘油、丙烯、乙二醇、水、乙醇等。如有需要，组合物还可以含有少量的润湿剂或乳化剂，或pH缓冲剂如乙酸盐、柠檬酸盐或磷酸盐。抗菌剂如苯甲醇或对羟基苯甲酸甲酯、抗氧化剂如抗坏血酸或亚硫酸氢钠、螯合剂如乙二胺四乙酸，以及调节张力的试剂如氯化钠或右旋葡萄糖也是可以预见的。这些组合物可以采取溶液、悬液、乳剂、片剂、丸剂、胶囊、散剂、缓释制剂等形式。该组合物可以用传统的粘合剂和载体如甘油三酯配制成栓剂。口服制剂可以包括标准载体，例如药物等级的甘露糖醇、乳糖、淀粉、硬脂酸镁、糖精钠、纤维素、碳酸镁等。合适的药物载体的实例在E.W.Martin的Remington's Pharmaceutical Sciences中有描述，在此通过引用并入本发明。此类组合物将含有临床有效剂量的抗体或抗原结合片段，优选以纯化后的形式，连同合适数量的载体，以提供适合于患者的给药形式。该制剂应该适用于给药模式。亲本制剂可以封装在安瓿瓶、一次性注射器或由玻璃或塑料制成的多剂量小瓶中。
术语“抗体药物偶联物”或“ADC”是指与一个或多个化学药物连接的结合蛋白(如抗体或其抗原结合单元)，其可以任选地为治疗剂或细胞毒性剂。在优选的实施例中，ADC包括抗体，药物(例如细胞毒性药物)和能够使药物与抗体附接或偶联的接头。可包含在ADC中的药物的非限制性实例是有丝分裂抑制剂、抗肿瘤抗生素、免疫调节剂、用于基因治疗的载体、烷化剂、抗血管生成剂、抗代谢物、含硼剂、化学保护剂、激素、抗激素剂、皮质类固醇、光活性治疗剂、寡核苷酸、放射性核素剂、拓扑异构酶抑制剂、激酶抑制剂(例如，TEC-家族激酶抑制剂和丝氨酸/苏氨酸激酶抑制剂)和放射增敏剂。
术语“抗体药物偶联物”和“ADC”可互换使用。术语“抗叶酸受体α抗体药物偶联物”、“抗FRα抗体药物偶联物”、“抗FRαADC”和“抗叶酸受体αADC”可互换使用，是指包含特异性结合叶酸受体α的抗体的ADC，其中抗体与一种或多种药物偶联。在一个或多个实施方式中，抗FRαADC包含与依喜替康偶联的抗体。在一个或多个实施方式中，抗FRα抗体或ADC与叶酸受体α(例如人叶酸受体α)结合。
术语“药物抗体偶联比”或“DAR”是指ADC的与抗体附接的药物(例如，依喜替康)的数量。ADC的DAR可以在1到10的范围内，但是取决于抗体上的连接位点的数量，更高的负载(例如20)也是可能的。提及负载到单个抗体上的药物的数量时，或可替代地，提及一组ADC的平均或均值DAR时，可以使用术语DAR。在一些实施方式中， 其值选自1、2、3、4、5、6、7、8、9或10。当考虑小分子药物的平均结合个数时，即抗体的药物平均结合数，或称为平均药物抗体偶联比，其值选自约0至约10，或约2至约8。在一些实施方式中，药物抗体偶联比为约3至约6。在另一些实施方式中，药物抗体偶联比为约6至约8，或约7至约8。DAR值在本文可用p表示。本领域技术人员理解同一ADC的不同批次的产品的平均DAR值(p)可以略有差异。ADC的DAR值可利用紫外可见吸收光谱法(UV-Vis)、高效液相色谱-疏水色谱(HPLC-HIC)、高效液相色谱-反相色谱(RP-HPLC)、液相色谱质谱联用(LC-MS)等测定。这些技术在Ouyang,J.Methods Mol Biol,2013,1045:p.275-83中有记载。
各种取代基如下定义。在一些情况下，取代基(例如，烷基、烯基、炔基、烷氧基、氨基烷氧基、氨基烷基、氨基烷基氨基、烷基氨基、杂环基、杂环氨基、和芳基)中碳原子的数量由前缀“Cx-Cy”或“Cx-y”指示，其中x是碳原子的最小值并且y是碳原子的最大值。因此，例如，“C1-C6烷基”是指含有从1至6个碳原子的烷基。如果取代基被描述为“被……取代的”，则碳或氮上的氢原子被非氢基团取代。例如，被取代的烷基取代基是烷基取代基，其中烷基上的至少一个氢原子被非氢基团取代。用于说明，单氟烷基是被一个氟基取代的烷基，并且二氟烷基是被两个氟基取代的烷基。应该认识到，如果在取代基上存在一个以上的取代，则每个取代可以是相同的或不同的(除非另有说明)。如果取代基被描述为“任选被……取代”，则取代基可以是(1)未被取代的或(2)被取代的。可能的取代基包括但不限于羟基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、C1-C6氨基烷氧基、卤素、硝基、氰基、巯基、烷硫基、氨基、C1-C6氨基烷基、C1-C6氨基烷基氨基、连接至杂环的C1-C6烷基、连接至杂环的C1-C6烷基氨基、杂环基、氨基取代的杂环基、杂环氨基、氨基甲酰基、吗啉-1-基、哌啶-1-基、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10。
“烷基”指饱和脂肪族烃基基团，该术语包括直链和支链烃基。例如，C1-C20烷基，如C1-C6烷基。C1-C20烷基指具有1至20个碳原子的烷基，例如具有1个碳原子、2个碳原子、3个碳原子、4个碳原子、5个碳原子、6个碳原子、7个碳原子、8个碳原子、9个碳原子、10个碳原子、11个碳原子、12个碳原子、13个碳原子、14个碳原子、15个碳原子、16个碳原子、17个碳原子、18个碳原子、19个碳原子或20个碳原子的烷基。烷基的非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、新戊基、正己基等。所述烷基可以是非取代的或被一个或多个取代基所取代，所述取代基包括但不限于烷基、烷氧基、氰基、羟基、羰基、羧基、芳基、杂芳基、胺基、卤素、磺酰基、亚磺酰基、膦酰基等。
术语“烯基”本身或作为另一取代基的一部分是指具有至少一个碳-碳双键的不饱和支链、直链或环状烷基，双键通过从母体烯烃的单个碳原子上除去一个氢原子而得到。 典型的烯基包括但不限于乙烯基；丙烯基(如丙-1-烯-1-基、丙-1-烯-2-基、丙-2-烯-1-基、丙-2-烯-2-基、环丙-1-烯-1-基)；环丙-2-烯-1-基；丁烯基(如丁-1-烯-1-基、丁-1-烯-2-基、2-甲基-丙-1-烯-1-基、丁-2-烯-1-基、丁-2-烯-2-基、丁-1,3-二烯-1-基、丁-1,3-二烯-2-基、环丁-1-烯-1-基、环丁-1-烯-3-基、环丁-1,3-二烯-1-基等)等。
术语“炔基”本身或作为另一取代基的一部分是指具有至少一个碳-碳三键的不饱和支链、直链或环状烷基，三键通过从母体炔烃的单个碳原子上除去一个氢原子而得到。典型的炔基包括但不限于乙炔基；丙炔基(如丙-1-炔-1-基、丙-2-炔-1-基等)；丁炔基(如丁-1-炔-1-基、丁-1-炔-3-基、丁-3-炔-1-基等)等。
“碳环基”是指仅仅由碳和氢原子组成的稳定的非芳香族的单环或多环的烃自由基，其可包括稠合或桥接环系统，具有3至15个碳原子，例如具有3至10个(例如3、4、5、6、7、8、9或10个)碳原子，并且其是饱和的或不饱和的并且通过单键与分子的剩余部分连接。单环自由基包括，例如环丙基、环丁基、环戊基、环己基、环庚基和环辛基。多环自由基包括，例如金刚烷基、降冰片基、十氢萘基等。当具体说明时，碳环基可被独立地选自下列中的一种或多种取代基任选取代：烷基、卤素、卤代烷基、氰基、硝基、氧代、芳基、芳烷基、碳环基、碳环基烷基、杂环基、杂环基烷基、杂芳基、杂芳基烷基。
“芳基”指具有完全共轭的π电子体系的全碳单环或全碳稠合环，通常具有5-14个碳原子，例如，6个、10个、12个、14个碳原子。芳基可以是非取代的，或被一个或多个取代基所取代，所述取代基包括但不限于烷基、烷氧基、氰基、羟基、羧基、芳基、芳烷基、胺基、卤素、磺酰基、亚磺酰基、膦酰基。非取代的芳基实例包括但不限于苯基、萘基和蒽基。
“杂环基”是指稳定的3元至18元芳香性或非芳香性环取代基，其由2至8个(例如2、3、4、5、6、7或8个)碳原子和选自氮、氧和硫中的1至6个(1、2、3、4、5或6个)杂原子组成。除非另外具体说明，杂环基可以是单环、双环、三环或四环环系统，其可以包括稠合或桥接环系统；且杂环基中的氮、碳或硫原子可以任选地被氧化；氮原子任选地被季铵化；且杂环基可以部分或完全饱和。此类杂环基的实例包括但不限于，二氧戊环基、二噁英基、噻吩基[1,3]二噻烷基、十氢异喹啉基、咪唑啉基、咪唑烷基、异噻唑烷基、异噁唑烷基、吗啉基、八氢吲哚基、八氢异吲哚基、2-氧代哌嗪基、2-氧代哌啶基、2-氧代吡咯烷基、噁唑烷基、哌啶基、哌嗪基、4-哌啶酮基、哌咯烷基、吡唑烷基、奎宁环基、噻唑烷基、1,2,4-亚噻二唑-5(4H)-基、四氢呋喃基、三氧杂环己基、三噻烷基、三嗪烷基(triazinanyl)、四氢吡喃基、硫代吗啉基、硫代吗啉基(thiamorpholinyl)、1-氧代-硫代吗啉基和1,1-二氧代-硫代吗啉基。当在说明书中具体说明时，杂环基可以被选自下列中的一个或多个取代基任选取代：烷基、烯基、卤素、卤代烷基、氰基、氧代、硫代(thioxo)、硝基、芳基、芳烷基、环烃基、环烃基烷基、任选取代的杂环基、任选取代的杂环基烷基、任选取代的杂芳基、任选取代的杂芳基烷基。
“烷氧基”是指式-O-(烷基)，其中烷基为本文定义的烷基。烷氧基的非限制性列举为甲氧基、乙氧基、正丙氧基、1-甲基乙氧基(异丙氧基)、正丁氧基、异丁氧基、仲丁氧基、叔丁氧基。烷氧基可为取代的或未取代的。
“卤素”是指氟(F)、氯(Cl)、溴(Br)、或碘(I)。
“氨基”指-NH 2。
“氰基”是指-CN。
“硝基”指-NO 2。
“羟基”是指-OH。
“羧基”是指-COOH。
“巯基”是指-SH。
“羰基”是指C＝O。
“立体异构体”指具有相同原子连接顺序，但原子在空间排列不相同的异构体化合物。立体异构体可具有一个或多个立体中心并且每个中心可以以R或S存在，立体异构体也可以是顺反异构体。本文提供的化合物立体异构体包括其所有非对映异构、对映异构和顺反异构形式的任何一个或它们的适当混合物。
药学上可接受的盐包括化合物与该技术领域众所周知的各种各样的有机和无机抗衡离子产生的药学上可接受的盐，仅仅示例性盐包括，当分子含有酸性官能团时，有机或无机盐如锂盐、钠盐﹑钾盐﹑钙盐﹑镁盐﹑铵盐﹑异丙胺﹑三甲胺﹑二乙胺基﹑三乙胺﹑三丙胺、乙醇胺、2-二甲胺基乙醇、2-二乙胺基乙醇、二环己基胺、赖氨酸、精氨酸、组氨酸、咖啡因、普鲁卡因、胆碱、甜菜碱、乙二胺、葡糖胺、甲葡糖胺、可可碱、嘌呤哌嗪、哌啶、N-乙基、哌啶、多胺树脂及四烷基铵盐等；以及当分子含有碱性官能团时，有机或无机酸盐如盐酸盐、氢溴酸盐、酒石酸盐、甲磺酸盐、醋酸盐、马来酸盐和草酸盐。酸的其它非限制例子包括硫酸、硝酸、磷酸、丙酸、乙醇酸、丙酮酸、丙二酸、琥珀酸、富马酸、酒石酸、柠檬酸、苯甲酸肉桂酸、扁桃酸、甲磺酸、乙磺酸、对甲苯磺酸水杨酸等。这些盐通常可以通过常规方法通过使例如适当的酸或碱与该化合物反应来制备。溶剂合物包括水合物。
本文中的其它化学术语根据本领域的常规用法使用，如The McGraw-Hill Dictionary of Chemical Terms(《麦格劳-希尔化学术语词典》)(Parker,S.编，格劳-希尔公司(McGraw-Hill)，旧金山(1985))。
本文中引用的所有出版物，和专利全部内容通过参考并入本文用于所有目的。
抗FRα抗体
本发明提供的抗体为抗叶酸受体α的抗体或其抗原结合单元。在一个或多个实施方式中，本发明的抗体能够特异性结合人叶酸受体α。在一个或多个实施方式中，本发明提供了人源化抗FRα抗体或其抗原结合单元。本文中，这些抗体被统称作抗FRα抗体。本发明的抗FRα抗体或其抗原结合单元具有包括但不限于与FRα(例如人FRα)体外结合、与表达FRα的细胞结合、高亲和力、强的内化能力的特性。
在一个或多个实施方式中，本发明所述抗FRα抗体能够与叶酸受体α(FOLR1)特异性结合，不与叶酸受体β(FOLR2)或叶酸受体γ(FOLR3)结合。
在一个或多个实施方式中，抗FRα抗体的抗原结合片段或抗原结合单元是Fab、Fab'、F(ab') 2、Fv、二硫键连接的Fv、scFv、单结构域抗体或双抗体。在一个或多个实施方式中，抗FRα抗体是多特异性抗体(例如，双特异性抗体)。
在一个或多个实施方式中，抗FRα抗体可以为单克隆抗体。
本发明公开的抗体或其抗原结合单元的结合特异性可以通过体外实验，例如免疫共沉淀、放射免疫实验(RIA)、表面等离子共振、流式细胞术(Facs)或酶联免疫吸附实验(ELISA)来检测。
本发明还包括与本文所述抗FRα抗体结合同一表位的抗体。例如，本发明的抗体特异性结合包括人FRα上一个或多个氨基酸残基的表位。
在一个或多个实施方式中，抗体包含重链恒定区，例如IgG1、IgG2、IgG3、IgG4、IgA、IgE、IgM或IgD恒定区。在一个或多个实施方式中，抗FRα抗体或其抗原结合单元包含选自人IgG恒定结构域、人IgA恒定结构域、人IgE恒定结构域、人IgM恒定结构域和人IgD恒定结构域的免疫球蛋白重链恒定结构域。在一个或多个实施方式中，抗FRα抗体或其抗原结合单元包含IgG1重链恒定区、IgG2重链恒定区、IgG3重链恒定区或IgG4重链恒定区。在一个或多个实施方式中，重链恒定区为IgG1重链恒定区或IgG4重链恒定区。在一个或多个实施方式中，抗体或其抗原结合单元包含轻链恒定区，例如κ轻链恒定区或λ轻链恒定区。在一个或多个实施方式中，抗体或其抗原结合单元包含κ轻链恒定区。
抗体的Fc部分介导若干种重要的效应功能(例如，细胞因子诱导、抗体依赖的细胞介导的细胞毒性(ADCC)、吞噬作用、补体依赖的细胞毒性(CDC)和抗体和抗原-抗体复合物的半衰期/清除率)。在一些情况下，这些效应功能为治疗性抗体所需的，但在其他情况下，视治疗目标而定，可能为不必要的或甚至有害的。某些人IgG同种型，尤其IgG1及IgG3，分别经由结合至FcγRs及补体C1q来介导ADCC及CDC。新生的Fc受体(FcRn)为决定抗体的循环半衰期的关键组分。在另一些实施方案中，抗体恒定区(例如抗体的Fc区)中的至少一个氨基酸残基发生置换，使得抗体的效应功能更改。抗体的Fc区中的氨基酸残基的替换以改变抗体效应功能在美国专利号5,648,260和5,624,821中有所描述，其通过引入并入本文。
在一个或多个实施方式中，本发明包括标记的抗FRα抗体或其抗原结合单元，其中抗体衍生或连接于一种或多种功能分子(例如，另一种肽或蛋白质)。例如，经标记抗体可以通过将本发明抗体或其抗原结合单元(通过化学偶联、基因融合、非共价结合或以其他方式)功能上连接至一种或多种其他分子实体来衍生，该一种或多种其他分子实体诸如另一种抗体(例如双特异性抗体或双功能抗体)、可检测试剂、药物制剂、可以介导抗体或其抗原结合单元与另一种分子(诸如抗生蛋白链菌素核心区或多聚组氨酸标签)的结合的蛋白质或肽和/或选自由以下组成的组的细胞毒性剂或治疗剂：有丝分裂抑制剂、抗肿瘤抗生素、免疫调节剂、基因治疗用载体、烷化剂、抗血管生成剂、抗代谢产物、含硼剂、化学保护剂、激素、抗激素剂、皮质类固醇、光活性治疗剂、寡核苷酸、放射性核素剂、拓扑异构酶抑制剂、激酶抑制剂、放射增敏剂及其组合。
在一个或多个实施方式中，将本发明抗体或其抗原结合单元连接至可检测试剂，例如，通过掺入放射性标记的氨基酸，或者附着于可由标记的亲和素(例如，含有荧光标记或可由光学方法或量热法检测的酶活性的链霉亲和素)检测的生物素基部分的多肽。在某些情况下，标记物或标记也可为治疗性的。标记多肽和糖蛋白的各种方法是本领域已知的并且可以使用。用于多肽的标记物的示例包括但不限于以下项：放射性同位素或放射性核素(例如， 3H、 14C、 15N、 35S、 90Y、 99Tc、 111In、 125I、 131I)，荧 光标记物(例如，FITC、罗丹明、镧系磷光体)，酶标记物(例如，辣根过氧化酶、β-半乳糖苷酶、荧光素酶、碱性磷酸酶)，化学发光标记，生物素酰基，被二级报告基因识别的预定多肽表位(例如，亮氨酸拉链对序列、二级抗体结合位点、金属结合结构域、表位标签)。在一个或多个实施方式中，标记通过各种长度的间隔臂连接以减小可能的空间位阻。
在一个或多个实施方式中，本发明的抗体或其抗原结合单元可用作检测样品中FRα(例如人FRα)是否存在。在一个或多个实施方式中，抗体包含可检测试剂。抗体为多克隆抗体，或更优选单克隆抗体。可使用完整的抗体或其抗原结合单元(例如Fab、scFv或F(ab') 2)。所述实施方案的检测方法可用于在体外及体内检测生物样品中的分析物mRNA、蛋白质或基因组DNA。例如，分析物mRNA体外检测技术包括Norhtern杂交和原位杂交；分析物蛋白质体外检测技术包括酶联免疫吸附测定(ELISA)、Western印迹、免疫沉淀、以及免疫荧光；分析物基因组DNA体外检测技术包括Southern杂交。(ELISA:Theory and Practice:Methods in Molecular Biology，第42卷，J.R.Crowther Human Press,Totowa,N.J.,1995；Immunoassay,E.Diamandis和T.Christopoulus,Academic Press,Inc.,San Diego,Calif.,1996；Practice and Theory of Enzyme Immunoassays,P.Tijssen,Elsevier Science Publishers,Amsterdam,1985)。此外，分析物蛋白质的体内检测技术包括向患者体内导入标记的抗分析物蛋白抗体。例如，可以用放射性标记标记抗体，然后可以通过标准成像技术检测患者体内该放射性标记物的存在和位置。
在一个或多个实施方式中，在生物样品中可检测叶酸受体α作为临床测试过程的一部分，例如，用于确定给定治疗方案的功效。将抗体偶联(如物理连接)到可检测物质可有利于检测。可检测物质的示例包括各种酶、辅基、荧光材料、发光材料、生物发光材料和放射性材料。合适的酶的示例包括辣根过氧化物酶、碱性磷酸酶、β-半乳糖苷酶或乙酰胆碱酯酶；合适的辅基复合物的示例包括链霉亲和素/生物素和亲和素/生物素；合适的荧光材料的示例包括伞形酮、荧光素、异硫氰酸荧光素、罗丹明、二氯三嗪氨荧光素、丹磺酰氯或藻红蛋白；发光材料的一个示例包括鲁米诺；生物发光材料的示例包括荧光素酶、荧光素和水母蛋白；合适放射性材料的示例包括 125I、 131I、 35S或 3H。
人源化抗体
本发明所述抗FRα抗体包括人源化抗体或其抗原结合单元。这些抗体或其抗原结合单元适用于给人施用，而不会造成人对所施用的免疫球蛋白产生有害的免疫应答。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元包含如SEQ ID NO:5所示的VH CDR1；如SEQ ID NO:6所示的VH CDR2；和如SEQ ID NO:7所示的VH CDR3。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元包含如SEQ ID NO:8所示的VL CDR1；如SEQ ID NO:9所示的VL CDR2；和如SEQ ID NO:10所示的VL CDR3。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元包含如SEQ ID NO:5所示的VH CDR1；如SEQ ID NO:6所示的VH CDR2；如SEQ ID NO:7 所示的VH CDR3；如SEQ ID NO:8所示的VL CDR1；如SEQ ID NO:9所示的VL CDR2；如SEQ ID NO:10所示的VL CDR3。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元还包含框架区。本文示例性的抗体VH和VL的框架区见表1。
表1抗体VH和VL的框架区
Figure PCTCN2022141572-appb-000071
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元，其包含如SEQ ID NO:1所示的VH FR1；如SEQ ID NO:5所示的VH CDR1；如SEQ ID NO:2所示的VH FR2；如SEQ ID NO:6所示的VH CDR2；如SEQ ID NO:3所示的VH FR3；如SEQ ID NO:7所示的VH CDR3；和如SEQ ID NO:11所示的VH FR4。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元，其包含如SEQ ID NO:29所示的VH FR1；如SEQ ID NO:5所示的VH CDR1；如SEQ ID NO:30所示的VH FR2；如SEQ ID NO:6所示的VH CDR2；如SEQ ID NO:31所示的VH FR3；如SEQ ID NO:7所示的VH CDR3；和如SEQ ID NO:11所示的VH FR4。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元，其包含如SEQ ID NO:12所示的VL FR1；如SEQ ID NO:8所示的VL CDR1；如SEQ ID NO:13所示的VL FR2；如SEQ ID NO:9所示的VL CDR2；如SEQ ID NO:4所示的VLFR3；如SEQ ID NO:10所示的VL CDR3；和如SEQ ID NO:14所示的VLFR4。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元，其包含如SEQ ID NO:12所示的VL FR1；如SEQ ID NO:8所示的VL CDR1；如SEQ ID NO:13所示的VL FR2；(4)如SEQ ID NO:9所示的VL CDR2；如SEQ ID NO:32所示的VLFR3；如SEQ ID NO:10所示的VL CDR3；和如SEQ ID NO:14所示的VL FR4。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元，其包含：重链可变区，包含如SEQ ID NO:1所示的VH FR1；如SEQ ID NO:5所示的VH CDR1；如SEQ ID NO:2所示的VH FR2；如SEQ ID NO:6所示的VH CDR2；如SEQ ID NO:3所示的VH FR3；如SEQ ID NO:7所示的VH CDR3；和如SEQ ID NO:11所示的VH FR4；和轻链可变区，包含如SEQ ID NO:12所示的VL FR1；如SEQ ID NO:8所示的VL CDR1；如SEQ ID NO:13所示的VL FR2；如SEQ ID NO:9所示的VL  CDR2；如SEQ ID NO:4所示的VL FR3；如SEQ ID NO:10所示的VL CDR3；和如SEQ ID NO:14所示的VLFR4。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元，其包含：重链可变区，包含如SEQ ID NO:29所示的VH FR1；如SEQ ID NO:5所示的VH CDR1；如SEQ ID NO:30所示的VH FR2；如SEQ ID NO:6所示的VH CDR2；如SEQ ID NO:31所示的VH FR3；如SEQ ID NO:7所示的VH CDR3；和如SEQ ID NO:11所示的VH FR4；和轻链可变区，包含如SEQ ID NO:12所示的VL FR1；如SEQ ID NO:8所示的VL CDR1；如SEQ ID NO:13所示的VL FR2；如SEQ ID NO:9所示的VL CDR2；如SEQ ID NO:32所示的VL FR3；如SEQ ID NO:10所示的VL CDR3；和如SEQ ID NO:14所示的VL FR4。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元，其重链可变区包含如SEQ ID NO:15所示的氨基酸序列，或与SEQ ID NO:15所示的氨基酸序列相比具有合适的序列同一性的氨基酸序列，比如具有至少80％序列同一性，或者至少90％序列同一性，或者至少95％序列同一性，或者至少99％序列同一性；和/或其轻链可变区包含如SEQ ID NO:16所示的氨基酸序列，或与SEQ ID NO:16所示的氨基酸序列相比具有合适的序列同一性的氨基酸序列，比如具有至少80％序列同一性，或者至少90％序列同一性，或者至少95％序列同一性，或者至少99％序列同一性。在一个或多个实施方式中，这些有序列同一性的氨基酸序列至少CDR不变。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元包含如SEQ ID NO:15所示的重链可变区和如SEQ ID NO:16所示的轻链可变区。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元还包含重链恒定区，所述重链恒定区包含如SEQ ID NO:17所示的氨基酸序列，或与SEQ ID NO:17所示的氨基酸序列相比具有合适的序列同一性的氨基酸序列，比如具有至少80％序列同一性，或者至少90％序列同一性，或者至少95％序列同一性，或者至少99％序列同一性。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元还包含轻链恒定区，所述轻链恒定区包含如SEQ ID NO:18所示的氨基酸序列，或与SEQ ID NO:18所示的氨基酸序列相比具有合适的序列同一性的氨基酸序列，比如具有至少80％序列同一性，或者至少90％序列同一性，或者至少95％序列同一性，或者至少99％序列同一性。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元的重链包含如SEQ ID NO:19所示的氨基酸序列，或与SEQ ID NO:19所示的氨基酸序列相比具有合适的序列同一性的氨基酸序列，比如具有至少80％序列同一性，或者至少90％序列同一性，或者至少95％序列同一性，或者至少99％序列同一性。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元的轻链包含如SEQ ID NO:20所示的氨基酸序列，或与SEQ ID NO:20所示的氨基酸序列相比具有合适的序列同一性的氨基酸序列，比如具有至少80％序列同一性，或者至少90％序列同一性，或者至少95％序列同一性，或者至少99％序列同一性。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元的重链还包含信号肽，例如MDWTWRILFLVAAATGAHS(SEQ ID NO:21)，其核苷酸序列 为atggattggacctggagaatcctgttcctggtggccgccgccaccggcgctcattct(SEQ ID NO:25)。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元的轻链还包含信号肽，例如MEAPAQLLFLLLLWLPDTTG(SEQ ID NO:22)，其核苷酸序列为atggaggcccctgcccagctgctgttcctgctgctgctgtggctgcctgataccaccggc(SEQ ID NO:26)。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元与FRα结合的结合解离平衡常数(KD)为约1μM或更低。在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元与FRα结合的KD在约100nM至约1pM之间或更低。在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元与FRα结合的KD在约10nM至约1pM之间或更低。在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元与FRα结合的KD在约1nM至约0.1nM之间或更低。
在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元与人FRα(例如SEQ ID NO:28所示的抗原FRα-His)结合的KD为约1μM至约1pM之间或更低。在一个或多个实施方式中，本发明的人源化抗FRα抗体或其抗原结合单元与人FRα结合的KD在约100nM至约1pM之间或更低；或者，在约10nM至约1pM之间或更低；或者，在约1nM至约1pM之间或更低。
抗体药物偶联物
本发明的抗FRα抗体或其抗原结合单元可以与药物偶联形成抗FRα抗体药物偶联物(抗FRαADC)。由于抗体药物偶联物(ADC)能够选择性地将一种或多种药物递送至靶组织(例如，表达FRα的肿瘤)，抗体药物偶联物(ADC)可以增加抗体在治疗疾病(例如癌症)中的治疗功效。在一个或多个实施方式中，本发明的抗体药物偶联物(ADC)，其包含本文所述的抗FRα抗体或其抗原结合单元和至少一种药物(例如依喜替康)。本发明的ADC具有包括但不限于与FRα(例如人FRα)体外结合、与表达FRα的细胞结合、高亲和力、强的内化能力、以及减少或抑制癌细胞或肿瘤生长的特性。
本发明的抗FRα抗体的抗原结合片段或抗原结合单元可以与本文所述的药物偶联。因此，在一个或多个实施方式中，本文所述的抗FRα抗体的抗原结合片段或抗原结合单元通过接头与药物偶联形成抗FRαADC。
本发明的抗FRαADC包含与一个或多个药物连接的特异性结合FRα(例如人FRα)的抗体或其抗原结合单元。ADC的特异性可以由抗体(例如抗FRα抗体)的特异性决定。在一个或多个实施方式中，抗FRα抗体与一种或多种药物(例如DNA拓扑异构酶抑制剂)连接，所述药物(例如DNA拓扑异构酶抑制剂)被递送至表达FRα的细胞，特别是表达FRα的癌细胞。在一个或多个实施方式中，抗FRα抗体药物偶联物包含通过接头与药物(例如依喜替康)偶联的抗FRα抗体。本文所述的抗FRα抗体为ADC提供了结合FRα的能力，使得附着于抗体的药物可以被递送至表达FRα的细胞，特别是表达FRα的癌细胞。
在一个或多个实施方式中，ADC为如式I所示的结构或其立体异构体或药学上可接受的盐或溶剂合物。
Figure PCTCN2022141572-appb-000072
其中Abu、M、B、G、L、D、p如本文所定义。
在一个或多个实施方式中，Abu为抗体1。
在一个或多个实施方式中，ADC为ADC1或ADC2或其药学上可接受的盐或溶剂合物。
在一个或多个实施方式中，本发明所述抗体偶联药物具有明显的旁观者效应。
在一个或多个实施方式中，本发明的ADC与FRα结合的结合解离平衡常数(KD)为约1μM或更低。在一个或多个实施方式中，本发明的ADC与FRα结合的KD在约100nM至约1pM之间或更低。在一个或多个实施方式中，本发明的ADC与FRα结合的KD在约10nM至约1pM之间或更低。在一个或多个实施方式中，本发明的ADC与FRα结合的KD在约1nM至约1pM之间或更低。
在一个或多个实施方式中，本发明的ADC与人FRα(例如SEQ ID NO:28所示的抗原FRα-His)结合的KD为约1μM或更低。在一个或多个实施方式中，本发明的ADC与人FRα结合的KD在在约100nM至约1pM之间或更低；或者，在约10nM至约1pM之间或更低；或者，在约1nM至约1pM之间或更低；或者，在约1nM至约0.1nM之间或更低；或者，在约0.5nM至约0.1nM之间或更低。
合成方法
本发明还提供了中间体及抗体药物偶联物的制备方法。本发明的中间体及抗体药物偶联物可以通过已知制剂和方法制备。在一个或多个实施方式中，制备中间体化合物1-7、化合物7的方法如下所述。
Figure PCTCN2022141572-appb-000073
第一步：通式1-1化合物和通式1-1’化合物在碱性条件下反应得到通式1-2化合物；
第二步：通式1-2化合物和通式(AA) i-(FF 1) f在缩合剂存在下、在碱性条件下反应得到通式1-3化合物；
第三步：去除通式1-3化合物氨基保护基W 1得到通式1-4化合物；
第四步：通式1-4化合物和通式1-5化合物在碱性条件下反应得到通式1-6化合物；
第五步：通式1-6化合物和二(对硝基苯)碳酸酯在碱性条件下反应得到通式1-7化合物。
Figure PCTCN2022141572-appb-000074
第一步：通式1化合物和通式1’化合物在碱性条件下反应得到通式2化合物；
第二步：通式2化合物和通式(AA) i-(FF 1) f在缩合剂存在下、在碱性条件下反应得到通式3化合物；
第三步：去除通式3化合物氨基保护基W 1得到通式4化合物；
第四步：通式4化合物和通式5化合物在碱性条件下反应得到通式6化合物；
第五步：通式6化合物和二(对硝基苯)碳酸酯在碱性条件下反应得到通式7化合物。
其中
W 1为氨基保护基，例如为9-芴甲氧羰基；W 2为羧酸活性酯，例如为琥珀酰亚胺酯。
其中，n、AA、R、i、f如本文所述，各FF 1独立为
Figure PCTCN2022141572-appb-000075
Figure PCTCN2022141572-appb-000076
其中各R F独立为C1-C6烷基、C1-C6烷氧基、-NO 2或卤素；z为0、1、2、3或4；其中*连接AA；各FF 2独立为
Figure PCTCN2022141572-appb-000077
Figure PCTCN2022141572-appb-000078
其中各R F独立为C1-C6烷基、C1-C6烷氧基、-NO 2或卤素；z为0、1、2、3或4；其中*连接AA；
在一个或多个实施方式中，R F为F。
在一个或多个实施方式中，z为0。
在一个或多个实施方式中，z为1或2。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000079
其中，R、n如本文所述。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000080
Figure PCTCN2022141572-appb-000081
其中，R、n如本文中所述。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000082
其中，n如本文所述。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000083
Figure PCTCN2022141572-appb-000084
其中，n如本文所述。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000085
Figure PCTCN2022141572-appb-000086
Figure PCTCN2022141572-appb-000087
Figure PCTCN2022141572-appb-000088
Figure PCTCN2022141572-appb-000089
Figure PCTCN2022141572-appb-000090
Figure PCTCN2022141572-appb-000091
Figure PCTCN2022141572-appb-000092
Figure PCTCN2022141572-appb-000093
上述碱性条件可以用试剂来提供，该试剂包括有机碱和无机碱类，所述有机碱类包括但不限于三乙胺、二乙胺、N-甲基吗啉、吡啶、六氢吡啶、N,N-二异丙基乙胺、正丁基锂、二异丙基氨基锂、醋酸钾、叔丁醇钠或叔丁醇钾，所述无机碱类包括但不限于氢化钠、磷酸钾、碳酸钠、碳酸钾、碳酸铯、氢氧化钠和氢氧化锂。
上述缩合剂可以选自N,N,N',N'-四甲基-O-(7-氮杂苯并三唑-1-基)六氟磷酸脲、4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐、1-羟基苯并三唑和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐、N,N'-二环己基碳化二亚胺、N,N'-二异丙基碳二酰亚胺、O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸酯、1-羟基苯并三唑、1-羟基-7-偶氮苯并三氮唑、O-苯并三氮唑-N,N,N',N'-四甲脲六氟磷酸酯、2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯、苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐或六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷。
在一个或多个实施方式中，制备中间体化合物1-8、化合物8方法如下所述。
Figure PCTCN2022141572-appb-000094
通式1-7化合物和D在缩合剂存在下、在碱性条件下反应得到通式1-8化合物。
Figure PCTCN2022141572-appb-000095
通式7化合物和D在缩合剂存在下、在碱性条件下反应得到通式8化合物。
其中，n、AA、R、i、f、FF 2、FF、D如本文所述。
在一个或多个实施方式中，所示中间体为：
Figure PCTCN2022141572-appb-000096
其中，R、n、D如本文所述。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000097
其中，R、n、D如本文所述。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000098
其中，n、D如本文所述。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000099
其中，n、D如本文所述。
在一个或多个实施方式中，所述中间体为：
Figure PCTCN2022141572-appb-000100
Figure PCTCN2022141572-appb-000101
Figure PCTCN2022141572-appb-000102
Figure PCTCN2022141572-appb-000103
Figure PCTCN2022141572-appb-000104
Figure PCTCN2022141572-appb-000105
Figure PCTCN2022141572-appb-000106
Figure PCTCN2022141572-appb-000107
Figure PCTCN2022141572-appb-000108
Figure PCTCN2022141572-appb-000109
上述碱性条件可以用试剂来提供，该试剂包括有机碱和无机碱类，所述有机碱类包括但不限于三乙胺、二乙胺、N-甲基吗啉、吡啶、六氢吡啶、N,N-二异丙基乙胺、正丁基锂、二异丙基氨基锂、醋酸钾、叔丁醇钠或叔丁醇钾，所述无机碱类包括但不限于氢化钠、磷酸钾、碳酸钠、碳酸钾、碳酸铯、氢氧化钠和氢氧化锂。
上述缩合剂可以选自N,N,N',N'-四甲基-O-(7-氮杂苯并三唑-1-基)六氟磷酸脲、4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐、1-羟基苯并三唑和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐、N,N'-二环己基碳化二亚胺、N,N'-二异丙基碳二酰亚胺、O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸酯、1-羟基苯并三唑、1-羟基-7-偶氮苯并三氮唑、O-苯并三氮唑-N,N,N',N'-四甲脲六氟磷酸酯、2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯、苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐或六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷。
在一个或多个实施方式中，制备中间体化合物1-9、化合物9方法如下所述。
Figure PCTCN2022141572-appb-000110
通式1-8化合物和Abu在弱酸性条件下偶联得到通式1-9化合物。
Figure PCTCN2022141572-appb-000111
通式8化合物和Abu在弱酸性条件下偶联得到通式9化合物。
其中，n、AA、R、i、f、FF、D、Abu如本文所述。
具体地，偶联示意图如图1所示，本发明提供的抗FRα抗体上的链间二硫键被硫醇类还原剂还原打开，产生游离的巯基，然后与通式8化合物发生偶联反应，得到通式9所示抗体药物偶联物。
上述弱酸性条件可以用试剂来提供，该试剂包括有机酸和无机酸类，所述有机酸类包括但不限于乙酸、苯甲酸、酒石酸、草酸、苹果酸、柠檬酸、抗坏血酸、柠檬酸、枸椽酸、水杨酸、咖啡酸、山梨酸、奎宁酸、齐墩果酸、丁二酸、绿原酸、甲酸、丙酸，所述无机酸类包括但不限于碳酸、亚硝酸、乙酸、次氯酸、氢氟酸，亚硫酸、氢硫酸、硅酸、偏硅酸、磷酸、偏磷酸、碳酸氢钠、亚硫酸氢钠。
药物偶联物可以采用常规方法进行纯化，例如用制备型高效液相色谱(prep-HPLC)等方法。
药物组合物
可将本发明所述抗FRα抗体或其抗原结合单元、偶联有抗FRα抗体的抗体药物偶联物掺入适于施用的药物组合物中。制备此类组合物所涉及的原理和考虑事项以及选择组分的指南在本领域中是熟知的，例如参见Remington's Pharmaceutical Sciences:The Science And Practice Of Pharmacy,第19版,Mack Pub.Co.,Easton,Pa.:1995；Drug Absorption Enhancement:Concepts,Possibilities,Limitations,And Trends,Harwood Academic Publishers,Langhorne,Pa.,1994；Peptide And Protein Drug Delivery,Advances In Parenteral Sciences,第4卷,1991,M.Dekker,NewYork。
此类组合物通常包含抗体或其抗原结合单元或抗体药物偶联物和药学上可接受的载体。在一个或多个实施方式中，使用抗体片段或抗原结合单元为与靶蛋白结合结构域特异性结合的最小抑制片段。如，基于抗体的可变区序列并保留结合靶蛋白质序列能力的肽。在一个或多个实施方式中，药物组合物还包含抗癌剂(例如免疫检查点抑制剂)。
如本文所用，术语“药学上可接受的载体”旨在包括与药物给药相容的任何和所有溶剂、稳定剂、缓冲剂、分散介质、包衣、抑菌剂、等渗剂和吸收延缓剂等。合适载体描述于Remington's Pharmaceutical Sciences中。此类载体或稀释剂可选择包括但不限于水、生理盐水、林格氏溶液、葡萄糖溶液和5％的人血清白蛋白。
在一个或多个实施方式中，待用于体内施用的制剂必须为无菌的，这可通过无菌滤膜过滤容易地实现。
药物组合物可以以剂量单位形式配制，易于施用，剂量均匀。如本文所用，剂量单位形式是指用于待治疗的患者，适合作为单位剂量的物理上可分离的单位；每个单位含有经计算与所需药物载体结合产生期望治疗效果的预定量的一种或多种所述抗体。
所述药物组合物可放于容器或分配器中，并与给药说明书一起包装。
本发明所述药物组合物还可根据要治疗的具体情况而包含其它活性成分，优选具有互补活性但对彼此无负面影响的那些。在一个或多个实施方式中，组合物可包含增强其功能的试剂，诸如细胞毒素试剂、细胞因子、化学治疗剂、或生长抑制剂。此类活性成分以对预期目的有效的量适当地联合存在。
本发明提供的药物组合物可以通过任何方便的途径施用，例如通过输注或推注，通过上皮或皮肤粘膜(例如口腔粘膜、直肠和肠粘膜等)吸收，并且可以与其他生物 活性剂共同施用。因此，所述药物组合物可以静脉给药、口服给药、直肠给药、肠胃外给药、脑池内给药、阴道内给药、腹腔内给药、外敷(如通过粉末，软膏，滴剂或透皮贴剂)、口腔给药或通过口服或鼻腔喷雾给药。
在一个或多个实施方式中，根据常规步骤将所述药物组合物配制成适合静脉内注射于人体的药物组合物。用于静脉内给药的药物组合物通常是在无菌等渗水性缓冲液中的溶液。药物组合物还可包含增溶剂和局部麻醉剂如利多卡因，从而缓解注射部位的疼痛。一般而言，有效成分以单位剂量形式单独供给或混在一起供给，如以干燥的冻干粉末或无水浓缩物的形式装在可指示活性剂份量的密封容器(如安瓿瓶或小袋)中。在通过输注施用药物组合物的情况下，可以用含有无菌药用级水或盐水的输液瓶来分装组合物。在通过注射施用药物组合物的情况下，可以使用注射用的无菌水或盐水的安瓿瓶，使得可以在施用之前混合有效成分。
本发明的组合物可以配制成中性的或盐的形式。
治疗方法和用途
本文所述的抗体或其抗原结合单元或ADC可用于多种应用中，包括但不限于治疗方法，例如肿瘤的治疗。在一个或多个实施方式中，所述抗体或其抗原结合单元或ADC可用于抑制肿瘤生长、减少肿瘤体积和/或降低肿瘤的致瘤性。使用方法可以是体外、离体或体内方法。在一个或多个实施方式中，本文所述的抗体或其抗原结合单元或ADC是其结合的FRα的拮抗剂。
在一个或多个实施方式中，抑制肿瘤生长的方法包括在体外使肿瘤与抗FRα抗体或其抗原结合单元或ADC或包含其的药物组合物接触。例如，将表达FRα的永生化细胞系或癌细胞培养在添加了抗FRα抗体或其抗原结合单元或ADC或包含其的药物组合物的培养基中。在一个或多个实施方式中，从患者样品中分离肿瘤细胞并将其添加到含有抗FRα抗体或其抗原结合单元或ADC或包含其的药物组合物的培养基中培养。在一个或多个实施方式中，抑制肿瘤生长的方法包括使肿瘤或肿瘤细胞与抗FRα抗体或其抗原结合单元或ADC或包含其的药物组合物在体内接触。
本发明提供的抗体或其抗原结合单元或ADC或包含其的药物组合物可以用于诊断、预后、监控、治疗、缓解和/或预防患者中FRα表达异常相关的疾病和病症。通过使用常规方法鉴定患者中存在FRα异常表达相关的疾病和病症时，可以给药本发明所述的抗体或其抗原结合单元或ADC或包含其的药物组合物。在一个或多个实施方案中，通过免疫组织化学(IHC)、流式细胞术或核酸杂交等来检测FRα表达的程度。WO 2014/036495和WO 2015/031815提供了用于检测FRα的示例性抗体，检测方法和试剂盒，其全部通过引用并入本文。
在一个或多个实施方式中，本发明涉及治疗以FRα为治疗靶点的相关疾病的方法，从而改善、减缓、抑制、治疗或预防FRα表达异常(例如，FRα过表达)相关的任何疾病或病症；涉及提供治疗患者肿瘤(包括良性肿瘤和癌症)的方法、缓解患者肿瘤(包括良性肿瘤和癌症)症状的方法、避免患者肿瘤(包括良性肿瘤和癌症)复发的方法，所述方法包括向患者施用有效量的本文所述的任何抗体或其抗原结合单元或ADC。
在一个或多个实施方式中，本发明提供了预防、治疗或改善疾病的方法，该方法包括向有需要的患者施用有效量的抗FRα抗体或其抗原结合单元或ADC或包含其的药物组合物。在一个或多个实施方式中，本发明提供了所述抗体或其抗原结合单元或ADC在制备用于预防、治疗或改善疾病的药物中的应用。在一个或多个实施方式中，本发明提供了所述抗体或其抗原结合单元或ADC在预防、治疗或改善疾病中的应用。在一个或多个实施方式中，所述疾病为FRα表达异常相关的疾病。在一个或多个实施方式中，所述疾病为FRα过表达相关的疾病。在一个或多个实施方式中，所述疾病为表达FRα的肿瘤。在一个或多个实施方式中，所述疾病为过表达FRα的肿瘤。在一个或多个实施方式中，所述疾病为过表达FRα的癌症。在一个或多个实施方式中，所述疾病为过表达人FRα的癌症。
在一个或多个实施方式中，本发明提供了治疗肿瘤(包括良性肿瘤和癌症)的方法，该方法包括向有需要的患者施用有效量的抗FRα抗体或其抗原结合单元或ADC或包含其的药物组合物。在一个或多个实施方式中，本发明提供了所述抗体或其抗原结合单元或ADC在制备用于治疗肿瘤(包括良性肿瘤和癌症)的药物中的应用。在一个或多个实施方式中，本发明提供了所述抗体或其抗原结合单元或ADC在治疗肿瘤(包括良性肿瘤和癌症)中的应用。
癌症的实例包括但不限于实体瘤、血液学癌及转移性病灶。此类癌症的具体实例包括但不限于大肠癌、肺癌、卵巢癌、子宫癌、子宫内膜癌、腹膜癌、输卵管癌、胰腺癌、头颈鳞形细胞癌、鼻咽癌、喉癌、肺腺癌、肝癌、乳腺癌、脑癌、肾癌、肾细胞癌、结肠癌、睾丸癌、子宫颈癌、膀胱癌、视网膜母细胞瘤、神经胶母细胞瘤、间皮瘤、口腔上皮样癌、绒毛膜癌和头颈癌。此类癌症的更具体实例包括卵巢癌、上皮性卵巢癌、卵巢原发性腹膜癌或输卵管癌。在一个或多个实施方式中，癌症是转移性或晚期癌症。在一个或多个实施方式中，患者为具有增加的FRα表达水平的患者。在一个或多个实施方式中，患者是人。此外，患者可以是已经引入FRα的哺乳动物(例如，通过给予FRα或通过表达FRα转基因)。可以将本发明的抗体或其抗原结合单元或ADC出于治疗目的给予人患者。此外，本发明的抗体或其抗原结合单元或ADC可以给予表达FRα的非人哺乳动物(出于兽医学目的或作为人类疾病的动物模型)。所述人类疾病的动物模型可用于评估本发明抗体或其抗原结合单元或ADC的治疗功效(例如，剂量测试和给药时间过程)。
对于任何特定患者的具体剂量和治疗方案将取决于各种因素，包括所使用的特定抗体或衍生物(例如ADC或药物组合物)、患者的年龄和体重、一般健康状况、性别和饮食，以及给药时间、代谢频率、药物组合，以及所治疗的特定疾病的严重程度。由包括在本领域普通技术人员范围内的医疗护理人员对这些因素进行判断。所述剂量还将取决于待治疗的个体患者、给药途径、制剂类型、所用化合物的特性、疾病的严重程度以及所需的效果。所用剂量可以通过本领域熟知的药理学和药代动力学原理确定。所述有效量是指活性化合物或药剂的量，其导致研究人员、兽医、医生或其他临床医生正寻求的组织、系统、动物、个体以及人的生物或药用响应，这包含治疗一种疾病。在一个或多个实施方式中，有效剂量的范围为从约0.1mg/kg到约100mg/kg，给药频率可以例如是每月给药一次，每两周给药一次，每三周给药一次，每三周给药两次，每四周给药三次，每周给药一次，每周给药两次等。例如，给药方式可以是静 脉输注，静脉推注，也可以是皮下注射、肌肉注射等。应注意，剂量值可随欲缓解的病状的类型及严重程度变化。此外应了解，对任何特定患者而言，特定给药方案可根据患者需要及给予组合物或监督组合物给予的人员的专业判断而随时调整，且本文所阐述的剂量范围仅为例示性的，且不意欲限制所要求的组合物的范畴或实践。
抗体或其抗原结合单元或ADC的施用方法包括但不限于真皮内、肌肉、腹腔、静脉、皮下、鼻腔、硬脊膜外和口服。药物组合物可以通过任何方便的途径施用，例如通过输注或推注，通过上皮或皮肤粘膜(例如口腔粘膜、直肠和肠粘膜等)吸收，并且可以与其他生物活性剂共同施用。因此，含有本发明抗体的药物组合物可以口服给药、直肠给药、肠胃外给药、脑池内给药、阴道内给药、腹腔内给药、外敷(如通过粉末，软膏，滴剂或透皮贴剂)、口腔给药或鼻腔喷雾给药。
本发明使用的术语“肠胃外”是指包括静脉内、肌肉内、腹腔内、胸骨内、皮下和关节内注射和输注的施用方式。
施用方式可以是全身施用或局部施用。此外，可能需要通过任何合适的途径将本发明的抗体或其抗原结合单元或ADC引入中枢神经系统，包括脑室内和鞘内注射；脑室内注射可以通过脑室内导管连接到如贮液囊(可以是Ommaya贮液囊)来辅助注射。也可以通过肺部给药，例如通过使用吸入器或喷雾器，以及使用雾化的制剂。
本发明抗体或其抗原结合单元或ADC可以局部施用于需要治疗的区域；可以通过但不限于以下方式：手术期间局部输注，例如与手术后伤口敷料联合的局部应用，通过注射，通过导管，借助栓剂或借助植入物来实现，所述植入物是多孔的、无孔的或凝胶状的材料，包括膜(例如硅橡胶膜)或纤维。优选地，当施用本发明的抗体或其抗原结合单元或ADC时，必须注意使用不吸收蛋白质的材料。
通常在进行体外测试用于治疗疾病的方法，包括施用本发明所述抗体或ADC，然后在可接受的动物模型中体内测试期望的治疗性或预防性活性，最后施用于人体。合适的动物模型(包括转基因动物)是本领域普通技术人员所公知的。例如，用于证明本发明所述抗体或其抗原结合单元或ADC的治疗用途的体外测定包括抗体或其抗原结合单元或ADC对细胞系或患者组织样品的影响。抗体或其抗原结合单元或ADC对细胞系和/或组织样品的作用可以利用本领域技术人员已知的技术进行检测，例如本发明其他部分公开的技术。根据本发明的内容，可用于确定是否施用抗体或其抗原结合单元或ADC的体外测定实验包括体外细胞培养实验，其中患者组织样品在培养物中培养，并暴露于或以其他方式施用抗体或其抗原结合单元或ADC，并观察这种抗体或其抗原结合单元或ADC对组织样品的影响。
各种已知输送系统可用于施用本发明抗体或其抗原结合单元或编码其的多核苷酸或ADC，例如包封于脂质体、微粒、微胶囊、能够表达所述化合物的重组细胞、受体介导的内吞作用(参见例如Wu and Wu,1987,J.Biol.Chem.262:4429-4432)、作为逆转录病毒或其它载体的一部分的核酸的构建等。
联合疗法
在一个或多个实施方式中，本发明抗体或其抗原结合单元或ADC可以结合其它治疗或预防方案，包括一种或多种本发明抗体或其抗原结合单元或ADC以及一种或多种其它治疗剂或方法一起使用或组合使用。对于组合治疗，抗体或其抗原结合单元或 ADC可以与其它治疗剂可同时或分开施用。当分开施用时，可以在施用另一种其它治疗剂之前或之后施用本发明抗体或其抗原结合单元或ADC。
在一个或多个实施方式中，在向患者施用本发明的抗体或其抗原结合单元或ADC时，还可以向患者联合施用本文公开的抗体或其抗原结合单元或ADC或药物组合物或免疫缀合物，以及一种或多种其它疗法，例如治疗方式和/或其它制剂(例如治疗剂)。
在一个或多个实施方式中，本发明抗体或其抗原结合单元或ADC可以与免疫检查点抑制剂一起使用。在一个或多个实施方式中，本发明抗体或其抗原结合单元或ADC与其它治疗或预防方案联合施用，例如放射性疗法。
此类联合疗法涵盖同时施用(其中两种或更多种制剂包含在同一配制剂或分开的配制剂中)，和分开施用，在该情况中，可以在施用别的疗法，例如治疗方式和/或治疗剂之前，同时，和/或之后发生本发明的抗体或其抗原结合单元或ADC的施用。抗体或其抗原结合单元或ADC和/或其他疗法，例如治疗剂或治疗方式可以在活动性疾病期间或在缓解或活动度更小的疾病期间施用。抗体或其抗原结合单元或ADC可以在其他治疗前、与其他治疗同时、治疗后或在疾病缓解期间施用。
抗体制备方法
在一个或多个实施方式中，本发明公开的抗体、抗原结合单元、或衍生物使用本领域公认的技术修饰以降低其免疫原性。例如，抗体可以被人源化、灵长类化、去免疫化或者可以制备嵌合抗体。这些类型的抗体来源于非人抗体，通常是鼠类或灵长类抗体，其保留或基本保留亲本抗体的抗原结合特性但在人体中免疫原性较低。其可以通过多种方法来实现，包括(a)将整个非人源的可变区移植到人源的恒定区以产生嵌合抗体；生产嵌合抗体的方法是本领域已知的，参见美国专利5,807,715、4,816,567和4,816,397，其全部内容通过引用并入本文；(b)将一个或多个非人类互补决定区(CDR)的至少一部分移植到人源的框架和恒定区中，保留或不保留关键的框架残基；或(c)移植整个非人源的可变区，但通过用类人源的部分置换表面残基从而“隐藏”它们。通常人框架区中的框架残基将被来自CDR供体抗体的相应残基取代，比如能够改善抗原结合的残基。这些框架替换可以通过本领域公知的方法鉴定，例如通过模拟CDR和框架残基的相互作用以鉴定对抗原结合起重要作用的框架残基和通过序列对比以鉴定特定位置上异常的框架残基(参考美国专利5,585,089；其全部内容通过引用并入本文)。可以使用本领域公知的多种技术使抗体人源化，例如CDR移植(EP 239,400；WO 91/09967；美国专利5,225,539,5,530,101和5,585,089)，修复或者表面重排(EP592,106；EP519,596)，以及链的重排(美国专利5,565,332)，其全部内容通过引用并入本文。
免疫原性降低的抗体的产生也使用适当的库经由人源化技术、嵌合化技术和展示技术来实现。应当理解，鼠抗体或来自于其它物种的抗体可使用本领域熟知的技术人源化或灵长类源化。参见例如Winter和Harris Immunol Today 14:43 46(1993)以及Wright等人Crit.Reviews in Immunol.12125-168(1992)。抗体可通过重组DNA技术进行工程化改造，以用相应的人序列取代CH1、CH2、CH3、铰链结构域和/或骨架结构域(参见WO 92102190和美国专利No.5,530,101；5,585,089；5,693,761；5,693,792；5,714,350；和5,777,085)。将Ig cDNA用于构建嵌合免疫球蛋白基因也为本领域已知 的(Liu等人P.N.A.S.84:3439(1987)和J.Immunol.139:3521(1987))。mRNA从产生抗体的杂交瘤或其它细胞中分离出并用于产生cDNA。cDNA可使用特异性引物通过聚合酶链反应来扩增(美国专利4,683,195和4,683,202)。另选地，构建并筛选库以分离所关注的序列。然后将编码抗体可变区的DNA序列与人恒定区序列融合。人恒定区基因的序列可见于Kabat等人发表的Sequences of Proteins of immunological Interest(N.I.H.publication no.91-3242(1991))。人C区基因可容易地从已知克隆中获得。同种型的选择将根据所期望的效应子功能，例如补体结合或抗体依赖性细胞毒性的活性来指导。优选的同种型为IgG1和IgG2。可使用任一种人轻链恒定区，即k或λ，然后通过常规方法表达嵌合人源化抗体。
去免疫化也可用于降低抗体的免疫原性。在本发明中，术语“去免疫化”包括改变抗体以修饰T细胞表位(参见例如WO/9852976 A1和WO/0034317 A2)。例如，分析来自起始抗体的重链可变区序列和轻链可变区序列，并产生来自每个可变区的人T细胞表位“图谱”，显示表位相对于互补决定区(CDRs)和序列内其它关键残基的位置。分析来自T细胞表位图的单个T细胞表位，以鉴定具有较低改变抗体活性风险的可选择的氨基酸取代。设计包含氨基酸取代组合的一系列可选的重链可变区序列和轻链可变区序列，随后将这些序列掺入到一系列结合多肽中。然后将包含修饰过的可变区和人类恒定区的完整重链和轻链的基因克隆到表达载体中，随后将质粒转入细胞系以产生完整的抗体。然后利用合适的生物化学和生物学实验中比较抗体，鉴定出最佳的抗体。
识别选择性表位的全人源抗体可以使用被称为“引导选择”的技术来生产。在该方法中，使用选择的非人单克隆抗体来引导识别相同表位的全人源抗体的筛选(参见美国专利5,565,332，其全部内容通过引用并入本文)。
单链Fv(scFv)可参见生产单链单元的技术(美国专利4,694,778)。通过氨基酸桥接Fv区的重链和轻链片段形成单链单元，产生单链融合肽。也可以使用在大肠杆菌中组装功能性Fv片段的技术(Skerra et al.,Science 242:1038-1041(1988))。
可用于生产scFv和抗体的技术的实例包括如美国专利4,946,778和5,258,498中所述。
在一个或多个实施方式中，抗原结合片段如Fab、F(ab’) 2和Fv可通过裂解完整的蛋白质来制备，例如通过蛋白酶或者化学裂解。包括但不限于：(i)用胃蛋白酶消化抗体分子得到F(ab’) 2片段；(ii)通过还原F(ab’) 2片段的二硫键得到Fab片段；(iii)用木瓜蛋白酶和还原剂处理抗体分子生成Fab片段，以及(iv)Fv片段。
使用常规重组DNA技术，可将本发明的抗体的一个或多个CDR插入框架区，例如插入到人类框架区以构建人源化抗体。框架区可以是天然存在的或共有的框架区，优选人类框架区(参见Chothia et al.,J.Mol.Biol.278:457-479(1998)，其列出一系列人类框架区)。一些多核苷酸可以编码框架区和CDR组合产生的与目标抗原的至少一个表位特异性结合的抗体。在框架区内可以进行一个或多个氨基酸取代，可以选择能够改善抗体与其抗原结合的氨基酸取代。另外，可用此法进行参与链间二硫键形成的一个或多个可变区中半胱氨酸残基的取代或缺失，从而产生缺少一个或多个链间二硫键的抗体分子。本领域技术范围内的对多核苷酸进行的其他改变也涵盖于本发明中。
抗体可以通过使用常规重组DNA技术制备。使用本领域技术人员公知的技术可以选择、构建和培养生产抗体的载体及细胞系等。这些技术在各种实验室手册和主要出版物中均有描述，例如Recombinant DNA Technology for Production of Protein Therapeutics in Cultured Mammalian Cells，D.L.Hacker,F.M.Wurm,in Reference Module in Life Sciences,2017，其全部内容包括补充内容通过引用并入全文。
在一个或多个实施方式中，对本发明的抗FRα抗体或其抗原结合单元进行糖基化修饰。例如，可以制备去糖基化的抗体(即，该抗体缺乏糖基化)。可更改糖基化以例如增加抗体对抗原的亲和力。此类修饰可由例如更改抗体序列内的一或多个糖基化位点来完成。举例而言，可进行一个或多个氨基酸取代，从而消除一个或多个可变区糖基化位点，以借此消除该位点的糖基化。此类去糖基化可增加抗体对抗原的亲和力。此类方法进一步详细描述于PCT公开案WO 2003016466 A2及美国专利5,714,350及6,350,861中，其各自以全文引用方式并入本文中。
抗体(例如抗FRα抗体)基因可以通过标准方法(例如，连接抗体基因片段和载体上的互补限制性位点，或者如果不存在限制性位点，则平端连接)插入表达载体内。表达载体可以为质粒、逆转录病毒、YAC、EBV衍生的附加体等等。为了表达抗体(例如抗FRα抗体)，可将编码全长轻链和重链的DNA插入表达载体内，使得基因与转录和翻译控制序列可操作地连接。“可操作地连接”意指抗体基因连接到载体内，使得载体内的转录和翻译控制序列发挥其调节抗体基因转录和翻译的预期功能。
重链和轻链的一致性序列J区可用于设计用作引物的寡核苷酸，以便在J区内引入有用的限制性位点，用于随后将V区片段连接于人C区片段。C区cDNA可通过定点诱变修饰，以在人序列的类似位置放置一个限制性位点。在一个或多个实施方式中，在插入抗体相关的轻链或重链基因序列之前，表达载体已经携带抗体恒定区序列。例如，将抗FRα抗体相关的VH和VL序列转换为全长抗体基因的一种方法是将它们分别插入已经编码重链恒定区和轻链恒定区的表达载体内，使得VH区段可操作地连接至载体内的CH区段，并且VL区段可操作地连接至载体内的CL区段。
重组表达载体可以编码促进宿主细胞分泌抗体重链和轻链的信号肽。或者，可以将抗体重链和轻链基因克隆到编码促进宿主细胞分泌抗体重链和轻链的信号肽的载体中，使得信号肽与抗体重链和轻链基因的氨基末端框内连接。信号肽可以是免疫球蛋白信号肽或异源信号肽(即，来自非免疫球蛋白蛋白的信号肽)，例如，MDWTWRILFLVAAATGAHS(SEQ ID NO:21)、MEAPAQLLFLLLLWLPDTTG(SEQ ID NO:22)。
除抗体重链和轻链基因之外，重组表达载体还可以携带控制抗体链基因在宿主细胞中表达的调节序列。调节序列包括控制抗体链基因的转录或翻译的启动子、增强子和其它表达控制元件(例如，多腺苷酸化信号)。此类调节序列在例如Goeddel，Gene Expression Technology:Methods in Enzymology 185，Academic Press，San Diego，CA，1990中有描述。本领域技术人员了解表达载体的设计，包括调节序列的选择可以取决于待转化的宿主细胞的选择、所需蛋白质的表达水平等因素。用于哺乳动物宿主细胞表达的合适调节序列包括指导哺乳动物细胞中的高水平蛋白质表达的病毒元件，如衍生自巨细胞病毒(CMV)(如CMV启动子/增强子)、猿猴病毒40(SV40)(如SV40启动子/增强子)、腺病毒(如腺病毒主要晚期启动子(AdMLP))和多瘤的启 动子和/或增强子。关于病毒调节元件及其序列的进一步描述，参见例如美国专利5,168,062，4,510,245和4,968,615。
除抗体链基因和调节序列之外，重组表达载体可以携带另外的序列，例如调节载体在宿主细胞中复制的序列(例如，复制起点)和可选择标记物基因。可选择标记物基因促进载体已引入其内的宿主细胞的选择(参见例如，美国专利4,399,216、4,634,665和5,179,017)。例如，通常可选择赋予已引入载体的宿主细胞针对药物(例如G418、潮霉素或氨甲蝶呤)的抗性的标记物基因。合适的可选择标记物基因包括二氢叶酸还原酶(DHFR)基因(用于在具有氨甲蝶呤选择/扩增的DHFR-宿主细胞中使用)、neo基因(用于G418选择)和GS基因。对于重链和轻链的表达，通过标准技术将编码重链和轻链的表达载体转染到宿主细胞内。
本发明的抗体(例如抗FRα抗体)可以通过在宿主细胞中重组表达抗体的重链和轻链基因来制备。例如，用一种或多种携带编码抗体的重链和轻链DNA片段的重组表达载体转染宿主细胞，使得重链和轻链在宿主细胞中表达，表达的抗体可以分泌到培养宿主细胞的培养基内，从所述培养基中可以回收抗体。“转染”指通常用于将外源DNA引入真核宿主细胞内的广泛多样的技术，例如电穿孔、脂转染、磷酸钙沉淀、DEAE-葡聚糖转染等等。用于获得抗体重链和轻链基因，将这些基因掺入表达载体内并将载体引入宿主细胞内的标准重组DNA方法在本领域众所周知，例如Molecular Cloning；A Laboratory Manual，第二版(Sambrook，Fritsch和Maniatis(编辑)，Cold Spring Harbor，N.Y.，1989)、Current Protocols inMolecular Biology(Ausubel，F.M.等人，编辑，Greene Publishing Associates，1989)以及美国专利号4,816,397中描述的那些。表达抗体重链和轻链的DNA可以置入同一载体中或置入不同载体中；若置入不同载体中，表达抗体重链的载体和表达抗体轻链的载体可以以适当比例转染宿主细胞(如Tihomir S.Dodev et al.,A tool kit for rapid cloning and expression of recombinant antibodies,Scientific Reports volume 4,Article number:5885(2014)；Stefan Schlatter et al.,On the Optimal Ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells,Biotechnol Progress,21:122-133(2005)；Hadi Bayat et al.,Evaluation of different vector design strategies for the expression of recombinant monoclonal antibody in CHO cells,Preparative Biochemistry&Biotechnology,48(8):822-829(2018))。在一个或多个实施方式中，抗体表达载体包括至少一个启动子元件，抗体编码序列，转录终止信号和polyA尾巴。其他元件可以包括增强子，Kozak序列(GCCACC，如SEQ ID NO:33所示)及插入序列两侧RNA剪接的供体和受体位点。可以通过SV40的前期和后期启动子，来自逆转录病毒的长末端重复序列如RSV、HTLV1、HIVI及巨细胞病毒的早期启动子来获得高效的转录，也可应用其它一些细胞的启动子如肌动蛋白启动子。合适的表达载体可包括pIRES1neo，pRetro-Off，pRetro-On，pLXSN，pLNCX，pcDNA3.1(+/-)，pcDNA/Zeo(+/-)，pcDNA3.1/Hygro(+/-)，pSVL，pMSG，pRSVcat，pSV2dhfr，pBC12MI，pCS2或pCHO1.0等。
本发明的抗体(例如抗FRα抗体)能够在真核宿主细胞中表达。在某些实施方案中，抗体的表达在真核细胞例如哺乳动物宿主细胞中进行。用于表达本发明抗体的示例性宿主细胞包括中国仓鼠卵巢细胞(CHO细胞)(例如CHO-K1细胞)或从CHO细胞修饰的CHO-S、CHO-dhfr-、CHO/DG44或ExpiCHO、NSO骨髓瘤细胞、COS细 胞、Cos1细胞、Cos7细胞、SP2细胞、CV1细胞、鼠L细胞、人胚肾细胞HEK293或从HEK293细胞修饰的HEK293T、HEK293F或HEK293E细胞。将编码抗体链基因的重组表达载体引入宿主细胞内后，将宿主细胞在培养基内培养允许抗体在宿主细胞中表达或抗体分泌到培养基的一段时间来产生抗体。可以使用标准蛋白质纯化方法从培养基中回收抗体。
通过使用本领域技术人员公知的技术可以选择、构建和培养生产抗体的细胞系。这些技术在各种实验室手册和主要出版物中均有描述，例如Recombinant DNA Technology for Production of Protein Therapeutics in Cultured Mammalian Cells，D.L.Hacker,F.M.Wurm,in Reference Module in Life Sciences,2017，其全部内容包括补充内容通过引用并入全文。
对于本发明的抗体(例如抗FRα抗体)的重组表达，可以用两种重组表达载体共转染宿主细胞，第一重组表达载体编码抗体重链，第二重组表达载体编码抗体轻链。两个重组表达载体可以含有相同的可选择标记物，或者它们可以各自含有分开的可选择标记物。可替代地，可以使用编码抗体重链和轻链的重组表达载体转染宿主细胞。
本发明的抗体(例如抗FRα抗体)还可以通过化学合成(例如，通过Solid Phase Peptide Synthesis，第2版，1984The Pierce Chemical Co.，Rockford，Ill.中描述的方法)来生产。还可以使用无细胞平台(参见例如，Chu等人，Biochemia No.2，2001(Roche Molecular Biologicals)以及Murray等人，2013，Current Opinion in Chemical Biology，17:420–426)生成变体抗体。
通过重组表达产生的本发明的抗体(例如抗FRα抗体)，可以通过本领域已知的用于纯化免疫球蛋白分子的任何方法将它纯化，例如通过层析(例如，离子交换、亲和层析和分级柱层析)、离心、差异溶解度、或纯化蛋白质的任何其它标准技术。例如利用蛋白A或蛋白G进行亲和层析，其主要提供了免疫血清中的IgG级分。另外，可将免疫球蛋白所靶向的特异抗原或其表位固定于柱上，以通过免疫亲和色谱来纯化免疫特异性抗体。本发明的抗体(例如抗FRα抗体)可以与本领域已知的异源多肽序列融合，以促进纯化。免疫球蛋白的纯化可参考D.Wilkinson的文章(The Scientist，由The Scientist,Inc.,Philadelphia Pa.出版，第14卷，第8期(2000年4月17日)，第25-28页)。
此外，可以使用本领域技术人员已知的标准技术在编码本发明的抗体的核苷酸序列中引入突变，包括但不限于导致氨基酸取代的定点突变和PCR介导的突变。变体(包括衍生物)编码相对于原重链可变区VH CDR1、VH CDR2、VH CDR3和轻链可变区VL CDR1、VL CDR2、VL CDR3来说少于50个氨基酸的取代、少于40个氨基酸的取代、少于30个氨基酸的取代、少于25个氨基酸的取代、少于20个氨基酸的取代、少于15个氨基酸的取代、少于10个氨基酸的取代、少于5个氨基酸的取代、少于4个氨基酸的取代、少于3个氨基酸的取代或少于2个氨基酸的取代。或者可以沿着全部或部分编码序列随机引入突变，例如通过饱和突变，以及可以筛选所得突变体的生物活性以鉴定保留活性的突变体。在一个或多个实施方式中，本文所述取代为保守氨基酸取代。
本发明示例性的抗体1重链的氨基酸序列如SEQ ID NO:19所示，其编码基因序列如SEQ ID NO:23所示。
SEQ ID NO:19如下：
Figure PCTCN2022141572-appb-000112
SEQ ID NO:23如下：
Figure PCTCN2022141572-appb-000113
本发明示例性的抗体1轻链的氨基酸序列如SEQ ID NO:20所示，其编码基因序列如SEQ ID NO:24所示。
SEQ ID NO:20如下：
Figure PCTCN2022141572-appb-000114
Figure PCTCN2022141572-appb-000115
SEQ ID NO:24如下：
Figure PCTCN2022141572-appb-000116
本发明对出版物和专利文献的引用并不表示承认上述任何内容是相关的在先技术，也并不表示承认其内容或日期。现在，本发明已以书面说明书方式描述，本领域技术人员应认识到可以多种实施方式实践本发明，而上文的说明书和下文的实施例旨在说明而非限制本发明的权利要求。本发明中引用的所有出版物，专利，和专利申请全部内容通过参考并入本发明用于所有目的。
实施例
下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径或已知方法得到。
实施例1：抗原的制备
抗原FRα-His制备：将编码抗原FRα-His(抗原FRα-His的氨基酸序列如SEQ ID NO:28所示，由人FRα胞外域(如SEQ ID NO:27所示，下划线标出部分为信号肽)C-末端添加8×HIS标签(HHHHHHHH)构建而成)的基因序列克隆至表达载体上，构建重组表达载体，然后稳转CHO-K1细胞，培养并纯化获得抗原FRα-His。
人FRα胞外域的氨基酸序列：
Figure PCTCN2022141572-appb-000117
抗原FRα-His的氨基酸序列：
Figure PCTCN2022141572-appb-000118
Figure PCTCN2022141572-appb-000119
实施例2：抗FRα抗体
抗FRα抗体的重链由VH与CH组成，轻链由VL与CL组成；CH的氨基酸序列如SEQ ID NO:17所示，CL的氨基酸序列如SEQ ID NO:18所示。其中VH CDR和VL CDR见表2，重链和轻链的框架区见表3，可变区的氨基酸序列见表4，恒定区的氨基酸序列见表5。对照抗体huMOV19的重链和轻链的氨基酸序列见表6。
将编码抗体重链和轻链的基因序列分别克隆至表达载体中，构建重组表达载体，然后瞬时转染HEK293F细胞，培养并纯化获得抗体。测序后与预期序列一致。
表2抗FRα抗体的VH CDR和VL CDR
Figure PCTCN2022141572-appb-000120
表3抗FRα抗体的框架区
Figure PCTCN2022141572-appb-000121
表4抗FRα抗体的可变区
Figure PCTCN2022141572-appb-000122
表5恒定区的氨基酸序列
Figure PCTCN2022141572-appb-000123
Figure PCTCN2022141572-appb-000124
表6对照抗体huMOV19的氨基酸序列
Figure PCTCN2022141572-appb-000125
实施例3：抗体的亲和力特异性和种属特异性检测
3.1抗体的亲和力特异性
实验试剂与耗材：
1.抗原：
FRα-His(即FOLR1)，通过实施例1制备得到；
FOLR2，购自Acro，货号为FO2-H5223，批号为2792C-88HF1-K6；
FOLR3，购自R&D，货号为5319-FR-050，批号为RBK0319041。
2.探头：Protein A Chip sensor，购自GE Healthcare，Cas#29127556。
3.试剂：
HBS-EP+(10×)：购自GE Healthcare，cat#BR-1006-69；
Glycine pH1.5：购自GE Healthcare，cat#BR100354；
运行缓冲液(Running Buffer)：取HBS-EP+(10×)50mL，加超纯水450mL，混匀。
实验仪器：Biacore：T200，购自GE Healthcare。
实验过程：
用Protein A芯片进行检测，使用运行缓冲液将抗体稀释至5μg/mL，以10μL/min的流速通过实验流路(Fc2、Fc4)，捕获15s使捕获量约为440RU；之后流速调为30μL/min，依次进分析物不同浓度的抗原稀释液(0nM、1.23nM、3.7nM、11.1nM、33.3nM、100nM，用运行缓冲液稀释)，同时经过实验流路(Fc2、Fc4)和参比流路(Fc1、Fc3)表面，结合时间180s，解离时间450s，最后用Glycine pH1.5对芯片进行再生60s，然后进行下一个循环。
结果处理：
用数据分析软件Evaluation Software 3.1对试验结果进行分析，将样品试验流路采集所得传感信号进行参比流路、样品空白双扣减，并选用动力学“1:1”模型进行拟合，得出各样品同抗原的动力学参数(Ka：结合速率；Kd：解离速率；KD：结合解离平衡常数)。结果如表7所示。
表7抗体与抗原的结合解离平衡常数KD
Figure PCTCN2022141572-appb-000126
注：“-”代表没有结合活性
通过表7的结果可以看出，抗体1可以与FOLR1特异性结合。
3.2抗体的种属特异性
将抗原用PBS稀释到1μg/mL，以每孔100μL的体积加入到酶标板(厂家：Corning，货号：42592)中，放在冰箱(2-8℃)中包被过夜。弃包被液，加入200μL封闭液(含5％脱脂奶粉，由PBS配制)，放在37℃电热恒温培养箱静置2h。弃封闭液，用0.05％PBST洗3次。加入不同浓度的抗体稀释液(初始浓度为6μg/mL，3倍稀释，共8个浓度梯度，用PBS稀释)，每孔100μL。放在37℃电热恒温培养箱静置2h。弃抗体稀释液，用0.05％PBST洗8次，拍干。加入100μL/孔1:10000稀释的Anti-Human Kappa Light Chains(Bound and Free)peroxidase antibody Produced in goat(厂家：sigma，货号：A7164-1ML)。放在37℃电热恒温培养箱静置1h。弃抗体稀释液，用0.05％PBST洗8次，拍干。加入100μL/孔单组分TMB显色液Ⅰ(厂家：湖州英创生物科技有限公司；货号：TMB-S-001)，放在37℃电热恒温培养箱避光静置10min。加入100μL/孔0.1M H 2SO 4终止反应。在SpectraMax Plus Absorbance Microplate Reader读数，吸收光波长为450nm。
表8抗体与抗原结合的亲和力
Figure PCTCN2022141572-appb-000127
注：“-”代表不结合
从表8可以看出，抗体1可结合FRα-His、食蟹猴FOLR1，不结合小鼠FOLR1和大鼠FOLR1。
实施例4：化合物(1S,9S)-1-氨基-9-乙基-4,5-二氟-9-羟基-1,2,3,9,12,15-六氢-10H,13H苯并[de]哌喃并[3',4':6,7]吲哚并[1,2-b]喹啉-10,13-二酮盐酸盐(D-1)的合成步骤
1.N,N'-(3,4-二氟-8-氧代-5,6,7,8-四氢萘-1,7-二基)二乙酰胺的合成
Figure PCTCN2022141572-appb-000128
氮气氛围中，将叔丁醇钾四氢呋喃溶液(42mL，1M)加入干燥反应瓶中搅拌，降温至0-5℃。将溶于四氢呋喃(25mL)的N-(3,4-二氟-8-氧代-5,6,7,8-四氢萘-1-基)乙酰胺(CAS号：143655-49-6，5g，21mmol)，缓慢滴加到反应瓶中，随后滴加亚硝酸叔丁酯(4.32g，2eq)(控温0-5℃)，升温至15-20℃搅拌2h。反应完全后，降温至0-5℃，滴加醋酸(25mL)、醋酸酐(25mL)(控温不超过10℃)，滴完搅拌20min。保持5-10℃根据N-(3,4-二氟-8-氧代-5,6,7,8-四氢萘-1-基)乙酰胺的量加锌粉(8eq)，20-25℃搅拌1h。过滤，乙酸乙酯(50mL)漂洗固体，降温至0-5℃，滴加15％NaCO 3水溶液(50mL)洗三次，乙酸乙酯(25mL)萃取，合并有机相，饱和NaCl水溶液洗涤。加入乙酸乙酯(10mL)，40℃搅拌30min，缓慢降至0-5℃搅拌2h。过滤，固体用乙酸乙酯/石油醚(1/2，10mL)洗涤。真空干燥得灰色粉末(2.1g，33.7％)。LC-MS:[M+H] +＝297。
2.N-(8-氨基-5,6-二氟-1-氧代-1,2,3,4-四氢萘-2-基)乙酰胺的合成
Figure PCTCN2022141572-appb-000129
将N,N'-(3,4-二氟-8-氧代-5,6,7,8-四氢萘-1,7-二基)二乙酰胺(500mg，1.68mmol)加入2M盐酸乙醇溶液(5mL)，50℃搅拌4h，检测反应完全后，加水(7.5mL)，降温至0-5℃，滴加三乙胺(1.03g)搅拌3h。过滤，分别用40％冷乙醇水溶液(3mL)，水(3mL)洗涤。真空干燥得灰色粉末(320mg，74.6％)。LC-MS:[M+H] +＝255。
3.N-((9S)-9-乙基-4,5-二氟-9-羟基-10,13-二氧-2,3,9,10,13,15-六氢-1H,12H苯并[de]哌喃并[3'；4':6,7]吲哚并[1,2-b]喹啉-1-基)乙酰胺的合成
Figure PCTCN2022141572-appb-000130
氮气氛围下将N-(8-氨基-5,6-二氟-1-氧代-1,2,3,4-四氢萘-2-基)乙酰胺(1.1g，1eq)、(S)-4-乙基-4-羟基-7,8-二氢-1H-哌喃并[3,4-f]吲哚嗪-3,6,10(4H)-三酮(1.15g，1eq)及甲苯(50mL)加入到反应瓶，升温至回流，搅拌1h后加入4-甲基苯磺酸吡啶(100mg)，继续搅拌回流20h。降至室温搅拌1h。过滤，固体分别用丙酮(10mL)，冷乙醇(5mL)洗涤。真空干燥得灰褐色粉末(1.1g，53％)。LC-MS:[M+H] +＝482。
4.(1S,9S)-1-氨基-9-乙基-4,5-二氟-9-羟基-1,2,3,9,12,15-六氢-10H,13H苯并[de]哌喃并[3',4':6,7]吲哚并[1,2-b]喹啉-10,13-二酮盐酸盐(D-1)的合成
Figure PCTCN2022141572-appb-000131
将N-((9S)-9-乙基-4,5-二氟-9-羟基-10,13-二氧-2,3,9,10,13,15-六氢-1H,12H苯并[de]哌喃并[3',4':6,7]吲哚并[1,2-b]喹啉-1-基)乙酰胺(1.1g，2.28mmol)、6M盐酸水溶液(44mL)加入到反应瓶，氮气氛围下回流搅拌4h。浓缩除去溶剂，HPLC纯化得到白色粉末(200mg，18％)。LC-MS:[M+H] +＝440。
实施例5：4-((30S,33S)-30-(2-(2,5-二氧-2,5-二氢-1H-吡咯-1-基)乙酰氨基)-33-异丙基-26,31,34-三氧-36-(3-脲丙基)-2,5,8,11,14,17,20,23-八氧-27,32,35-三氮杂三十七烷-37-胺基)苯甲基(4-硝基苯基)碳酸酯(CB07)的合成步骤
Figure PCTCN2022141572-appb-000132
1)(S)-30-((((9H-芴-9-基)甲氧基)羰基)氨基)-26-氧-2,5,8,11,14,17,20,23-八氧杂-27-氮杂-三十一烷-31-酸(CB01)的合成。
Figure PCTCN2022141572-appb-000133
0-5℃氮气保护下，将8.14g N2-芴甲氧羰基-L-2,4-二氨基丁酸(CB00-2)用40mL二甲基甲酰胺(DMF)溶解，加入10g 4,7,10,13,16,19,22,25-八氧杂二十六烷酸-N-琥珀酰亚胺酯(CB00-3)和10mL DMF，保持0-5℃滴加6.5mL DIPEA，加完1h后室温下搅拌反应4h，反应完成后减压除去DMF，硅胶柱层析(二氯甲烷和甲醇体积比20:1作为洗脱溶剂)得到淡黄色油状液体14.2g CB01。
2)[(S)-1-[[(S)-1-[[4-(羟甲基)苯基]氨基]-1-氧代-5-脲基戊烷-2-基]氨基]-3-甲基-1-氧代丁-2-基]氨基甲酸(9H-芴-9-基)甲酯(CB02)的合成。
Figure PCTCN2022141572-appb-000134
室温氮气保护下，11g(S)-2-((S)-2-((((9H-芴-9-基)甲氧基)羰基)氨基)-3-甲基丁酰氨基)-5-脲基戊酸(CB00-4)和5.5g对氨基苯甲醇(CB00-5)用400mL二氯甲烷和200mL甲醇溶解，机械搅拌下，分批加入17g 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉(EEDQ)，避光下反应15h。反应完成后减压除去溶剂得到糊状固体，硅胶柱层析(二氯甲烷和甲醇体积比20:1作为洗脱溶剂)得到灰白色固体11.9g CB02。
3)(S)-2-((S)-2-氨基-3-甲基丁酰胺基)-N-(4-(羟基甲基)苯基)-5-脲基戊酰胺(CB03)的合成。
Figure PCTCN2022141572-appb-000135
室温氮气保护下，11.9g[(S)-1-[[(S)-1-[[4-(羟甲基)苯基]氨基]-1-氧代-5-脲基戊烷-2-基]氨基]-3-甲基-1-氧代丁-2-基]氨基甲酸(9H-芴-9-基)甲酯(CB02)中加入300mL乙腈，搅拌下滴加18mL哌啶，滴加完毕后室温下反应2h。反应完成后减压蒸馏除去溶剂和哌啶，硅胶柱层析(二氯甲烷和甲醇体积比20:1作为洗脱溶剂)得到白色固体7.5g CB03。
4)(9H-芴-9-基)甲基((30S,33S)-41-氨基-36-((4-(羟甲基)苯基)氨基甲酰基)-33-异丙基-26,31,34,41-四氧-2,5,8,11,14,17,20,23-八氧杂-27,32,35,40-四氮杂-30-基)氨基甲酸酯(CB04)的合成。
Figure PCTCN2022141572-appb-000136
0℃氮气氛围下，将14.2g(S)-30-((((9H-芴-9-基)甲氧基)羰基)氨基)-26-氧-2,5,8,11,14,17,20,23-八氧杂-27-氮杂-三十一烷-31-酸(CB01)溶解于100mL DMF中，分批加入11g N,N,N′,N′-四甲基-O-(7-氮杂苯并三唑-1-基)六氟磷酸脲(HATU)，搅拌反应30min后，加入7.5g的(S)-2-((S)-2-氨基-3-甲基丁酰胺基)-N-(4-(羟基甲基)苯基)-5-脲基戊酰胺(CB03)，保持0℃下反应2.5h。反应完成后减压蒸馏除去溶剂，硅胶柱层析(二氯甲烷和甲醇体积比10:1作为洗脱溶剂)得到固体9.66g CB04。
5)N-((3S)-3-氨基-4-(((2S)-1-((1-((4-(羟甲基)苯基)胺基)-1-氧代-5-脲基戊烷-2-基)胺基)-3-甲基-1-氧丁烷-2-基)胺基)-4-氧基)-2,5,8,11,14,17,20,23-八氧杂二十六烷-26-酰胺(CB05)的合成。
Figure PCTCN2022141572-appb-000137
室温氮气保护下，9.66g的(9H-芴-9-基)甲基((30S,33S)-41-氨基-36-((4-(羟甲基)苯基)氨基甲酰基)-33-异丙基-26,31,34,41-四氧-2,5,8,11,14,17,20,23-八氧杂-27,32,35,40-四氮杂-30-基)氨基甲酸酯(CB04)溶解于50mL DMF，加入12mL二乙胺，搅拌反应1.5h。 反应完成后减压蒸馏除去溶剂，硅胶柱层析(二氯甲烷和甲醇体积比7.5:1作为洗脱溶剂)得到淡黄色固体7.7g CB05。
6)N-((3S)-3-(2-(2,5-二氧-2,5-二氢-1H-吡咯-1-基)乙酰氨基)-4-(((2S)-1-((1-((4-(羟甲基)苯基)胺基)-1-氧-5-脲基戊烷-2-基)胺基)-3-甲基-1-丁酮-2-基)胺基)-4-氧代)-2,5,8,11,14,17,20,23-八氧杂二十六烷-26-酰胺(CB06)的合成。
Figure PCTCN2022141572-appb-000138
7.7g N-((3S)-3-氨基-4-(((2S)-1-((1-((4-(羟甲基)苯基)胺基)-1-氧代-5-脲基戊烷-2-基)胺基)-3-甲基-1-氧丁烷-2-基)胺基)-4-氧基)-2,5,8,11,14,17,20,23-八氧杂二十六烷-26-酰胺(CB05)溶于40mL DMF中，0-5℃氮气氛围下，分批加入马来酰亚胺基乙酸琥珀酰亚胺酯(CB00-1)，保持0-5℃下反应4h。反应完成后减压蒸馏除去溶剂，硅胶柱层析(二氯甲烷和甲醇体积比10:1作为洗脱溶剂)得到淡黄色固体9.5g CB06。
7)4-((30S,33S)-30-(2-(2,5-二氧-2,5-二氢-1H-吡咯-1-基)乙酰氨基)-33-异丙基-26,31,34-三氧-36-(3-脲丙基)-2,5,8,11,14,17,20,23-八氧-27,32,35-三氮杂三十七烷-37-胺基)苯甲基(4-硝基苯基)碳酸酯(CB07)的合成。
Figure PCTCN2022141572-appb-000139
9.5g N-((3S)-3-(2-(2,5-二氧-2,5-二氢-1H-吡咯-1-基)乙酰氨基)-4-(((2S)-1-((1-((4-(羟甲基)苯基)胺基)-1-氧-5-脲基戊烷-2-基)胺基)-3-甲基-1-丁酮-2-基)胺基)-4-氧代)-2,5,8,11,14,17,20,23-八氧杂二十六烷-26-酰胺(CB06)溶于50mL DMF中，0℃氮气氛围下，加入14.0g二(对硝基苯)碳酸酯((PNP) 2CO)，溶解后再加入8.2mL N,N-二异丙基乙胺(DIPEA)，保持0℃反应4h。反应完成后减压蒸馏除去溶剂，硅胶柱层析(二氯甲烷和甲醇体积比8:1作为洗脱溶剂)得到白色固体2.6g CB07。
实施例6：4-((18S,21S)-18-(2-(2,5-二氧-2,5-二氢-1H-吡咯-1-基)乙酰胺基)-21-异丙基-14,19,22-三氧-24-(3-脲丙基)-2,5,8,11-四氧-15,20,23-三氮杂二十五烷-25-胺基)苯甲基(4-硝基苯基)碳酸酯(CB14)的合成
Figure PCTCN2022141572-appb-000140
CB14的制备参考实施例5中CB07的合成，将4,7,10,13,16,19,22,25-八氧杂二十六烷酸-N-琥珀酰亚胺酯替换为4,7,10,13-四氧杂十四烷酸-N-琥珀酰亚胺酯。最终得到白色固体CB14。
实施例7：中间体(CB07-Exatecan)的合成
4-(30S,33S)-30-(2-(2,5-二氧六环-2,5-二氢-1H-吡咯-1-基)乙酰氨基)-33-异丙基-26,31,34-三氧代-36-(3-脲基丙基)-2,5,8,11,14,17,20,23-三七庚基-37-乌头烷基)-(1s,9s)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃[3’,4’:6,7]吲哚啉[1,2-b]喹啉-1-氨基甲酸酯(CB07-Exatecan)的合成。
Figure PCTCN2022141572-appb-000141
将4-((30S,33S)-30-(2-(2,5-二氧-2,5-二氢-1H-吡咯-1-基)乙酰氨基)-33-异丙基-26,31,34-三氧-36-(3-脲丙基)-2,5,8,11,14,17,20,23-八氧-27,32,35-三氮杂三十七烷-37-胺基)苯甲基(4-硝基苯基)碳酸酯(CB07)(2.6g，2.21mmol)与N,N-二甲基甲酰胺(23mL)加入反应瓶R1，氮气保护下搅拌降温至0-5℃。同时取(1S,9S)-1-氨基-9-乙基-5-氟-9-羟基-4-甲基-1,2,3,9,12,15-六氢-10H,13H-苯并[3’,4’:6,7]吲哚啉[1,2-b]喹啉-10,13-二酮甲磺酸盐(依喜替康甲磺酸盐，0.98g，1.84mmol，Advanced ChemBlocks公司)与N,N-二甲基甲酰胺(5mL)加入到另一个反应瓶R2，0-5℃滴加三乙胺(230mg，2.27mmol)，搅拌至全溶后。将反应瓶R2中溶液滴加到反应瓶R1中，然后用N,N-二甲基甲酰胺(2mL)洗涤反应瓶R2后，洗涤液加入到反应瓶R1中。再称取1-羟基苯并三唑(497mg，3.68mmol)、吡啶(1.45g，18.4mmol)加入到反应瓶R1。0-5℃搅拌10min，升至室温搅拌5.5h反应完全后，35℃减压浓缩除去溶剂。用制备型高效液相色谱(prep-HPLC)纯化，冻干，得到白色粉末(CB07-Exatecan，1.6g，59％)。LC-MS:[1/2M+H] +＝737。
实施例8：中间体(CB07-D-1)的合成
4-(30S,33S)-30-(2-(2,5-二氧六环-2,5-二氢-1h-吡咯-1-基)乙酰氨基)-33-异丙基-26,31,34-三氧代-36-(3-脲基丙基)-2,5,8,11,14,17,20,23-三七庚基-37-乌头烷基)-(1S,9S)-9-乙基-4,5-二氟-9-羟基-10,13-二氧-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃[3’,4’:6,7]吲 哚啉[1,2-b]喹啉-1-氨基甲酸酯(CB07-D-1)的合成。
Figure PCTCN2022141572-appb-000142
将4-((30S,33S)-30-(2-(2,5-二氧-2,5-二氢-1H-吡咯-1-基)乙酰氨基)-33-异丙基-26,31,34-三氧-36-(3-脲丙基)-2,5,8,11,14,17,20,23-八氧-27,32,35-三氮杂三十七烷-37-胺基)苯甲基(4-硝基苯基)碳酸酯(CB07)(220mg，0.189mmol)与N,N-二甲基甲酰胺(5ml)加入反应瓶R1，氮气保护下搅拌降温至0-5℃。同时取(1S,9S)-1-氨基-9-乙基-4,5-二氟-9-羟基-1,2,3,9,12,15-六氢-10H,13H苯并[de]哌喃并[3',4':6,7]吲哚并[1,2-b]喹啉-10,13-二酮盐酸盐(D-1)(90mg，0.189mmol)与N,N-二甲基甲酰胺(5mL)加入到另一个反应瓶R2，0-5℃滴加三乙胺3滴，搅拌至全溶后。将反应瓶R2中溶液滴加到反应瓶R1中，再称取1-羟基苯并三唑(60mg，0.44mmol)、吡啶(0.5mL)加入到反应瓶R1。0-5℃搅拌10min，升至室温搅拌3h反应完全后，减压浓缩除去溶剂。用制备型高效液相色谱(prep-HPLC)纯化，冻干，得到白色粉末(CB07-D-1，55mg，20％)。LC-MS:[1/2M+H] +＝739。
实施例9：中间体(CB14-Exatecan)的合成
4-(18S,21S)-18-(2-(2,5-二氧六环-2,5-二氢-1h-吡咯-1-基)乙酰氨基)-21-异丙基-14,19,22-三氧代-24-(3-脲基丙基)-2,5,8,11-四氧-15,20,23-三氮杂二十五烷-25-胺基)-(1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃[3’,4’:6,7]吲哚啉[1,2-b]喹啉-1-氨基甲酸酯(CB14-Exatecan)的合成。
Figure PCTCN2022141572-appb-000143
类似地，将4-((18S,21S)-18-(2-(2,5-二氧-2,5-二氢-1H-吡咯-1-基)乙酰氨基)-21-异丙基-14,19,22-三氧-24-(3-脲丙基)-2,5,8,11-四氧-15,20,23-三氮杂二十五烷-25-胺基)苯甲基(4-硝基苯基)碳酸酯(190mg，0.19mmol)与N,N-二甲基甲酰胺(23mL)加入反应瓶R1，氮气保护下搅拌降温至0-5℃。同时取(1S,9S)-1-氨基-9-乙基-5-氟-9-羟基-4-甲基-1,2,3,9,12,15-六氢-10H,13H-苯并[3’,4’:6,7]吲哚啉[1,2-b]喹啉-10,13-二酮甲磺酸盐(依喜替康甲磺酸盐；101mg，0.19mmol；Advanced ChemBlocks公司)与N,N-二甲基甲酰胺(5mL)加入到另一个反应瓶R2，0-5℃滴加三乙胺(3滴)，搅拌至全溶后。将反应瓶R2中溶液滴加到反应瓶R1中，然后用N,N-二甲基甲酰胺(1mL)洗涤反应瓶R2后，洗涤 液加入到反应瓶R1中。再称取1-羟基苯并三唑(60mg，0.44mmol)、吡啶(0.5mL)加入到反应瓶R1。0-5℃搅拌10min，升至室温搅拌5.5h反应完全后，35℃减压浓缩除去溶剂。用制备型高效液相色谱(prep-HPLC)纯化，冻干，得到白色粉末CB14-Exatecan。
实施例10：ADC的合成
Figure PCTCN2022141572-appb-000144
ADC1偶联工艺(批次1)：
还原反应：使用偶联缓冲液(10mM琥珀酸水溶液)将抗体1浓度调整至18g/L，加入0.1M EDTA水溶液至EDTA终浓度为2mM，根据抗体物质的量加入5.4摩尔当量0.2M TCEP水溶液，调pH至7，25℃180rpm搅拌反应2h，使抗体链间二硫键被还原为游离巯基。
使用30KD的超滤膜包超滤换液10个体积，去除体系中的还原剂TCEP。
偶联反应：根据抗体物质的量，加入15倍摩尔当量的100mM CB07-Exatecan的二甲基乙酰胺(DMA)溶液，25℃180rpm搅拌反应2h。最后加入0.2M的N-乙酰半胱氨酸水溶液至其终浓度为2mM，继续反应15min终止偶联反应，反应混合物经纯化、超滤后获得浓度为23.56mg/mL的ADC1，通过反向色谱测得的DAR即p为8。除非特别说明，以下实施例中ADC1为批次1。
ADC2偶联工艺：
还原反应：使用偶联缓冲液(10mM琥珀酸水溶液)将抗体1浓度调整至约18g/L，加入0.1M EDTA水溶液至EDTA终浓度为2mM，根据抗体物质的量加入2.5摩尔当量10mM TCEP水溶液，调pH至7，25℃摇床振荡反应2h，使抗体链间二硫键被还原为游离巯基。
超滤换液10个体积，去除体系中的还原剂TCEP。
偶联反应：根据抗体物质的量，加入6倍摩尔当量的100mM CB07-Exatecan的二甲基乙酰胺(DMA)溶液，25℃摇床振荡反应1小时。最后加入0.1M的N-乙酰半胱氨酸水溶液至其终浓度为1.5mM，继续反应15min终止偶联反应，反应混合物经纯化后获得浓度为1.34mg/mL的ADC2，通过反向色谱测得的DAR即p为4。
实施例11：ADC1的体外活性测定
1)ADC1对JEG-3细胞的结合活性(FCM)
用流式检测ADC1和抗体1对JEG-3细胞的结合活性。
实验过程：
1.把JEG-3细胞铺板于96孔板(厂家：Corning，货号：3897)，每孔30万细胞。用离心机1500rpm离心5min，去上清。
2.分别加入稀释好的ADC1和抗体1稀释液，200μL/孔，浓度从25nM开始两倍稀释，共10个浓度梯度。每个浓度设置3个复孔。设置空白对照和孵育二抗对照。冰上孵育1h。
3.在离心机1500rpm离心5min，弃上清。加入200μL PBS吹打均匀，1500rpm离心5min，弃上清。
4.加入100μL/孔1：500稀释的Anti-Hu IgG(Fcγ-specific)PE(厂家：eBioscience，货号：12-4998-82)，冰上避光孵育0.5h。
5.在离心机1500rpm离心5min，弃上清。加入200μL PBS吹打均匀，1500rpm离心5min，弃上清，重复一次。
6.加入200μL PBS吹打均匀。用CytoFLEX检测结果。
7.用GraphPad Prism进行数据分析。
表9抗体1和ADC1对JEG-3细胞的结合活性
样品 EC 50
抗体1 1.405nM
ADC1 1.592nM
结果如表9所示，抗体1和ADC1与JEG3细胞均有强的结合活性。
2)ADC1对FRα-His的结合活性(Biacore)
采用Biacore T200表面等离子体共振(SPR)技术评价ADC1和抗体1与FRα-His的亲和力。
试剂：
HBS-EP+(10×)：购自GE Healthcare，cat#BR-1006-69；
Glycine pH1.5：购自GE Healthcare，cat#BR100354；
运行缓冲液(Running Buffer)：取HBS-EP+(10×)50mL，加超纯水450mL，混匀。
实验仪器：Biacore：T200，购自GE Healthcare。
实验过程：
用Protein A芯片进行检测，使用运行缓冲液将药物(ADC1或抗体1)稀释至5μg/mL，以10μL/min的流速通过实验流路(Fc2、Fc4)，捕获15s使捕获量约为440RU；之后流速调为30μL/min，依次进分析物不同浓度的FRα-His稀释液(0nM、1.23nM、3.7nM、11.1nM、33.3nM、100nM，用运行缓冲液稀释)，同时经过实验流路(Fc2、Fc4)和参比流路(Fc1、Fc3)表面，结合时间180s，解离时间450s，最后用Glycine pH1.5对芯片进行再生60s，然后进行下一个循环。
结果处理：
用数据分析软件Evaluation Software3.1对试验结果进行分析，将样品试验流路采集所得传感信号进行参比流路、样品空白双扣减，并选用动力学“1:1”模型进行拟合， 得出各样品同抗原的动力学参数(Ka：结合速率；Kd：解离速率；KD：结合解离平衡常数)，结果如表10所示。结果表明，抗体1和ADC1对FRα-His具有相似的亲和力。
表10抗体1与ADC1对FRα-His的亲和力
药物 Ka(1/Ms) Kd(1/s) KD(M)
ADC1 1.178E+06 3.848E-04 3.265E-10
抗体1 1.021E+06 2.927E-04 2.867E-10
实施例12：ADC1在FRα表达细胞系中的内吞
利用共聚焦显微镜观察ADC1在FRα表达细胞系KB中的内吞，以FRα阴性细胞SNU-1作为对照。细胞培养皿培养过夜后，加入溶酶体染色的LysoBrite Red solution(BBI Life Sciences,中国上海)，细胞孵育1.5小时。洗涤后用fitc标记的ADC1(10μg/mL)处理细胞，在4℃下结合ADC120分钟，然后用PBS洗涤3次，去除未结合的ADC1。然后在37℃培养细胞，使ADC1内化。在每个时间点，用4％多聚甲醛固定细胞，在蔡司LSM 710共聚焦显微镜下观察。如图2所示，在细胞内化之前，细胞内没有fitc标记的ADC1。但内化3小时后，细胞内检测到更多fitc标记的ADC1，且多数与溶酶体重合。
实施例13：ADC1体外细胞毒性
以FRα阳性细胞株JEG-3、MCF-7评价ADC1介导的体外细胞毒性。通过胰蛋白酶收获细胞，用梯度稀释的ADC1培养，然后在37℃孵育。使用CCK-8在5天后测定生存能力。在SpectraMax Gemini(美谷分子)上读取和分析，以确定IC 50(半最大抑制浓度)值。
实验过程：
1)JEG-3细胞用DMEM+10％FBS调整细胞密度为6万个细胞/mL，并以每孔100μL接种于96孔板(厂家：Corning，货号：3599)中，放在Series Ⅱ Water Jacketed CO2Incubator中37℃，5％CO 2条件下静置3h。
MCF-7细胞用DMEM+2％FBS调整细胞密度为4万个细胞/mL，并以每孔100μL接种于96孔板(厂家：Corning，货号：3599)中，放在SeriesⅡWater Jacketed CO2 Incubator中37℃，5％CO 2条件下静置2h。
2)用对应细胞的培养基稀释ADC1。
JEG-3细胞：ADC1浓度从1000nM开始4倍稀释，共8个浓度梯度，再以每孔100μL的体积加入到细胞中。
MCF-7细胞：ADC1浓度从250nM开始4倍稀释，共8个浓度梯度，再以每孔100μL的体积加入到细胞中。
致死对照选用3000nM Exatecan。空白对照为对应细胞的培养基。
每个浓度设置3个复孔。
3)放在Series Ⅱ Water Jacketed CO2 Incubator中培养5天，条件为37℃，5％CO 2。
4)5天后弃培养上清，加入含10％CCK-8的RPMI基础培养基1640(1×)，放在Series Ⅱ Water Jacketed CO2 Incubator中37℃，5％CO 2条件下静置1h左右。
5)在酶标仪SpectraMax M3进行读数，吸收光波长为450nm。
6)数据分析整理：以Exatecan处理孔数据为完全杀伤对照，以空白对照为零杀伤对照。计算细胞活率公式如下：
细胞活率(％)＝(实验组-致死对照组)/(空白对照组-致死对照组)×100
7)用GraphPad Prism处理数据和分析数据。
结果如表11所示。结果表明，ADC1对FRα阳性细胞株具有很高的体外细胞毒性。
表11 ADC1对FRα阳性细胞株的体外细胞毒性
细胞系 IC 50(nM)
JEG-3 3.611
MCF-7 0.645
实施例14：ADC1旁观者效应
为了证实ADC1诱导的旁观者效应，我们进行了体外共培养细胞杀伤试验和条件培养基(CM)细胞毒性试验。
选择了FRα阳性的JEG-3细胞以及FRα阴性的A549细胞(ADC1对A549细胞基本没有杀伤作用。)进行实验。分别用ADC1处理JEG-3细胞2、3、4天。然后将CM转移到A549细胞，监测细胞活力的变化，可以发现A549细胞的活力显著下降。
实验过程：
1)JEG-3用DMEM+10％FBS调整细胞密度为10万个细胞/mL，并以每孔100μL接种于96孔板(厂家：Corning，货号：3599)中，放在Series Ⅱ Water Jacketed CO2 Incubator中37℃，5％CO 2条件下静置2h。
2)用DMEM+10％FBS培养基稀释ADC1，浓度从2000nM开始4倍稀释，10个浓度梯度，再以每孔100μL的体积加入到细胞中。
3)在第二天和第三天重复步骤1)和2)。
4)在第五天用DMEM+2％FBS培养基调整A549细胞密度为4万个细胞/mL，并以每孔100μL接种于96孔板中，放在Series Ⅱ Water Jacketed CO2 Incubator中37℃，5％CO 2条件下静置2h。并加入步骤1)、2)、3)的培养上清，每孔100μL。在列1中加入100μL 3000nM Exatecan作为致死对照，在列12中加入100μL DMEM+2％FBS培养基作为空白对照。
5)放在Series Ⅱ Water Jacketed CO2 Incubator中培养3天。培养条件为37℃、5％CO 2。
6)弃培养液，加入含10％CCK-8的DMEM培养基。放在Series Ⅱ Water Jacketed CO2 Incubator中，37℃避光显色1h。随后在酶标仪SpectraMax M3进行读数，吸收光波长为450nm。
7)整理数据。细胞活力计算公式如下：
细胞活力(％)＝(实验孔-致死孔)/(空白孔-致死孔)*100
8)用GraphPad Prism进行数据分析。
结果如图3所示，ADC1与FRα阳性的JEG-3细胞体外共培养的培养上清对A549细胞有显著的杀伤作用。
实施例15：ADC体内动物实验
1)试验药物在
Figure PCTCN2022141572-appb-000145
卵巢癌OV3756皮下异种移植BALB/c nude雌性小鼠模型中的药效学评价。分组及给药方案见表12。
表12分组及给药方案
Figure PCTCN2022141572-appb-000146
从
Figure PCTCN2022141572-appb-000147
卵巢癌异种移植模型OV3756荷瘤小鼠收取肿瘤组织，切成直径为2-3mm的瘤块接种于6-7周龄雌性BALB/c nude小鼠右前肩胛处皮下。
当荷瘤鼠平均肿瘤体积到达约137.55mm 3时，将小鼠随机分组给药。分组当天设定为第0天，给药开始于第0天。
肿瘤接种后，常规监测包括了肿瘤生长及治疗对动物正常行为的影响，具体内容有实验动物的活动性，摄食和饮水情况，体重增加或降低(体重每周测量2次)情况，眼睛、被毛及其它异常情况。肿瘤体积计算公式：肿瘤体积(mm 3)＝1/2×(a×b 2)(其中a表示长径，b表示短径)。
表13 OV3756异种移植模型中各组药效分析表
Figure PCTCN2022141572-appb-000148
注：a.数据以“平均值±标准误差”表示；
b.TGI％＝[1-(Ti-T0)/(Ci-C0)]x100其中T0及C0分别是给药组及溶媒对照组分组当天(Day 0)平均肿瘤体积，Ti及Ci分别是给药组及溶媒对照组Day 25时的平均肿瘤体积；
c.*P<0.05，**P<0.01及***P<0.001与溶媒对照组肿瘤体积相比。
OV3756异种移植模型各治疗组和对照组肿瘤生长情况见表13和图4。从表13和图4可以看出，ADC1和ADC2可显著抑制OV3756异种移植模型肿瘤生长。
2)实验药物在Balb/c裸鼠JEG-3皮下模型体内抗肿瘤疗效研究，目的是考察ADC1在JeG-3模型的体内药效。分组及给药方案见表14。
表14分组及给药方案
Figure PCTCN2022141572-appb-000149
Figure PCTCN2022141572-appb-000150
选用6-8周雌性Balb/c nude小鼠，将1×10 6个JEG-3细胞悬浮于含50％基质胶的100μL EMEM培养基中，于小鼠右侧皮下接种。当平均肿瘤体积达到约118mm 3时，根据动物体重和肿瘤体积随机分组给药，每组8只。
开始给药后，每周测量两次肿瘤体积。肿瘤体积计算公式为：肿瘤体积(mm 3)＝0.5a×b 2(其中a表示肿瘤长径，b表示肿瘤短径)。
结果如图5所示，与对照组相比，用ADC1治疗具有显著肿瘤抑制作用，且呈剂量依赖性(p<0.001)。至给药后第8天，TGI分别为98.98％(2.5mg/kg)和100.00％(5mg/kg)。值得注意的是，ADC1使肿瘤完全消退并维持到实验结束。
3)实验药物在
Figure PCTCN2022141572-appb-000151
肺癌LU11554皮下异种移植NOD/SCID小鼠模型中的药效学评价
从
Figure PCTCN2022141572-appb-000152
肺癌异种移植模型LU11554荷瘤小鼠收取肿瘤组织，切成直径为2-3mm的瘤块接种于NOD/SCID小鼠右前肩胛处皮下。
当荷瘤鼠平均肿瘤体积到达约165.15mm 3时，将小鼠按照表15随机分组。分组当天设定为第0天，给药开始于第0天。详细的给药方法、给药剂量和给药途径见表15。
表15.
Figure PCTCN2022141572-appb-000153
肺癌LU11554皮下异种移植模型中的给药途径、剂量及方案
Figure PCTCN2022141572-appb-000154
注：分组当天定义为第0天，给药从第0天开始。
肿瘤接种后，常规监测包括了肿瘤生长及治疗对动物正常行为的影响，具体内容有实验动物的活动性，摄食和饮水情况，体重增加或降低(体重每周测量2次)情况，眼睛、被毛及其它异常情况。肿瘤体积计算公式：肿瘤体积(mm 3)＝1/2×(a×b 2)(其中a表示长径，b表示短径)。当小鼠体重下降超过20％一次即安乐死。
LU11554异种移植模型各治疗组和对照组肿瘤生长情况见表16和图6。
表16.LU11554异种移植模型中各组药效分析表(肿瘤体积)
Figure PCTCN2022141572-appb-000155
注：a.数据以“平均值±标准误差”表示；
b.TGI％＝[1-(Ti-T0)/(Ci-C0)]x100,其中T0及C0分别是给药组及溶媒对照组分组当天(第0天)的平均肿瘤体积，Ti及Ci分别是给药组及溶媒对照组第24天时的平均肿瘤体积。
c. nsP>0.05，*P<0.05，**P<0.01及***P<0.001与溶媒对照组肿瘤体积相比。
以肿瘤体积为指标：该模型的对照组(第1组)在给药24天后平均瘤体积达到1189.51mm 3。1mg/kg、3mg/kg和5mg/kg ADC1(即第2、3、4组)给药24天后，平均肿瘤体积分别为1172.94mm 3、812.00mm 3和672.27mm 3，相对肿瘤抑制率TGI分别为1.60％(P＝9.99e-01 ns)、36.87％(P＝4.76e-02*)和50.49％(P＝4.40e-03**)。
4)实验药物在
Figure PCTCN2022141572-appb-000156
肺癌LU5197皮下异种移植NOD/SCID小鼠模型中的药效学评价
从
Figure PCTCN2022141572-appb-000157
肺癌异种移植模型LU5197荷瘤小鼠收取肿瘤组织，切成直径为2-3mm的瘤块接种于NOD/SCID小鼠右前肩胛处皮下。
当荷瘤鼠平均肿瘤体积到达约146.50mm 3时，将小鼠按照表17随机分组。分组当天设定为第0天，给药开始于第0天。详细的给药方法、给药剂量和给药途径见表17。
表17.
Figure PCTCN2022141572-appb-000158
肺癌LU5197皮下异种移植模型中的给药途径、剂量及方案
Figure PCTCN2022141572-appb-000159
注：分组当天定义为第0天，给药从第0天开始。
肿瘤接种后，常规监测包括了肿瘤生长及治疗对动物正常行为的影响，具体内容有实验动物的活动性，摄食和饮水情况，体重增加或降低(体重每周测量2次)情况，眼睛、被毛及其它异常情况。肿瘤体积计算公式：肿瘤体积(mm 3)＝1/2×(a×b 2)(其中a表示长径，b表示短径)。当小鼠体重下降超过20％一次即安乐死。
LU5197异种移植模型各治疗组和对照组肿瘤生长情况见表18和图7。
表18.LU5197异种移植模型中各组药效分析表(肿瘤体积)
Figure PCTCN2022141572-appb-000160
注：a.数据以“平均值±标准误差”表示；
b.TGI％＝[1-(Ti-T0)/(Ci-C0)]x100,其中T0及C0分别是给药组及溶媒对照组分组当天(第0天)的平均肿瘤体积，Ti及Ci分别是给药组及溶媒对照组第28天时的平均肿瘤体积。
c. nsP>0.05，*P<0.05，**P<0.01及***P<0.001与溶媒对照组肿瘤体积相比。
以肿瘤体积为指标：该模型的对照组(第1组)在给药28天后平均瘤体积达到595.89mm 3。1mg/kg、3mg/kg和5mg/kg ADC1(即第2、3、4组)给药28天后，平均肿瘤体积分别为541.48mm 3、277.93mm 3和204.69mm 3，相对肿瘤抑制率TGI分别为12.12％(P＝4.56e-01 ns)、70.75％(P＝6.62e-05***)和87.04％(P＝1.33e-07***)。
实施例16：药代动力学研究
观察食蟹猴单次静脉输注给予注射用ADC1或Exatecan Mesylate(依喜替康甲磺酸盐)后，于不同时间点采集血样，采用ELISA分析方法测定血清中分析物ADC1和总抗体浓度，采用LC-MS/MS分析方法测定血浆中分析物Exatecan浓度，并计算其主要药代动力学参数。
采用24只普通级3～5岁食蟹猴(雌雄各半)，随机分为4组，每组雌性和雄性动物各3只。每组动物未禁食分别单次静脉输注1、3、10mg/kg注射用ADC1和0.25mg/kg Exatecan Mesylate，给药结束后血样采集至504小时。通过血药浓度数据，运用Phoenix
Figure PCTCN2022141572-appb-000161
7.0软件采用非房室模型计算其主要药代动力学参数AUC (0-t)、AUC (0-∞)、T 1/2、C max、T max、CL、MRT等，结果见表19、20和21。
表19单次静脉输注分别给予食蟹猴注射用ADC1或Exatecan Mesylate后血清中ADC1主要药代动力学参数(Mean±SD)
Figure PCTCN2022141572-appb-000162
Figure PCTCN2022141572-appb-000163
表20单次静脉输注分别给予食蟹猴注射用ADC1或Exatecan Mesylate后血清中总抗体主要药代动力学参数(Mean±SD)
Figure PCTCN2022141572-appb-000164
Figure PCTCN2022141572-appb-000165
表21单次静脉输注分别给予食蟹猴注射用ADC1或Exatecan Mesylate后血浆中Exatecan主要药代动力学参数(Mean±SD)
Figure PCTCN2022141572-appb-000166
Figure PCTCN2022141572-appb-000167
NA：不适用。
在1～10mg/kg剂量范围内，未禁食单次静脉输注给予雄性和雌性食蟹猴注射用ADC1后，血清中ADC1、总抗体和血浆中Exatecan的系统暴露量AUC (0-t)无明显性别差异，系统暴露量随给药剂量增加而增加；未禁食单次静脉输注给予雄性和雌性食蟹猴0.25mg/kg Exatecan Mesylate后，血浆中Exatecan的系统暴露量AUC (0-t)无明显性别差异。
单次静脉输注给予未禁食食蟹猴剂量比值为1:0.025(10mg/kg的注射用ADC1对应的Exatecan Mesylate剂量水平约为0.25mg/kg)的注射用ADC1和Exatecan Mesylate时，雄性和雌性动物血浆中Exatecan系统暴露量比值分别为1:5.20和1:2.37，表明注射用ADC1进入体内后解离出的Exatecan较少。
实施例17：ADC1的临床研究
本研究为多中心、开放性、剂量递增、剂量扩展的I期临床研究，探索ADC1在晚期实体瘤患者中的安全性、耐受性和PK特征。
研究分为两部分：
第一部分：剂量递增研究。采用“3+3”的剂量递增规则来探索ADC1的安全性、耐受性和药代动力学特征。
共设置5个剂量组，分别为1.5mg/kg组、3.0mg/kg组、4.5mg/kg组、6.5mg/kg组、8.5mg/kg组，按标准“3+3”规则进行剂量递增研究。
第二部分：剂量扩展研究，进一步探索ADC1治疗晚期实体瘤的安全性及临床有效性。
或者，
第一部分：剂量递增研究。采用快速滴定和“3+3”的剂量递增规则来探索ADC1的安全性、耐受性和药代动力学特征。
共设置6个剂量组，分别为1.2mg/kg组、2.4mg/kg组、3.5mg/kg组、5.0mg/kg组、6.5mg/kg组、8.0mg/kg组。其中1.2mg/kg组采用快速滴定方法进行剂量递增，2.4mg/kg组、3.5mg/kg组、5.0mg/kg组、6.5mg/kg组及8.0mg/kg组按标准“3+3”规则进行剂量递增研究。
给药方案：静脉输注给药，每3周给药1次(Q3W)，第1周期输注时间建议≥90分钟，如果未出现输液反应，则后续周期可在30min内输注完成。
剂量限制性毒性(DLT)的定义：
根据美国国家癌症研究所不良事件通用术语标准(NCI CTCAE)5.0版对AE进行分级。DLT是指受试者首次用药后21天内发生的任何3级或以上的与试验药物相关毒性，并符合以下定义：
■肝脏毒性DLT的定义：
·4级AST或ALT升高
·肝细胞癌或伴肝转移的受试者，如基线时AST或ALT≤3倍ULN，DLT评价期AST或ALT升高＞5倍ULN并持续＞7天
·肝细胞癌或伴肝转移的受试者，如基线时AST或ALT＞3倍ULN，DLT评价期AST或ALT升高＞8倍ULN并持续＞7天
·未出现肝转移的受试者，AST或ALT升高＞5倍ULN并持续＞7天
·AST或ALT＞5倍正常范围上限(ULN)，伴≥2级血胆红素升高
■血液学毒性DLT的定义：
·4级中性粒细胞减少并持续＞7天
·≥3级中性粒细胞减少伴发热
·4级贫血
·4级血小板减少
·≥3级血小板减少并持续＞7天
·≥3级血小板减少并伴出血
·4级淋巴细胞减少并持续≥14天
■非肝脏毒性、非血液学毒性DLT的定义：
·其他≥3级非肝脏毒性、非血液学毒性
■以下TEAE不视为DLT：
·3级疲劳持续＜7天
·3级恶心、呕吐、腹泻或厌食症在3天内缓解至≤2级
·未出现临床相关症状或体征的实验室检查异常，包括ALP升高、尿酸升高、血淀粉酶升高或脂肪酶升高至3或4级，基线时出现的1级低钠血症升级为3级但持续＜72小时
·3级淋巴细胞减少
耐受性与安全性评价：
耐受性评价指标：剂量限制性毒性(DLT)事件及其发生率。
安全性评价指标：生命体征、体格检查、实验室检查(血常规、血生化、心功能、甲状腺功能、凝血常规、尿常规、便常规、妊娠试验)、ECOG评分、心电图、不良事件(包括免疫相关不良事件)等。
药代动力学评价：
所有剂量组的受试者在治疗期间(前6个治疗周期)的规定时间点需要收集血样，在给药前2小时内监测血浆浓度(Ctrough)。检测血清中ADC1、Exatecan、总抗体的浓度水平，研究ADC1的药代动力学(PK)特征。
通过实际给药剂量、实际采样时间和非房室模型计算下述PK参数：
单次给药：C maxT max、T 1/2、CL、Vd、Ke、MRT、AUC (0-τ)、AUC (0-∞)；
多次给药：C max,ss、C avg,ss、C min,ss、AUC (0-τ)ss、AUC (0-∞)ss、T max,ss、T 1/2,ss、CL、V ss、Ke、MRT、蓄积指数(R ac)、波动指数DF。
免疫原性评价：
所有剂量组的受试者在治疗期间的特定时间点需要收集血样，检测血清中抗药抗体与中和抗体。
免疫原性评价指标如下：
抗ADC1抗体(ADA)的样品阳性率和个体阳性率；
·ADA阳性的样本将继续检测是否为中和抗体(Nab)；
ADA抗体及Nab阳性受试者例数及百分比。
药效学评价：
1、检测给药前血清中FRα水平；
2、存档肿瘤组织样本或筛选期新鲜采集的肿瘤组织样本叶酸受体表达水平。
临床有效性评价：
根据RECIST 1.1定义的客观缓解率(ORR)、缓解持续时间(DOR)、疾病控制率(DCR)、无进展生存期(PFS)及总生存期(OS)。
表22临床数据(未成熟，施用ADC1，批次2)
Figure PCTCN2022141572-appb-000168
*已接受的治疗周期，患者仍继续接受治疗。

Claims (23)

  1. 一种抗体或其抗原结合单元，其特征在于，所述抗体或其抗原结合单元特异性结合叶酸受体α，并且包含(a)-(f)中一个或多个：
    (a)VH CDR1包含如SEQ ID NO:5所示的氨基酸序列；
    (b)VH CDR2包含如SEQ ID NO:6所示的氨基酸序列；
    (c)VH CDR3包含如SEQ ID NO:7所示的氨基酸序列；
    (d)VL CDR1包含如SEQ ID NO:8所示的氨基酸序列；
    (e)VL CDR2包含如SEQ ID NO:9所示的氨基酸序列；
    (f)VL CDR3包含如SEQ ID NO:10所示的氨基酸序列；可选的
    包含(g)-(n)中一个或多个：
    (g)VH FR1包含如SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列，或与SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:1或SEQ ID NO:29所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
    (h)VH FR2包含如SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列，或与SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:2或SEQ ID NO:30所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
    (i)VH FR3包含如SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列，或与SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:3或SEQ ID NO:31所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
    (j)VH FR4包含如SEQ ID NO:11所示的氨基酸序列，或与SEQ ID NO:11所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:11所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
    (k)VL FR1包含如SEQ ID NO:12所示的氨基酸序列，或与SEQ ID NO:12所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:12所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
    (l)VL FR2包含如SEQ ID NO:13所示的氨基酸序列，或与SEQ ID NO:13所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:13所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
    (m)VL FR3包含如SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列，或与SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:4或SEQ ID NO:32所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；
    (n)VL FR4包含如SEQ ID NO:14所示的氨基酸序列，或与SEQ ID NO:14所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:14所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
  2. 如权利要求1所述的抗体或其抗原结合单元，其特征在于，所述抗体或其抗原结合单元包含如SEQ ID NO:5所示的VH CDR1、如SEQ ID NO:6所示的VH CDR2和如SEQ ID NO:7所示的VH CDR3。
  3. 如权利要求1所述的抗体或其抗原结合单元，其特征在于，所述抗体或其抗原结合单元包含如SEQ ID NO:8所示的VL CDR1、如SEQ ID NO:9所示的VL CDR2和如SEQ ID NO:10所示的VL CDR3。
  4. 如权利要求1-3任一项所述的抗体或其抗原结合单元，其特征在于，所述抗体或其抗原结合单元包含如SEQ ID NO:5所示的VH CDR1、如SEQ ID NO:6所示的VH CDR2、如SEQ ID NO:7所示的VH CDR3、如SEQ ID NO:8所示的VL CDR1、如SEQ ID NO:9所示的VL CDR2和如SEQ ID NO:10所示的VL CDR3。
  5. 一种抗体或其抗原结合单元，其特征在于，所述抗体或其抗原结合单元特异性结合叶酸受体α，并且包含重链可变区和轻链可变区，其中：
    所述重链可变区包含如SEQ ID NO:15所示的氨基酸序列，或与SEQ ID NO:15所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:15所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和/或
    所述轻链可变区包含如SEQ ID NO:16所示的氨基酸序列，或与SEQ ID NO:16所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:16所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
  6. 如权利要求1-5任一项所述的抗体或其抗原结合单元，其特征在于，所述抗体或其抗原结合单元是IgG同种型，其选自IgG1亚型、IgG2亚型、IgG3亚型、或者IgG4亚型。
  7. 如权利要求1-5任一项所述的抗体或其抗原结合单元，其特征在于，所述抗体或其抗原结合单元还包含重链恒定区和轻链恒定区，其中：
    所述重链恒定区包含如SEQ ID NO:17所示的氨基酸序列，或与SEQ ID NO:17所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:17所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和/或
    所述轻链恒定区包含如SEQ ID NO:18所示的氨基酸序列，或与SEQ ID NO:18所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:18所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
  8. 一种抗体或其抗原结合单元，其特征在于，所述抗体或其抗原结合单元特异性结合叶酸受体α，并且包含重链和轻链，其中：
    所述重链包含如SEQ ID NO:19所示的氨基酸序列，或与SEQ ID NO:19所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:19所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列；和/或
    所述轻链包含如SEQ ID NO:20所示的氨基酸序列，或与SEQ ID NO:20所示的氨基酸序列相比具有至少90％序列同一性的氨基酸序列，或与SEQ ID NO:20所示的氨基酸序列相比具有一个或多个位点取代、缺失或插入的氨基酸序列。
  9. 如权利要求1-8任一项所述的抗体或其抗原结合单元，其特征在于，所述取代为保守氨基酸取代。
  10. 一种生物材料，为
    (1)一种多聚核苷酸，其特征在于，所述多聚核苷酸编码权利要求1-9任一项所述的抗体或其抗原结合单元；或，
    (2)一种表达载体，其特征在于，所述表达载体包含编码权利要求1-9任一项所述的抗体或其抗原结合单元的多聚核苷酸；或，
    (3)一种细胞，其特征在于，所述细胞包含编码权利要求1-9任一项所述的抗体或其抗原结合单元的一种或多种多聚核苷酸。
  11. 一种抗体药物偶联物，其特征在于，包含通过接头与药物偶联的权利要求1-9任一项所述的抗体或其抗原结合单元，或其药学上可接受的盐或溶剂合物；或者，所述接头为可裂解的接头。
  12. 一种抗体药物偶联物，其特征在于，具有如式I所示的结构或其立体异构体或药学上可接受的盐或溶剂合物：
    Figure PCTCN2022141572-appb-100001
    其中，
    Abu为结合叶酸受体α的抗体或其抗原结合单元；或者，Abu为权利要求1-9任一项所述的抗体或其抗原结合单元；
    D为药物；
    M为
    Figure PCTCN2022141572-appb-100002
    其中*连接Abu，**连接B，R选自：-(CH 2) r-、-(CHR m) r-、C3-C8碳环基、-O-(CH 2) r-、亚芳基、-(CH 2) r-亚芳基-、-亚芳基-(CH 2)r-、 -(CH 2) r-(C3-C8碳环基)-、-(C3-C8碳环基)-(CH 2) r-、C3-C8杂环基、-(CH 2) r-(C3-C8杂环基)-、-(C3-C8杂环基)-(CH 2) r-、-(CH 2) rC(O)NR m(CH 2) r-、-(CH 2CH 2O) r-、-(CH 2CH 2O) r-CH 2-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-CH 2-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-CH 2-和-(CH 2CH 2O) rC(O)NR m(CH 2) r-；其中各R m独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各r独立为1、2、3、4、5、6、7、8、9或10；或R为-(CH 2) r-，或r为1或5；
    B为
    Figure PCTCN2022141572-appb-100003
    或为
    Figure PCTCN2022141572-appb-100004
    其中*连接M，**连接L，***连接G；
    L为-(AA) i-(FF) f-，其中，AA为氨基酸或多肽，i是1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20；或各AA独立选自以下氨基酸或肽序列：Val-Cit、Val-Lys、Phe-Lys、Lys-Lys、Ala-Lys、Phe-Cit、Leu-Cit、Ile-Cit、Trp、Cit、Phe-Ala、Phe-Phe-Lys、D-Phe-Phe-Lys、Gly-Phe-Lys、Leu-Ala-Leu、Ile-Ala-Leu、Val-Ala-Val、Ala-Leu-Ala-Leu、β-Ala-Leu-Ala-Leu和Gly-Phe-Leu-Gly；或AA为Val-Cit，i为1；各FF独立为
    Figure PCTCN2022141572-appb-100005
    其中各R F独立为C1-C6烷基、C1-C6烷氧基、-NO 2或卤素；z为0、1、2、3或4，其中*连接AA，**连接D；或各FF独立为
    Figure PCTCN2022141572-appb-100006
    Figure PCTCN2022141572-appb-100007
    Figure PCTCN2022141572-appb-100008
    Figure PCTCN2022141572-appb-100009
    f为1、2、3、4、5、6、7、8、9或10，其中*连接AA，**连接D；或FF为
    Figure PCTCN2022141572-appb-100010
    f为1；其中*连接AA，**连接D；或L为
    Figure PCTCN2022141572-appb-100011
    Figure PCTCN2022141572-appb-100012
    Figure PCTCN2022141572-appb-100013
    其中*连接B，**连接D；
    G为
    Figure PCTCN2022141572-appb-100014
    其中n为1-24；或n为4-12；或n为4-8；或n为4或8；
    p为1-10；或p为2-8；或p为4-8；或p为6-8；或p为7-8；或p为7.4；或p为7；或p为8。
  13. 一种抗体药物偶联物，其特征在于具有式I-1、I-2、I-2-1、I-3、I-4、I-4-1、I-5、I-5-1、I-6、I-6-1、I-7、I-7-1、I-8、I-8-1、I-9、I-9-1、I-10、I-10-1、I-11或I-11-1的所示的结构或其立体异构体或药学上可接受的盐或溶剂合物，其中
    所述式I-1为：
    Figure PCTCN2022141572-appb-100015
    所述式I-2、I-2-1为：
    Figure PCTCN2022141572-appb-100016
    所述式I-3为：
    Figure PCTCN2022141572-appb-100017
    所述式I-4、I-4-1为：
    Figure PCTCN2022141572-appb-100018
    所述式I-5、I-5-1为：
    Figure PCTCN2022141572-appb-100019
    Figure PCTCN2022141572-appb-100020
    所述式I-6、I-6-1为：
    Figure PCTCN2022141572-appb-100021
    所述式I-7、I-7-1为：
    Figure PCTCN2022141572-appb-100022
    所述式I-8、I-8-1为：
    Figure PCTCN2022141572-appb-100023
    Figure PCTCN2022141572-appb-100024
    所述式I-9、I-9-1为：
    Figure PCTCN2022141572-appb-100025
    所述式I-10、I-10-1为：
    Figure PCTCN2022141572-appb-100026
    所述式I-11、I-11-1为：
    Figure PCTCN2022141572-appb-100027
    Figure PCTCN2022141572-appb-100028
    其中
    Abu为权利要求1-9任一项所述的抗体或其抗原结合单元；
    R选自：-(CH 2) r-、-(CHR m) r-、C3-C8碳环基、-O-(CH 2) r-、亚芳基、-(CH 2) r-亚芳基-、-亚芳基-(CH 2)r-、-(CH 2) r-(C3-C8碳环基)-、-(C3-C8碳环基)-(CH 2) r-、C3-C8杂环基、-(CH 2) r-(C3-C8杂环基)-、-(C3-C8杂环基)-(CH 2) r-、-(CH 2) rC(O)NR m(CH 2) r-、-(CH 2CH 2O) r-、-(CH 2CH 2O) r-CH 2-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-、-(CH 2) rC(O)NR m(CH 2CH 2O) r-CH 2-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-、-(CH 2CH 2O) rC(O)NR m(CH 2CH 2O) r-CH 2-和-(CH 2CH 2O) rC(O)NR m(CH 2) r-；其中各R m独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各r独立为1、2、3、4、5、6、7、8、9或10；或R为-(CH 2) r-，或r为1或5；
    D为药物；
    n为1-24的整数；或n为4-12；或n为4-8；或n为4或8；
    p为1-10；或p为2-8；或p为4-8；或p为6-8；或p为7-8；或p为7；或p为8；或p为7.4。
  14. 如权利要求11-13任一项所述的抗体药物偶联物，其特征在于，所述药物为抗癌药物、细胞毒性药物、细胞分化因子、干细胞营养因子、类固醇类药物、治疗自身免疫疾病的药物、抗炎症药物或治疗传染性疾病的药物；或所述药物为抗癌药物；或所述药物为微管蛋白抑制剂、DNA损伤剂或DNA拓扑异构酶抑制剂；或所述微管蛋白抑制剂选自海兔毒素、奥瑞他汀类、及美登素类；或所述药物为奥瑞他汀类，选自MMAE、MMAF或AF；或所述药物为DNA损伤剂，选自卡奇霉素类、倍癌霉素类、安曲霉素类衍生物PBD；或所述药物为DNA拓扑异构酶抑制剂或其盐，选自伊立替康、伊立替康盐酸盐、依喜替康衍生物，喜树碱、9-氨基喜树碱、9-硝基喜树碱、10-羟基喜树碱、9-氯-10-羟基喜树碱、喜树碱类衍生物SN-38、22-羟基旱莲木碱、拓扑替康、勒托替康、贝洛替康、依喜替康、硅基高喜树碱、6,8-二溴-2-甲基-3-[2-(D-吡喃木糖基氨基)苯基]-4(3H)-喹唑啉酮、2-氰基-3-(3,4-二羟基苯基)-N-(苯基甲基)-(2E)-2-丙烯酰胺、2-氰基-3-(3,4-二羟基苯基)-N-(3-羟基苯基丙基)-(E)-2-丙烯酰胺、12-β-D-吡 喃萄萄糖基-12,13-二氢-2,10-二羟基-6-[[2-羟基-1-(羟基甲基)乙基]氨基]-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑-5,7(6H)-二酮、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺二盐酸盐、N-[2-(二甲基氨基)乙基]-4-吖啶甲酰胺；或所述DNA拓扑异构酶抑制剂为喜树碱、10-羟基喜树碱、拓扑替康、贝洛替康、伊立替康、22-羟基旱莲木碱或依喜替康；或其药学上可接受的盐或溶剂合物。
  15. 如权利要求11-13任一项所述的抗体药物偶联物，其特征在于，所述药物为
    Figure PCTCN2022141572-appb-100029
    其中
    X 1和X 2各自独立地为：
    H，
    羟基，
    C1-C6烷基，
    被一个或多个羟基、卤素、硝基或氰基取代的C1-C6烷基，
    C2-C6烯基，
    C2-C6炔基，
    C1-C6烷氧基，
    C1-C6氨基烷氧基，
    卤素，
    硝基，
    氰基，
    巯基，
    烷硫基，
    氨基，被氨基保护基取代的氨基，在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基，
    在氨基部分任选被氨基保护基或C1-C6烷基取代的C1-C6氨基烷基氨基，
    连接至杂环的C1-C6烷基，所述杂环任选被一个或多个C1-C6烷基、C1-C6烷氧基、氨基、卤素、硝基或氰基取代，
    连接至杂环的C1-C6烷基氨基，所述杂环任选被C1-C6烷基、C1-C6烷氧基取代，所述氨基任选被氨基保护基、卤素、硝基、氰基或保护基取代，
    氨基取代的杂环基，其在杂环部分的氮原子或氨基部分任选被保护基或一个或多个C1-C6烷基取代，
    杂环氨基，其在杂环部分的氮原子或氨基部分任选被保护基或C1-C6烷基取代，
    任选被氨基甲酰基保护基或C1-C6烷基取代的氨基甲酰基，
    吗啉-1-基，或
    哌啶-1-基；
    X 3为C1-C6烷基；
    X 4为H、-(CH 2) q-CH 3、-(CHR n) q-CH 3、C3-C8碳环基、-O-(CH 2) q-CH 3、亚芳基-CH 3、-(CH 2) q-亚芳基-CH 3、-亚芳基-(CH 2) q-CH 3、-(CH 2) q-(C3-C8碳环基)-CH 3、-(C3-C8碳环基)-(CH 2) q-CH 3、C3-C8杂环基、-(CH 2) q-(C3-C8杂环基)-CH 3、-(C3-C8杂环基)-(CH 2) q-CH 3、-(CH 2) qC(O)NR n(CH 2) q-CH 3、-(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) q-CH 2-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 3、-(CH 2CH 2O) qC(O)NR n(CH 2CH 2O) q-CH 2-CH 3、或-(CH 2CH 2O) qC(O)NR n(CH 2) q-CH 3；其中各R n独立为H、C1-C6烷基、C3-C8碳环基、苯基或苄基；并且各q独立为1、2、3、4、5、6、7、8、9或10；或者，X 4为H或C1-C6烷基；
    **与所述抗体药物偶联物其他部分连接；
    y为0、1或2；
    Y为O、S或CR 1R 2，其中R 1和R 2各自独立地为H或C1-C6烷基；
    s和t各自独立为0、1或2，但不同时为0；
    或所述药物为
    Figure PCTCN2022141572-appb-100030
    Figure PCTCN2022141572-appb-100031
    其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；或所述C1-C6烷基为-CH 3；或所述卤素为F；**与所述抗体药物偶联物其他部分连接；
    或所述药物为
    Figure PCTCN2022141572-appb-100032
    Figure PCTCN2022141572-appb-100033
    其中X 1和X 2各自独立地为C1-C6烷基、卤素或-OH；或所述C1-C6烷基为-CH 3；或所述卤素为F；**与所述抗体药物偶联物其他部分连接。
  16. 一种抗体药物偶联物，其特征在于，具有如式I-12、I-12-1、I-13、I-13-1、I-14、I-14-1、I-15、I-15-1、I-16、I-16-1、I-17、I-17-1、I-18、I-18-1、I-19、I-19-1、I-20、I-20-1、I-21、I-21-1、I-22、I-22-1、I-23、I-23-1、I-24、I-24-1、I-25或I-25-1所示的结构或其立体异构体或药学上可接受的盐或溶剂合物，其中所述I-12、I-12-1、I-13、I-13-1、I-14、I-14-1、I-15、I-15-1、I-16、I-16-1、I-17、I-17-1、I-18、I-18-1、I-19、I-19-1、I-20、I-20-1、I-21、I-21-1、I-22、I-22-1、I-23、I-23-1、I-24、I-24-1、I-25或I-25-1为：
    Figure PCTCN2022141572-appb-100034
    Figure PCTCN2022141572-appb-100035
    Figure PCTCN2022141572-appb-100036
    Figure PCTCN2022141572-appb-100037
    Figure PCTCN2022141572-appb-100038
    Figure PCTCN2022141572-appb-100039
    Figure PCTCN2022141572-appb-100040
    Figure PCTCN2022141572-appb-100041
    Figure PCTCN2022141572-appb-100042
    Figure PCTCN2022141572-appb-100043
    Figure PCTCN2022141572-appb-100044
    Figure PCTCN2022141572-appb-100045
    其中
    Abu为权利要求1-9任一项所述的抗体或其抗原结合单元；
    p为1-10；或p为2-8；或p为4-8；或p为6-8；或p为7-8；或p为7；或p为7.4；或p为8。
  17. 一种药物组合物，其特征在于，所述药物组合物包含权利要求1-9任一项所述的抗体或其抗原结合单元或权利要求11-16任一项所述的抗体药物偶联物，以及药学上可接受的载体、赋形剂和/或辅料。
  18. 一种药物组合物，其特征在于，所述药物组合物包含权利要求1-9任一项所述的抗体或其抗原结合单元或权利要求11-16任一项所述的抗体药物偶联物以及一个或多个其他抗癌药物。
  19. 权利要求1-9任一项所述的抗体或其抗原结合单元、权利要求11-16任一项所述的抗体药物偶联物或权利要求17或18所述的药物组合物在治疗和/或预防疾病或在制备治疗和/或预防疾病的药物中的应用；或者所述疾病为叶酸受体α表达相关的疾病；或者所述疾病为叶酸受体α过表达相关的疾病；或者所述疾病为肿瘤；或者所述治疗肿瘤的药物还包含其他抗癌药物。
  20. 一种治疗和/或预防疾病的方法，其特征在于，所述方法包括：向有需要的患者给药有效量的权利要求1-9任一项所述的抗体或其抗原结合单元、权利要求11-16任一项所述的抗体药物偶联物或权利要求17或18所述的药物组合物。
  21. 如权利要求20所述的方法，其特征在于，所述疾病为叶酸受体α表达相关的疾病；或者，所述疾病为叶酸受体α过表达相关的疾病；或者，所述疾病为肿瘤；或者，所述疾病为癌症；或者，所述癌症为大肠癌、肺癌、卵巢癌、子宫癌、子宫内膜癌、腹膜癌、输卵管癌、胰腺癌、头颈鳞形细胞癌、鼻咽癌、喉癌、肺腺癌、肝癌、乳腺癌、脑癌、肾癌、肾细胞癌、结肠癌、睾丸癌、子宫颈癌、膀胱癌、视网膜母细胞瘤、神经胶母细胞瘤、间皮瘤、口腔上皮样癌、绒毛膜癌或头颈癌。
  22. 如权利要求20或21所述的方法，其特征在于，所述抗体或其抗原结合单元或抗体药物偶联物的单次给药剂量为1mg/kg-10mg/kg；或者，50mg-1000mg；或者，100mg-600mg；或者，给药周期为每周给药1次、每2周给药1次、每3周给药1次、每4周给药1次、每5周给药1次或每6周给药1次；或者，给药方式为注射给药；或者，给药方式为静脉注射给药；或者，给药方式为静脉输注给药。
  23. 一种试剂盒，其特征在于，包含权利要求1-9任一项所述的抗体或其抗原结合单元、权利要求11-16任一项所述的抗体药物偶联物或权利要求17或18所述的药物组合物以及用于指导患者给药的说明书。
PCT/CN2022/141572 2021-12-24 2022-12-23 抗FRα抗体及其抗体药物偶联物和用途 Ceased WO2023116911A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP22910217.3A EP4455164A1 (en) 2021-12-24 2022-12-23 ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
US18/722,899 US20250059274A1 (en) 2021-12-24 2022-12-23 ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
JP2024537958A JP2024547111A (ja) 2021-12-24 2022-12-23 抗ＦＲα抗体及びその抗体薬物コンジュゲート並びに使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111602429 2021-12-24
CN202111602429.4 2021-12-24
CN202211408028 2022-11-10
CN202211408028.X 2022-11-10

Publications (1)

Publication Number Publication Date
WO2023116911A1 true WO2023116911A1 (zh) 2023-06-29

Family

ID=86879676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/141572 Ceased WO2023116911A1 (zh) 2021-12-24 2022-12-23 抗FRα抗体及其抗体药物偶联物和用途

Country Status (5)

Country Link
US (1) US20250059274A1 (zh)
EP (1) EP4455164A1 (zh)
JP (1) JP2024547111A (zh)
CN (1) CN116333135A (zh)
WO (1) WO2023116911A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118791615A (zh) * 2024-07-22 2024-10-18 上海生物制品研究所有限责任公司 抗FRα抗体或抗原结合片段、抗体偶联药物及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025003396A1 (en) * 2023-06-28 2025-01-02 Université De Tours Pegylated linkers and uses thereof
WO2025036307A1 (zh) * 2023-08-11 2025-02-20 百奥泰生物制药股份有限公司 抗frα抗体药物偶联物在治疗疾病中的应用
WO2025140416A1 (zh) * 2023-12-28 2025-07-03 上海宏成药业有限公司 抗folr1特异性抗体的发明及应用
CN120919340A (zh) * 2024-05-09 2025-11-11 百奥泰生物制药股份有限公司 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用

Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR50E (fr) 1901-07-17 1902-10-13 Roche Un nouveau procédé de dégrisage du velours
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1991009967A1 (en) 1989-12-21 1991-07-11 Celltech Limited Humanised antibodies
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0519596A1 (en) 1991-05-17 1992-12-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0592106A1 (en) 1992-09-09 1994-04-13 Immunogen Inc Resurfacing of rodent antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5693792A (en) 1992-02-18 1997-12-02 Otsuga Kagaku Kabushiki Kaisha β-lactam and cephem compounds and processes for their production
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
JP4968615B2 (ja) 2004-12-16 2012-07-04 日本電気株式会社 二次電池用電解液及び二次電池
WO2014036495A2 (en) 2012-08-31 2014-03-06 Immunogen Inc. Diagnostic assays and kits for detection of folate receptor 1
WO2014057687A1 (ja) * 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
WO2015054400A2 (en) * 2013-10-08 2015-04-16 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
CN105308072A (zh) * 2013-05-14 2016-02-03 伊缪诺金公司 抗folr1免疫缀合物给药方案
WO2019243825A1 (en) * 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
US20210093733A1 (en) * 2016-11-21 2021-04-01 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
CN112739717A (zh) * 2018-06-29 2021-04-30 璟尚生物制药公司 三特异性拮抗剂
CN115429893A (zh) * 2021-06-02 2022-12-06 百奥泰生物制药股份有限公司 药物偶联物及其用途

Patent Citations (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR50E (fr) 1901-07-17 1902-10-13 Roche Un nouveau procédé de dégrisage du velours
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (zh) 1985-03-28 1990-11-27 Cetus Corp
US4683195B1 (zh) 1986-01-30 1990-11-27 Cetus Corp
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
WO1991009967A1 (en) 1989-12-21 1991-07-11 Celltech Limited Humanised antibodies
EP0519596A1 (en) 1991-05-17 1992-12-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5693792A (en) 1992-02-18 1997-12-02 Otsuga Kagaku Kabushiki Kaisha β-lactam and cephem compounds and processes for their production
US6350861B1 (en) 1992-03-09 2002-02-26 Protein Design Labs, Inc. Antibodies with increased binding affinity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0592106A1 (en) 1992-09-09 1994-04-13 Immunogen Inc Resurfacing of rodent antibodies
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
JP4968615B2 (ja) 2004-12-16 2012-07-04 日本電気株式会社 二次電池用電解液及び二次電池
WO2014036495A2 (en) 2012-08-31 2014-03-06 Immunogen Inc. Diagnostic assays and kits for detection of folate receptor 1
WO2014057687A1 (ja) * 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
CN105308072A (zh) * 2013-05-14 2016-02-03 伊缪诺金公司 抗folr1免疫缀合物给药方案
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
WO2015054400A2 (en) * 2013-10-08 2015-04-16 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
US20210093733A1 (en) * 2016-11-21 2021-04-01 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2019243825A1 (en) * 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
CN112739717A (zh) * 2018-06-29 2021-04-30 璟尚生物制药公司 三特异性拮抗剂
CN115429893A (zh) * 2021-06-02 2022-12-06 百奥泰生物制药股份有限公司 药物偶联物及其用途

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1989, GREENE PUBLISHING ASSOCIATES
"Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends", 1994, HARWOOD ACADEMIC PUBLISHERS
"Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR
"Proteins: Structures and Molecular Principles", 1984, W. H. FREEMAN AND COMPANY
"The Scientist", vol. No, 17 April 2000, SCIENTIST, INC., pages: 25 - 28
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CHOTHIA ET AL., J. MOL. BIOL., vol. 278, 1998, pages 457 - 479
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883
CHU ET AL., BIOCHEMIA, no. 2, 2001
DAVIES ET AL., ANNUAL REV BIOCHEM, vol. 59, 1990, pages 439 - 473
E. DIAMANDIST. CHRISTOPOULUS: "Immunoassay,", 1996, ACADEMIC PRESS, INC.
GOEDDEL: "Gene Expression Technology: Methods in Enzymology", vol. 185, 1990, ACADEMIC PRESS
HADI BAYAT ET AL.: "Evaluation of different vector design strategies for the expression of recombinant monoclonal antibody in CHO cells", PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY, vol. 48, no. 8, 2018, pages 822 - 829
J. IMMUNOL., vol. 139, 1987, pages 3521
J. R. CROWTHER: "Remington's Pharmaceutical Sciences: The Science And Practice Of Pharmacy,", vol. 42, 1995, MACK PUB. CO.
KABAT ET AL.: "Peptide And Protein Drug Delivery, Advances In Parenteral Sciences", vol. 4, 1991, N.I.H. PUBLICATION
KABAT, E ET AL.: "Sequences of Proteins of Immunological Interest", 1983, U.S. DEPT. OF HEALTH AND HUMAN SERVICES
LIU ET AL., P.N.A.S, vol. 84, 1987, pages 3439
MURRAY ET AL., CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 17, 2013, pages 420 - 426
NATURE, vol. 361, 1993, pages 186 - 87
OUYANG, METHODS MOL BIOL, vol. 1045, 2013, pages 275 - 83
P. TIJSSEN: "Practice and Theory of Enzyme Immunoassays", 1985, ELSEVIER SCIENCE PUBLISHERS
ROCHE MOLECULAR BIOLOGICALS
ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083
SKERRA ET AL., SCIENCE, vol. 242, 1988, pages 1038 - 1041
STEFAN SCHLATTER ET AL.: "On the Optimal Ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells", BIOTECHNOL PROGRESS, vol. 21, 2005, pages 122 - 133, XP072298569, DOI: 10.1021/bp049780w
THORNTON ET AL., NATURE, vol. 354, 1991, pages 105
TIHOMIR S. DODEV ET AL.: "A tool kit for rapid cloning and expression of recombinant antibodies", SCIENTIFIC REPORTS, vol. 4, 2014
WINTERHARRIS, IMMUNOL TODAY, vol. 14, no. 43, 1993, pages 46
WRIGHT ET AL., CRIT. REVIEWS IN IMMUNOL., 1992, pages 12125 - 168
WUWU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118791615A (zh) * 2024-07-22 2024-10-18 上海生物制品研究所有限责任公司 抗FRα抗体或抗原结合片段、抗体偶联药物及其应用

Also Published As

Publication number Publication date
CN116333135A (zh) 2023-06-27
JP2024547111A (ja) 2024-12-26
US20250059274A1 (en) 2025-02-20
EP4455164A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US20240269315A1 (en) Drug conjugate and use thereof
US12138313B2 (en) Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
EP4455164A1 (en) ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
US20250262316A1 (en) Antibody-drug conjugate and application thereof
JP2020527332A (ja) 抗−ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
EP4538291A1 (en) Anti-nectin-4 antibody, and antibody-drug conjugate and use thereof
EP4556027A1 (en) Anti-nectin-4 antibody drug conjugate and use thereof
EP4534105A1 (en) Anti-cldn18.2 antibody, and antibody-drug conjugate and use thereof
HK40087898A (zh) 药物偶联物及其用途
HK40014209A (zh) 抗-含cub结构域蛋白1 (cdcp1)抗体、抗体药物缀合物及其使用方法
HK40014209B (zh) 抗-含cub结构域蛋白1 (cdcp1)抗体、抗体药物缀合物及其使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22910217

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024537958

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022910217

Country of ref document: EP

Effective date: 20240724